Protocol development for analysis of the DMPK repeat in

preimplantation genetic diagnosis and the investigation of

gene expression in human oocytes and blastocysts by Kakourou, G.
1
Protocol development for analysis of the DMPK repeat in
preimplantation genetic diagnosis and the investigation of
gene expression in human oocytes and blastocysts
by
Georgia Kakourou
A thesis submitted for the degree of Doctor of Philosophy at
University College London
March 2009
UCL Centre for PGD
Institute for Women’s Health
University College London2
'I, Georgia Kakourou, confirm that the work presented in this thesis is my
own. Where information has been derived from other sources, I confirm that
this has been indicated in the thesis.'3
Acknowledgments
First of all, I would like to thank my supervisor, Dr Sioban SenGupta for always being
available to discuss all arising lab issues and guide me in my research. I would like to
thank her for being so patient with me, for motivating me to work with enthusiasm, for
managing to create such a nice working atmosphere that helped us endure and even
enjoy many difficult situations, including working at 2am at night! I really hope that
this work can make her proud of her first PhD student.
I would like to express my sincerest gratitude to Prof. Joy Delhanty, who I feel has been
looking after me and supporting me since I first joined the group as an MSc student, and
has had a major influence on the way I work in the lab; her words of advice often come
to my mind, though she might not be aware of that!
Dr Joyce Harper was the person who actually introduced me to the field of
preimplantation genetics when, as a BSc student, I attended one of her lectures. Her
enthusiasm in everything she does has been an inspiration.
Some people have been very important on the practical side of things. I would like to
thank: Dr John Short (St George’s Hospital Medical School) for providing me with the
DM1 DNA control samples, Dr Paul Smyth (Trinity Centre for Health sciences) for all
his help towards the microarray work, for tirelessly responding to the numerous emails
and answering so many questions, Ms Catherine King (Wolfson Institute for
Biomedical research) for training on several equipment use, Dr Jiang Zhu (Beijing
Institute of Genomics) for providing me with the list of common housekeeping genes,
Mrs Jane Galbraith (UCL Department of Statistical science) for her suggestions
regarding the statistical analysis in this project, the embryologists of the Assisted
Conception Unit, especially Suzanne Cawood, for her help with sample collection and
for kindly responding to all my emails, and finally Mr Paul Serhal for funding the
microarray project.
I would like to further acknowledge all the people that I have been working with every
day and have made Chenies Mews a very special place for me.
Seema and Thalia for playing such a major role in my every day lab life and all the
PGD work, for always motivating me to keep going, for their constant help, for
enduring long discussions about work and life in general, for putting up with my
singing, for helping me develop my skill of having a conversation while using a mouth4
pipette and for sharing so many PCR team-jokes that I could not possibly mention here.
Thank you Seema for allowing me to take over your computer to finish off my writing
and Thalia for sharing our thoughts on msn every night! I would like to thank Souraya
for keeping me sane throughout the microarray work that we did together, Stavro for
always being interested in my progress and supporting me, Anna for her advice on
writing, Karen for all her kind words throughout, Leoni, Barbara and all the other
people in the lab for being there.
A very warm thanks should go to all those outside the lab whose presence has been
invaluable to me throughout the years. Elpida thank you so much for all that you have
done for me, for advising me and calming me down whenever I was stressed, for
putting pressure on me when I was not feeling stressed, for convincing me to start
writing up my thesis at the right time and guiding me all the way! Also many thanks to
my friends Eleni, Angie, Thanasis, Maria, Sanjiv and all the others who I know are
there for me whenever I need them.
Many thanks should go to my brother for being a wonderful housemate for the last 1.5
years, for putting up with my constant worry, especially towards the end, for all the
interesting scientific and non-scientific conversations, for his help with all my computer
problems, for all his advice and recommendations regarding my write up, for being the
only person that can do all these things and at the same time drive me up the wall so
often!! I want to thank my sister for calling me and supporting me every day and for
making me her maid of honour which was a very happy moment in my life!
Lastly, I want to thank my parents for everything and I would like to dedicate this thesis
to them. Thank you for the enormous amount of faith you have in me, for all your
support throughout all my studies at University, for creating such a great environment at
home, where I wrote the biggest part of my thesis, for all the advice, strength, courage
and love I always receive from you.5
To my parents6
Abstract
Myotonic dystrophy type 1 (DM1) is an autosomal dominant disorder caused by
expansion of an unstable CTG repeat within the 3’UTR of the DMPK gene, which
expands further in length during transmission from generation to generation. Prenatal
diagnosis is available, although the decision for pregnancy termination can be difficult
due to the variable phenotypic expression of DM1. In vitro fertilisation with
preimplantation genetic diagnosis (PGD), offer another reproductive option for affected
couples, which involves genetic analysis and selection of an unaffected embryo to
establish a pregnancy. These technologies have also provided access to human gametes
and preimplantation embryos and encouraged research aimed at understanding the
molecular pathways controlling human preimplantation development.
The first part of this study focused on the improvement of existing techniques for PGD
and the development of universal multiplex fluorescent PCR PGD protocols for the
efficient and accurate diagnosis of DM1. The second part of the study involved follow-
up analysis of DM1 affected and unaffected embryos donated for research with the aim
to investigate transmission of the CTG repeat from the affected and unaffected parent to
the preimplantation embryo. The final objective was to obtain a global gene expression
profile by microarray analysis of human oocytes and blastocysts, with a focus on
important functional pathways.
The protocols developed achieved high efficiency and accuracy of diagnosis, reduced
the genetic work-up time, overall supporting PGD for DM1 as an effective and practical
alternative to prenatal diagnosis. This study also adds to current evidence regarding
CTG repeat transmission and provides information on repeat expansion and embryo
quality in DM1. A comparison of expression in the healthy oocyte and blastocyst is
presented, including the identification of oocyte-unique and blastocyst-unique genes.
The microarray data from this study will guide experiments to identify cases where
normal gene expression is disrupted.7
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1. Introduction21
1.1 Preimplantation genetic diagnosis
Preimplantation genetic diagnosis (PGD) involves testing of the preimplantation stage
embryo, created with in vitro fertilisation (IVF) technology, for inheritable
chromosomal abnormalities or single-gene defects and transfer of unaffected embryos to
the womb to establish a pregnancy. PGD requires a multidisciplinary approach. Couples
receive an initial counselling by a clinical geneticist and disease specialists. Following
that, doctors and embryologists of the IVF clinic are responsible for counselling on the
IVF aspects and performing a successful IVF treatment, while the genetics team are
responsible for counselling on PGD and developing and applying a reliable and efficient
diagnostic protocol for the embryo stage. PGD is not an easy reproductive option and
several difficulties may be encountered during the whole procedure. These include the
considerable cost per cycle, the chance of misdiagnosis and the low success rate. In
addition, commencing treatment does not guarantee the availability of embryos for
transfer. This can be the result of poor ovarian response, failed fertilisation, poor quality
embryos, diagnosis of all embryos as affected or having inconclusive results (Sermon et
al., 2004). Despite these potential difficulties, PGD is a very appealing option to many
patients, particularly those with moral or religious objections to termination of
pregnancy (TOP) and those having undergone several TOPs. In fact, in one of the early
studies reporting on the patient’s view on PGD, 86% of women stated that avoidance of
TOP was the main advantage they saw in PGD (Pergament, 1991). This was confirmed
in a later study reporting the views of patients who had actually experienced PGD
(Lavery et al., 2002). Another group of patients who may choose to undergo PGD are
those with infertility problems who therefore have an independent indication for IVF
treatment and also carry a genetic disorder (Delhanty et al., 1994;Delhanty and Wells,
2002).
The first established pregnancies following PGD were reported in 1990 for two couples
with X-linked recessive disorders, adrenoleukodystrophy and X-linked mental
retardation. In these cases diagnosis involved sexing of the foetus by amplification of a
Y-specific DNA sequence and selection of female embryos for transfer (Handyside et
al., 1990). The first clinical application of PGD for monogenic disorders was for cystic
fibrosis in 1992 (Handyside et al., 1992). It is estimated that over 7000 PGD cycles have
been carried out to date. During the last eighteen years the practice of PGD has changed22
considerably, not only from the technical point of view but also regarding its general
application, often being the centre of ethical debates (Kuliev and Verlinsky,
2005;Kuliev and Verlinsky, 2008). PGD is no longer limited to conditions that present
at birth, but has also been applied for the diagnosis of late-onset disorders with genetic
predispositions, as a screening test for various high-risk population groups
(preimplantation genetic screening, PGS) or even for non-disease associated human
leukocyte antigen (HLA) testing in order to obtain compatible offspring to affected
siblings who require transplantation therapy (Fiorentino et al., 2004;Rechitsky et al.,
2004;Delhanty, 2006;Mantzouratou et al., 2007; Renwick et al., 2007). Legislation for
PGD practice differs between countries (Soini, 2007). In the UK PGD is strictly
regulated by the Human Fertilisation and Embryology Authority (HFEA) and,
internationally, PGD data are collected by the European Society for Human
Reproduction and Embryology (ESHRE). Over 2000 children have been born
worldwide and to date studies on the health of PGD and PGS children have not
indicated the PGD procedure to be unsafe (Banerjee et al., 2008;Goossens et al.,
2008b;Nekkebroeck et al., 2008).
1.1.1 Embryo biopsy and diagnosis
The first step of the PGD procedure involves puncture or removal of part of the zona
pellucida, the thick membrane that surrounds the oocyte or embryo, in order to obtain
the cells for genetic analysis (biopsy procedure). Biopsy can be performed using acid
Tyrode’s solution, laser or mechanical means, at different stages of development, either
around the time of fertilisation of the woman’s oocyte with her partner’s sperm, to allow
testing of the polar bodies, or during the cleavage or blastocyst stages of
preimplantation embryo development, to obtain blastomeres or trophectoderm cells
respectively (Boada et al., 1998;Inzunza et al., 1998;Harper and Thornhill, 2001) (figure
1.1).23
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Figure 1. 1: Sequence of events following human oocyte fertilisation. A: Mature oocyte (MII) with
first polar body present, surrounded by cumulus cells. B: Fertilisation: formation of the male and female
pronuclei (2PN) and extrusion of the second polar body. C: Human zygote. D: First mitotic division. E-F:
Mitotic divisions leading to a 4-cell and an 8-cell embryo. G: Morula stage of preimplantation
development. H: Blastocyst stage embryo where cells have differentiated into the trophectoderm (the
surrounding cells) and inner cell mass.
Polar body (PB) biopsy is the only option available in countries where diagnosis at the
embryo stage is not legal; an example of this is Germany, though it is interesting to note
that the German public opinion differs to the government regulation (Borkenhagen et al.,
2007). PB biopsy is labour-intensive as it requires removal and testing of the first polar
body, produced after completion of the first meiotic division, while confirmation of
findings is possible by subsequent removal of the second polar body, produced after
fertilisation (Sermon et al., 2004). In the case of a maternal defect or an X-linked
disorder, PB biopsy permits detection of the mutation-free oocytes; embryos derived
from these do not require further testing. With PB biopsy, however, paternally-inherited
abnormalities or other defects originating following fertilisation cannot be detected,
while, for single-gene disorders PB diagnosis may be associated with problems arising
due to meiotic cross-over (Swanson et al., 2007). Additionally, for X-linked or recessive
conditions, some of the oocytes that are discarded as “affected”, could lead to
unaffected embryos depending on the paternal genetic contribution (Soini et al., 2006).24
Cleavage stage embryo biopsy is the most common method used in PGD. It involves
blastomere removal on day 3 of development, when the embryo is at the 6-8 cell stage.
This is generally considered as the best approach, as the cells at this stage are regarded
as totipotent, compaction has not yet occurred and there is sufficient time for the
diagnostic protocol to be carried out prior to embryo transfer on day 4 or day 5 (De Vos
and Van Steirteghem, 2001). The main debate regarding this method of obtaining cells
has been directed on whether one or two blastomeres should be biopsied. Investigators
have assessed the impact of one or two-cell biopsy on the diagnosis rate, the risk of
misdiagnosis, embryo development and implantation potential. At the present time, as
there are not any specific practice guidelines on this issue, each PGD centre follows its
own guiding principles when performing cleavage stage biopsy (Lewis et al.,
2001;Goossens et al., 2008a;Dreesen et al., 2008).
Finally, blastocyst stage biopsy may be performed on day 5, by removing several cells
from the trophectoderm layer, which gives rise to the placental membranes. The
availability of more than one cell facilitates diagnosis and increases the overall
diagnosis rate, though the occurrence of mosaicism could have consequences on PGD
accuracy, particularly for the diagnosis of chromosomal disorders (Kokkali et al., 2007).
Higher implantation rates are generally achieved with transfer of human blastocysts
rather than transfer of day 3 embryos (Gardner et al., 1998a;Gardner et al., 1998b;Blake
et al., 2007). Transfer of blastocysts following blastocyst biopsy has also been
associated with an improved implantation rate compared to transfer of blastocysts where
cleavage stage biopsy was performed, although notably only 40-50% of embryos
develop to the blastocyst stage by day 5 (Kokkali et al., 2007;McArthur et al., 2008).
Additionally, with blastocyst stage biopsy, embryo cryopreservation may be necessary
to allow time for the diagnosis to be completed (Wilton et al., 2001; McArthur et al.,
2005;Magli et al., 2006).
Following embryo biopsy, the polymerase chain reaction (PCR) is commonly used for
the diagnosis of single gene disorders. This is discussed in more detail below. The main
method for detection of chromosomal abnormalities has been the fluorescence in situ
hybridization (FISH) technique, performed on human blastomeres since 1992 (Griffin et
al., 1992). This technique requires fixing the single blastomere on a slide prior to25
labelling with chromosome-specific fluorescent probes. FISH allows detection of
abnormalities that may arise in embryos of carriers of Robertsonian or reciprocal
translocations as well as other chromosomal rearrangements such as inversions,
insertions, deletions, or the formation of ring chromosomes. The technique has also
been employed as a screening test to detect numerical chromosomal abnormalities in
embryos from couples of advanced maternal age (AMA), or couples with repeated
failed IVF cycles (three or more) or repeated miscarriages, as the above have been
associated with chromosomal aneuploidy. This test is known as preimplantation genetic
screening (PGS) (Fragouli, 2007). The main drawback with FISH has been the restricted
number of probes that can be used in the same experiment (up to 5). Several PGS
protocols have been reported, generally allowing for testing of up to 15 different
chromosomes following consecutive FISH rounds on a single blastomere (Baart et al.,
2007a;Baart et al., 2007b;Mantzouratou et al., 2007). The anticipated positive clinical
benefit of the PGS treatment has been under debate (Cohen et al., 2007). To overcome
the limitations of FISH, a technique known as comparative genomic hybridization
(CGH), which allows the simultaneous analysis of all chromosomes in a cell, has been
optimised to work on single cells (Wells et al., 1999). The technique has been applied to
blastomeres from day 3 embryos, as well as to polar bodies and blastocyst stage
embryos (Wells and Delhanty, 2000; Wilton et al., 2001;Wells et al., 2002; Fragouli et
al., 2006a;Fragouli et al., 2006b;Fragouli et al., 2008). Its main limitations have been
the long time required to obtain a result (4-5 days) and the need for particular expertise
to accurately carry out the analysis. To allow enough time for completion of the analysis,
embryos are cryopreserved and, following diagnosis, the selected embryos are thawed
for transfer in a new treatment cycle. This methodology has been associated with
reduced implantation of thawed embryos, but the constant improvement of
cryopreservation techniques is gradually overcoming this drawback (Sher et al., 2009).
Another more recent development, array CGH (aCGH), overcomes the above
limitations as the results can be obtained within 24 hours and the analysis can be easily
automated (Hu et al., 2004;Le et al., 2006). aCGH, using oligonucleotide probes, has
already been applied clinically (Hellani et al., 2008). Other microarray platforms have
also become available for the detection of aneuploidy, although further work is needed
to optimise their use and overcome problems associated with variation in performance,
resolution, diagnostic accuracy, interpretation of results and high cost, to encourage
their wide clinical application (reviewed in Wells et al., 2008). It is, however,26
noteworthy that the single nucleotide polymorphism (SNP) arrays present an
opportunity for simultaneous detection of chromosomal and single gene disorders,
which has traditionally been a challenge for PGD.
1.1.2 PGD for single gene disorders
Following embryo biopsy the PGD procedure involves gentle lysis of the membranes of
the biopsied cells in order to make the DNA accessible. Since the advent of PGD,
various protocols have been tested for their efficiency in single cell lysis. Methods of
lysis prior to performing PCR for the diagnosis of single gene disorders have included
consecutive rounds of freezing and thawing in distilled water, boiling, the use of
alkaline lysis buffers (ALB), or the use of buffers containing proteinase K (PK) and
detergents. The ALB and PK lysis methods are currently the most widely used
(Thornhill et al., 2001). Following cell lysis, PCR is used for amplification of the DNA,
around 6pg from a single cell, to a level where mutation detection techniques can be
applied. Through the years, the single-cell PCR strategies have evolved with the
purpose of achieving better diagnostic efficiency, more accurate diagnostic results and,
consequently, a lower misdiagnosis rate.
The main aim has been to minimise the PCR problems that are exacerbated when
amplifying from a single genome, as opposed to highly-concentrated DNA samples
used in routine PCR. These include amplification failure, allele dropout or
contamination and can result either in failure to make a diagnosis or in misdiagnosis.
Bearing in mind that single-cell PCR amplification can be performed only once, taking
measures for prevention of the above becomes critical, especially as several
misdiagnoses have been reported since the introduction of PGD (Goossens et al., 2008a).27
1.1.2.1 Single-cell PCR features
1.1.2.1.1 Amplification failure
The most common causes for amplification failure include loss of the cell during
transfer to the PCR tube, biopsy of an anucleate or poor quality (lysing or degenerating)
cell, inadequate cell lysis or use of a suboptimal PCR protocol. Amplification failure
reduces the numbers of diagnosed embryos and therefore, the chances of embryo
transfer, implantation and pregnancy. Care should be taken during protocol design for
PGD, so that lack of amplification does not mimic an ‘unaffected’ result, in order to
avoid misdiagnosis. Standard PGD practice should, therefore, entail careful monitoring
of the cell status during the biopsy procedure, as well as cautious single-cell
manipulation and use of optimised and well tested single-cell protocols. In most studies,
the amplification success rate for single buccal cells or single lymphocytes is around 90-
95% and, similarly, amplification failure has been estimated to occur in approximately
10% of isolated blastomeres (Harper and Wells, 1999).
1.1.2.1.2 Allele dropout (ADO)
ADO is a phenomenon generally affecting 5-20% of single cell amplifications, whereby
one of the two alleles in a heterozygote sample fails to amplify to a detectable level. The
cause of ADO is mainly technical, due to inefficient priming during PCR, and has also
been associated with poor embryo quality. ADO can affect either of the alleles in a
heterozygous cell. When it occurs on amplification of the mutated region, it can be
responsible for false negative and false positive diagnostic results. ADO of the mutant
allele during PGD for a dominant disorder can lead to transfer of an affected embryo. In
PGD for recessive disorders, ADO of the unaffected allele can reduce the number of
heterozygous (carrier) embryos detected (figure 1.2). For recessive disorders that are
due to a combination of two different mutations (compound heterozygotes), an embryo
might be given a carrier rather than affected diagnosis in case of allele dropout at one of
the loci (Wells and Sherlock, 1998).28
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Figure 1. 2: Allele Dropout (ADO). Failure of amplification of the normal allele mistakenly leads to
erroneous interpretation as a homozygous affected genotype. When the mutant allele fails to amplify the
genotype appears to be that of a homozygous unaffected individual.
Various techniques aimed at reducing the chance of ADO have been applied in PGD,
for example increasing the PCR denaturation temperature for the first ten amplification
cycles or using alternative cell lysis buffers (Ray and Handyside, 1996;el Hashemite
and Delhanty, 1997;Piyamongkol et al., 2003). In addition, the highly sensitive
technique of fluorescent PCR (F-PCR), where primers in a PCR reaction are end-
labelled with fluorescent molecules and products are analyzed on a fluorescent capillary
detector, has been used to detect cases of preferential allele amplification, which, with
conventional PCR, would appear as ADO (Findlay et al., 1995). Finally, the use of
multiplex PCR allows the simultaneous amplification of a polymorphic intragenic or
linked marker along with the mutated region. The marker’s phase allele, the allele
inherited on the same chromosome with the mutation, is detected by linkage analysis
and its presence confirms the presence of the mutation (Rechitsky et al., 1998;Sherlock
et al., 1998). It is important that linked polymorphic markers are in close proximity to
the gene to ensure that the chance of the mutation and the phase allele having separated
by meiotic recombination is reduced. The higher the number of linked polymorphic
markers available for the gene under study, the higher the chance that, should ADO of
the mutant allele occur, it will be detected (figure 1.3).29
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Figure 1. 3: Detection of the phase allele in a two-generation family. D indicates the presence of the
disease and 1-5 indicate different sized alleles of the linked polymorphic marker. The proband (affected
mother) is heterozygous at the disease (D/d) and the linked polymorphic marker locus (alleles 2/4).
Marker allele 2 is present in the mother’s affected father and her two affected children. The unaffected
child has inherited allele 4 from the mother. It can, therefore, be inferred that allele 2 is inherited along
with the disease allele (D), i.e. allele 2 is the phase allele. Detection of allele 2 in an embryo would
therefore be associated with the presence of the mutated allele.
A combination of multiplex and fluorescent PCR is possible as technological advances
have allowed the simultaneous analysis of up to five fluorescent dyes at a time. Products
of different size can be differentiated even if labelled with the same fluorescent dye so
this further increases the number of primers that can be multiplexed in a single F-PCR
reaction.
Finally, it should be noted that other events can also make a heterozygous sample
appear as homozygous and give the appearance of ADO, such as chromosomal
mosaicism, the presence of haploid cells, mitotic nondisjunction or anaphase lagging by
which monosomy can occur (Dreesen et al., 2008). A well-designed multiplex PCR
PGD protocol may differentiate between the above and true ADO.30
1.1.2.1.3 Contamination
Contamination is a major problem with single cell PCR, mainly because of the large
number of cycles (40-65) needed for sufficient amplification from a single genome.
Measures to prevent contamination are, for example, separating the single cell PCR set-
up and analysis areas, performing PCR in a laminar-flow hood, using dedicated
equipment for single cell work, carrying out filtration and testing of reagents as well as
UV irradiation of all equipment and consumables prior to use. Apart from extraneous
contamination, another source of contamination in PGD comes from sperm or cumulus
cells embedded in the zona pellucida (ZP) that can get released during the biopsy
procedure. To prevent this, the cumulus cells are removed from around the oocyte and
the embryo before biopsy, while intracytoplasmic sperm injection (ICSI) is used for
fertilisation instead of standard IVF, to ensure there is no excess sperm present (De Vos
and Van Steirteghem, 2001). In addition to these precautions, biopsied cells are usually
washed in 2-3 droplets of buffer medium that has been cleared of contamination, before
transfer to the PCR tube (Thornhill et al., 2005).
Subsequent to the biopsy and transfer procedures, contamination can also occur during
PCR set up. It is, therefore, important that a stringent optimised single cell PCR
protocol is run with appropriate positive and negative controls so that any contamination
can be detected. Moreover, multiplex PCR PGD protocols involve the simultaneous
amplification of polymorphic markers, often referred to as ‘contamination markers’ as
they can be used to indicate the presence or absence of contamination (Harper and
Wells, 1999). An informative polymorphic marker, one for which all parental alleles are
of different size and can easily be differentiated, can be used to determine not only the
origin but also the purity of DNA from amplified single cells (figure 1.4).31
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Figure 1. 4: Example of polymorphic marker informativity in four couples, indicating all possible
embryo genotypes. The different polymorphic marker allele sizes are indicated by the numbers 1, 2, 3
and 4. A) Fully informative marker. All parental alleles are of different size. B) Informative marker with
unaffected partner homozygous for the marker alleles. Maternal and paternal alleles differ. C) Semi-
informative polymorphic marker. The couple shares one of the marker alleles and D) Uninformative
marker. The couple shares all of their alleles. Polymorphic markers with informativity similar to
examples B and C may be of use in a diagnosis in case the marker is linked and the phase allele can be
identified, however, in both cases, contamination may not be detected and these markers, should,
therefore, be used in conjunction with another fully informative polymorphic marker.
The polymorphic marker can be intragenic, linked, or non-linked to the gene of interest.
An intragenic or linked marker can also provide confirmatory results to mutational
analysis and, therefore, increase the reliability of the diagnostic strategy (Piyamongkol
et al., 2001a;Dhanjal et al., 2007).
Finally, carry-over contamination, the accidental amplification of DNA fragments
generated during previous experiments, is also a major source of false positive results.
The technique of nested PCR has been used to reduce the risk of carry-over
contamination. It involves two sequential amplification reactions, where the larger
fragment produced in the first PCR round is used as a template for the second round of
amplification. Since a different set of internal (nested) primers is used in the second
PCR, the outer first round products cannot get amplified by the second reaction. The
two amplification rounds of a nested PCR significantly increase the efficiency of DNA
amplification from a single cell. Lower stringency is usually employed during the first32
round of PCR and higher stringency in the second round (Wells and Sherlock, 1998)
(figure 1.5).
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Figure 1. 5: Schematic representation of nested-PCR. The technique involves two sequential
amplification reactions. The first amplification reaction employs the outer set of primers to amplify the
sample DNA template. An aliquot of the PCR product is taken to set up the second amplification reaction,
where the inner set of primers is used. “X” indicates the mutated region.
Contamination is monitored during a PGD case by obtaining and testing negative
controls (blanks) from the last wash of each biopsied cell and from the PCR mix to
allow testing of the PCR reagents. The general contamination risk may also be assessed
during workup by testing tubes that have been left open for some time into the room and
hood where the single cell PCR is set up (Thornhill et al., 2005).33
1.1.2.2 Mutation detection in PGD for single gene disorders
The ideal PGD protocol needs to be simple, sensitive, quick, accurate, and fairly
inexpensive. Several analysis techniques have been applied in PGD for single gene
disorders, depending on the nature of the mutation. Size differences are the easiest to
detect and are usually analyzed by F-PCR. Other techniques have been used to detect
substitutions, deletions or insertions, for example, amplification refractory mutation
system (ARMS), restriction fragment length polymorphism (RFLP), single stranded
conformational polymorphism (SSCP) and heteroduplex analysis (HA) techniques. A
modification of the sequencing technique, known as “mini-sequencing”, has also been
performed for direct mutation detection and is becoming common practice in PGD ( Ao
et al., 1998; Abou-Sleiman et al., 2002; Harper et al., 2002; Bermudez et al., 2003;
Fiorentino et al., 2003; Moutou et al., 2003;Moutou et al., 2007). More recently,
quantitative real-time PCR and linear after the exponential-PCR (LATE-PCR) have also
been used on single cells to allow accurate quantification of the number of copies of an
amplicon present in a sample (Rice et al., 2002;Pierce et al., 2003).
Designing, optimising and validating a PGD protocol on single cells can take months.
Attempts have been made to establish more universal PGD protocols to bypass the need
for development of mutation-specific tests, and decrease the workup times. The linkage
strategy, based on detection of the linked markers’ phase alleles, as previously described,
is an indirect mutation detection method that can be applied to more than one family
affected with mutations in the same gene, even if the causative mutation is different.
Unfortunately, the optimisation of multiplex PCR protocols for the co-amplification of a
number of markers linked to the disease gene can be very difficult and time-consuming
when working with single cells. Whole genome amplification (WGA), which allows
non-specific amplification of the entire genome, overall increasing DNA concentration
and providing sufficient templates for many subsequent PCR analyses, has been used to
overcome these difficulties. Several WGA techniques have been developed and applied
on single cells or low amounts of DNA template, for use in preimplantation and non-
invasive prenatal diagnosis. Examples include the primer extension preamplification
(PEP) method, degenerate oligonucleotide primed PCR (DOP-PCR), tagged random
primers PCR (T-PCR), linker- adaptor PCR (LA-PCR), the T7-based linear
amplification of DNA (TLAD) and multiple displacement amplification (MDA)
(reviewed in Peng et al., 2007, Spits and Sermon, 2009).34
PEP was the first WGA method with clinical application in PGD for the diagnosis of a
dominant cancer predisposition syndrome, familial adenomatous polyposis coli (Ao et
al., 1998). Following that, DOP-PCR and CGH was performed on single polar bodies
and blastomeres, while MDA was first applied for PGD for beta-thallasaemia and cystic
fibrosis (Wells et al., 2002;Hellani et al., 2005). More recently, MDA was also used as
the first step in preimplantation genetic haplotyping (PGH) by linkage analysis, which
allows bypassing the need for development of patient specific tests for carriers of the
same monogenic disease (Renwick et al., 2006). It should, however, be noted that
linkage analysis cannot be applied in cases of de novo mutations or when there are no
family members available. Testing of single sperm cells or polar bodies has been
performed to enable linkage analysis in these couples (Spits et al., 2006). However,
even when the phase alleles are known, diagnosis may still not be possible if the couple
is uninformative for the polymorphic markers.
According to the most recent report of the ESHRE PGD consortium (data collection
VIII), the most common indication for PGD for autosomal dominant diseases is
myotonic dystrophy type I (76 cycles), followed by Huntington’s disease (HD) (44
cycles, plus 12 cycles for Huntington exclusion testing). In total, ESHRE data
collections I-VIII have reported 393 PGD cycles for DM1 and 326 cycles for HD and
HD exclusion testing (Goossens et al., 2008b).35
1.2 Myotonic dystrophy type I
1.2.1 Clinical characteristics
Myotonic dystrophy type I (DM1, Online Mendelian Inheritance in Man database
(OMIM) number 160900) is also known as dystrophia myotonica, myotonia atrophica
or Steinert disease. DM1 shows autosomal dominant inheritance and is the most
common adult muscular dystrophy. Its prevalence varies between different areas but is
generally estimated at 1:8000 worldwide, the highest being 1:500, in the Saguenay-Lac-
Saint-Jean region of Quebec, Canada (Meola, 2000;Yotova et al., 2005).
The clinical findings have been categorized into three overlapping phenotypes, the
classic form (adult-onset, appearing in late 20s or early 40s, or late-onset, appearing
after 40 years of age), the juvenile-onset (appearing after birth and in teen years), or the
congenital form (present from birth). The classic form of DM1 was first described in
1909, the disorder was characterized as ‘multisystemic’ in 1936 and the congenital form
of DM1 (CDM1) was described in 1960 (Schara and Schoser, 2006). Patients with DM1
present with changes in muscle but in addition, and in contrast to other types of
muscular dystrophy, multiple organs and tissues are affected, for example, the eyes,
heart, endocrine system, central and peripheral nervous systems, gastrointestinal organs,
bone and skin. DM1 manifests with cataracts and myotonia (tonic muscle spasm with
delayed relaxation) in the late-onset form, muscle weakness, muscle wasting,
cardiomyopathy and cardiac conduction abnormalities, in the juvenile form, and
additional baldness, bowel dysmotility, gall stones, or diabetes in the adult-onset form.
Infantile hypotonia, respiratory and feeding difficulties, delayed motor and speech
development and mental retardation are described in the congenital form. At least 20%
of CDM1 infants die in the neonatal period (Edstrom, 1999;Salehi et al., 2007). In the
other DM1 forms, sudden death may occur due to the cardiac complications or due to
respiratory insufficiency following weakness of the diaphragm (Schara and Schoser,
2006).
DM1 has also been associated with reduced fertility in men, due to testicular atrophy
and oligozoospermia (Sarkar et al., 2004). A recent analysis of 44 PGD cycles from 22
couples with DM1 indicated ovarian dysfunction, poor response to ovarian stimulation36
and production of lower grade embryos in affected women following ICSI/PGD
treatment compared to controls (Feyereisen et al., 2006). Poor response to ovarian
stimulation of PGD patients with DM1 was also reported in a subsequent study of 15
PGD cycles from 15 couples with DM1, though no differences in embryo quality and
also in oocyte quality compared to controls were observed (Sahu et al., 2008). In
contrast to the above, a larger study on DM1 and female fertility (78 couples with DM1,
205 cycles) did not support an impaired gonadal function in the female patients with
DM1 undergoing PGD; the authors attributed their findings to the smaller study
population of the previous studies (Verpoest et al., 2008).
1.2.2 Molecular characteristics: a triplet repeat disorder
DM1 belongs to the class of triplet repeat disorders. The first trinucleotide repeat
expansions were identified in 1991, when the mutations causing fragile X syndrome and
spinal and bulbar muscular atrophy were described (Kremer et al., 1991;La Spada et al.,
1991;Verkerk et al., 1991). It is now known that tetrameric, pentameric and
dodecameric repeats can also expand, associated with myotonic dystrophy type 2,
spinocerebellar ataxia type 10 and progressive myoclonus epilepsy respectively, but the
largest class of human diseases caused by repetitive element instability involves
trinucleotide repeat expansions (Lalioti et al., 1997; Matsuura et al., 2000;Liquori et al.,
2001;Gatchel and Zoghbi, 2005). Based on the relative location of the trinucleotide
repeat to a gene, triplet repeat disorders can be categorized into two subclasses. The first
subclass involves repeat expansion in non-coding sequences, resulting in altered RNA
function, whereas the second subclass is characterized by (CAG)n repeats within gene
exons that code for polyglutamine tracts, resulting in altered protein function. The
repeats observed in subclass I disorders are usually larger (showing hundreds of triplets)
and their exact size is not always known, whereas in subclass II disorders, the repeats
are much smaller in number and variation, and repeat sizes fall into well-defined ranges
(Cummings and Zoghbi, 2000;Everett and Wood, 2004).
The mutation causing DM1 was identified in 1992, as an expansion of a CTG repeat,
mapped on the long arm (q) of chromosome 19 in the 3’ untranslated region of the37
myotonic dystrophy protein kinase (DMPK) gene, at 19q13.3 (Brook et al., 1992; Fu et
al., 1992;Mahadevan et al., 1992;Mahadevan et al., 1993a). The CTG repeat is highly
polymorphic and relatively stable within the general population, ranging from 5-37
repeats. Alleles between 38-54 repeats are known as premutation alleles and they are
very unstable and liable to frequent expansions. Alleles greater than 55 repeats are
associated with disease and are also highly unstable in the germline; they can expand to
several hundreds or even thousands of copies. The larger expansions are generally
associated with more severe symptoms and an earlier age of onset, evident from
generation to generation. This characteristic of trinucleotide repeat disorders is
commonly referred to as ‘anticipation’ and the most striking example of this is of an
individual with the classic form of DM1 having a congenitally affected child.
Anticipation was first described in 1918 for myotonic dystrophy and has since been
observed in all dominant trinucleotide repeat disorders, i.e. except for Friedreich’s
ataxia (FRDA), which is recessively inherited (Schara and Schoser, 2006).
A second type of myotonic dystrophy was first described in 1994 and the mutation, a
CCTG expansion, was mapped in 1998 to the long arm of chromosome 3 (3q21), in
intron 1 of the zinc finger protein 9 (ZNF9) (Ranum et al., 1998;Ricker et al., 1999;
Liquori et al., 2001). The condition was identified as myotonic dystrophy type II (DM2)
in 2001 and has a prevalence of 1:1000 (Liquori et al., 2001;Schara and Schoser, 2006).
DM1 and DM2 (OMIM number 602668) both demonstrate an autosomal dominant
mode of inheritance, are both the result of a repeat expansion (CTG or CCTG), share
many clinical features, for example myotonia and cataracts, but also have some
important differences. For example, the severe congenital form and mental retardation
have only been reported in DM1. Anticipation has generally only been observed in
DM1, although recently the lack of anticipation in DM2 has been questioned as a case
of a 2-year old boy born in a family with DM2 history was described. The patient had a
14.5 kb CCTG expansion detected by Southern blotting in ZNF9, while expansion of
the DMPK CTG repeat was excluded. The CCTG expansion was similar to the
expansion in the mother, although such comparisons are complicated by the presence of
somatic heterogeneity (Kruse et al., 2008). Muscle weakness is predominantly of distal
muscles in DM1 and of proximal muscles (body trunk) in DM2 (hence commonly
known as PROMM or proximal myotonic myopathy), while muscle pain is a
characteristic of DM2. In addition, only few patients with DM2 become severely38
disabled by the 6
th-8
th decade of life, respiratory problems do not normally occur and
sudden cardiac death does not seem common in DM2. Finally, repeat size correlates
with age of disease presentation in DM1, but not in DM2 (Day et al., 2003;Kurihara,
2005).
Patients with symptoms related to myotonic dystrophy and lacking the DM1 and DM2
mutations have been identified by several investigators. A third locus of myotonic
dystrophy has been suggested on chromosome 16p, although this study is still ongoing
(Udd et al., 2006). Another unusual multisystemic myotonic dystrophy disorder was
described in 2004. Following molecular analysis, no mutations were detected in
chromosomes 3 or 19, while a linkage to chromosome 15 was observed. It was
suggested that this new type of myotonic dystrophy is referred to as myotonic dystrophy
type 3 (DM3), however it was subsequently shown that the reported family had a
disease known as inclusion body myopathy with Paget disease and frontotemporal
dementia (IBMPFTD) that had not been previously strongly associated with the
observed symptoms (Le Ber et al., 2004).
1.2.3 DM1 inheritance
1.2.3.1 DMPK haplotype and transmission of the DMPK repeat
A 1kb insertion/deletion polymorphism (Alu+/-) located approximately 5kb telomeric to
the DMPK mutation has been closely associated with the larger repeat alleles, therefore
supporting a haplotype founder effect regarding transmission of the DMPK alleles
(Mahadevan et al., 1993b). In most populations, 5 CTG repeats, the most common
repeat allele present in unaffected individuals, are associated with the Alu+
polymorphism allele, 11-13 CTG repeat alleles are associated with the Alu- allele and
alleles larger than 19 repeats are associated with the Alu+ allele. Two evolution models
have been proposed, one suggesting that 19CTG/Alu+ alleles occurred from expansion
of 5CTG/Alu+ alleles and a second one suggesting that both 5CTG/Alu- and
5CTG/Alu+ haplotypes are present, with 5CTG/Alu+ being the most common, and that
repeat alleles independently expanded from both haplotypes with a different rate of39
expansion (Imbert et al., 1993;Neville et al., 1994;Deka et al., 1996). Analysis of many
populations of different ethnic groups has indicated that the prevalence of DM1 in a
population correlates well with the frequency of large unaffected repeat sizes detected in
the population sample (Pan et al., 2001;Culjkovic et al., 2002;Alfadhli et al.,
2004;Acton et al., 2007).
Because of the low reproductive fitness associated with DM1, it has been suggested that
preferential transmission of large alleles must be what maintains the frequency of DM1
in the population. Transmission ratio distortion (TRD) may result from meiotic drive,
gametic selection or postzygotic viability and has generally been observed in humans,
for example, in retinoblastoma, cone-rod retinal dystrophy and several of the
trinucleotide repeat disorders, such as dentatorubral-pallidoluysian atrophy (DRPLA),
Machado-Joseph disease (MJD), and fragile X mental retardation syndrome (FRAXA)
(Evans et al., 1994;Ikeuchi et al., 1996; Riess et al., 1997; Drasinover et al., 2000;
Girardet et al., 2000;Zollner et al., 2004).
Several studies have investigated the transmission of the DMPK repeat alleles and
report segregation distortion of repeat alleles away from Mendelian predictions, though
data has generally been contradictive. Early studies of healthy individuals heterozygous
for the DMPK repeat region supported a hypothesis for meiotic drive and preferential
transmission of alleles over 19 repeats mostly by males (Carey et al., 1994;Hurst et al.,
1995). Investigations on sperm, however, did not show any evidence for altered
segregation patterns or an effect of alleles on sperm viability, though a selective
advantage of sperm carrying large alleles during fertilisation remained a possibility
(Leeflang et al., 1996). Chakraborty et al., (1996) reanalyzed the previous data and
performed additional investigations of transmission to children, overall reporting
preferential transmission of large alleles during female, and not male, meiosis. It was
also suggested that TRD mechanisms might differ between the different repeat classes.
More recently, Dean et al., (2006a) investigated the transmission of normal DMPK
repeats in preimplantation embryos from general IVF patients and observed TRD in
maternal transmissions of large normal alleles and also TRD preferentially to the female
embryos.
In addition to the studies on unaffected individuals, other studies focused on the
transmission of expanded DMPK alleles, reporting preferential transmission of the DM140
expansion (Gennarelli et al., 1994;Zatz et al., 1997;Magee and Hughes, 1998). Contrary
to these initial results, however, a subsequent study, which investigated the transmission
of mutated alleles from prenatal molecular studies of 83 fetuses from 62 affected
mothers and 21 affected fathers, excluded preferential transmission of the expanded
allele (Zunz et al., 2004). The findings in the latter study were attributed to the use of
prenatal data contrary to pedigree analysis that only investigates offspring that survive
to term.
Another prenatal diagnosis study confirmed these results, excluding preferential
transmission of the DM1 gene, and also observed a much higher intergenerational
expansion when the transmitting parent was the mother compared to when it was the
father (Martorell et al., 2007).
1.2.3.2 Repeat instability
1.2.3.2.1 Intergenerational instability
Intergenerational instability has been shown at the level of offspring both for mutant
alleles but also for DMPK repeats in the normal range (Dean et al., 2006b). Imbert et al.,
(1993) predicted 19 CTG repeats to be the point at which further instability begins,
leading to disease. Expansion of the CTG repeat tract during parent-offspring
transmission is thought to occur in two stages. First, a moderate repeat expansion occurs
from the normal to the premutation state and this increases the chances that the repeat
will further expand to the full mutation state in the next generation (Martorell et al.,
2001;Nag, 2003).
For many trinucleotide repeat loci, instability varies depending upon the sex of the
transmitting parent. For example, CAG expansion diseases tend to be more unstable on
paternal transmission, while in FRAXA, the passage from pre-mutation to full-mutation
status occurs most commonly with transmission from the mother and FRAXA males
carrying a full mutation in their somatic cells usually transmit a premutated allele to
their daughters (Nolin et al., 2003;Zeesman et al., 2004;Wheeler et al., 2007). For DM1,
the effect of parental gender on repeat instability varies depending upon the CTG tract41
length. For CTG lengths of around 200-600 repeats, a bias for expansion is seen in both
paternal and maternal transmissions, while for lengths greater than 600 CTG repeats,
there is a bias for maternal transmission of very large (>1000) repeat expansions in a
single generation, resulting in the severe CDM1 (Lavedan et al., 1993). Cases of
asymptomatic women giving birth to CDM1 children and rare instances of paternally
transmitted CDM1 have, however, also been reported (Nakagawa et al., 1994;Die-
Smulders et al., 1997;Tanaka et al., 2000).
Contraction of the repeat size during transmission has been reported in DM1 as well as
other trinucleotide repeat disorders, for example in FRDA, spinocerebellar ataxia 8
(SCA8) and spinobulbar muscular atrophy (SBMA) (Cleary and Pearson, 2003). In a
study of DM1 parent-offspring pairs, the frequency of contraction was 6.4% (data from
1489 DM1 offspring) and was found to be mostly associated with paternal rather than
maternal transmissions (Ashizawa et al., 1994). A similar finding was reported in a
study of human gametes and embryos, where a larger number of contractions was
detected in spermatozoa and embryos from affected males than in oocytes and embryos
from affected females (De Temmerman et al., 2004). A complete reduction of the repeat
size back to the normal range, referred to as reverse mutation, is rarer than a partial
reduction in the repeat. Reversion into the normal range is a male germline specific
phenomenon (Monckton et al., 1995). An example of reverse mutation was seen in a
case where a 200 repeat expansion from a father affected with DM1, reverted back to a
normal size of 30 repeats when transmitted to the child (Amiel et al., 2001).
The above observations have raised several hypotheses, for example that some affected
individuals might have a predisposition to reduction during transmission, that a male-
specific factor might contribute to repeat deletions, or that there might be a negative
selection against sperm carrying the largest expansions.
1.2.3.2.2 Somatic instability
Variability of repeat length also emerges in different cells and tissues of an individual.
As a general rule, both the somatic heterogeneity and expansion size increase with age
(Wong et al., 1995;Martorell et al., 1998). The rate of instability has been estimated by
testing samples from the same individual taken over a period of time. In DM1 the42
expansion is thought to be 50-80 repeats per year, contrary to DM2 where a 2000bp
expansion was observed over 3 years in an individual (Martorell et al., 1998;Liquori et
al., 2001). The level of mosaicism depends on the patient’s age, repeat number and type
of tissue. In DM1, repeat expansions are found to be smallest in blood and largest in the
cardiac muscle, skeletal muscle, brain (except cerebellar cortex), skin and kidney
(Monckton et al., 1995;Zatz et al., 1995;Abe, 2002). This tissue-specific somatic
instability complicates the evaluations of genotype-phenotype correlation (Marchini et
al., 2000). The presence of larger mutant alleles in skeletal muscle, the primary affected
tissue, weakly correlates with clinical findings (Zatz et al., 1995). On the other hand, a
significant correlation has been found in cases with small expansions between repeat
size in lymphocyte DNA and patient’s age at time of disease onset (Martorell et al.,
1995;Hamshere et al., 1999).
Somatic instability has implications for the analysis of intergenerational transmissions,
which are usually investigated by blood DNA analysis of parents and offspring. Careful
investigation is needed to distinguish true repeat contractions from cases where the
germ-line expansion has been masked by the age-dependent somatic expansion in the
parent (Martorell et al., 2000).
1.2.3.2.3 Mechanisms of repeat instability
Suggested mechanisms of repeat instability in DM1 relate to the processes of DNA
replication, repair and methylation.
Experiments in vitro have shown that repeat sequences are able to form structures
comprising both Watson-Crick (WC) and non-WC base pairs, for example hairpins,
tetrahelical structures, triplexes or duplexes (Baldi et al., 1999; Mankodi et al.,
2000;Heidenfelder et al., 2003;Sarkar et al., 2004;Savouret et al., 2004;Ranum and Day,
2004). CUG repeats, in particular, can form hairpins with U-U mismatches and G-C
base pairs that can have an effect during DNA replication, leading to instability. The
effect is dependent on the repeat orientation, i.e. whether it is in the template strand or
the Okazaki fragment, or its proximity to the replication origin (Yang et al.,
2003;Mirkin, 2006). Hairpin formation can lead to both contractions and expansions,
either by replication across the hairpin structures or by DNA slippage, respectively
(Heidenfelder et al., 2003). DNA slippage causes the DNA polymerase to dissociate and43
re-associate with the template strand. During re-association, a misalignment between the
template and the newly synthesized strand would generate a single-strand loop that can
form a hairpin structure, which is thought to protect the expansion from repair activities
of the cell, including mismatch repair and flap endonuclease. The hairpin structures can
trap the MSH2/MSH3 dimers of the mismatch repair complex, therefore impairing its
ATPase activity and as a result stabilizing the repeats. In addition, the formation of
hairpin structures during gap repair DNA synthesis can prevent the function of flap-
endonuclease 1 (FEN1), therefore predisposing alleles to further expansion (Mirkin,
2006).
The replication model might explain the differences between male and female
transmission of CTG repeats, since, for example, spermatogenesis is characterized by
more mitotic cell divisions than oogenesis (Jansen et al., 1994). Expansion during
mitosis was also observed in cultured fibroblasts and lymphoblastoid cell lines.
Expanded cells of the lymphoblastoid cell lines had a growth advantage over those with
smaller expansions or contractions, attributable to increased cell proliferation, but lower
survival rate (Zatz et al., 1995;Khajavi et al., 2001). In addition, larger CTG expansions
have been observed in tumours of patients with DM1 relative to their nonneoplastic
tissue suggesting that expansion can also occur during acquired cell proliferation (Yang
et al., 2003). Finally, increased stability in mutants (Fen1/rad27) deficient in Okazaki
fragment processing also favors the replication model (Callahan et al., 2003;Yang and
Freudenreich, 2007).
Evidence supporting the involvement of the DNA repair mechanism has come from
experiments on DM1 mice where it has been shown that the absence of Msh2 shifts the
instability from expansions to contractions, both in somatic tissues and through
generations. Therefore, in DM1, Msh2 appears to be required for the formation of
somatic and intergenerational expansions (Savouret et al., 2003;Savouret et al., 2004).
Msh3 and Msh6 deficiency, both partners of Msh2, have the effect of completely
blocking the instability or encouraging the expansion respectively (van den Broek et al.,
2002). Mouse models have also indicated the mismatch-repair gene, Pms2, as a major
component of the expansion pathway; its deficiency decreased the rate of CTG repeat
expansion but also increased the frequency of deletions (Gomes-Pereira et al., 2004).44
Finally, the involvement of CpG methylation, which is highly regulated in a tissue- and
development-specific manner, in repeat instability, restricted to specific loci and tissues
and occurring only during specific developmental stages, has also been suggested
(Cleary and Pearson, 2003). Methylation status may affect the rate and fidelity of DNA
polymerases synthesis, thereby influencing DNA replication and favouring or not the
formation of mutagenic intermediates, such as slipped structures (Nichol and Pearson,
2002). DM1 cells with large expansions over 1000 repeats were previously found to be
hypermethylated at the CpG island 5’ of the CTG repeat (Steinbach et al., 1998). Two
CTC-binding factor (CTCF) binding sites flank the CTG repeat forming an insulator
unit, which has a role in either blocking enhancers from regulating promoters or
protecting from gene silencing. CTCF binding protects the DM1 region from
methylation. Expansion in CDM1 is associated with loss of CTCF binding, spread of
heterochromatin and regional CpG methylation. Contrary to this, the CpGs of the repeat
region are not methylated in classic DM1 (Filippova et al., 2001;Cho et al., 2005).
1.2.3.2.4 Timing of CTG repeat instability
The size of the CTG repeat has been shown to be particularly unstable during
spermatogenesis and oogenesis. Male DM1 patients with large repeats in their
lymphocytes showed even larger expansions in their mature sperm, while expansion has
also been detected in oocytes before completion of the second meiotic division
(Abbruzzese et al., 2002;Dean et al., 2006b).
Postzygotically, blastomeres from the same embryo show comparable repeat sizes on
analysis but further expansion has been detected to have occurred between day 3 and
day 4 in an embryo, though more research is needed to confirm this (Dean et al., 2006b).
A pre- and post- zygotic expansion model has also been suggested for another triplet
repeat disorder, Fragile X (Florencia et al., 2006).
Expansion is more pronounced during the early embryonic stages. The first wave of
somatic instability has been suggested to occur between 13 and 16 weeks of gestation,
leading to major heterogeneity between the tissues (Martorell et al., 1997). The second45
wave of instability persists throughout adulthood and the remaining life of an affected
individual (Martorell et al., 1998).
1.2.4 Mechanisms of DM1 pathogenesis
The first two models of DM1 pathogenesis proposed a mutation effect altering DMPK
transcription or retaining transcripts in the cell nucleus or causing changes in chromatin
configuration, leading to either a decrease in the amount of the DMPK protein (DMPK
haploinsufficiency) or disrupted expression of neighbouring genes, the SIX5
(homologue of Drosophila sine oculis homeobox 5- SIX5) and DMWD (dystrophia
myotonica-containing WD repeat motif). Though expression of the SIX5 is suppressed
in affected individuals, experiments on Dm15 knock-out mice (the mouse DMPK
homolog) and six5 knock-out mice, provided evidence for only some of the
multisystemic features of DM1, namely skeletal muscle weakness, abnormal cardiac
conduction and cataract formation, while DMPK-over expressing mice showed skeletal
muscle fiber degeneration (Jansen et al., 1996;Berul et al., 1999;Sarkar et al.,
2000;Klesert et al., 2000;O'Cochlain et al., 2004;Bates and Gonitel, 2006).
At the same time, the fact that a different repeat mutation (DM2), in a different gene on
a different chromosome also caused the predominant clinical features of DM,
questioned the DM1 equivalence of both of the above models (Ranum and Day, 2004).
Most studies, therefore, have focused on detecting the common pathogenic mechanism
between DM1 and DM2 by investigating the potential effect of their common feature,
the mutant expanded RNA. Mice expressing mRNA with extended CUG repeats
developed myotonia and characteristic DM1 histological features as well as
intergenerational repeat instability (Mankodi et al., 2000;Seznec et al., 2001;Gomes-
Pereira et al., 2007). Since then, the formation of long hairpin loops by mutant RNA has
surfaced as a major factor in DM1 pathogenesis (Sobczak et al., 2003). The expanded
CUG repeats are unable to exit the nucleus and as a result accumulate in nuclear foci,
where they sequester essential RNA binding proteins, for example CUG binding protein
1 (CUGBP1), muscleblind-like 1 protein (MBNL1) as well as transcription factors (TFs)
and prevent their function (Ranum and Cooper, 2006).
CUGBP1 appears to be upregulated in the presence of extended CUG repeats, while two
transgenic mouse models of CUGBP1 over-expression develop muscle phenotypes46
(Timchenko et al., 2001;Timchenko et al., 2004;Wang et al., 2007). MBNL specifically
binds long CUG tracts and colocalizes in vivo with repeats, leading to the depletion and
loss of the protein function (Fardaei et al., 2001). Mbnl knock-out mouse models show
several features of DM, for example DM-like eye and muscle phenotypes (Kanadia et
al., 2003;Hao et al., 2008).
The CUGBP1 overexpression and MBNL loss are responsible for the splicing
misregulation of a wide group of developmentally regulated genes in DM1. These
include the insulin receptor (IR), cardiac troponin T (c-TNT), muscle chloride channel
(CLCN1), MBNL1, the dystrophin gene in skeletal muscle, the microtubule associated
protein Tau, the N-methyl-D-aspartate receptor NR1 subunit, the amyloid precursor
protein in the brain as well as RYR1, SERCA1, SERCA2 and myotubularin related
protein 1 (MTMR1) (Mankodi et al., 2002;Ho et al., 2004;Dansithong et al.,
2005;Osborne and Thornton, 2006;Guiraud-Dogan et al., 2007;Nakamori et al., 2007;
Wheeler and Thornton, 2007). The disrupted regulation of alternative splicing results in
the preferential expression of fetal or neonatal isoforms, inappropriate for a particular
tissue (Botta et al., 2008). Overexpression of CUGBP1 has also been suggested to result
in binding to inappropriate target mRNAs, enhancing deadenylation and inducing their
decay (Moraes et al., 2006).
The binding of TFs by mutant RNA induces their redistribution from chromatin toward
a ribonucleoprotein fraction of the nuclear matrix, causing disrupted gene expression
patterns, including that of TFs themselves. The multisystemic and multisymptomic
nature of DM1 findings can be explained by a common requirement for basic TFs in
different tissues. Transcription factor specificity protein-1 (SP1) is one of the TFs most
affected by mutant RNA binding (Ebralidze et al., 2004).
Finally, DMPK is thought to be indirectly involved in cell cycle checkpoints and
chromosome segregation, accounting for the fact that DM1 patients can present with
clinical syndromes commonly associated with chromosomal abnormalities, in particular
chromosome loss, chromosomal numerical syndromes, or chromosome instability
(Rolland et al., 1999;Asano et al., 2000;Casella et al., 2003). It has also been suggested
that the DMPK expansion might alter some normal functions, such as telomere function,
thereby leading to mitotic instability of chromosome 19. This theory is supported by the
fact that several of the genes associated with some of the DM1 symptoms, for example47
changes in cholesterol metabolism and insulin resistance associated with the low density
lipoprotein (LDL) receptor gene or the insulin receptor gene, are located on
chromosome 19 (Francke et al., 1984;Yang-Feng et al., 1985).
1.2.5 DM1 management
At present, there is no causative therapy for DM1 and clinical management is aimed at
the early detection of complications and treatment of the symptoms. This may involve
pulmonary and cardiac investigations, orthopaedic surgery, physiotherapy, management
of motor and mental handicaps, cataract and ptosis surgery, pacemaker implantation, or
treatment with antimyotonic or anti-diabetic drugs (Kurihara, 2005;Schara and Schoser,
2006). Psychological and pharmacological intervention has also been suggested to DM1
patients for preventing or reducing problems of social isolation, anxiety and depression
(Antonini et al., 2006;Laberge et al., 2007).
The extreme variability of the DM1 phenotype, the incidence of anticipation and the
impact of the affected parent’s sex on repeat transmission, raise difficult issues for
genetic counseling, particularly with regards to family planning. The diagnosis of DM1
has a major impact on future pregnancies, offspring as well as other family members. It
is often the case that very mildly affected individuals remain subclinically affected and
the disease is only diagnosed after the birth of an affected infant, resulting in the
parents’ families being screened for disease (Fokstuen et al., 2001). On the other hand,
individuals with slightly more expanded repeats might not transmit the disease if repeat
contraction takes place. The clinical signs, age of onset and family history, along with
results from molecular analysis determining a patient’s repeat expansion size, all play a
role in assessing the risk of having an affected child (Magee et al., 2002). It is worth
noting that a familial predisposing effect has been observed where affected sisters give
rise to children affected with the same type of the disease (Lavedan et al., 1993).
CDM1 can be suspected prenatally in the late mid- or early third trimester of pregnancy,
as certain obstetric complications can be identified sonographically, such as
polyhydramnios, talipes, ventriculomegaly or reduced fetal movements. Because these
features can be present in other conditions as well, the presence of a DM1 family history48
is necessary to support a CDM1 diagnosis. As CDM1 inheritance is mostly associated
with maternal transmission, testing for maternal grip myotonia is recommended in these
cases, as an additional diagnostic aid in identifying fetuses at risk (Zaki et al., 2007).
Definitive diagnosis during pregnancy is possible by prenatal diagnosis (PND). This is
performed by obtaining fetal cells invasively by chorionic villus sampling (CVS) or
amniocentesis (AC), and applying PCR protocols to amplify the non-expanded repeat
alleles (<100bp) or Southern blotting to allow an estimation of the expanded repeat size
(Zuhlke et al., 2000). Less-invasive PND of DM1 has also been reported, where
trophoblast cells are retrieved from the lower part of the uterine cavity or foetal DNA is
isolated from maternal plasma (Massari et al., 1996;Amicucci et al., 2000).
Because of the unpredictability in DM1 inheritance and the consequent difficulties
associated with PND and pregnancy termination, PGD might offer a better reproductive
option for DM1 patients.
1.2.6 Preimplantation Genetic Diagnosis for DM1
Due to the very limited amount of DNA obtained from a single cell, routine techniques
used for PND, such as Southern blotting for estimation of the repeat size in DM1,
cannot be applied to PGD.
The first clinical application of PGD for DM1 was reported in 1997. A hemi-nested
PCR protocol was used for amplification of the non-expanded DMPK allele from the
affected parent, since the expanded allele cannot be amplified by conventional PCR.
This protocol could be used for diagnosis of fully informative couples only, where the
healthy DMPK allele of the affected parent was different from the alleles of the
unaffected parent so that both parental alleles could be clearly distinguished in the
embryo (Sermon et al., 1997). Following amplification, PCR products were separated
on agarose gel. Results indicated a high ADO rate of 24 and 32% on research
blastomeres and clinical DM1 cases respectively. This initial hemi-nested PCR protocol
was later replaced by a more sensitive fluorescent PCR protocol, also amplifying the49
non-expanded DMPK alleles, which allowed a statistically significant reduction of ADO
to between 5.2 to 6.5% (Sermon et al., 1998a). Following this, and in order to provide
PGD for couples that were either non-informative or semi-informative for the DMPK
region, the same group (Centre for Medical Genetics, Brussels University) optimised,
for use at the single cell level, the triplet repeat-primed PCR (TP-PCR) protocol, which
had been introduced in 1993 for amplification across expanded repeat regions (Warner
et al., 1996;Sermon et al., 2001).
A PGD misdiagnosis occurred when using the first hemi-nested protocol, reported in
1998, where contamination was the possible cause of misdiagnosis in an embryo where
only one cell had been analysed (Sermon et al., 1998b). Since then it was decided that
diagnosis with protocols based on sole amplification of the DMPK repeat region, should
incorporate results from two cells from an embryo. This practice is supported by two
studies investigating the risk of misdiagnosis in PGD using PCR, proposing that
accurate and reliable diagnosis may be possible if results of two genotypes (either two
genotypes in a single cell, or a single genotype in two cells) are acquired (Lewis et al.,
2001;Navidi and Arnheim, 1991). The incidence of misdiagnosis underlined the
importance of using multiplex PCR to allow co-amplification of polymorphic markers
along with the mutated region in order to increase the chances of detecting cases of
contamination. This led to the development of multiplex PCR protocols for PGD for
DM1 (Spits and Sermon, 2009).
The first clinical experience using a multiplex fluorescent PCR protocol, was described
in 2001 and aimed not only at reducing the risk of misdiagnosis but also at increasing
the diagnosis rate by using a marker linked to the disease gene. Two single-cell PCR
protocols were developed where diagnosis was based on co-amplification of DMPK
with the APOC2 linked polymorphic marker or with the D21S1414 unlinked
polymorphic marker depending on patient informativity for the short tandem repeat
(STR) markers (Piyamongkol et al., 2001b;Harper et al., 2002). At the same time,
another group reported on the use of two rounds of PCR to allow amplification of the
DMPK region and one of two closely mapped, highly heterozygous, STRs on
chromosome 19, D19S219 and D19S559 (Dean et al., 2001). D19S207 has also been
used in a two-round multiplex PCR protocol for PGD for DM1 (Fiorentino et al., 2006).
Aside from improving on the diagnosis of DM1, current research focuses on
understanding more about the development and progression of the disease. A main part50
of this research has been the identification of characteristic gene expression changes in
affected samples. This work has so far mainly involved experiments on affected adult
tissue or animal models, as described above. More recently, an embryonic stem cell line
was derived from DM1 affected PGD embryos that may be used as a tool to further
study the behaviour of CTG repeats (Mateizel et al., 2006). Additional to the stem cell
lines, it would be of great interest to further investigate the expression patterns in human
embryos during the preimplantation stage of development. A focus on DM1-associated
genes may provide some information regarding the impact of the presence of expanded
repeats in a cell.51
1.3 Investigation of gene expression in preimplantation development
1.3.1 Human oocyte to blastocyst development
The development of the human oocyte occurs in parallel with the development of the
surrounding follicular granulosa cell (GC) layers and communication between the two is
vital. The GCs comprise of the mural granulosa cells that line the follicle wall, and the
cumulus cells that remain in close proximity to the oocyte during growth and following
ovulation. The oocyte secretes factors that act on the granulosa cells to induce the
expression of genes that regulate all stages of follicle development, and, concurrently,
the granulosa cells supply the nutrients that support oocyte growth (Dekel and Beers,
1980;Larsen et al., 1986;Buccione et al., 1990;Zhang et al., 2005). Oocyte-secreted
factors include members of the transforming growth factor β (TGF-β) superfamily, for
example the bone morphogenic protein- 15 (BMP-15) and growth differentiation factor-
9 (GDF-9), that act via downstream SMAD2/3 or SMAD1/5/8 pathways to control
cumulus cell lineage and expansion. The impact of these on oocyte growth has been
demonstrated by in vitro maturation experiments, while the importance of GC-oocyte
interactions has been underlined by experiments on mice homozygous for mutations in
BMP-15 and GDF-9, which found a phenotype of infertility and defective follicular
development (Li et al., 2008). The human oocyte is very active in transcription and
translation throughout its growth phase, but becomes transcriptionally inactive late in
oogenesis, when it reaches its maximal size (approximately 100µm in the human).
Some of the synthesized messenger RNAs (mRNAs) are used for immediate translation,
but a large number of them accumulate in the oocyte cytoplasm, stored in an inactive
form, and are only recruited when needed at later stages to support maturation,
fertilisation and early development (Assou et al., 2006).
During most of folliculogenesis the human oocyte is held in meiotic arrest, at the
diplotene stage of the first prophase. Prior to ovulation into the oviduct, following a
surge of luteinizing hormone (LH) from the pituitary gland, the oocyte completes the
first meiotic division, extruding the small first polar body, and re-arrests at the
metaphase stage of the second meiotic division (oocyte maturation). Oocyte maturation
is characterized by the disappearance of the large nucleus of the arrested immature
oocyte, the germinal vesicle (GV), a process known as GV breakdown (GVBD) to52
allow progress into the next steps of meiosis I (MI). A sequence of other events takes
place in the MI oocyte, such as chromosome condensation, spindle formation, and
separation of homologous chromosomes, overall resulting in the mature meiosis II (MII)
oocyte. Apart from the nuclear changes, cytoplasmic changes also take place, including,
for example, the maturation of cortical granules, which is responsible for the block to
polyspermy (Abbott et al., 1999).
Both meiotic arrest and meiotic maturation are mediated by the communication between
the oocyte and the layers of granulosa cells that closely surround it (Corn et al.,
2005;Andreu-Vieyra et al., 2006). High levels of LH activate molecular pathways
leading to cumulus cell expansion and production of hyaluronic acid (McKenzie et al.,
2004;Mehlmann, 2005;Picton et al., 2008). These events are regulated by oocyte-
secreted factors that induce the expression of the appropriate cumulus cell genes. The
progress from GV to MII is mediated by a decrease in intracellular cAMP in the oocyte,
though it still remains unknown exactly how the LH surge stimulates resumption of
meiosis, especially since the oocytes lack LH receptors (Kawamura et al., 2004;Jones,
2008).
When the mature oocyte is fertilised, the second meiotic division is completed and the
second polar body is released. A series of chromatin modifications guide the formation
of two haploid pronuclear masses of equal size, the maternal and paternal, within 3-10
hours post-insemination. In several occasions, during IVF, pronuclei might not be seen
in the fertilised oocyte or the oocyte might be abnormally fertilised with a variable
number and appearance of pronuclei (Verlinsky and Kuliev, 2000). The pronuclear
stage is followed by formation of the zygote, which approximately 20 hours post-
insemination starts undergoing mitotic divisions every 12-18 hours (cleavage stage),
reaching the morula and eventually the blastocyst stage, of 100-200 blastomeres, prior
to implantation. Embryonic transcription is not required for cleavage to occur, as the
initial stages of development are dependent on the proteins and transcripts that
accumulated in the oocyte during its long developmental arrest in the prophase of
meiosis I. In humans, embryonic genome activation (EGA) occurs at the 4-8 cell stage
(48-72 hours post-fertilisation), while in the mouse it occurs at the 2-cell stage (24-48
hours) (Braude et al., 1988;Nothias et al., 1995). At the point of EGA the genes that are
required for growth and differentiation in the embryo are expressed for the first time. At
the blastocyst stage, the cells have differentiated into the outer epithelial trophectoderm53
(TE), the surrounding cells that initiate implantation and form extra-embryonic
structures, such as the placenta, and a small group of cells called the inner cell mass
(ICM), that has the capacity to form all the tissues of the fetus (Duranthon et al., 2008).
Fertilisation and early development are controlled by genetic and epigenetic
mechanisms, in which DNA methylation, the addition of methyl groups to cytosine
residues, plays a major part. DNA methylation controls the allele-specific expression of
imprinted genes, as well as X-chromosome inactivation (lyonization), which occurs at
the 10-20 cell stage in humans (Dobson et al., 2004). DNA methylation is mediated by
the DNA methyltransferases (DNMTs) including DNA methyltransferase 1 (Dnmt1),
the maintenance enzyme responsible for methylation of hemimethylated CpG
dinucleotides, and Dnmt3a and Dnmt3b, responsible for de novo DNA methylation of
unmethylated regions during development. Dnmt1o and the recently identified Dnmt1s,
are Dnmt1 isoforms, detected in oocytes and preimplantation embryos (Hirasawa et al.,
2008). Another protein, Dnmt3L has no DNMT activity, but colocalizes with Dnmt3a
and Dnmt3b and is thought to be essential for establishing methylation imprints in the
female germ line (Suetake et al., 2004). Expression of the Dnmt3L gene is essential
during murine oogenesis, while in the human transcripts of the DNMT3L gene are only
detected after fertilisation, suggesting different imprinting mechanisms between the two
species (Huntriss et al., 2004).
The correct pattern of DNA methylation is required for normal mammalian
development. In summary, remodelling of the sperm chromatin after fertilisation, which
involves removal of protamines and replacement by acetylated histones, is followed by
an active demethylation of paternal DNA which is completed before DNA replication.
At the same time the maternal genome exhibits a relatively high level of DNA
methylation and undergoes de novo methylation in human zygotes. During the first
cleavages, a passive DNA demethylation of the whole embryonic genome progressively
occurs, resulting in a low methylation level at the morula stage, followed by differential
de novo methylation at the blastocyst stage (Monk et al., 1991;Reik et al., 2001;Fulka et
al., 2004).54
1.3.2 Gene expression studies
Experiments defining the gene expression profile for each of the stages of
preimplantation development, aimed to provide an insight into the molecular pathways
that control them. Earlier attempts involved the use of real-time PCR to provide
information on gene expression of several genes at a time (Steuerwald et al., 2000;Liss,
2002;Cauffman et al., 2005). Other techniques included serial analysis of gene
expression (SAGE) or construction of cDNA libraries and investigation of expressed
sequence tags (ESTs) (Adjaye et al., 1997;Neilson et al., 2000; Stanton et al., 2007).
Interesting findings include the abundance of SUMO mRNAs in oocytes, that probably
have an important role in both maturation and development, the role of CaSR in the
control of meiosis resumption, the association of BRCA1 with chromatin remodeling,
and the role of germ specific Y-box protein (MSY2) in the control and translation of
maternal mRNAs (Li et al., 2006;Dell'Aquila et al., 2006). The expression pattern of
certain genes during development has also given some interesting results. OCT4 is
abundantly expressed in the oocyte but its expression varies between blastomeres of the
same embryo (Cauffman et al., 2005;Hartshorn et al., 2007). RB1 is low in oocytes and
other preimplantation stages but high in blastocysts, potentially indicating a role in
apoptosis and differentiation of TE and ICM. Beta-actin (ACTB) is high in both oocytes
and blastocysts, which might be related to the role in the cytoskeleton, while DNA
repair is generally high in the oocytes, decreases during development and increases
again in the blastocysts, though different genes seem to function at each of these stages
(Wells et al., 2005b;Hamatani et al., 2006).
More recently, microarray technology has enabled the analysis of many thousands of
genes from a sample, accelerating the progress of discovery in this area (Bermudez et al.,
2004;Dobson et al., 2004;Assou et al., 2006;Kocabas et al., 2006;Li et al., 2006).
Because of the small amount of RNA that can be obtained from human oocytes and
embryos, 55-100pg from an oocyte and around 20pg from day 3 embryos, an RNA
amplification step is required to provide enough RNA for the microarray setup (Neilson
et al., 2000;Dobson et al., 2004;Kocabas et al., 2006;Jones et al., 2007). Even though
microarray analysis has been performed on individual oocytes following RNA
amplification, most work has involved pooling several samples together in order to
improve detection of low template mRNA. It has been recommended that a minimum of55
three oocytes are pooled prior to RNA extraction and amplification (Jones et al., 2007).
If the oocytes are from different donors, this methodology also allows overcoming the
individual variation and obtaining a general profile for the tested sample.
Both real-time and microarray results require a kind of normalization prior to analysis,
in order to correct for inter-sample variation and other differences involving the quantity
and quality of input RNA, efficiency of reverse transcription and amplification
processing as well as handling errors. Techniques of normalization include the use of
reference genes, RNA mass quantity or exogenous template (Mamo et al., 2007;Mamo
et al., 2008). Commonly used reference genes are the so –called housekeeping genes
(HKGs), which are responsible for maintaining basic cell functions and are thought to
be expressed highly and stably in a variety of tissues. It is important that their
expression profile is validated relative to the cell type, stage, or experimental conditions,
prior to use for normalization of gene expression results.
Most of the microarray work to date has involved human cumulus cells and oocytes
from the GV to MII stage, while limited microarray work has been done on human
embryos, as these are more difficult to obtain. Cumulus cells display a very different
transcriptome compared to the oocytes. For example, they are more active in cell-to-cell
communication, which is in keeping with their very different biological function (Assou
et al., 2006). On the other hand, oocytes overexpress genes that are involved in DNA
and RNA metabolism, microtubule activity, ubiquitin ligase complex and chromatin
modification, as these functions are necessary for the process of meiosis, for
remodelling of sperm chromatin upon fertilisation and also metabolizing RNA to
support fertilisation and early development (Wassarman and Kinloch, 1992;Kocabas et
al., 2006). Other important oocyte pathways are associated with cell maintenance, cell
cycle, cell proliferation, apoptosis, energy metabolism and mitochondrial activities
(Wells et al., 2005b;Zhang et al., 2005). GVs and MIs have shown similar expression
profiles in contrast to MIIs, where many genes are found under- or over-expressed in
comparison. This expression pattern, however, may reflect changes due to the
completion of meiosis or due to the longer incubation time (Andreu-Vieyra et al., 2006).
Finally, investigation of oocytes that failed to fertilize has indicated increased
expression of genes for immunological and ribosomal proteins, indicative of shock and
defense, elevated inhibin beta-a and beta-b subunits and increased interleukin-1 (Zhang
et al., 2005).56
The least amount of information is available for human blastocyst stage embryos. It has
generally been shown that the blastocyst ICM and the TE express common but also
distinct genes and synthesize different proteins, reflecting their ability to differentiate
into different cell lines (Adjaye et al., 2005). As indicated in mouse embryos, imprinted
X inactivation of the paternal X chromosome occurs in early embryos and is maintained
in the trophectoderm, while cells of the ICM undergo reactivation of the paternal X
chromosome and random X inactivation (Mak et al., 2004). Mouse blastocysts show
increased levels of genes involved in adherens junction, glycolysis and glyconeogenesis
and work on human blastocysts has indicated that genes differentially expressed
between dormant and activated blastocysts are involved in cell cycle, energy and
metabolic pathways, including calcium signalling and adhesion molecules (Hamatani et
al., 2006).
Another important aim of the gene expression work has been to identify markers that
may indicate oocyte fertilisation potential and embryo development. The selection of
best quality oocytes and embryos during IVF, would aim to not only increase the chance
of a successful pregnancy, but also move towards single embryo transfer and reduce the
incidence of multiple gestations, that are associated with increased fetal morbidity and
mortality as well as obstetric complications to the mother (Pinborg et al., 2003;Walker
et al., 2004). Findings include the association of pentraxin 3 (PTX3), hyaluronic acid
synthase 2 (HAS2) and gremlin 1 (GREM1) cumulus cell transcript levels or of the
oocyte BCL2 and proliferating cell nuclear antigen (PCNA) family expression levels
with oocyte fertilisation and embryo development. Additionally, the expression of
cumulus cell glutathione peroxidase 3 (GPX3), chemokine receptor 4 (CXCR4), cyclin
D2 (CCND2) and catenin delta 1 (CTNND1) has been correlated with early-cleavage
rates, a marker of predicting pregnancy (Yan et al., 2001;Zhang et al., 2005; Cillo et al.,
2007;van Montfoort et al., 2008). More recently, the genes BCL2L11, PCK1 and NFIB,
which are also expressed in cumulus cells, were identified as biomarkers for pregnancy
outcome (Assou et al., 2008). Markers of DNA damage have also been investigated and
abnormal embryo morphologies have been associated with changes in gene expression
of several genes, such as TP53 (Wells et al., 2005b;Wells et al., 2005a). Recent
advances have also led to the development of methods for proteomic analysis of oocytes
and embryos, looking into changes in post-translational events rather than the number of
mRNA transcripts (Patrizio et al., 2007).57
Further research aiming to determine the expression levels of groups of genes of a
certain molecular function or involved in particular biological processes in healthy,
normal embryos should enable to define cases where the normal expression is disrupted.
This is facilitated by available databases, for example PANTHER or Gene ontology,
that provide a description of gene products in terms of the process in which they are
involved or their activity at the molecular level, while also allowing an association
between the two, as a gene product may be active in one or more biological processes
and perform one or more molecular functions (www.pantherdb.org,
www.geneontology.org).
Many interesting molecular pathways remain to be investigated in human oocytes and
embryos. Expression studies on human embryonic stem cells (hESCs), derived from the
ICM of human blastocysts with the potential to differentiate into a variety of specific
cell types, might provide interesting data for comparison with preimplantation stage
embryos (Thomson et al., 1998). Genes encoding components of the microRNA
processing machinery are also of interest. MicroRNAs have been shown to regulate up
to one third of human genes by repressing the expression of complementary messenger
RNAs, thereby controlling many biological processes in development, differentiation,
growth and metabolism (Bartel, 2004;Lewis et al., 2005). Additionally, microRNAs are
also known to play a critical role in mouse oocyte maturation and embryo development
and have been shown to be implicated in ESC differentiation (Murchison et al.,
2007;Tang et al., 2007;Laurent et al., 2008). The expression of genes involved in the
microRNA processing pathway has not been previously investigated at the human
preimplantation stage.
A comparison of the normal to disease state expression is also possible due to the
availability of embryos from PGD patients and may facilitate assessment of disease
mechanism for many different disorders.58
1.4 Aims of this study
The first aim of this study was to identify the most favorable strategies for the
development of single-gene PGD protocols, with a focus on the development of
protocols for PGD of DM1, aiming to achieve optimal diagnostic efficiency and
accuracy. The ultimate aim was to design a universal protocol for the diagnosis of
DM1, to reduce time for single-cell optimisation and reduce patient waiting time for
treatment. Follow-up analysis of embryos following PGD was performed for all
DM1 PGD cycles.
The second aim was to investigate the transmission of the DMPK repeat in
preimplantation embryos. This required initial assessment of the TP-PCR protocol
in estimating the size of the CTG repeat allele on genomic DNA, single buccal cells
or single lymphocytes, and subsequently on single blastomeres from DM1 PGD
cycles. Additionally, analysis of data from diagnosis and follow-up was used to
investigate the potential occurrence of transmission ratio distortion, as well as the
timing of the expansion, and to detect whether differences exist in preimplantation
embryo development of DM1 affected and unaffected embryos.
Finally, the third aim was to generate gene expression data and define the
molecular portrait of human blastocysts, where limited information is currently
available, in comparison to the human oocyte, using microarray technology. The
microarray data was used to further investigate the level of expression of genes
implicated in specific pathways of interest, in human oocytes and embryo
blastocysts.59
2. Materials and Methods60
An overview of the PGD workflow and general code of practice will be presented at
first. Following that, the Methods section has been organized into the following
subsections, to describe the procedures associated with each of the aims of this study:
 Sample collection and preparation: includes all methods used for PGD-related
work, for example nucleic acid extraction or single-cell isolation procedures, as
well as collection of samples donated for research from patients undergoing
PGD (aims 1 and 2) and collection of samples donated for the expression work
(aim 3).
 Sample processing: describes all methods used for DNA amplification,
including primer design (aims 1 and 2), followed by a description of techniques
for RNA isolation, reverse transcription and RNA amplification (aim 3).
 Sample analysis: describes the techniques used for analysis of fluorescent-PCR
products, together with DNA sequencing, employed for investigation of allele
transmission (aims 1 and 2), and concludes with the microarray experiments
(aim 3).
 The methods used throughout for assessment of sample quality and integrity, as
well as details of statistical analysis performed, are described last (aims 1-3).
All plastic consumables (tubes, racks, Pasteur pipettes, tips, filter tips) were obtained
from VWR International Ltd. The nuclease-free 0.2/0.5ml PCR tubes were obtained
from Molecular BioProducts, Inc, UK. Chemicals were purchased by BDH (now
merged with VWR International Ltd.) and Sigma-Aldrich, Inc. Enzymes were obtained
from Roche Diagnostics Ltd. UK (High Fidelity polymerase and Expand Long
Template polymerase) and Applied Biosystems Inc., UK (for Amplitaq Gold). Details
for preparation of work solutions and constituency of other reagents are provided in
appendix 1 (A1).61
2.1 Summary of the PGD procedure
2.1.1 Patient referral
Overall, twenty-three couples at risk of transmitting DM1 to their offspring underwent
PGD between June 2004 and June 2008.
The PGD procedure involved an initial consultation with a genetic nurse specialist to
provide general counseling on both IVF and PGD procedures, followed by reproductive
assessment (semen analysis, assessment of ovarian reserve) to ensure a couple’s
suitability for treatment. Blood samples were then taken and work-up for the PGD
protocol was initiated. Couples received a final “full consultation” with the genetics
team and fertility specialists. Any other necessary health tests (for example
cardiological assessment) were completed prior to commencing IVF/PGD treatment.
2.1.2 PGD Workup
Five millilitres (ml) of blood was collected in tubes containing 15% ethylene-diamine-
tetraacetic acid (EDTA) from the patient, the unaffected partner and affected or
unaffected family members when possible. Buccal cell swabs were used to obtain DNA
from young children. In some cases, where DNA from previously terminated
pregnancies was available, this was also tested to obtain additional information for the
PGD work-up for that couple. The genomic DNA extracted from each partner and any
relatives was used for the preliminary genetic analysis of the mutated region, along with
an assessment for polymorphic markers closely linked to the mutated gene. Each PGD
protocol was optimised on genomic DNA and then on single cells, which were either
single buccal cells or single lymphocytes. Following optimisation, the final protocol
was tested on at least 50 single cells to determine the efficiency of diagnosis prior to
clinical application.62
2.1.3 IVF/PGD cycle
The IVF treatment was performed at the Assisted Conception Unit, University College
London Hospital. In summary, it involved gonadotropin administration to induce the
development of multiple follicles as described by Sahu et al., 2008. Ultrasound-guided
vaginal oocyte collection was performed at 37 h post-human chorionic gonadotropin
(hCG) injection. Oocytes were denuded from their surrounding cumulus cells at 40 h
post-hCG, by treating with hyaluronidase, HYASE
TM-10x (Vitrolife, UK), according to
the manufacturer’s instructions. ICSI was performed instead of classical IVF, at 41 h
post-hCG, in order to prevent contamination with sperm. Fertilisation was evaluated at
18–20 h post-insemination. Embryos were cultured in IVF medium (GIII series,
Vitrolife, UK) and embryo development was evaluated on day 2 and then again on day
3, prior to embryo biopsy. Embryo biopsy was performed in calcium- and magnesium-
free biopsy medium (G-PGD, Vitrolife, UK), using either acid Tyrode’s solution (in the
early PGD cycles) (MediCult (UK) Ltd.) or a 1.48µm diode laser (OCTAX Laser
shot™ system, MTG – Medical Technology Vertriebs-GmbH, HUNTER Scientific
Limited, UK), for breaching of the zona pellucida, followed by aspiration of the
blastomeres through the hole using a biopsy pipette.
Two cells were removed from embryos with six or more blastomeres on day 3, whereas
one cell was biopsied from embryos that had five cells or less. If the embryos
undergoing protocols that required results from two cells for diagnosis had not grown to
at least the six-cell stage by day 3, their biopsy was either deferred to day 4, or
proceeded with the removal of one cell; embryos with an unaffected result from this
single cell were re-biopsied on day 4 to obtain a second-cell confirmation. Deferred
biopsy or re-biopsy, were also generally performed for slow-growing embryos and
embryos with inconclusive results. The single biopsied blastomeres were analysed using
the already determined patient-specific PGD protocol. If available, a maximum of two
unaffected embryos were transferred into the uterus on days 4 or 5 post-insemination
and in one case on day 6. Supernumerary unaffected embryos that had reached the
blastocyst stage of development were cryopreserved.63
2.2 General code of practice
2.2.1 Work-flow
The areas for general laboratory work, nucleic acid isolation, setting up PCR and
product analysis were physically separated in order to prevent contamination. The
direction of the workflow was always from the main laboratory area to the analysis area.
Each of these areas had dedicated pipettes and laboratory coats, as well as reagents and
equipment as necessary.
2.2.2 Single cell work
Single cell work practice followed guidelines as described by Thornhill et al., 2005. All
single cell work was carried out in a positive pressure room, used only by authorised
personnel, which maintained twenty complete air changes per hour to reduce the
accumulation of DNA. Designated reagents and other consumables were kept inside the
room. Latex or nitrile gloves, hair cover and dedicated disposable lab coats were worn
at all times and changed frequently. The room was equipped with a Microflow advanced
Bio-safety cabinet class II for setting up single cell PCR. The class II hood was
equipped with a UV bulb to allow decontamination of the PCR workspace, pipettes, tips
and tubes, at 254nm. Other plastic consumables, cold racks and trays were cleaned with
ethanol and exposed to UV irradiation at 254nm in a Template Tamer (Qbiogene, UK)
prior to performing PCR. All work surfaces were cleaned with ethanol and dilute bleach
weekly and prior to a PGD case. The tubes used for single cell isolation were 0.2ml
thin-wall PCR tubes, certified DNA-, DNase-, RNase- and pyrogen-free (Molecular
BioProducts, Inc, UK), provided in small bags of 100 pieces to further minimise the risk
of contamination. The 0.5ml centrifuge tubes used for PCR setup were also certified
DNA-, DNase-, RNase- and pyrogen-free (Molecular BioProducts, Inc, UK).64
2.3 Sample collection and preparation
2.3.1 PGD-work
2.3.1.1 DNA extraction protocols
Details of solutions used in DNA extraction are shown in appendix 1, section A1.2.1.
2.3.1.1.1 DNA extraction from blood
DNA extraction was performed as described by Lahiri and Nurnberger, Jr., 1991. Five
milliliters of blood were transferred into a 15 ml centrifuge tube and 5 ml of TKM1
were added. The cells were lysed by adding 125 µl of IGEPAL® CA-630 (Sigma-
Aldrich chemical company). The mixture was centrifuged at 2500 rpm for 10 minutes
(Heraeus Labofuge 400 Benchtop Centrifuge) and the supernatant was carefully
discarded. The nuclear pellet was washed in 5 ml of TKM1 buffer, 125 µl of IGEPAL®
CA-630 was added again and the tube was centrifuged at 2500 rpm for another 10
minutes (Heraeus Labofuge 400 Benchtop Centrifuge). The TKM1 and IGEPAL® CA-
630 washes were repeated until the pellet became white, indicating that all the red blood
cells were removed. After the last wash, the supernatant was again discarded. The pellet
was gently resuspended in 100µl of TKM1, to which 800 µl of high concentration salt
buffer TKM2 and 50 µl of 10% sodium dodecyl sulphate (SDS) were added to lyse the
white blood cells. The solution was thoroughly mixed by pipetting up and down several
times using a 1ml Pasteur pipette (Alpha Laboratories Limited, UK) and then
transferred, using the same pipette, into a 1.5ml microcentrifuge tube. The mixture was
incubated at 55°C in a waterbath for approximately 2h until the pellet had completely
dissolved and then 300µl of 6 M NaCl were added. The solution was mixed well by
tilting the tube several times before centrifuging at 12000 rpm for 5 minutes
(MicroCentaur Sanyo MSE). The supernatant was transferred to a new 1.5ml centrifuge
tube and the precipitated protein pellet was discarded. Two volumes of 100% ice-cold
ethanol were added at room temperature (RT) to the supernatant containing DNA. The
tube was inverted several times until the DNA was precipitated and then centrifuged at
1200 rpm for 10mins (MicroCentaur Sanyo MSE). The DNA pellet was resuspended in
1 ml of ice-cold 70% ethanol and the mixture was centrifuged at 12000 rpm for 565
minutes (MicroCentaur Sanyo MSE). The supernatant was discarded and the DNA
pellets were air-dried. Each of the pellets was dissolved in 200 μl of 1xTE buffer and
stored at 4C until further use.
2.3.1.1.2 DNA extraction from buccal cells
The buccal cell sample was obtained by gently scraping the inside of the cheek with a
sterile mouth swab (VWR, UK) and the cells were suspended in 500µl phosphate
buffered saline (PBS) (Sigma Chemical Company, UK) in a 1.5ml microfuge tube. To
this, 5µl of 2.6mg/ml recombinant, PCR grade, Proteinase K (PK) (Roche Diagnostics
Ltd, UK) and 15µl of 10% SDS (Sigma® Chemical Company, UK) were added and
mixed well. Cell lysis was performed by heating at 37C for 1hr in a waterbath.
Following that, the tube was heated at 96C for 15min in a thermal cycler, in order to
inactivate the PK, and 150µl of 6M NaCl were added. After mixing well, the tubes were
spun at 12,000 rpm for 5min (MicroCentaur Sanyo MSE). The protein pellet was
discarded and a volume of ice-cold 100% ethanol, equal to [2x volume of the
supernatant], was added to the supernatant and mixed by inversion. The tube was then
centrifuged for 5min at 13,000rpm (MicroCentaur Sanyo MSE). The supernatant was
removed and the remaining precipitated DNA was washed in 1ml of ice-cold 70%
ethanol. After spinning for 5min at 10,000rpm, the supernatant was removed and the
pellet was left to air-dry. DNA was suspended in 50µl TE buffer and stored at 4C until
further use.
2.3.1.2 Isolation of lymphocytes from blood
The lymphocyte isolation procedure was based on a protocol described by Boyum, 1968.
Fresh blood was collected in Lithium Heparin tubes. Six millilitres of 0.9% NaCl were
mixed with 6ml blood in a 14ml centrifuge tube by inversion. Eight millilitres of the
diluted blood was gently pipetted using a Pasteur pipette (Alpha Laboratories Limited,
UK) in another tube already containing 6ml of Ficoll-Paque Plus (GE Healthcare Life
Sciences, UK) so that the blood formed a layer on top of Ficoll without mixing with it.
In order to do that, the tube containing Ficoll was tilted and the blood was slowly66
trickled in the side of the tube. Tubes were centrifuged for 30min at 1300rpm at room
temperature (Heraeus Labofuge 400 Benchtop Centrifuge). The centrifuge brake was
turned off to permit slow deceleration at the end of the centrifugation cycle and allow
slow separation of the lymphocytes (figure 2.1). After separation, the lymphocyte layer
(buffy coat) was carefully removed using a clean Pasteur pipette and transferred to a
clean 14ml tube which was then filled up with 0.9% NaCl. The solution was mixed well
and centrifuged, as previously, at 1300rpm for 15 minutes at room temperature with the
centrifuge break allowed back on to hasten centrifuge spin-down. The supernatant was
discarded and the cell pellet was resuspended in 14ml of 0.9% NaCl and again spun at
1300rpm for 15min with the break on. Washing of the pellet with 0.9% NaCl was
performed twice before resuspending in 2ml of 0.9% NaCl. The lymphocyte suspension
was stored at 4C and kept for subsequent isolation of single lymphocytes for up to a
maximum of three days.
Figure 2. 1: Procedure for isolation of lymphocytes using Ficoll-Paque PLUS (GE Healthcare Life
Sciences, UK). 1. Fresh blood, diluted with NaCl, is layered on top of Ficoll and the tube is centrifuged
for a short period of time. 2. Differential migration during centrifugation results in the formation of
distinct layers containing different cell types. Lymphocytes are found between plasma and Ficoll along
with other slowly sedimenting particles. The lymphocyte layer is carefully removed, placed in a clean
centrifuge tube and subjected to several washing steps.67
2.3.1.3 Isolation of cell clumps and single cells
Buccal cells were obtained as previously described using a sterile mouth swab (VWR,
UK) and the cells were suspended in 1ml of calcium- and magnesium-free PBS
containing 0.1% w/v polyvinyl alcohol (PVA) (Sigma® Chemical Company, UK). The
lymphocyte suspension was isolated from blood as previously described (section
2.3.1.2).
A cell aliquot (buccal cell or lymphocyte) was placed on a Petri dish, on a drop of either
PBS/PVA or dissociation buffer (DB) containing 4% bovine serum albumin (BSA)
(section A1.2.3), depending on the type of lysis (as described on section 2.3.1.5),
(Sterilin, Bibby Sterilin Ltd, UK) and observed under a dissecting microscope (x100
magnification). Another Petri dish containing several 10l droplets of either PBS/PVA
or DB/BSA was also prepared and the cells from the initial aliquot were passed through
at least three fresh droplets, using a mouth pipette and a 0.2μm diameter microcapillary
(Biohit, UK). In this way, either clumps (3-5 cells) or single cells were isolated. Each
clump or single cell was washed at least three times in three clean buffer droplets and
then transferred to a 0.2ml PCR tube containing the lysis solution. An aliquot from the
last washing droplet was also transferred in another lysis buffer tube to serve as a
control.
2.3.1.4 Isolation of single blastomeres for PGD
A new sterile 0.2μm diameter microcapillary (Biohit, UK) was used for blastomere
manipulation from each embryo. Each single blastomere was washed in a separate clean
petri dish containing droplets of the appropriate wash buffer as previously described
(section 2.3.1.3) and then transferred into a transparent 0.2ml microcentrifuge tube
containing the lysis buffer.
A small volume of washing medium from the last wash droplet of each single
blastomere was transferred in a separate lysis buffer tube and served as a negative
control to monitor for PCR contamination.68
2.3.1.5 Single cell lysis
Single cell lysis was performed with either PK or an alkaline lysis method following
cell isolation as described in section 2.3.1.3. Prior to PK lysis the cells were isolated in
droplets of PBS/PVA buffer, while for subsequent alkaline lysis the cells were isolated
in DB/BSA buffer. Details of each method are described below.
Proteinase K (PK) lysis: The isolated cells were transferred in 0.2ml sterile thin-walled
microcentrifuge tubes containing 3l of the PK lysis buffer (section A1.2.3). Samples
and blanks were incubated at 37C for 1 hour. Following this, PK was inactivated by
incubation at 95C for 15 minutes. All cells were stored at -80C for 1.5 hours prior to
performing PCR or for up to a few months until further use.
Alkaline lysis: The cells were transferred in 0.2ml thin-walled microcentrifuge tubes
containing 2.5 l of the alkaline lysis buffer (ALB) and kept at -80C for 1 hour if they
were to be used immediately or up to 2 weeks until further use. Subsequently cell lysis
was achieved by heating the sample at 65C for 10minutes. The tubes containing the
lysed cells were then transferred to a 0.2ml PCR Cooler (Eppendorf UK Limited) to be
kept cold while setting up the PCR. Before PCR amplification the sample was
neutralized by adding 2.5l of 200mM Tricine (Sigma® Chemical Company, Poole,
Dorset) into the PCR master mix (Cui et al., 1989).
2.3.2 Collection of samples donated for research from PGD patients
All patients attending the Assisted Conception Unit (ACU), University College London
Hospital, were given an information sheet with details on all ongoing research projects.
All embryos and oocytes for this project were collected after patients had given their
informed consent (Human Fertilisation and Embryology Authority license number
RO113). Donated samples were transported from the ACU to the Human
Preimplantation Genetics Group and processed immediately (within 30 minutes).
Assessment of oocyte maturational status and embryo morphology was performed by69
the ACU embryologists. All samples were re-evaluated at the time of processing, to
ensure the accuracy of information.
2.3.2.1 Collection of spare embryos following PGD for PCR analysis
Spare embryos following PGD included embryos diagnosed as affected and/or
unaffected embryos unsuitable for embryo transfer or cryopreservation. Several drops of
either PBS/PVA or DB/BSA were placed on a petri dish, as previously described
(section 2.3.1.3), and a drop of acidified Tyrode’s solution (MediCult Ltd, UK) was also
added to a separate site on the petri dish. Samples were first placed in the drop of
Acidified Tyrode’s and observed under a dissecting microscope until the zona pellucida
had dissolved. The process was facilitated by in- and out- pipetting with the aid of the
0.3μm microcapillary (Biohit, UK), overall taking between 10-30 seconds. On several
occasions the blastomeres were easily removed with embryo manipulation from within
the zona through the biopsy hole, therefore, use of acid Tyrode’s was avoided.
After complete separation of the zona from the embryo, the embryos were then
immediately transferred to the clean droplets of wash buffer (PBS/PVA or DB/BSA) on
the dish and washed thoroughly as previously described. Embryos were either tubed
intact or disaggregated into blastomere clumps or single blastomeres using a 0.2μm
microcapillary (Biohit, UK). The capillary was regularly rinsed with wash buffer
between each blastomere manipulation.
The single isolated blastomeres, blastomere clumps or whole embryos were transferred
in a minimal volume of buffer into individual 0.2ml PCR microcentrifuge tubes
containing the lysis buffer. A control blank was taken from the last wash drop as
previously described.70
2.3.2.2 Collection of cumulus cells and oocytes for PCR analysis
All oocytes were treated with hyaluronidase (HYASE
TM-10x supplied by Vitrolife, UK),
as previously described (section 2.1.3), to allow their separation from the surrounding
cumulus cells prior to ICSI. When needed, these cumulus cells were collected and
isolated in clumps or single cells according to the standard procedure. Acidified
Tyrode’s was used to enable lysis of the oocyte zona.
Donated immature oocytes were separately washed and then transferred to separate
microcentrifuge tubes containing PBS/PVA and stored at -80C until further use.
2.3.3 Collection of samples for gene expression work from general IVF
patients
2.3.3.1 Precautions
Every effort was made to maintain strict aseptic techniques throughout all gene
expression-related work, i.e. cell isolation, RNA isolation or RNA amplification
procedures. Pipettes and tube racks used were designated for RNA work only. All work
surfaces and equipment were cleaned with ethanol, then with RNase ZAP (Ambion, Inc.,
UK), rinsed with distilled water and dried so as to eliminate RNase contamination.
Sterile tubes and filtered pipette tips were utilized and gloves were worn at all times and
frequently changed. All reactions of the RNA amplification protocol were set up in a
Microflow bio-safety cabinet class II.
2.3.3.2 Collection of oocytes and embryos for gene expression analysis
Donated oocytes and embryos were collected in sterile conditions and processed rapidly
to minimize RNA degradation. Removal of cumulus cells and the zona pellucida was
carefully performed as previously, to prevent contamination with nucleic acids. Samples
were rapidly washed in PBS containing 0.1% PVA and 0.3 U/μl of RNasin Plus RNase
inhibitor (Promega, UK Ltd). Following washing, oocytes and whole embryos were71
transferred to DNA-, DNase-, RNase-free microcentrifuge tubes in approximately 1μl of
fluid and then immediately stored at -80°C prior to use.
Fifteen immature human oocytes (MI) were collected from twelve IVF patients with
primary or secondary infertility, following patient consent. For four of the couples there
was a male factor for infertility (abnormal sperm parameters), while in another couple
the female had polycystic ovarian syndrome. There was no known cause for infertility
for the remaining seven couples.
All oocytes had matured (MII) in culture and were randomly pooled together in groups
of three prior to processing (samples MIIa, MIIb, MIIc, MIId and MIIe). The mean
maternal age of all oocytes collected was 36.5yrs±4.47. A more detailed age range for
each of the three oocyte sample sets is indicated below:
MIIa: (40+36+36) yrs, MIIb: (36+35+35) yrs, MIIc: (35+40+37) yrs,
MIId: (30+43+39) yrs, MIIe: (25+40+40) yrs.
Similarly, twelve cryopreserved IVF blastocyst stage embryos were thawed following
patient consent and pooled together in groups of three prior to processing (samples Ba,
Bb, Bc and Bd). Three fresh DM1 affected blastocyst stage embryos, were also donated
for research by patient no. 22, affected with DM1, who had undergone two cycles of
PGD for DM1. These three DM1 blastocysts were also pooled together (sample DMa).
2.4 Sample processing
2.4.1 Polymerase chain reaction
Polymerase chain reactions were set up on ice in a laminar flow cabinet (Microflow
advanced Bio-safety cabinet class II) using dedicated pipettes, sterile pipette filter tips
and certified RNase-, DNAse-, DNA- and pyrogen-free microcentrifuge tubes (ABgene,
Surrey, UK). Thermal cycling was carried out in Applied Biosystems 0.2 or 0.5ml
GeneAmp® PCR System 9700 or the 0.2/0.5ml Eppendorf Mastercycler® Gradient.72
For PGD workups, PCR was initially performed using genomic DNA as the template
and the genotypes of each family member were determined for the mutated region as
well as for several polymorphic markers (linked, such as APOC2 and D19S112 or
unlinked markers). All diagnostic protocols involved direct analysis of the mutated
region along with simultaneous amplification in a multiplex PCR of one or two
polymorphic markers. Each protocol was first tested on control genomic DNA, and
occasionally on diluted genomic DNA (up to a 1/1000 dilution, achieving a
concentration of approximately 0.7ng/μl), before being optimised on single cells. The
final protocol was tested on at least 50 single cells prior to clinical application in order
to determine the percentage of amplification and allele dropout rate (ADO). The
percentage of ADO was estimated by counting the number of heterozygote cells
whereby only one of the two alleles had amplified, and dividing this by the total number
of cells that showed positive amplification. Human blastomeres were also used on two
occasions to confirm the single cell amplification efficiencies and allele-dropout rates
prior to the clinical application but this practice was stopped, as mentioned in section
4.1.
 Oligonucleotides
Oligonucleotides were ordered from Eurogentec Ltd, UK or Applied Biosystems, UK
and supplied as dry pellets, which were reconstituted to a concentration of 50 or 100μM
with nuclease-free water (Promega Corp., UK). Details of primer sequences, primer
binding sites and product sizes are shown in tables A1.1, A1.2, A1.3 in appendix 1.
Aliquots of the stock solution, 20μl each, were prepared in 0.2ml PCR tubes and diluted
to a final concentration of 50μM with nuclease-free water. The pre-aliquoting of the
stock solution was done in order to prevent repeat freeze-thawing cycles that would
have been necessary if aliquots were prepared from the primer stock on an ad-hoc basis.
Working aliquots were stored at -20°C and the remaining primer stock solution was
stored at -80°C.
 Oligonucleotide design
Genomic DNA sequences were obtained from the Ensemble Genome Browser website,
ensembl release 50 (http://www.ensembl.org/).
The DNA sequence incorporating the mutation or polymorphism was transferred into
the Primer3 program via a web interface (http://primer3.sourceforge.net/), and the
targeted region was specified. The Primer3 program allowed selection of the best primer73
pair for amplification, according to criteria such as primer length (18-30 bases long),
primer melting temperature (Tm) (55-65°C) and guanine-cytosine base content (40-
60%). Primers were chosen to have minimal self-complementarity and minimal
complementarity to each other at their 3’-ends. Specificity of the selected primers was
verified using a Basic Local Alignment Search Tool (BLAST) program, BLASTN, in
the Ensemble BlastView in order to search for nucleotide sequence similarities against
the entire human genomic DNA sequence. The Ensembl database also provided
information for the location of single nucleotide polymorphisms (SNPs) in the gene
sequence (Ensembl genomic sequence information, transcript information and gene
variation info). Oligonucleotide primers were designed to avoid any SNPs within the
primer, to prevent interference with primer annealing. SNPs within the PCR product
were also avoided, so as not to affect mutation detection or the annealing of any inner
primers where required.
The oligonucleotides for amplification of the short tandem repeat (STR) polymorphic
markers were obtained using the Ensembl Genome Browser or the GDB Human
Genome Database (the latter subsequently shut down on 1
st June 2008). Specificity of
the STR primer pairs was verified on Ensembl, as above.
2.4.1.1 Standard PCR
The approximate annealing temperatures for the oligonucleotide primers were estimated
to be 5°C below the temperature of the primer melting point (Tm). This was calculated
using the formula: Tm= 2(A+T) + 4(G+C). The working optimal annealing
temperatures were determined empirically by gradient PCR reactions with temperatures
either side of the original estimate using the Mastercycler Gradient® thermal cycler. A
temperature gradient of ±10°C from the calculated Tm was applied across the block,
allowing testing of 12 different temperatures in a single experiment. The temperatures
giving the most intense amplified products, as determined by agarose gel
electrophoresis, were chosen as the working annealing temperatures.
A variety of conditions were tested during PCR optimisation for PGD protocols. These
included testing different cell types (buccal cells/lymphocytes) or lysis conditions
(PK/ALB), performing a series of modifications in the PCR reaction components, such74
as MgCl2, deoxyribonucleotide triphosphate (dNTP) and primer concentrations or type
of enzyme, use of chemical additives in the PCR reaction such as dimethyl sulfoxide
(DMSO) and glycerol or modification of the PCR cycling conditions.
A standard PCR mixture consisted of 0.1-0.6M of each primer, 0.2-0.7mM for each of
the dNTPs, (deoxyadenosine triphosphate (dATP), deoxyguanosine triphosphate
(dGTP), deoxycytidine triphosphate (dCTP) and deoxythymidine triphosphate (dTTP)),
(Promega, Madison, USA), 1x PCR buffer (Amplitaq Buffer, High Fidelity (Hifi)
Buffer 2 or Expand Long Template (ELT) Buffer 3), 1.5-4mM MgCl2, 1.25-2 units
DNA Polymerase (Amplitaq Gold/High Fidelity or Expand Long Template
polymerases), and was made up to a total volume of 24µl with nuclease-free water
(Promega, Madison, USA). High Fidelity and Expand Long Template enzymes and
buffers were purchased from Roche Diagnostics Ltd. UK. Amplitaq and Amplitaq Gold
were purchased from Applied Biosystems Inc., UK.
A PCR “master mix” was prepared to cover the volume of reagents required for all
samples and 24µl of the mix were aliquoted into each of the nuclease-free thin-wall
0.2ml PCR tubes. One microlitre of genomic DNA (approximate concentration 0.5-1
µg/µl), was added to each 24µl reaction mix. An extra tube with no DNA was taken as a
PCR-mix negative control for each reaction. During PCR set-up for a PGD case two
PCR-mix negative controls were made, one after preparation of the PCR master mix and
prior to aliquoting the mix into the single-cell tubes, and one at the end of all aliquoting.
In cases where contamination was detected the two negative controls provided
information on whether the contamination had occurred during cell tubing/PCR set-up
or during PCR aliquoting.
PCR for single cells was performed according to the standard PCR protocol, the only
difference being that the reagent mixture was made up to a total volume of 21.5μl or
22μl with nuclease-free water (depending on the method of cell lysis, section 2.3.1.5). A
volume of 21.5μl or 22μl was added in each of the 0.2ml microcentrifuge tubes already
containing the lysed single cells as well as in each of the cell-negative control tubes,
containing ~2µl of solution from the last wash drop of each cell. All tubes were
centrifuged briefly and then placed in the PCR cycler to start the amplification.75
The general conditions of PCR amplification involved an initial denaturation step to
activate the enzyme, performed at 94C for 12 minutes when using Amplitaq Gold
polymerase or 95C for 2 minutes for High Fidelity and Expand Long Template (ELT)
polymerases. This was followed by denaturation at 96C for 15-45 seconds (94C after
the first ten cycles), annealing at 52-65C for 45s to 1 min and extension at 72C for 45s
to 1 min. Each step was repeated for 15, 40 or 46 cycles depending on the PCR protocol.
This was followed by a final extension at 72C for 5-10min.
The exact PCR conditions for all protocols with clinical application are given in
appendix table A2.2.
For other single PCR reactions, the PCR mixture consisted of 0.1M of each primer,
0.2mM for each of the dNTPs, (Promega, Madison, USA), 1x Hifi buffer, 1.5mM
MgCl2, 1.25 units High Fidelity DNA Polymerase and was made up to the required
volume with nuclease-free water (Promega, Madison, USA). The following PCR
program was performed: 95C for 2min, (96C for 15secs, TmC for 45secs, 72C for
45seconds) x 10cycles, (96C for 15secs, Tm for 45secs, 72C for 45seconds) x 30
cycles. Melting temperatures for DMPK7/8, ACTB4/5 and AMELXY primers were
57C, 62C, 59C respectively, and 60C for other remaining polymorphic markers.
Primer details and cycling parameters for detecting expression of β-actin were as
described in Salpekar et al., 2001.
2.4.1.2 Multiplex PCR
Multiplex PCR allowed amplification of the mutation marker and one or two
polymorphic markers at the same time. The reaction mixture and conditions were
similar to those of standard PCR, but more than one set of primers were added in the
PCR mixture. The concentration of primers, other PCR reagents and annealing
temperatures were modified as necessary during PCR optimisation to achieve optimal
amplification efficiency of all targeted regions.
A “split PCR” reaction was performed to allow better overall amplification. This
involved an initial multiplex PCR amplification for 15 cycles, followed by a second76
round of individual PCR reactions for each of the oligonucleotide sets included in the
first round, and performed for an additional 40 cycles. The reaction mixture for second
round PCRs was made up to 22μl, to which 3μl of the first round PCR product were
added prior to amplification.
2.4.1.3 Fluorescent PCR
Labeling of the forward or the reverse primer used in the amplification reaction with a
fluorescent dye, allowed detection of the PCR product on an automated laser
fluorescence sequencer (ABI 310, 3100 or 3730 Genetic Analyzer); table 2.1 provides
information on commonly used fluorescent dyes. The PCR mixture preparation was the
same as for the standard PCR protocol (section 2.4.1.1).
In a multiplex fluorescent PCR, where more than one primer pairs were co-amplified,
care was taken to label primers giving an overlapping product size with different
fluorescent labels, in order to allow differentiation of the products.
The primer set being amplified under the least favorable conditions in the multiplex
reaction, and therefore giving the lowest intensity product, was labeled when possible
with a dye of higher fluorescence intensity.77
Table 2. 1: Details of absorbance and emission wavelengths for chemical dyes used in fluorescent-
PCR. The size of the colour marker in the first column indicates the relative fluorescence intensity
(information from Applied Biosystems Inc. and Eurogentec Ltd., www.appliedbiosystems.com,
www.eurogentec.com).
Relative
Intensity
Dye Chemical Name Absorbance
maximum
Emission
maximum
(6, 5)
FAM™
Fluorescein, derivatized as
NHS ester via a carboxyl at
position 5 or 6
495nm 520nm
HEX™ Hexachlorofluorescein, NHS ester.
Can only be used on 5' end of oligo 535nm 555nm
JOE™ 6-carboxyl-4',5'-dichloro-2',7'-
dimethoxyfluorecein, NHS ester 529nm 555nm
ROX™ Carboxy X-rhodamine, NHS ester 588nm 608nm
TAMRA™ Carboxy tetramethyl rhodamine,
available as NHS ester, or direct
linked
559nm 583nm
TET™ Tetramethyl fluorescein. NHS ester.
Can only be used on 5' end of oligo. 522nm 539nm
NED™ ABI proprietary "yellow" 553nm 575nm
Dragonfly
Orange
TM
Eurogentec Ltd, UK alternative to
NED 554nm 576nm
VIC® ABI proprietary "green".
Same emission wavelength as JOE,
but narrower spectral peak and
brighter signal
538nm 554nm
Yakima
Yellow®
Eurogentec Ltd, UK,
alternative to VIC 530.5nm 549nm
PET™ ABI proprietary "red" 558nm 595nm
LIZ™
ABI proprietary "orange" 638nm 655nm
2.4.1.4 TP-PCR
The triplet primed PCR, specifically used for the amplification across the CTG repeat of
the DMPK gene, was carried out according to Warner et al., (1996) with some
modifications. Primer P2 was a fluorescently-labeled primer complementary to a
sequence close to the CTG repeat that was used in combination with a pair of primers,
P4CAG and P3R. P4CAG consisted of a 3’-end sequence containing a tandem repeat of
5 CAG trinucleotides, and a 5’ tail of 21bp with no homology to the human genome.
Primer P3R was only represented by the 21bp sequence of primer P4CAG (figure 2.2).78
Figure 2. 2: Primers of the TP-PCR method (P2, P3R and P4CAG) used for amplification along the
expanded region. Primer P3R was complementary to the 21bp unique sequence of primer P4CAG (black
bar).
2.4.1.5 Whole-Genome Amplification
Whole genome amplification (WGA) was performed by isothermal strand displacement
using the GenomiPhi HY DNA amplification kit (GE Healthcare UK Limited) for
confirmation of diagnosis in some of the PGD spare embryos. Following blastomere
isolation in DTT/KOH lysis buffer (appendix section A1.2.3), DNA was briefly
denatured by heating to 95°C for 3 minutes, and then cooled to 4°C in buffer containing
random hexamers that non-specifically bind to the DNA. A master-mix containing
Phi29 DNA polymerase, additional random hexamers, nucleotides, salts and buffers was
added and isothermal amplification was performed at 30°C for 6 hours. Following
amplification, the enzyme was heat-inactivated by incubating at 65°C for 10 minutes, in
order to prevent degradation of the amplification product. Amplification products were
stored at -20°C.79
The WGA products were tested for the amplification of the DMPK triplet repeat region,
APOC2, D19S112 and AMELXY polymorphic markers (appendix table A1.1).
2.4.2 Processing of samples for gene expression analysis
2.4.2.1 RNA extraction
Total RNA was isolated from clumps of lymphocytes, single oocytes, and whole
embryos using either the Absolutely RNA NanoPrep Kit (Stratagene- Agilent
Technologies UK Limited) or the AllPrep DNA/RNA Micro kit (Qiagen Ltd., UK),
according to the manufacturer’s instructions. Centrifugation steps were performed using
a Hettich® Mikro
TM 200R benchtop refrigerated centrifuge.
The Absolutely RNA NanoPrep Kit was used for RNA isolation during optimisation of
the RNA extraction technique from single cells. In summary, the Absolutely RNA
NanoPrep Kit protocol (Stratagene, UK) employs a lysis buffer that contains a strong
protein denaturant, the chaotropic salt guanidine thiocyanate, to lyse cells and prevent
RNA degradation by ribonucleases (RNases). Following cell lysis, the sample was
transferred to an RNA-binding nano-spin cup sitting within a 2-ml collection tube to
enable the RNA to bind to a silica-based fiber matrix. A DNase digestion step,
performed at 37C for 15 minutes, removed contaminating DNA and then a series of
washes removed the DNase and other proteins. Lastly, 10l of elution buffer (low-
ionic-strength buffer), pre-warmed to 60C, was added directly onto the fiber matrix
inside the spin cup and the sample was incubated at room temperature for 2 minutes.
The purified RNA was eluted in the collection tube by centrifugation at ≥ 12,000x g for
5 minutes, then transferred to a 0.2ml microcentrifuge tube and stored at -20C for up to
one month or at -80C for long-term storage.
RNA was extracted from all samples used for microarray analysis using the AllPrep
DNA/RNA Micro kit (Qiagen Ltd., UK). Oocytes and blastocyst-stage embryos from
different patients were randomly pooled together in groups of three, prior to RNA80
extraction. Each set of samples was first lysed in a highly denaturing guanidine-
isothiocyanate–containing buffer in order to inactivate DNases and RNases and ensure
isolation of intact DNA and RNA. The lysate was first passed through an AllPrep DNA
spin column that binds genomic DNA of an average length of 15-30kb. Ethanol was
added to the flow-through from the AllPrep DNA spin column to provide appropriate
binding conditions for RNA. The samples were then applied to an RNeasy MinElute
spin column, where total RNA, longer than 200 nucleotides, was bound to the
membrane, allowing contaminants to be efficiently washed away. High-quality RNA
was eluted in approximately 14 μl water. This procedure allowed RNAs smaller than
200 nucleotides, (such as 5.8S rRNA, 5S rRNA, and tRNAs, which together comprise
15–20% of total RNA) to be selectively excluded, therefore, providing an enrichment
for mRNA. Despite the limited starting material, no carrier RNA was used during the
purification process, in order to escape interference with the reverse transcription step
and oligo-dT primers of the amplification procedure.
2.4.2.2 Reverse transcription
Reverse transcription was performed following RNA extraction with the Absolutely
RNA NanoPrep Kit (Stratagene- Agilent Technologies UK Limited) for initial single-
cell RNA work practice.
Five microlitres of each RNA sample (extracted with the Absolutely RNA NanoPrep
Kit) was mixed in a 0.2ml microcentrifuge tube with 1μl 10mM dNTPs (Promega, UK),
1μl random hexamers (50ng/μl) (Superscript III First Strand Synthesis System for RT-
PCR, Invitrogen) and nuclease-free water to make final volume up to 10μl. The mixture
was incubated at 65C for 5 minutes and then placed on ice for at least one minute. 10μl
of cDNA synthesis mix was then prepared for each reaction, comprising of 2μl 10x RT
buffer (Superscript III First Strand Synthesis System for RT-PCR, Invitrogen Ltd., UK),
4μl 25mM MgCl2, 2μl DL-Dithiothreitol (DTT) (0.1M), 1μl RNaseOUT (40 U/μl) and
1μl Superscript III RT (200U/μl; Superscript III First Strand Synthesis System for RT-
PCR, Invitrogen Ltd., UK). This was added to each RNA/primer mixture, mixed gently,
collected by brief centrifugation and then incubated at 25C for 10 minutes followed by
50 minutes at 50C. The reaction was terminated by incubating at 85C for 5 minutes81
and then placing on ice. The reactions were collected by brief centrifugation. 1μl RNase
H (Invitrogen Ltd., UK) was added to each tube followed by incubation at 37C for 20
minutes. The resultant cDNA samples were stored at -20C or used for PCR
immediately.
The primers for cDNA amplification were designed to span one intron of each genomic
sequence tested, in particular intron 4-5 of the ACTB gene and intron 7-8 of the DMPK
gene. In this way, genomic contamination could be detected by giving a larger PCR
product size than the product generated from the cDNA. Primer details are provided in
the appendix table A1.3. Exon/intron positions were confirmed using the Ensembl
database, release 53 (ACTB Ensembl transcript ID ENST00000331789 and DMPK
Ensembl transcript ID ENST00000291270).
Total HeLa RNA (provided in the Superscript III First Strand Synthesis System for RT-
PCR, Invitrogen Ltd. UK) was used as a positive control to confirm successful reverse
transcription and cDNA amplification. Two negative controls were tested alongside
each amplification; an RNA negative control, which contained HeLa RNA with no
reverse transcriptase enzyme, and a PCR negative control, containing all PCR reagents
with no cDNA. Nuclease-free water was added instead of RNA/cDNA in the negative
control samples.
2.4.2.3 RNA amplification
RNA extracted with the AllPrep DNA/RNA Micro kit (Qiagen Ltd., UK) was amplified
in a two-round in vitro transcription procedure and converted into digoxigenin (DIG)-
labeled complementary RNA (cRNA), using the NanoAmp RT-IVT Labeling kit
(Applied Biosystems,UK) according to the company-provided protocol (figure 2.3).
Each round of amplification was completed within 6 hours, followed by an overnight
incubation step and the two rounds were completed within three consecutive days (~15
hours). Three to four samples were processed at a time. All reagents, apart from the
enzymes, were vortexed using Vortex Genie-2 Scientific Industries Inc (VWR
international, UK) and briefly centrifuged prior to use (MicroCentaur Sanyo MSE).
Standard laboratory practices for RNA-work were followed (section 2.3.3.1) and
nuclease-free tips and reagents were used throughout. All steps requiring incubation at82
temperatures between 25ºC and 70ºC were carried out in the GeneAmp® PCR System
9700 (Applied Biosystems, UK) thermal cycler.
The first round of amplification involved reverse transcription using T7-Oligo (dT)
primers to make single-stranded complementary DNA (cDNA). This was performed at
25°C for 10 minutes, 42°C for 2 hours, followed by 5 minutes at 70°C to inactivate the
reverse transcription enzyme (NanoAmp RT-IVT Labeling kit, Applied Biosystems,
UK) and an indefinite hold at 4°C. The reaction tube (20μl cDNA mixture) was kept
cold on a 0.2ml PCR Cooler (Eppendorf UK Limited), while the components for setting
up the first-round second-strand synthesis were added to make a final volume of 100μl.
The second-strand synthesis reaction was performed at 16°C for 2 hours followed by 5
minutes at 70°C for enzyme inactivation as before. The double stranded cDNA was
purified using the DNA purification columns provided with the kit, according to the
protocol provided. The next step involved an in vitro transcription (IVT) labelling
reaction, which was set up at room temperature by adding 4μl of each of the reaction
components (10x IVT Buffer, NTP mix, IVT enzyme mix) to the cDNA output and
performed overnight, at 37°C for 9 hours to obtain cRNA.
The cRNA was purified using the RNA purification columns and eluted in 100μl of
nuclease-free water in a RNA collection tube. The purified cRNA was concentrated by
vacuum centrifugation (Concentrator plus, Eppendorf Limited, UK), using the 4°C
temperature setting, to achieve a final volume of approximately 10μl.
The entire volume of concentrated purified cRNA (10μl) was used in the second round
of amplification, similarly comprising of reverse-transcription, second-strand synthesis,
cDNA purification and second-round IVT labelling (overnight reaction). During the
second round of amplification, Digoxigenin-11-uridine-5'-triphosphate solution (DIG-
UTP) (Roche Molecular Biochemicals) was incorporated into the IVT labelling reaction,
permitting subsequent chemiluminescent detection after hybridization to a Human
Genome Survey Microarray v2.0 (Applied Biosystems, UK). The amplified labelled
cRNA was purified and its integrity and concentration were assessed as described in
section 2.5.4.83
Figure 2. 3: Summary of the Nano-Amp RT-IVT labelling protocol for RNA in vitro transcription
and amplification. Two rounds of reverse transcription, second strand synthesis and in vitro transcription
were completed. The 1
st round cRNA was concentrated using speed vac centrifugation so that the whole
amount could be used in the 2
nd round of amplification (Concentrator plus, Eppendorf UK Limited).
Labeled nucleotides were incorporated into the RNA during the second amplification step to allow
detection following hybridization on the microarrays.
ss-cDNA: single stranded complementary DNA. ds: double-stranded, O/N: overnight84
2.5 Product analysis
2.5.1 Analysis of fluorescent PCR (F-PCR) products
The genomic-DNA F-PCR amplification products were diluted to a ratio 1:10 with
nuclease-free water prior to fragment analysis. This was done in order to prevent the
appearance of artifactual peaks and corruption of the automatic sizing and analysis that
are observed with very strong fluorescent signals. The control DNA included in every
PCR, not only served as a positive control for the PCR amplification but also allowed
monitoring of sizing precision during analysis.
2.5.1.1 F-PCR analysis using ABI Prism 310
A mixture of 1.5l diluted fluorescent PCR product, 12l Hi-Di Formamide (Applied
Biosystems, UK) and 0.5l of Genescan
TM 500 TAMRA, Genescan
TM 350 TAMRA or
Genescan
TM 500 ROX size standard (PE Applied Biosystems, Warrington, UK) was
prepared in a 0.5ml genetic analyzer sample tube (Applied Biosystems, Warrington,
UK). Hi-Di formamide was frozen in aliquots at -20°C to prevent degradation due to
multiple freeze-thawing cycles. The sample tube was capped with rubber septa (the
rubber septum was squeezed to make sure the hole of the lid that the genetic analyzer
capillary goes through for sample collection, was open). Samples were denatured at
95C for 5 minutes and kept on ice for a short time prior to loading on to a 48-tube
autosampler tray of the ABI Prism
TM310 sequencer (PE Applied Biosystems,
Warrington, UK). Samples were injected into the single 30cm capillary for 5 sec at
15,000 V. Separations were performed at 15,000V for 24min with a run temperature of
60
oC using 310 Genetic Analyzer performance optimised polymer POP-6
TM (Applied
Biosystems, UK) and 1x Genetic Analyzer Buffer with EDTA. Two matrix standard
sets were used to generate a spectral matrix for the following dye sets 6’-FAM™,
HEX™, TET™ and TAMRA™ or 6’-FAM™, NED™, VIC® and ROX™.85
2.5.1.2 F-PCR analysis using ABI Prism® 3100/3730 Genetic Analyzers
The samples were prepared for analysis in a MicroAmp™ Optical 96-Well Reaction
Plate (Applied Biosystems, UK). Similar to the preparation of samples for the ABI
Prism® 310, 1l of diluted fluorescent PCR product was added to 12l of Hi-Di
Formamide (Applied Biosystems, UK) and 0.5l of a size standard, either Genescan
TM
500 ROX for use with the ABI Prism® 3100 or Genescan
TM 500 LIZ for the ABI
Prism® 3730. Samples were injected onto the ABI 3100 16-capillary array for 5 sec at
1,000V or onto the ABI 3730 96-capillary array for 5 sec at 2,000V. Separations were
performed at 15,000V for 22 min, with a run temperature of 60
oC, using the POP-6
TM
sieving polymer for 3100 or POP-7
TM polymer for the 3730, 1x genetic analyzer buffer
with EDTA and a 36cm array. The data was analysed using Genemapper analysis
software version 3.5 (PE Applied Biosystems, Warrington, UK). The matrix standard
set was used to generate a spectral matrix for the five dyes 5’-FAM™, NED™ or
Yakima Yellow®, VIC® or Dragonfly Orange™, PET™ and ROX™.
2.5.2 Preparation of PCR amplified template for DNA sequencing
DNA sequencing allowed sizing of the CTG repeat on the non-expanded DMPK allele.
Primers DMPK2 and DMPK3 were used to amplify the DMPK repeat region, at a
concentration of 0.2μM each in a standard PCR using High Fidelity polymerase (Roche
applied science, UK). The PCR product was purified using Centricon
®-100 columns
(Applied Biosystems, UK) and the DNA quality was assessed on an agarose gel. The
sequencing reaction was set up in 20μl reactions containing 0.15μM of either DMPK2
or DMPK3 sequencing primer, 0.5x BigDye
® Terminator sequencing buffer (5x), 0.5x
BigDye
® Terminator ready reaction mix, with up to 10ng of PCR product according to
the BigDye
® Terminator v1.1 sequencing kit (Applied Biosystems, UK) protocol. The
sequencing reaction program involved an initial denaturation at 96°C for 1min, followed
by 25 cycles of [96°C for 10 seconds, 50°C for 5 seconds, 60°C for 4 minutes].
Extension products were purified following an Ethanol/EDTA/sodium acetate
precipitation method according to protocol, in order to remove unincorporated dye86
terminators prior to electrophoresis. Each sample pellet was dried by heating at 37°C for
5-15 minutes, then resuspended in 10μl Hi-Di
TM Formamide (Applied Biosystems, UK)
and transferred onto a MicroAmp® 96-well reaction plate (Applied Biosystems, UK).
Sample electrophoresis was performed on the ABI Prism® 3100 Genetic Analyzer
using POP-6
TM polymer.
2.5.3 Microarray analysis
Eight microarrays were run with human MII oocytes and human blastocyst-stage
embryos. A highly sensitive microarray platform was employed, the Applied
Biosystems Human Genome Survey Microarray v2.0, which has 32,878 60-mer
oligonucleotide probes for the interrogation of 29,098 genes. Prior to hybridization, the
labelled cRNA product was fragmented by mixing 90μl of 5 or 10μg cRNA product and
nuclease free water with 10μl of cRNA fragmentation buffer (Chemiluminescence
detection kit, Applied Biosystems) and incubating at 60°C for 30 minutes. The reaction
was neutralized by adding 50 μl of the cRNA Fragmentation Stop Buffer from the kit
and keeping on ice. Hybridization of the sample to the microarray, antibody binding and
the chemiluminescent reaction were performed as described in the Applied Biosystems
Chemiluminescent detection kit. Detection of chemiluminescence, image capture and
processing was performed on the Applied Biosystems 1700 Chemiluminescent
Microarray Analyzer (Expression Array System Software v1.1.1). Microarray
hybridization and image acquisition was carried out by Dr Paul Smyth (Molecular
Histopathology laboratory, Trinity Centre for Health Sciences, Dublin, Ireland).
2.5.4 Sample assessment
2.5.4.1 DNA and RNA agarose gel electrophoresis
A 2% agarose gel was prepared by heating 1g of agarose type I (Sigma® Chemical
Company, Poole, Dorset) in 50ml 1xTBE (appendix 1, section A1.2.4). The mixture
was brought to boiling using a microwave oven at medium intensity for 1-2 minutes
with 30 second intervals to mix until the agarose was dissolved completely. The87
dissolved solution was left to cool, then 8-10l of 10mg/ml ethidium bromide (Sigma®
Chemical Company, Poole, Dorset) was added into it, and it was subsequently poured
into a mini gel tank with a 16-well gel slot former and left to set for 30 minutes at room
temperature. The stoppers and comb were then carefully removed and 50ml of 1xTBE
added to the electrophoresis apparatus.
A 5-10l aliquot of each PCR product, of negative control or 2μl of labelled cRNA was
mixed with 1-2μl of agarose gel loading buffer (appendix 1, section A1.2.4) and loaded
into the well slots. A DNA molecular weight marker, HyperLadder VI, (Bioline
Research) or an RNA molecular weight marker, 0.5-10kb RNA Ladder (Invitrogen Ltd,
UK) was loaded alongside the PCR products or labeled cRNA to allow evaluation of the
DNA/RNA fragment size respectively. The RNA ladder was denatured at 72°C for 10
minutes prior to loading. Electrophoresis was performed at 60 Volts for approximately
30 minutes. The gels were examined under a UV transilluminator (Alpha Innotech
Corporation, MultiImage Light Cabinet, Flowgen Staffordshire).
2.5.4.2 Assessment and analysis of whole genome amplification products
The range of DNA fragment sizes produced following WGA was determined by
electrophoresis on a 1% agarose gel stained with ethidium bromide as previously
described (section 2.5.4.1). Electrophoresis also revealed whether or not any of the
degenerate or semi-degenerate primers used had preferential annealing sites within the
genome, indicated by distinct bands on the gel. The intensity of fluorescence observed
on the gels was an indication of the amount of amplification.
2.5.4.3 NanoDrop® ND-1000 Spectrophotometer
1.2μl of the labeled cRNA sample was loaded on the NanoDrop® ND-1000
Spectrophotometer, providing accurate concentration readings (ng/μl) as well as a
260/280 and a 260/230 nm ratio giving further information on cRNA quality. RNA
samples were considered of good quality for further analysis only if the absorbance ratio
at wavelengths of 260/280 nm was greater than 1.8, indicative of little DNA
contamination. Samples with a lower than 1.8 260/280 ratio may indicate the presence88
of protein, phenol or other contaminants that absorb strongly at or near 280nm. 260/280
ratios over 2.1 indicate the presence of degraded RNA, truncated cRNA transcripts
and/or excess free nucleotides. In addition, samples with a low 260/230 ratio (less than
1.8) were avoided as the low ratio indicates a significant presence of the reagents used
in RNA extraction, which absorb light at 230nm wavelength, and would interfere with
the downstream processes.
2.5.4.4 Agilent Bioanalyzer 2100
The quality and size of each labelled cRNA, as well as the absence of DNA
contamination or RNA degradation, were verified using the Agilent bioanalyzer 2100
(Agilent Technologies UK Limited). Extracted RNA from all samples prior to RNA
amplification was tested by analyzing on a Eukaryote Total RNA Pico Series II chip,
while amplified RNA was tested on a Eukaryote Total RNA Nano Series II chip. The
RNA concentration, rRNA ratio (28s/18s) and RNA Integrity Number (RIN) were
recorded. An rRNA ratio greater than 2.0 indicates little RNA degradation. The RIN
number is assigned by the Agilent Bioanalyzer software to assess RNA quality in terms
of degradation and allow comparison between samples. It is based on a numbering
system from 1 to 10, with 1 being the most degraded profile and 10 being the most
intact (Schroeder et al., 2006).
2.5.5 Statistical and microarray analysis
The binomial test and Fisher’s exact test were mainly used for analysis of data from
PGD cases, as indicated in the results sections 3.1 and 3.2. Values of p <0.05 were
considered statistically significant.
For the expression work, analysis of data was performed using Spotfire© Application
Package for Data Analysis of the Applied Biosystems 1700 Chemiluminescence
Expression System. Signals from each microarray were subjected to quantile
normalization and filtered for signal to noise ratios < 3 and flags over 5000
(detectability filter). After normalization, the data for each gene were reported as a
logarithm of the expression ratio, i.e the normalized value of the expression level of the89
gene divided by the normalized value of the control. The experimental factor of the
analysis was the cell type. Data from blastocyst embryos was compared to the data from
the MII oocytes, which were used as controls. Relative fold changes were calculated for
comparison of individual samples. A t-test analysis was performed and genes were
characterized as differentially expressed for p-values <0.05 (the initial array analysis
was performed by Dr Paul Smyth).
A dendogram was produced with agglomerative hierarchical clustering, to allow visual
interpretation of the results and identify genes showing similar patterns of expression.
Additionally, data from each gene was reported as a logarithmic value (log2) of the
expression ratio (log2(ratio)), i.e. the ratio of the expression level of the particular gene
in the test sample (blastocyst) divided by its value for the control. According to this, a
gene upregulated by a factor of 2 (ratio=2) would have a log2 (2) of 1, whereas a gene
downregulated by a factor of 2 (ratio=0.5) has a log2 (0.5) of -1. Genes expressed at a
constant level (ratio=1), would have a log2 (1) of zero. An example is also provided in
table 2.2. The log transformation of the microarray data is commonly performed to
allow easier association of the fold change with the “expression distance value” between
two genes.
The functions of genes were deduced using the online tool PANTHER Classification
System, supported by Applied Biosystems Inc., UK, (http://www.pantherdb.org/)
(Thomas et al., 2003). The PANTHER database was also used to assign expressed genes
to different categories based upon biological or molecular function (Mi et al., 2005;Mi
et al., 2007). The number of genes in each category was compared to a reference list
comprising all of the genes in the human genome using a binomial test available on the
online database and applying the Bonferroni correction for multiple testing. By
identifying over- and underrepresented classes of genes, an indication of processes
activated or repressed within the oocytes and blastocysts was obtained.
For further analysis, the raw microarray data was entered into a Microsoft Office Excel
2007 spreadsheet and filtered, as before, for signal to noise ratios < 3 and flags over
5000. Lists of gene groups of interest were obtained from the PANTHER database,
based on their Celera ID, and loaded onto a separate Excel spreadsheet. A Visual Basic
for Applications language program was used to identify whether the genes of interest90
appeared on the microarray expression list, and also whether their expression differed
significantly between blastocysts and oocytes.
Table 2. 2: Logarithmic transformation of the microarray data. The log2 ratio facilitates the
interpretation of fold change and difference in expression between two genes. The negative values
indicate under-expression of a gene relative to a control.
Expression ratio Log2 of expression ratio
Gene 1
(10 fold
increase)
10 3.32
Gene 2 1 0
Gene 3
(10 fold
decrease)
0.1 -3.3291
3. Results92
3.1 PGD for DM1
3.1.1 Protocol development
3.1.1.1 Patient details
All patients with DM1 referred for PGD, went through an initial consultation and
provided blood samples for testing of genomic DNA, however, not all of them
proceeded with the IVF/PGD treatment due to personal or medical reasons (Methods,
section 2.1.1). The twenty-three patients and their partners who started IVF treatment
with an aim to undergo PGD for DM1 are discussed here.
Out of the 23 patients, there were 19 affected females and 4 affected males. One patient
was asymptomatic but the remaining 22 patients showed clinical signs of DM1. The
most common reason for referral was the presence of a family history of DM1. Overall,
22 out of 23 patients had DM1-affected family members. Fourteen out of the 23 couples
had not experienced a pregnancy, either because of their choice to avoid an affected
pregnancy, or due to their inability to conceive naturally (seven couples). One couple
had a natural unaffected pregnancy occurring after referral for PGD. The remaining
eight patients with their partners had a personal experience of an affected pregnancy. In
particular, two couples had lost a congenitally affected child, five had undergone
termination of pregnancy (TOP) following Prenatal Diagnosis and one couple had an
affected daughter and had also had two TOPs (figure 3.1, table 3.1). In the case of
couple number 10, it was the birth of an affected child following the birth of two
unaffected children that prompted the diagnosis of DM1 in the mother.
Figure 3. 1: Reasons to opt for PGD in our group of patients: Family History: 22 referred couples had
one to seven affected relatives. Affected pregnancy: TOP: termination of pregnancy (six couples). Three
couples had experienced one TOP, two couples had had two TOPs and another couple had three TOPs.
One of the couples who had a TOP also had an affected daughter. Two other couples had a CDM1 baby.
Affected
pregnancy
Number of
affected relatives
Number
of
couples93
Table 3. 1: DM1 patient history: The number of known affected relatives is shown for each patient and
the number of these relatives who were first-degree is shown in brackets. Cases where an affected relative
was an offspring are specified in the reproductive history column. Affected pregnancies are indicated in
bold type. F: Female, M: Male, TOP, termination of pregnancy; CDM1, congenital myotonic dystrophy
type 1; CVS, chorionic villus sampling; FSHD, facioscapulohumeral muscular dystrophy.
Patient
number
Affected
Partner
Total number of
affected relatives
(1st degree relatives)
Reproductive History
1 F 5 (3) No previous pregnancies,
infertile
2 F 1 (1) Two TOPs following CVS
3 M 1 (1)
No previous pregnancies;
partner infertile
(low sperm count)
4 F 1 (0) No previous pregnancies
5 F 1 (1) One TOP following CVS
6 M 0 Four pregnancies, three TOPs,
one unaffected child
7 F 3 (2)
One TOP; infertile
(female anovulatory,
partner has low sperm count)
8 F 2 (2) No previous pregnancies
9 F 5 (2) No previous pregnancies
10 F 1 (1)
Three pregnancies;
two unaffected children
(one from previous partner);
One CDM1 baby with current partner died
11 F 4 (2) No previous pregnancies
12 M 1 (1)
No previous pregnancies;
partner infertile (azoospermia);
used egg donor to avoid FSHD carried by
partner
13 F 6 (2) One TOP following CVS
14 F 5 (2)
No previous pregnancies;
partner infertile
(severe oligospermia)
15 F 2 (2) One CDM1 son died at 18 hours;
early miscarriage in second pregnancy
16 F 2 (2) Natural unaffected pregnancy
(occurred after referral for PGD)
17 M 2 (2) No previous pregnancies
18 F 4 (4) No previous pregnancies, infertile
(has endometriosis and tubal disease)
19 F 1 (1) No previous pregnancies
20 F 1 (1) 2 TOPs following PND, affected daughter
21 F 7 (1) No previous pregnancies
22 F 6 (2) No previous pregnancies
23 F 3 (2) 2 year history of subfertility
(depleted ovarian reserve)94
3.1.1.2 Genomic DNA PCR analysis
Genomic DNA from affected individuals and their partners was tested for the DMPK
repeat expansion as well as polymorphic markers linked or unlinked to the DMPK gene.
Figures 3.2 and 3.3 show examples of fluorescent PCR analysis for the main markers
used (section 2.4.1, table A2.1).
Figure 3. 2: ABI 3100 fluorescent PCR results for DMPK, APOC2 and D19S112 polymorphic loci
for couple number 19 (affected female). The x-axis shows the length of the PCR product in base pairs
and the y-axis shows the fluorescence intensity in relative fluorescence units (RFU). The affected female
shows only the non-expanded allele at the DMPK locus, as the allele with the expansion is refractory to
PCR amplification. The markers are labelled with different fluorescent dyes to allow simultaneous
analysis and can also be differentiated by their stutter pattern.Allele sizes are indicated in base pairs (bp)
next to the corresponding peaks.
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Figure 3. 3: Example of results from the TP-PCR protocol. Unaffected and affected individuals are
differentiated by the number of peaks detected after amplification of the CTG repeat region. x-axis: PCR
product size in bp, y-axis: fluorescence intensity (RFU).
Appendix table A2.1 shows the genetic analysis results for the DMPK mutated region as
well as APOC2 and D19S112 polymorphic markers for 23 couples (46 individuals) and
36 relatives. In an unaffected partner the two non-expanded alleles might be either of
the same (homozygous) or of different (heterozygous) size. Examples of this are the
unaffected males of couples 1 and 2 respectively (table A2.1). A summary of findings
from marker analysis is given in tables 3.2 and 3.3 below. The F-PCR results for the
other polymorphic markers tested are not shown here as they did not have clinical
application.
Table 3. 2: Polymorphic marker analysis for 23 patients, their partners and relatives Thirty-seven
out of the 82 individuals tested were unaffected (23 partners and 14 relatives). Heterozygosity for the
triplet repeat region was calculated from the unaffected individuals only.
Marker
Homozygous
(two same-size
alleles)
Heterozygous
(two different-size
alleles)
CTG repeat
Unaffected partners only
All unaffected partners and relatives
6/23 (26.1%)
12/37 (32.4%)
17/23 (73.9%)
25/37 (67.6%)
APOC2 13/82 (15.9%) 69/82 (84.1%)
D19S112 13/82 (15.9%) 69/82 (84.1%)96
A couple was said to be informative, semi-informative or uninformative for a specific
locus, based on the following definitions:
Informative: the couple have no alleles in common at a given locus. This allows clear
differentiation of the maternal and paternal alleles in an embryo (e.g. couple no. 10 in
appendix table A2.1 is informative for APOC2 and D19S112 markers).
In several cases where a couple had no alleles in common at a specific locus, one or
both of the partners were homozygous for the marker tested. In these cases, the couple
was still considered to be informative as the maternal and paternal contribution would
be identified in an embryo, however, detection of contamination would not be possible
if testing only for that marker.
Semi-informative: the couple share one of their alleles at a given locus (e.g. couple
number 1 is semi-informative for both APOC2 and D19S112 markers).
Linkage analysis was performed for informative or semi-informative linked markers and,
where the identified phase allele was not a shared allele, the use of these markers
enabled indirect mutation detection.
Uninformative: the couple share all of their alleles at a given locus (e.g. couple no.12 is
uninformative for DMPK).
Table 3.3 summarises the marker results regarding informativity for each of the couples,
based on the information provided in the appendix table A2.1. Eleven out of 23 couples
were informative for the DMPK repeat region, fifteen couples were informative for the
APOC2 polymorphic marker and thirteen couples were informative at the D19S112
locus. DNA from family members was available for 19 out of the 23 couples. In 2 cases
CVS samples from previous pregnancies were available and in another two cases DNA
was extracted from buccal cells of two affected children (couples no.5, 6, 10 and 20,
appendix table A2.1). The phase of the linked markers, i.e. the allele that segregates
along with the affected copy of the gene, can be detected by testing of affected or
unaffected relatives, only for couples who are informative or semi-informative for the
linked marker. The phase allele was not known for patients 1, 3, 11 and 23, as DNA
from a relative was not available for the analysis. Similarly, the unaffected relative of
patient 14 shared the same alleles for both markers as the patient, so the phase was not
identified. For eight of the patients the phase alleles were identified at both marker loci,
APOC2 and D19S112, according to results on table A2.1.97
Examples of the process of determining the phase are shown in figures 3.4 and 3.5.
Apart from confirming the presence or absence of the mutation, polymorphic markers
also allow detection of contamination and are therefore necessary in a PGD protocol in
order to reduce the chance of misdiagnosis.
Table 3. 3: Marker informativity for the CTG repeat region, APOC2 and D19S112 polymorphic
markers Only one couple (no. 10) was informative for both the repeat region and the polymorphic
markers. Overall, the phase allele for the D19S112 locus was known in 18/23 cases and this facilitated the
diagnosis for those couples. hm: indicates cases where one or both of the partners were homozygous for
the marker alleles.
Couple
No. Polymorphic marker
CTG repeat APOC2 D19S112 Phase
known
1 Informative Semi-informative Semi-informative no
2 Semi-informative Informative Informative yes
3 Informative Informative (hm) Semi-informative no
4 Semi-informative Informative Informative yes
5 Informative Informative Informative (hm) yes
6 Informative Informative Semi-informative yes
7 Uninformative Informative Semi-informative yes
8 Uninformative Informative Semi-informative yes
9 Uninformative Semi-informative Semi-informative yes
10 Informative Informative Informative yes
11 Informative Informative (hm) Semi-informative no
12 Uninformative Semi-informative Informative yes
13 Semi-informative Semi-informative Informative (hm) yes
14 Uninformative Informative Informative (hm) no
15 Semi-informative Informative Informative yes
16 Semi-informative Informative Informative (hm) yes
17 Informative Uninformative (hm) Semi-informative yes
18 Informative Uninformative (hm) Informative yes
19 Informative Informative (hm) Semi-informative yes
20 Uninformative Semi-informative Informative yes
21 Informative Semi-informative Informative yes
22 Informative Informative Semi-informative yes
23 Uninformative Informative (hm) Informative (hm) no98
Figure 3. 4: Determining the phase for the affected female of couple no.21 The patient inherited the
affected chromosome (*) from her father. Haplotype analysis shows that the affected female could only
have got the 151bp and 128bp alleles from her affected father. Therefore, the APOC2 151bp marker allele
and the D19S112 128bp allele seem to have segregated along with the affected copy of the gene.
Detection of these alleles would confirm diagnosis of an affected embryo. It is advisable to test as many
relatives and family generations as possible, in order to confirm the phase in a particular family.99
Figure 3. 5: Example of DM1 triplex PCR results for a couple and an affected relative (this couple
chose not to undergo IVF treatment and is therefore not included in the list of patients in tables 3.1 or
A2.1). x-axis: PCR product size in bp, y-axis: fluorescence intensity (RFU). Lane 1: APOC2 locus, lane
2: DMPK, lane 3: D19S112. The affected female shows only the single non-expanded allele at the DMPK
locus compared to her unaffected partner who has two normal-sized alleles of 122bp and 176bp size. The
affected female and her affected relative share the 128bp allele at the D19S112 locus (underlined phase
allele). The couple is semi-informative for APOC2. The affected female and her affected relative are
uninformative for APOC2 so the phase cannot be determined. The allele peaks are highlighted and the
remaining peaks are stutters. Different stutter patterns are observed for each marker.
Based on the parental genotype and information on the phase alleles, all possible
embryo genotypes can be predicted prior to the PGD case. Any deviation from the
expected genotypes could indicate PCR contamination, allele dropout or cross-over
events (figure 3.6).100
Figure 3. 6: Possible embryo genotypes for couple no. 20. The marker alleles on the affected copy of the gene were identified by PCR analysis of DNA from the affected daughter.
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3.1.1.3 Single cell optimisation
Each PGD protocol was optimised on single buccal cells or single lymphocytes using
two different methods of lysis, either Proteinase K/SDS or alkaline lysis. The efficiency
of diagnosis was determined by testing the final protocol on at least 50 cells prior to
clinical application. The results from testing the protocol on single buccal cells or single
lymphocytes for the five protocols with clinical application for the diagnosis of DM1
are shown in table 3.4 below (protocols 1-5) and details of the single-cell optimised
PCR conditions are shown in table A2.2 of the appendix.
Optimisation involved modifications in the PCR program, concentration of reagents, as
well as the incorporation of chemical additives, such as glycerol and DMSO in the PCR
(Methods, section 2.4.1.1).
Differences were observed depending on the method of cell lysis and the type of cell
used. A better amplification was achieved in protocol 2 (DM1/D19S112), when using
ALB rather than PK/SDS lysis (testing on single buccal cells). In particular, DM1 and
D19S112 amplification was 89.2% and 98.3% respectively with PK/SDS lysis vs. 96%
and 100% respectively, when ALB lysis was used. The ADO rate following PK/SDS
lysis was 28.97% for DM1 and 17.59% for D19S112, while following ALB lysis, the
rate was reduced to 10% and 8% respectively. The drop in ADO at the DMPK locus
with ALB vs. PK lysis was found to be statistically significant (p<0.05, Fisher’s exact
test).
In addition, amplification from single lymphocytes was higher and ADO rate was lower,
compared to results from single buccal cells (table 3.4). The highest amplification
(100%) was achieved for all loci of protocol 3 (DM1 triplex: DM1/APOC2/D19S112),
following testing of single lymphocytes lysed with ALB. The ADO at the DM1 locus
was 3.64%, lower than the ADO for DM1 when the same protocol was applied on
single buccal cells (11.3%). The lowest ADO (0%) was achieved for the APOC2 and
D19S112 loci, contrary to the buccal cell results, which were 3.78% and 5.67% ADO
respectively. TP-PCR amplification (protocol 4) was 99% from testing on single
lymphocytes and 81.2% from single buccal cell analysis. This difference was also found
to be statistically significant using the Fisher’s exact test (p<0.05).
Protocols 3 (DM1/APOC2/D19S112) and 5 (TP-PCR/DM1/D19S112, described in
more detail in the next section) involve multiplexing of more primer sets in a single
PCR reaction compared to the other protocols. These new protocols minimised the
work-up time for all patients with DM1 to less than one week. Following the initial102
DNA extraction of parental or relative DNA, an appropriate protocol was selected
depending upon the informativity of the couple.
Some protocols required results from two blastomeres of an embryo in order to achieve
a diagnosis. A one-cell diagnosis could be obtained only for couples informative for the
DMPK region and one or more of the linked markers, where the phase allele was also
known.
A larger number of cells were tested with protocols number 4 (TP-PCR) and 5 (TP-
PCR/DM1/D19S112) of table 3.4, due to several difficulties encountered with the TP-
PCR protocol. In brief, suboptimal amplification and difficulties with sample analysis
and scoring were observed, depending on the cell type and the size of the CTG repeat
that was amplified. These are discussed further in sections 3.1.1.4 and 3.1.1.5. Results
from two cells were always required for reaching a diagnosis when using any TP-PCR
protocol.103
Table 3. 4: Results from PCR analysis of single lymphocytes or single buccal cells for the five protocols with clinical application in PGD for DM1. Amplification and allele
dropout rates were generally improved when using ALB rather than PK/SDS lysis, as well as when using single lymphocytes compared to single buccal cells. The protocols with the
highest amplification efficiency and lowest allele dropout rates are highlighted in bold typing. *TP-PCR protocols are discussed in more detail in the following sections.
Protocol No.
(markers) Cell lysis Cell type
No. of
Cells
tested
Amplification (%) Allele dropout (ADO) (%)
P2/P3R/
P4CAG
(TPPCR)
DM1 APOC2 D19S112 DM1 APOC2 D19S112
1
(DM1/APOC2) PK/ SDS buccals 69 68/69
(95.6%)
67/69
(97.1%)
7/68
(10.3%)
9/67
(13.4%)
PK/ SDS buccals 120 107/120
(89.2%)
118/120
(98.3%)
31/107
(28.97%)
19/108
(17.59%) 2
(DM1/
D19S112) ALB buccals 50 48/50
(96%)
50/50
(100%)
5/50
(10%)
4/50
(8%)
ALB buccals 53 53/53
(100%)
53/53
(100%)
53/53
(100%)
6/53
(11.3%)
2/53
(3.78%)
3/53
(5.67%)
3
(DM1/
APOC2/
D19S112) ALB lymphocytes 55 55/55
(100%)
55/55
(100%)
55/55
(100%)
2/55
(3.64%)
0/55
(0%)
0/55
(0%)
ALB buccals 345 280/345
(81.2%) 4*
(TP-PCR)
ALB lymphocytes 109 108/109
(99%)
5*
(TP-PCR/
DM1/
D19S112)
ALB lymphocytes 224 224/224
(100%)
224/224
(100%)
223/224
(99.6%)
1/89
(1.12%)
3/148
(2.03%)104
3.1.1.4 Standard PCR vs. TP-PCR
The techniques of standard PCR and TP-PCR were evaluated in terms of their ability to
detect both normal-range and expanded CTG repeat alleles.
Standard PCR
With standard PCR amplification, the electropherogram of heterozygous unaffected
individuals displayed two fluorescent peaks, representing the two non-expanded
different-size alleles. Homozygous unaffected individuals (for example 12/12 CTG)
showed one peak on analysis, as the amplification products from the two alleles were of
equal size (in this example, two products of 143bp each). Although the expansion size
of most affected individuals from our group of patients was not known, they were
presumably all over 100 repeats, as no large alleles were detected by standard PCR.
Therefore, for affected individuals (e.g. 12 CTG/expansion), where only the non-
expanded allele could be amplified by standard PCR, electropherograms displayed only
one peak (143bp) on analysis.
Standard PCR, therefore, cannot distinguish between homozygous unaffected samples
from affected samples carrying the same size non-expanded allele.
TP-PCR
Amplification of unaffected heterozygous samples by TP-PCR produced a ladder,
where the two main peaks, showing increased fluorescence signal, could be clearly
visualized. Fluorescence intensity dropped to zero almost immediately beyond the
larger allele peak. Contrary to standard PCR, TP-PCR could differentiate between the
homozygous unaffected and affected genotypes by producing a characteristic
amplification pattern from the expanded allele. The affected individuals, with over 100
CTG repeats present, gave a pathognomonic continuous ladder appearance following
TP-PCR. An example of TP-PCR amplification of an affected sample was shown in
figure 3.3. Figure 3.7 below gives a comparison of an affected vs. an unaffected sample,105
carrying a large repeat allele and figure 3.8 indicates the TP-PCR ladder pattern for an
individual carrying a 22 CTG repeat and a 50 CTG repeat allele.
Figure 3. 7: TP-PCR amplification of a sample with a large DM1 allele and of an affected sample.
x-axis: PCR product size in bp, y-axis: fluorescence intensity (RFU). In the first lane, the two DM1
alleles are indicated by the peaks of higher fluorescence, one near 95bp and the second one near 240bp.
The fluorescence intensity reduces to zero shortly after the second high peak. In contrast, the affected
sample, lane 2, shows the diminishing ladder pattern as in figure 3.3.
Figure 3. 8: TP-PCR amplification of a sample with 22/50 CTG repeat alleles. x-axis: PCR product
size in bp, y-axis: fluorescence intensity (RFU). The two DM1 alleles are indicated by the peaks of higher
fluorescence, one near 119bp and the second one near 207bp. The fluorescent intensity reduces to zero
shortly after the second high peak.106
The typical three-base pair ladder appearance of TP-PCR was not detected on analysis
of the 5 CTG repeat homozygous samples. The presence of 5 repeats in the amplified
region, corresponding to the 5 repeats of the P4CAG TP-PCR primer as in table A1.1,
produced one peak, rather than a peak ladder, following amplification. This pattern
could be mistaken for overall amplification failure (amplification of a degenerate or
anucleate cell) or a case of ADO of a larger or maybe affected allele. The apparent lack
of amplification in these cases was described as an inconclusive result, thus rendering
TP-PCR diagnosis of 5 CTG repeat homozygous samples, problematic (figure 3.9).
Figure 3. 9: TP-PCR of a 5 CTG repeat homozygous sample and a negative control. x-axis: PCR
product size in bp, y-axis: fluorescence intensity (RFU). Top lane: the presence of the 5 CTG repeat is
indicated by the 68bp amplification product. A triplet repeat ladder pattern is not detected. Bottom lane:
the negative sample does not show amplification of the high 68bp peak. Random peaks, possibly primer-
dimers, may appear in some negative controls. A triplet repeat ladder is not detected.
3.1.1.5 Multiplex TP-PCR/DM1/D19S112 PGD protocol (mTP-PCR)
Standard PCR and TP-PCR were combined in a single reaction in order to overcome the
difficulties in diagnosis associated with each method, as described above. The standard
PCR DMPK2 primer and the TP-PCR P2 primer were each labelled with a different
fluorescent dye so that the resulting electropherograms allowed detection of the107
genotype by both methods (figure 3.10). In this way, diagnosis of 5 CTG homozygous
samples, where the ladder pattern was absent following TP-PCR giving the impression
of failed amplification, was supported by the simultaneous evidence of a single
amplified peak with the “standard PCR” amplification.
Because of the P2 and DMPK2 primers both being fluorescently labeled, the
P2/DMPK2 product, as in figure 3.10, was seen in both the green and blue colours on
analysis. Highly concentrated samples demonstrated additional bleed-through of the
green into the blue fluorescent dye during fluorescent analysis. Dilution of the PCR
product overcame this problem. Examples of results are shown in figure 3.11.
Following initial testing of the DM1/TP-PCR protocol on genomic DNA and single
cells, the D19S112 linked marker was also incorporated in the reaction. This new
protocol (mTP-PCR) provided additional information on contamination, ADO as well
as enabling detection of the “phase allele”, where possible (figure 3.12).108
Figure 3.10: TP-PCR/standard PCR multiplex protocol design showing location of primers relevant to the triplet repeat region (underlined sequence). This protocol allows
simultaneous TP-PCR amplification (primers P2, P4CAG, P3R) and standard PCR amplification of non-expanded alleles (P2/DMPK2 primers).109
Figure 3.11: Results of TP-PCR and DM1 multiplex amplification. TP-PCR P2 primer is labelled in
FAM fluorescent dye (blue colour) and DMPK2 primer is labelled in VIC (green colour). x-axis: PCR
product size in bp, y-axis: fluorescence intensity (RFU). The 5 CTG repeat homozygous sample on the
left side, indicates the presence of a 68bp peak with no triplet repeat ladder and a 122bp product with
standard PCR amplification. A range of peaks is detected at TP-PCR for the 122/140bp sample (right
side, top) while a diminishing ladder pattern is detected for the 149bp/expansion affected sample. *
indicate the P2/DMPK2 standard PCR peaks that are detected in both the green and the blue fluorescent
dye.
Figure 3.12: mTP-PCR results: A) 5 CTG repeat homozygous unaffected individual B) heterozygous
unaffected individual C) Affected individual. x-axis: PCR product size in bp, y-axis: fluorescence
intensity (RFU). The size of the last sizeable peak is indicated in base pairs (bp).110
3.1.1.6 Comparison of mTP-PCR with TP-PCR amplification
Amplification with standard TP-PCR and mTP-PCR was compared by the parallel PCR
and analysis of several genomic DNA samples (table 3.5). A similar pattern of
amplification was detected between the two protocols; therefore, the inclusion of the
DM1 and D19S112 markers in the mTP-PCR protocol did not seem to influence the
amplification. For five individuals the size of the DM1 expansion was known, as
indicated in table 3.5. The size of the last ladder peak, as detected by the genetic
analyzer, did not correlate with the expansion size. This observation was made
following amplification for both protocols.
Table 3. 5: Comparison of TP-PCR and mTP-PCR amplification of 16 genomic DNA samples. The
size of the largest sizeable peak at the 310 genetic analyzer is indicated. The size of the last peak of the
TP-PCR ladder that could be seen but not sized by the machine is given in brackets.
Case Number/
DNA source
(number of repeats)
TP-PCR mTP-PCR
4/ Affected female
(580) 169 (174) 165 (171)
8/ Affected female 153 (265) 134 (206)
9/Affected female 162 (392) 177 (279)
9/ Female’s father 246 (263) 302 (317)
10/ Affected female 127 (246) 230 (377)
10/Affected son
(<1000) 186 (306) 183 (275)
13/ Affected female 258 (398) 259 (313)
17/ Affected male
(108) 168 (311) 180 (290)
17/ Male’s brother
(200) 186 (339) 213 (358)
19/ Affected female 134 (191) 126 (130)
19/ Female’s father 127 (251) 210 (250)
20/ Affected female 180 (351) 171 (293)
21/ Affected female 174 (311) 198 (311)
21/ Female’s father 162 (419) 198 (449)
22/ Affected female 155 (251) 173 (298)
23/ Affected female
(250) 195 (389) 177 (310)111
3.1.1.7 Summary of TP-PCR and mTP-PCR protocol optimisation
Figure 3.13 summarizes the steps towards TP-PCR optimisation and development of the
mTP-PCR protocol.
Scoring of unaffected samples following TP-PCR amplification was performed on an
individual-specific basis. A minimum of twenty single cells isolated from each
individual were tested using TP-PCR, to determine the size of the last ladder peak
following amplification, indicating the size of the larger non-expanded allele. Following
the testing on single cells, blind experiments were performed, where cells from a known
unaffected individual were isolated along with cells from affected individuals. The tubes
were randomly labelled by a laboratory colleague so that the results could be scored
blindly following amplification. During blind scoring, any samples showing even a
slightly larger than the expected product size, based on results from prior optimisation
using the known unaffected individual’s cells, were scored as affected. This was
because it was thought that they could indicate suboptimal amplification of an affected
sample, although they could also be due to polymerase slippage or the true presence of a
slightly larger, not in the affected range, repeat.
These false-positive (FP) results, i.e. the number of unaffected cells scored as affected
over the total number of unaffected cells tested, as indicated in figure 3.13, therefore,
include samples where although the TP-PCR ladder did not show the characteristic
diminishing pattern of an affected sample, the last sizeable peak was larger than
expected. The number of these FP results is, therefore, thought to be possibly inaccurate,
especially since TP-PCR scoring generally improved with experience. It is worth
mentioning however, that even at the early stage of TP-PCR testing, buccal cell
amplification with PK lysis produced overall inconsistent results and presented
difficulties with scoring.
Additionally, more FP results were obtained with blind testing of buccal cell
amplification following ALB lysis rather than lymphocytes following ALB lysis.
The uncertainties with scoring were avoided during a PGD case, as corresponding
results from two cells were required for a diagnosis from each embryo.
The false negative (FN) results indicate the number of affected cells scored as
unaffected over the total number of affected cells. FN results were only observed with
buccal cell testing. Multiplex PCR protocols allowing TP-PCR amplification along with
one or two polymorphic markers (initially TP-PCR/DM1 or TP-PCR/D19S112,
followed by mTP-PCR), reduced the number of both FP and FN results to zero.112
Figure 3. 13: Development of the mTP-PCR protocol. Blind scoring tests were performed during initial
testing of the TP-PCR protocol. Scoring improved with the use of single lymphocytes compared to buccal
cells and with experience. Table 3.4 indicates amplification results when using the optimised TP-PCR and
mTP-PCR protocols. * Protocol TP-PCR/D19S112 is not included in table 3.4 as it did not have clinical
application. Amplification results are indicated here. Details of PCR setup and PCR program for all
protocols are indicated in the appendix table A2.2. FP: false positive, FN: false negative.
mTP-PCR protocol
(single cell optimisation involved modifications of dNTP, MgCl2, primer
concentrations, PCR program and incorporation of glycerol)
Protocol results statistics as in table 3.4, PCR conditions as in table A2.2
Buccal cells + PK lysis
TP-PCR protocol
160 cells tested: inconsistent results
Buccal cells + ALB lysis
TP-PCR protocol
Blind scoring test: 99 cells, 16% FP, 9.7% FN
Lymphocytes + ALB lysis
TP-PCR protocol
Blind scoring test: 54 cells, 9.5% FP, 0% FN
Problems with the diagnosis of 122
homozygous samples
PCR modifications did not improve
Lymphocytes+ALB lysis
Optimisation of TP-PCR with D19S112*
43 cells tested (21 affected, 22 unaffected): 97.7% amplification at both
loci, 0% ADO at both loci (0/21 for TPPCR, 0/43 for D19S112), no FP
or FN Incorporation of DM1 in PCR testing on genomic DNA113
3.1.1.8 mTP- PCR and large non-expanded DM1 allele
Patient number 19 had the largest non-expanded DM1 allele from our group of patients,
with 24 CTG repeats. Diagnosis for this patient was performed using the DM1 triplex
protocol, as the couple was informative for DM1 and APOC2 loci, semi-informative for
the D19S112 locus and the phase allele was known. In order to test amplification of
large DM1 alleles with the mTP-PCR protocol, cumulus cells were collected following
egg collection during the patient’s IVF/PGD cycle. Amplification of single cumulus
cells as well as of clumps of cumulus cells, showed lower amplification for the large
DM1 allele (approximately 100 fluorescent units), when compared to the TP-PCR
ladder and the D19S112 marker result (figure 3.14).
Figure 3.14: mTP-PCR amplification of a cumulus cell clump of patient 19. x-axis: PCR product size
in bp, y-axis: fluorescence intensity (RFU). Amplification of the DM1 180bp allele (24 repeats, as sized
by TP-PCR) was compatively low, prompting further investigation by testing of single lymphocytes.
Twenty single lymphocytes were also isolated and tested with the mTP-PCR protocol
from this patient. Analysis confirmed general failure of amplification for the large non-
expanded DM1 allele compared to results from amplification of single lymphocytes114
from other DM1 patients, where the size of the non-expanded DM1 allele ranged from
122bp-149bp (table 3.6). Prior to this observation protocol optimisation had focused on
single cell amplification from these other patients, as they were the ones in need of an
improved PGD protocol because of their uninformativity for DM1 and/or linked
markers. Several cells had also been tested from patient number 22 (affected), who had
a 168bp DM1 allele, but problems with amplification were not observed in this case.
Table 3. 6: mTP-PCR lymphocyte amplification for different sized non-expanded DM1 alleles. Low
amplification was detected for the larger 180bp DM1 allele of patient 19
Non-expanded
DM1 allele of
affected
individual
Cell type
No. of
cells
tested
Amplification (%) Allele dropout
(ADO) (%)
P2/P3R/
P4CAG
(TP-PCR)
DM1 D19S112 DM1 D19S112
122-168bp
DM1 alleles lymphocytes 224 224/224
(100%)
224/224
(100%)
223/224
(99.6%)
1/89
(1.12%)
3/148
(2.03%)
180bp DM1
allele
(patient 19)
lymphocytes 20 20/20
(100%)
7/20
(35%)
20/20
(100%) n/a 0/20
Further investigation of amplification of the larger DM1 allele was performed by testing
embryos from this couple that were donated for research following PGD. In particular,
three unaffected 2PN embryos and one unaffected 0PN were re-tested for this
investigation. Spare embryos were disaggregated and single blastomeres were tubed in
either DTT/NaOH or DTT/KOH, to allow comparison of amplification from
blastomeres of the same embryo using either the DM1 triplex protocol
(DM1/APOC2/D19S112) or the mTP-PCR protocol, which required different cell lysis
conditions (table 3.7). Several blastomeres were also saved for MDA amplification.
These are further discussed in section 3.2.1.3.
In summary, four blastomeres were tested with the DM1 triplex and all showed
successful amplification with no allele dropout for all markers. Six blastomeres were
tested with the mTP-PCR protocol and all showed amplification at all loci. No allele
dropout was detected for D19S112, while all cells showed ADO of the large 180bp
DM1. This ADO would not hinder successful diagnosis in any of the cases, due to the115
presence of the D19S112 marker and the absence of the phase allele on analysis.
Amplification from some of the single blastomeres indicated a product over 125bp in
size, which would be the expected for amplification of 24 repeats.
Unfortunately, following this PGD cycle, there were no more cells from a patient with a
similarly large normal DM1 allele available for further testing and optimisation.
Table 3. 7: Testing of blastomeres from four embryos, diagnosed as unaffected during PGD for
patient 19. ADO of the 180bp DM1 allele was observed with the mTP-PCR protocol. The TP-PCR
column indicates the size of the last sizeable peak at the 310 genetic analyzer. Exp: expansion
Cell
number
Protocol
number F-PCR reading
Parental genotype TP-PCR DM1 D19S112 APOC2
Affected female 186 180/Exp 128/130 157/157
Unaffected male 100 122/148 130/133 129/137
Unaffected
Embryo tested/
PN scoring
1 DM1 triplex 122/180 128/130 129/157
2 mTP-PCR 126 122/ADO 128/130 1/2PN
3 mTP-PCR 136 122/ADO 128/130
1 DM1 triplex 148/180 128/133 137/157
2 mTP-PCR 131 148/ADO 128/133 2/2PN
3 mTP-PCR 131 148/ADO 128/133
1 DM1 triplex 148/180 128/133 137/157 3/2PN
2 mTP-PCR 141 148/ADO 128/133
1 DM1 triplex 122/180 128/130 129/157 4/0PN
2 mTP-PCR 134 122/ADO 128/130116
3.1.2 Results and follow-up from DM1 PGD cycles
3.1.2.1 Response to IVF treatment and embryo biopsy
Five out of the 35 IVF/PGD treatment cycles started were cancelled before oocyte
retrieval due to either poor response to the IVF treatment (patient number 5, 14, 17 and
18) or hyperstimulation (patient number 4, first cycle). In another two cycles oocytes
were collected and fertilized but there were only two embryos available for biopsy on
day 3. In both cases PGD was cancelled and the embryos were discarded.
From the remaining 28 cycles, 317 oocytes were collected, 285 of which were mature
and were inseminated and 177 were normally fertilised (2PN) (62.1% fertilisation rate).
The average maternal age was 33.4±3.1 years. Seventy-four oocytes were abnormally
fertilized (sixty-six 0PN, six 1PN and two 3PN), three oocytes cleaved prematurely and
one oocyte was described by embryologists as being “out of the zona membrane”. The
remaining thirty oocytes had disintegrated following insemination (table 3.8).
One hundred and sixty seven out of the 177 (94.4%) of the 2PNs were of sufficient
quality for biopsy on day 3 post fertilisation. Five 0PNs, one 1PN and one 3PN from
four cycles, had grown to the 6-8 cell stage and were also biopsied (table 3.9). The total
number of biopsied embryos was, therefore, 174.117
Table 3. 8: Summary of oocytes collected and inseminated by ICSI for DM1 PGD cycles. The seven
cancelled cycles are marked in red colour. Normally fertilized oocytes showed two pronuclei (2PN) 18-20
hours post-insemination. 0PNs, 1PNs, 3PNs and other abnormalities are also indicated. Thirty oocytes
disintegrated post-insemination. ‘Total’ numbers shown do not include the cancelled cycles. Yrs: years.
Disint: disintegrated, PC: prematurely cleaved, Z: out of zona. *2PN from a giant ovum
Patient
Number/
Cycle
Female
Age
(yrs)
Oocytes
collected
Oocytes
inseminated
2PN 0PN 1PN 3PN Disint. Other
1/1 33 7 7 3 4
2/1 34 10 5 4 1
3/1 28 7 7 2
4/1 27 Hyperstimulation
4/2 27 11 10 7 3 2
5/1 29 Poor response
6/1 36 13 13 11
7/1 35 18 16 10 6
8/1 33 9 9 6 3
8/2 34 16 14 5 4 4 1PC
8/3 35 13 12 3* 7 2
9/1 27 6 5 4 1
9/2 28 13 10 8
9/3 29 7 6 2
10/1 34 9 9 5 2 1 1
11/1 33 14 14 12 1 1Z
11/2 34 19 17 15 2
12/1 35 12 11 3 8 2
13/1 33 13 12 4 3 3 2PC
13/2 33 20 20 10 2 1 7
13/3 34 15 13 4 6 1
14/1 36 Poor response
15/1 39 9 8 6 2
16/1 34 10 10 10
17/1 35 Poor response
18/1 37 Poor response
19/1 30 11 11 6 3 2
19/2 31 12 10 6 2 2
19/3 31 9 8 5 3
20/1 35 6 4 2 1 1
21/1 31 9 9 8 1
22/1 34 16 13 9 2 2
22/2 35 8 6 5 1
23/1 39 4 4 3 1
23/2 39 5 5 3 1 1
Total 33.4±3.1 317 285 177 66 6 2 30 4118
Table 3. 9: Details of embryos biopsied from each of 28 PGD cycles. PN: pronuclei, 2PN: two
pronuclei seen, 0PN: no pronuclei seen
Patient number/
Cycle number
Embryos biopsied
2PN 0PN Other
1/1 3 1
2/1 4
3/1 n/a
4/1 n/a
4/2 7
5/2 n/a
6/1 10
7/1 10
8/1 6
8/2 5
8/3 3
9/1 4
9/2 8
9/3 n/a
10/1 4
11/1 12
11/2 15
12/1 3
13/1 4
13/2 10
13/3 4 3 1 (1PN)
14/1 n/a
15/1 6
16/1 10
17/1 n/a
18/1 n/a
19/1 2
19/2 5
19/3 5
20/1 2 1 1 (3PN)
21/1 7
22/1 7
22/2 5
23/1 3
23/2 3
Total 167 5 2119
Most embryos (119/174, 68.39%) had two cells biopsied. On several occasions,
however, it was necessary to remove more than two cells from a single embryo (figure
3.15).
If during biopsy on day 3 a biopsied cell was found to be anucleate or lysed, then an
additional cell was removed if the embryo development stage permitted (>6 cells
remaining, see methods section 2.1.3). In some cases additional cells were removed on
day 4, if results from previously biopsied cells on day 3 had not yielded a clear
diagnosis (detection of cells showing amplification from one parental genome, cross-
over, allele dropout, contamination or amplification failure) or if the embryo stage on
day 3 had not permitted biopsy of two cells at that time.
In cases where the protocol required results from two cells if, on day 3, the embryo
development stage only permitted the removal of one cell, a re-biopsy was performed
on day 4 to obtain confirmation of diagnosis for embryos with an unaffected result.
Re-biopsy was performed in 6 PGD cycles, for a total of 16 embryos. In four of the 6
cycles this was for confirmation of an unaffected embryo in a two-cell requiring
protocol.
Figure 3. 15: Number of embryos with one to four cells biopsied. Graph includes the sixteen
rebiopsied embryos120
Amplification rate, allele dropout and overall diagnosis rate per protocol used are
summarised in table 3.10. A more detailed analysis of blastomere amplification for each
case and protocol used may be found in the appendix tables A2.3-A2.7. For one couple,
the diagnosis was performed using two different protocols.121
Table 3. 10: Summary of blastomere results from all DM1 PGD cases showing overall amplification, allele dropout and diagnosis rate per protocol. The allele dropout for
the DM1 locus could be obtained only from the unaffected heterozygous cells. A more detailed analysis per case is shown in table A2.3-A2.7 of the appendix. Protocol 1a is a
modification of protocol 1, involving a ‘split PCR’ reaction, which was performed in one PGD cycle, as indicated in the appendix. The best protocols in terms of amplification, ADO
rate and number of markers tested, are indicated in bold typing. H: embryos where the two biopsied cells indicated amplification from only one of the parental genomes *: diagnosis
for cycle 2 of patient no.8 was performed using two different protocols, thus making the total number of cases reported here 29.
Protocol
Number
(markers)
No. of
cases*
No. of
embryos
No. of
blastomeres Amplification Allele dropout Diagnosis
P2/P3R/
P4CAG DM1 APOC2 D19S112 DM1 APOC2 D19S112
1
(DM1/
APOC2)
4 30 48 38/48
(79.2%)
35/48
(72.9%)
1/12
(8.3%)
3/29
(10.3%)
19/30
(63.33%)
1a 1 4 6 5/6
(83.3%)
3/6
(50%) n/a 1/3
(33.3%)
3/4
(75%)
2
(DM1/
D19S112)
2 11 24 21/24
(87.5%)
20/24
(83.3%) 0/3 1/13
(7.7%)
8/11
(72.7%)
3
(DM1/
APOC2/
D19S112)
11 69 122 110/122
(90.2%)
107/122
(87.7%)
107/122
(87.7%) 0/43 0/80 0/70 52/69
(75.36%)
4H
(non-transferable)
56/69
(81.2%)
4
(TP-PCR)
5 37 75 46/56
(82.1%)
30/37
(81.08%)
5
(mTP-PCR)
6 28 60 52/60
(86.7%)
48/56
(85.7%)
52/60
(86.7%)
1/6
(16.7%) 0/40 22/28
(78.57%)
4H
(non-transferable)
26/28
(92.9%)122
All cases where amplification from only one of the parental genomes was detected, are
indicated in the appendix 2 tables A2.3, A2.5 and A2.7. When both of the biopsied cells
indicated alleles from one of the parents only and considering a low chance of ADO
simultaneously occurring at all three amplified loci, the embryo was scored as
potentially indicating monosomy for chromosome 19.
Five multinucleate blastomeres were biopsied in three cycles from patients/cycle
number 6/1, 11/1 and 12/1 (patient 12 had two multinucleate cells biopsied from one
embryo and another multinucleate cell from a different embryo). Additionally, four
binucleate blastomeres were biopsied from patients/cycle number 13/1, 13/2, 19/3 and
22/2, and in another two cases, for patients/cycle number 11/2 and 21/1, micronuclei
were observed during biopsy in all embryos and in one of the biopsied embryos
respectively.
Three out of the five multinucleate cells gave an unaffected result on diagnosis, and the
two cells that were biopsied from the same embryo (patient/cycle 12/1) gave an
inconclusive result (paternal contribution on one marker, shared alleles on the other two
markers). All four embryos, corresponding to these biopsied multinucleate cells, were of
poor quality. Two of them had arrested at the four-cell stage, as scored on day 4 and 5,
and the other two embryos had seven and eight cells on day 4. One of these embryos,
the 8-cell embryo of patient/cycle 12/1, was transferred but a pregnancy was not
established.
Of the binucleate cells, three gave a result on analysis, two of them, patient/cycle 13/2
and 19/3, indicated affected embryos and the third one, patient/cycle 22/2, indicated
amplification of the maternal genome only (affected). Scoring of these three embryos on
day 4 indicated two 6-cell embryos (patients 13 and 22) and a 11-cell embryo (patient
19). The binucleate cell that failed to give a result (patient/cycle 13/1) came from an
embryo where other biopsied cells gave an unaffected result on diagnosis. This embryo
had eight cells on day 4 and was transferred but a pregnancy was not established. One
of the cells where micronuclei were observed did not give a result. In the other case
(11/2) where micronuclei were generally observed during embryo biopsy, there were no
problems with diagnosis; two embryos were transferred on day 5, both blastocysts, both
of which implanted.
Thirty-three cells began to lyse during the embryo biopsy and tubing procedure,
however, the nucleus was seen in all cases by the embryologists and the cells were
tubed without delay. Only four out of these 33 cells failed to amplify. On the contrary,123
forty-two cells were considered to be cytoplasmic fragments or anucleate cells during
the biopsy and all, apart from one, failed to give a result following PCR. Results from
analysis of all cells recorded as fragments and anucleate cells during biopsy were
excluded from the investigation of protocol efficiency and diagnosis rate of table 3.10.
Protocols DM1/APOC2/D19S112 and mTP-PCR provided the most information from a
single cell. These protocols allowed the identification of eight embryos where, in both
cells, only one of the parental genomes was detected. It is likely that these embryos are
true haploid embryos or embryos with monosomy 19, as the results were confirmed
from the amplification of three markers in two cells from each embryo. A diagnosis
rate of 75.36% and 78.57% was achieved with these two protocols respectively (table
3.10 also indicates the potential diagnosis rate of 81.2% and 92.9%, to include the eight
embryos where the presence of only one parental genome was detected).
Protocols DM1/APOC2 (1, 1a) and DM1/D19S112 were associated with low
amplification and diagnosis rate (63.33%, 75% and 72.7% respectively). The TP-PCR
protocol, which is commonly used for DM1 testing, gave a diagnosis of 81.08%,
however this protocol requires results from two cells from an embryo for diagnosis,
while providing no information regarding the presence of contamination.
Overall, from all 28 DM1 PGD cases completed, using all of the above protocols, a
diagnosis was achieved for 129 out of 174 embryos (74.12%). Of these, 55 embryos
were diagnosed unaffected (42.6%) and 74 were diagnosed affected (57.4%). Eight
embryos could not be diagnosed due to the biopsied cells indicating the presence of one
parental genome only. In addition, twenty-seven embryos gave inconclusive results, as
discussed in section 3.1.2.4, while no results were obtained from 10 embryos due to
total amplification failure (5.7%) (figure 3.16).
The impact that a one-cell biopsy practice would have on the diagnosis rate was
investigated by reanalysis of results from the cycles where protocol
DM1/APOC2/D19S112 was used for diagnosis, as this was the protocol most likely to
allow a one-cell diagnosis. One out of the 11 cycles where this protocol was used, was
excluded because diagnosis in that case required results using two different protocols
(table 3.10 and A2.5). Results indicated that if diagnosis was based on results from the
first biopsied cell only, the diagnosis rate from these cycles would drop significantly
from 73.4% to 53.1% (p<0.05, Fisher’s exact test) (table 3.11).124
Figure 3. 16: Number of embryos diagnosed during PGD for DM1. 129 out of 174 embryos gave a
clear diagnosis. Fifty-five embryos were unaffected and seventy-four were affected. Inconclusive results
were due to one of the following: contamination, ADO, marker uninformativity, detection of one parental
genome, result from one cell or other observations as indicated in table 3.15. (Embryos with result from
one parental genome are shown separately).
Table 3. 11: Reanalysis of 10 DM1 PGD cycles to estimate diagnosis rate based on the results of a
single (first-biopsied) cell
Patient
number
/ Cycle
Number
of
embryos
Number of
embryos
rebiopsied
Cells biopsied-
number of embryos Diagnosis
Diagnosis
based on result
from the first
biopsied cell
1-cell 2-cell 3-cell
10/1 4 2 3 1 0 3/4 1/4
11/1 12 0 2 10 0 8/12 6/12
12/1 3 0 0 3 0 1/3 1/3
11/1 15 0 3 7 5 12/15 8/15
15/1 6 0 5 1 0 1/6 1/6
19/1 2 0 0 2 0 2/2 2/2
22/1 7 2 2 5 0 7/7 4/7
19/2 5 0 0 5 0 5/5 3/5
22/2 5 0 3 2 0 4/5 4/5
19/3 5 0 1 4 0 4/5 4/5
Total 64 4 19 40 5 47/64
(73.4%)
34/64
(53.1%)125
Table 3.12 indicates the number of cases where contamination was detected. This
analysis excludes cases with TP-PCR amplification, where polymorphic marker analysis
for contamination detection was not included in the protocol. A total of 260 single
blastomeres were analysed. Contamination was detected in 8 out of the 260 cells (3%),
and in 14 out of the 260 cell negative controls (5.4%) (overall 19/260, i.e. 8.46%). In
three occasions (patient/cycle number 6/1, 11/1, 11/2) two PCR master mixes had to be
prepared because of the high number of tubes. The PCR master mix negatives indicated
a low level of external contamination in two cases.
Table 3. 12: Detection of contamination in PGD. The PGD results for each of these cycles may be
found in appendix table A2.3-A2.7. External contamination was detected in 7/260 blastomeres. One
blastomere (*) indicated maternal cumulus cell contamination and fourteen cell negatives indicated the
presence of external contamination. Contamination was not detected in a cell and its corresponding
negative control at the same time. Pre- (PCRM) and post-aliquoting (PCRN) negative controls of the PCR
master mix, were obtained from all prepared master mixes.
Patient
Number/
Cycle
Number
of
blastomeres
Cells
with
contamination
Cell negatives
with
contamination
PCRM1 PCRM2 PCR1N PCR2N
1/1 8 0 0 - -
2/1 6 0 0 - -
4/1 14 0 1 - -
6/1 15 1 0 - - - -
7/1 13 0 0 - -
8/1 12 0 3 - -
8/2 8 0 1 - -
8/3 6 1 0 - -
9/1 10 0 0 - -
10/1 5 0 0 - -
11/1 22 1* 2 - - - -
11/2 32 2 4 cont cont cont cont
12/1 6 1 0 - -
13/3 17 0 0 - -
15/1 7 0 0 - -
19/1 4 0 0 - -
19/2 10 2 2 - -
19/3 9 0 0 - -
20/1 8 0 0 - -
21/1 13 0 0 - -
22/1 12 0 0 - -
22/2 7 0 0 - -
23/1 6 0 0 - -
23/2 10 0 1 cont cont
Total 260 8 14126
3.1.2.2 Detection of cross-over
A cross-over event between DM1 and APOC2 was observed during the analysis of the
biopsied cells in one embryo from couple number 6. The maternal DM1 178bp allele
was expected to be transmitted along with the 142bp APOC2 allele, but in this case, the
125bp APOC2 allele was detected instead. This suggested cross-over between the two
alleles. Alternatively the findings could have occurred by the combination of maternal
contamination with concurrent allele dropout of the APOC2 142bp and the DMPK
155bp products, though this is a highly unlikely occurrence. In any case, the paternal
non-expanded 142bp allele was seen in the embryo along with one of the non-expanded
maternal alleles (178bp) and the embryo was therefore considered as unaffected and
suitable for transfer (figure 3.17).
Two embryos were transferred on day 4, including the embryo where cross-over was
detected, leading to the establishment of a clinical pregnancy and the birth of a healthy
male infant.
During PGD for couple number 10, a similar cross-over event was observed in one of
the embryos diagnosed as unaffected (figure 3.18). The embryos were scored on day 5;
a four-cell (with cross-over) and a five-cell embryo were transferred. A clinical
pregnancy was established and a healthy child was born.
Buccal cells were collected from the babies born in both cases and tested using the DM1
triplex protocol. The results confirmed that, in both cases, the implanted embryos were
the ones where the crossover event had been detected (figure 3.19).127
Figure 3. 17: Haplotype diagram for couple 6 (affected father) indicating a cross-over event
detected in embryo 2 during diagnosis. Allele sizes for APOC2 and DM1 are shown. CVS samples
from previous pregnancies were available to allow detection of the phase allele (APOC2 151bp). Exp
indicates the expanded allele which was refractory to PCR. Underlined alleles show the phase. Embryos
6, 8 and 10 were affected; embryos 1, 2, 5 and 11 were unaffected. Cross-over was detected between
DM1 and APOC2 in embryo 2. This was an unaffected embryo, showing the normal paternal alleles for
both DM1 and APOC2 regions however the 125bp APOC2 maternal allele was detected instead of the
142bp allele due to cross-over. Embryos 4 and 7 showed inconclusive results while there was no result for
embryo 3. (Kakourou et al., 2007)128
Figure 3. 18: PGD results for couple 10 (affected mother) where a cross-over event was detected in
embryo 3. Underlined alleles indicate the phase. Embryo 2 was affected, embryos 3 and 4 were
unaffected. Cross-over was detected between DM1 and APOC2 in embryo 3. This was an unaffected
embryo that showed the normal maternal alleles for both DM1 and D19S112 regions whereas the
maternal disease-associated allele was detected for APOC2 (Kakourou et al., 2007)129
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Figure 3. 19: Results from buccal cell analysis of two babies born following PGD. x-axis: PCR
product size in bp, y-axis: fluorescence intensity (RFU). A) Buccal cell analysis from baby born
following PGD for couple 6. The results correspond to the genotype of embryo 2, as indicated in figure
3.17 B) Buccal cell analysis from baby born following PGD for couple 10. The results correspond to the
genotype of embryo 3, as indicated in figure 3.18.
3.1.2.3 Pregnancies
Thirty-six unaffected embryos were transferred into the mother’s womb in 20 out of the
28 cycles. In 16/20 cycles resulting in an embryo transfer, two unaffected embryos were
transferred, while in the remaining four cycles transfer of a single embryo took place.
Embryo transfer was on day 4 for nine cycles and on day 5 for another nine cycles. For
couple 16, embryo transfer was on day 6 and for cycle 2 of couple 23 the best quality
embryo was transferred on day 4 and a second embryo was selected and transferred on
day 5.130
There were two additional embryo transfers, both for patient number 8. During the
patient’s second PGD cycle, all five biopsied embryos were diagnosed unaffected. Two
embryos were transferred and two surplus unaffected embryos were cryopreserved. A
pregnancy was not established, so the two cryopreserved embryos were thawed and
transferred in a separate stimulation cycle, following which, implantation was,
unfortunately, again unsuccessful. The same patient had a third treatment cycle, where
she developed ovarian hyperstimulation syndrome (OHSS) after oocyte collection. The
diagnosis was still completed, and the single embryo, diagnosed unaffected, was
cryopreserved, then thawed and transferred in a separate treatment cycle, as before.
Unfortunately an empty sac was detected at the 6 week scan. Another pregnancy was
also lost as patient 23 miscarried in her second cycle at 7 weeks.
In case number 11, both of the transferred embryos implanted, therefore making the
total number of implanted embryos eleven. The implantation rate, defined as the number
of gestational sacs detected per total number of embryos transferred, was 28.2% (eleven
out of thirty-nine embryos transferred overall). Seven pregnancies have led to the birth
of healthy infants, in one case of twins and one pregnancy is ongoing. The clinical
pregnancy rate per embryo transfer, defined as the number of gestational sacs and fetal
heartbeat at 7 weeks detected per cycle with embryo transfer, was 40% (8/20) or 36.4%
(8/22) respectively, including the two embryo transfers of frozen-thawed embryos, and
the pregnancy rate per cycle to PGD was 28.57% (8/28) (table 3.13).131
Table 3. 13: Summary of embryo transfers (ET) and outcome from DM1 IVF/PGD cycles
*cryopreserved/thawed unaffected embryos
Patient
number/
cycle
No. of
embryos
transferred
ET Day Pregnancy Outcome
1 2 4 Y Girl
2 0 n/a n/a
4 2 4 N
6 2 4 Y Boy
7 2 5 Y Girl
8/1 0 n/a N
8/2 2 5 N
2
* new cycle N
8/3 hyperstimulation n/a n/a
1
* new cycle Y empty sac
9/1 0 n/a n/a
9/2 2 4 N
10 2 5 Y Girl
11/1 2 5 N
11/2 2 5 Y Boy and girl
12 1 4 N
13/1 1 4 N
13/2 0 n/a n/a
13/3 2 5 Y Girl
15 0 n/a n/a
16 2 6 N
19/1 2 4 N
19/2 2 5 N
19/3 2 5 Y Ongoing
20 1 4 N
21 0 n/a n/a
22/1 2 5 N
22/2 1 4 Y Girl
23/1 0 n/a n/a
23/2 2 4+5 Y Miscarried at
seven weeks132
Seven out of the eleven embryos that implanted were at the morula to blastocyst stage,
while the remaining four had 8 cells or fewer at the time of transfer. In two cases
(number 6 and 10), the two embryos transferred had a different genotype and it was
possible to identify which embryo had implanted by testing DNA from buccal cells of
the baby born. In both cases, the embryos that implanted were the ones where a
crossover event between DMPK and APOC2 had been detected during diagnosis. For
patient number 10, the 5-cell embryo that implanted had also been re-biopsied. Re-
biopsied embryos implanted in another two cases (patient 13, cycle 3 and patient 23,
cycle 2), though in one of them the patient subsequently miscarried at seven weeks
(table 3.14).
Table 3. 14: Grade of implanted embryos In cases 6 and 10, it was possible to identify which of the two
transferred embryos had implanted by testing DNA from the baby born. These are indicated in bold
typing. In three cases, the implanted embryos had been rebiopsied (patients10, 13 cycle 3 and 23 cycle 2).
M: morula stage embryo, or B: blastocyst stage embryo, *: rebiopsied embryo
Patient
Number/Cycle
Embryos transferred
(number of cells, grade)
Implanted
Embryo/s
1 1)6-cell, 2+
2)6-cell, 1- *
≤ 8-cell
6 1)7-cell, 1-
2)8-cell, 1-
≤ 8-cell
7 1)Cavitating morula
2)Cavitating morula
M
10 1)5-cell, 1- *
2)5-cell, 1-, arrested
≤ 8-cell *
11/2 1)Blastocyst, 1
2)Hatching blastocyst
B, B
13/3 1)Hatching blastocyst *
2)Morula *
M or B *
8/3 1)Morula M
22/2 1)8-cell, 2+ ≤ 8-cell
23/2 1)Morula *
2)Hatching blastocyst *
M or B *
(miscarried)
19/3 1)Morula
2)Hatching blastocyst
M or B133
3.1.2.4 Analysis of spare embryos for confirmation of diagnosis
Following PGD, most patients consented to the use of their spare embryos either for
retesting and confirmation of diagnosis or for use in other research work.
Out of the 55 embryos diagnosed unaffected, 39 were transferred in 22 ETs and, nine
out of the remaining sixteen embryos, unsuitable for cryopreservation, were retested for
confirmation of diagnosis. Eight embryos were confirmed unaffected whereas one
embryo gave an inconclusive result (detection of one parental genome). Similarly, forty-
five out of the 74 affected embryos were retested, of which forty were confirmed
affected, three gave an inconclusive result and two gave no result.
Moreover, twenty embryos with inconclusive results on diagnosis, five embryos with no
result on diagnosis and seven embryos that had not been suitable for biopsy on day 3
were also tested following PGD. Results are summarised on tables 3.15 and 3.16.
In summary, including results from diagnosis and all follow-up testing, 150 embryos
were diagnosed, of which 67 were unaffected (44.7%) and 83 affected (55.3%). The
difference in the number of affected and unaffected embryos was not found to be
statistically significant (binomial test, p=0.22).
Seven of the couples that had PGD (nine cycles) had previously experienced an affected
pregnancy. From these couples, there were 44 embryos diagnosed, including analysis of
the non-transferred embryos following PGD, of which 27 (61.4%) were affected and 17
(38.6%) unaffected. From all the remaining couples, that did not have a previous TOP
or an affected child, there were 106 embryos, of which 56 (52.8%) were affected and 50
(47.2%) unaffected. In spite of a markedly higher number of affected embryos in the
first group of patients, there was no statistically significant difference (NS) on analysis
(Fisher’s exact test, p=0.37).134
Table 3. 15: Reanalysis of embryos with inconclusive results during PGD *For two embryos where contamination was detected in one cell, the second biopsied cell indicated the
presence of only one parental genome. ** “other”: refers to the detection of odd/unexpected alleles, e.g. two paternal alleles
Table 3. 16: Summary of all spare embryo follow-up analysis following a PGD case. Forty out of the 55 embryos that were diagnosed unaffected were transferred following
PGD and eight out of the remaining 15 embryos were reanalysed. The table indicates results from reanalysis of 86 embryos, 53 of which had received a diagnosis (45 affected/ 8
unaffected) during PGD. ET: embryo transfer.
Results from reanalysis
Inconclusive results Affected Unaffected No result Inconclusive Not Tested Consent for
other research
Observation Number of
embryos
Result from one cell 1 1
Detection of one parental genome 8 8
Contamination* 5 2 1 2
Allele Dropout 3 1 1 1
Uninformative markers/ Shared alleles 14 3 7 4
Other** 4 3 1
Total 35 5 4 1 10 1 14
174 biopsied
Embryos Spares Consent for
other research Not Tested Reanalysed
Embryos Affected Unaffected No
result Inconclusive
Unaffected 55
(40 had ET ) 15 5 2 8 7 1
Affected 74 74 24 5 45 40 2 3
Inconclusive 35 35 14 1 20 5 4 1 10
No Result 10 10 4 6 2 3 1
Non-biopsied - 7 7 2 5135
3.1.3 Summary of findings for section 3.1: PGD for DM1
 Section 3.1.1: Protocol development
o Better amplification and lower ADO was achieved with ALB vs. PK
lysis and with single lymphocytes vs. single buccal cells.
o TP-PCR amplification on buccal cells was very inconsistent, indicating
the impact of DNA quality on amplification.
o TP-PCR can differentiate between the homozygous unaffected and
affected samples but cannot give a clear diagnosis for the 5 CTG repeat
homozygous samples.
o Design of a new protocol, mTP-PCR, to overcome difficulties with
scoring of the 5 CTG repeat homozygous samples. Along with
amplification of the repeat region, this protocol provides additional
information on contamination, ADO and the presence of the phase allele.
o Clinical application in PGD for DM1, of two new optimised protocols,
DM1 triplex and mTP-PCR.
 Section 3.1.2: Results and follow-up from DM1 PGD cycles
o Embryo grade and quality of the biopsied cell (ie. anucleate cell, lysing
cell, cell fragments) reflects amplification rate and overall diagnosis rate.
o Higher diagnosis rate with two-cell vs. one-cell biopsy.
o Detection of cross-over between DM1 and APOC2 markers.
o Overall encouraging diagnosis and pregnancy rates.
o Analysis of spare embryos
 No false positive or false negative results detected in follow-up
study.
 No statistically significant difference in the number of embryos
diagnosed affected vs. unaffected, including results from
diagnosis and follow-up analysis.
 Higher percentage of affected embryos from parents with
previously affected children but not reaching significance.136
3.2 Investigation of DMPK repeat transmission
3.2.1 Determination of the repeat number by triplet-primed amplification
(TP-PCR or mTP-PCR)
3.2.1.1 TP-PCR on genomic DNA
Unaffected individuals
Amplification of non-expanded alleles (of a maximum of 24 repeats) was generally
consistent and allowed accurate sizing of the repeat, with some variation of ±1-2 repeats
detected (figure 3.20).
Figure 3. 20: Sizing of non-expanded DM1 alleles by TP-PCR. x-axis: PCR product size in bp, y-axis:
fluorescence intensity (RFU). Top lane: genomic DNA TP-PCR amplification of a 12 CTG repeat
homozygous individual. Bottom lane: genomic DNA TP-PCR amplification of a 13 CTG repeat
homozygous individual. The first detected peak indicates 5 CTG repeats. The one CTG repeat size
difference between the two samples is clearly visualized.
Affected individuals
Contrary to the accurate sizing of non-expanded alleles, when expanded repeats were
amplified by either TP-PCR or mTP-PCR, the last sizeable peak of the diminishing
ladder was variable both for genomic DNA and single lymphocytes. The pattern of
triplet-repeat amplification was tested on a number of single lymphocytes from each137
parent prior to PGD, in order to obtain the expected amplification “peak range” for the
expanded repeat.
The triplet primed PCR protocols were also evaluated for their ability to discriminate
between considerably different expansion sizes. Four control DNA samples were kindly
provided by Dr. John Short (S.W. Thames Molecular Genetics Diagnostic Laboratory)
from affected individuals with expansion sizes of 150, 550, 1100 and 1600 repeats. All
sizes had been measured against a DNA ladder on a Southern blot. DNA samples from
several of the DM1 patients, with known expansion size, were also analyzed along with
the control DNA samples. Figure 3.21 gives an example of amplification from the four
control DNA samples, in an attempt to detect some differences in amplification amongst
the different expansions. Current analysis indicates that TP-PCR cannot be used to
discriminate even between the strikingly different expansion sizes.
One consideration was that the different sizes of the non-expanded alleles from each
affected sample could be influencing the pattern of amplification. It was, therefore,
decided that only samples sharing the same non-expanded allele should be compared to
allow detection of differences due to the presence of the expanded allele only. Five
DM1 patients, where the expansion size was also known, shared a 122bp (5 CTG repeat)
non-expanded allele. From all remaining samples, only two patients shared a 146bp
non-expanded allele. Results from amplification for the 122bp/expansion patients are
shown in figure 3.22. The graphs shown in figure 3.22 were also plotted against the log
of the peak height in order to compare the slopes of the linear regression line (figure
3.23).
Modifications of the P2/P3R/P4CAG primer concentration ratio, as well as the PCR
program conditions (shorter annealing and extension times), were attempted to
encourage different amplification depending on repeat number but no differences were
detected. Therefore no conclusions could be drawn from this analysis.138
Figure 3. 21: Amplification of four control DNA samples of known repeat size. x-axis: PCR product
size in bp, y-axis: fluorescence intensity (RFU). Arrows indicate the presence of the non-expanded allele
in each case. The last sizeable peak on analysis was 131bp, 122bp, 116bp and 122bp for controls 1, 2, 3
and 4, respectively. This indicates that amplification is not relevant to the repeat size.
Figure 3. 22: Amplification from 5 DM1 patients, of known expansion size, sharing a common
122bp non-expanded allele. x-axis: PCR product size in bp, y-axis: fluorescence intensity (RFU). All
samples, irrespective of expansion size, showed comparable triplet repeat amplification.139
Figure 3. 23: Regression analysis of figure 3.22 TP-PCR amplification graphs. x-axis: PCR product
size in bp, y-axis: fluorescence intensity (RFU). The 5/150 CTG repeat control was included in the
analysis. All samples shared a 5 CTG repeat allele and had expanded alleles of different size. No
differences were observed between the 6 samples, despite the differences in the size of the DM1
expansion.
3.2.1.2 TP-PCR single cell analysis
TP-PCR and mTP-PCR analysis was performed on single biopsied blastomeres from 11
PGD cycles (7 patients). The standard TP-PCR protocol was used for diagnosis in five
cycles while the mTP-PCR protocol was used in the remaining six cycles. For two of
the patients (number 8 and 13), both standard TP-PCR and mTP-PCR diagnosis was
performed in different IVF/PGD cycles. Table 3.17 presents all fluorescent PCR
blastomere readings, showing the size in base pairs (bp) of the last genetic analyzer
sizeable peak of the ladder pattern, allowing comparison with results from amplification
of single parental lymphocytes and parental genomic DNA. All cell readings presented
in the table are from the 310 fluorescent genetic analyzer, so as to avoid differences in
analysis due to machine variation. Analysis of fifty single cumulus cells was also
performed for four of the patients (number 8, 13, 16 and 23) and results were
comparable to amplification from single lymphocytes.
In the five cycles with standard TP-PCR diagnosis (indicated as 8/1, 9/2, 13/1, 13/2 and
16/1 on table 3.17), lack of amplification, that might indicate a 5 CTG homozygous
sample, was taken as failure of amplification as this was the practice until application of
the new mTP-PCR protocol.140
Overall, all genomic DNA readings indicated a bigger product, i.e. more ladder peaks,
compared to the single cell analysis. Readings from single affected lymphocytes were
obtained from amplification of a minimum of 20 single cells, isolated and tested prior to
each IVF/PGD case. These readings varied from cell to cell for the same individual,
with the maximum difference detected being, on average, 52bp. The last peak of the TP-
PCR ladder also varied from embryo- to embryo and from blastomere-to-blastomere.
Thirty-seven blastomeres were scored as unaffected. Most unaffected blastomeres gave
a similar pattern of amplification between them, with a ± 1-2 CTG repeat difference
detected in some cases. This was similar to amplification from single lymphocytes. In
cycle 2 of patient 23, three single blastomeres from two different embryos showed a
peak pattern unexpected for a 5 CTG homozygous sample, with the triplet repeat ladder
pattern extending to 89bp.
Fifty-eight blastomeres showed the diminishing ladder pattern following TP-PCR or
mTP-PCR, indicating an affected cell. In one cycle, the mTP-PCR protocol enabled
detection of an embryo and a single blastomere showing amplification of one parental
genome only (case number 21/1). The last detected peak of the ladder varied
considerably between the affected blastomeres from an embryo, but was generally
within the expected range as seen from amplification of single affected lymphocytes
(patient specific analysis). Eleven blastomeres showed an increase in the size of the last
detected fluorescent peak. In two out of the 58 blastomeres the product was over 50bp
bigger than the biggest product detected in a single parental lymphocyte.
Follow-up analysis was performed on day 5 for two unaffected embryos (cycles 13/2
and 16/1) and nineteen affected embryos.
One of the unaffected embryos was tubed whole for amplification (patient 16), while the
second embryo was disaggregated and two single blastomeres were isolated and
amplified separately (cycle 2 of patient 13). Amplification from the embryo that was
tubed whole and from one of the single blastomeres showed an increase in the number
of CTG repeats by TP-PCR, of five and nine repeats respectively, compared to their day
3 result. This product was larger than the corresponding genomic DNA result.141
Three out of the nineteen affected embryos that were available for testing, were tubed
whole, a blastomere clump was isolated from another affected embryo and 31 single
blastomeres were isolated from the remaining 15 embryos.
Fifteen of the single blastomeres, as well as the blastomere clump and the three embryos,
showed an increase in the size of the last detected fluorescent peak compared to their
day 3 result. In four of the single blastomeres the increase was over 50bp, compared to
the maximum single lymphocyte parental size, while in a single blastomere from patient
9, the last peak was even larger than the genomic DNA amplification. Additionally,
seven affected blastomeres showed a smaller ladder product on day 5 analysis,
compared to the parental single lymphocytes, although the difference was less than
50bp in size.
Due to the inability of TP-PCR to accurately size the affected-range expanded alleles, as
well as due to the association of poor cell quality with inferior triple-primed
amplification, as detected mostly during buccal cell TP-PCR amplification, the
significance of the above remains unclear.142
Table 3. 17: TP-PCR blastomere results from 11 PGD cycles with follow-up analysis. The size of the last sizeable peak is indicated. Results from blastomeres of the same embryo are put
in brackets. Arrows point to results from follow-up analysis. Bold type indicates unusual observations (red colour for follow up results), *: use of mTP-PCR, rather than TP-PCR, w:whole
embryo, cl:clump, h, H:one or two-cell results respectively showing analysis from only one parental genome
Patient
number/
Cycle
Parental
DMPK
genotype
Unaffected
genomic DNA
(bp)
Unaffected
Lymphocytes
(bp)
Unaffected
Blastomeres
(bp)
Affected
genomic
(bp)
Affected
lymphocytes
(bp)
Range
(bp)
Affected
blastomeres (bp)
Non-biopsied
embryos
(bp)
8/2 96-99 90-93 (93), (93,93) 189-224 147-189 42 n/a 93, 96
(190), (135)
8/3*
122/Exp
122/146
96 93-103 (68,68) 148 125-198 73 (116, 166), (172, 189)
9/2 122/Exp
122/149 96-105 93-105 (96,99), (96,96) 225-258 113-195 82 (183, 199), (201), (189, 260 300)
13/1 93-97 87-94 (87,90) 220-253 142-197 55 (176,194 110,194),
(142,145 152,213)
(152,155, 185194)
13/2 92-94 87-94 (89, 89 116, 89) 195-255 142-197 55
212, (128,156 120),
(194147,151,160,201,231)
(104,128 144,160,163)
(206,215160)
(188,208131)
116
113
13/3*
122/Exp
122/142
90-93 89-93, av. 90 (68,68), (68,68) (92,92) 254-314 132-230 98 (170,223), (204,206)
16/1 139/Exp
122/139 86 89-93 (90,90),
(89,89104w) 263 125-188 63
(149 124, 184, 249), (133270),
(260258w), (188,200246cl)
(204,208252w),
(180258w)
(170131,154,252)
20/1* 141/Exp
122/141 89 87-94 (86,86), (95), (86, 86) 198 129-162+236 33 (159, 162) 104,104
88,88
21/1* 144/Exp
122/147 95 92-101 n/a 224 137-185 48 (153,156), (127,171), (98
h,150),
(165,184), (144,165), (160, 180)
H 155,187
23/1* 68 (122hm) 68 (122hm) n/a 147-295 170-192 22 (118,149140,143,165),
(148,154143,180)
(125,139 133,183)
23/2*
122/Exp
122/122
68 (122hm) 68 (122hm) (68,68),(68,68,86,89),
(68,68,86) 253-272 125-133 8 n/a n/a143
3.2.1.3 Assessment of triplet repeat amplification following MDA
Amplification of the triplet repeat region from single cells following MDA was assessed
in several lymphocytes and PGD spare embryos (table 3.18), in order to determine
whether the whole genome amplification PGD methodology could offer any advantages
in the diagnosis of DM1. Though only a few cells were obtained for MDA and post-
MDA testing, i.e. three cells with the DM1 triplex protocol (protocol number 3) and
eight cells with the mTP-PCR protocol (protocol 5), current results indicate generally
poor amplification. A very high allele dropout rate was detected for both protocols used.
Additionally, there seemed to be a bigger size product following triplet-primed
amplification post-MDA, while in one cell there was a difference in sizing of the
D19S112 marker allele, compared to sizing following standard PCR amplification. An
aliquot of some of the MDA products was used for embryo sexing using AMELXY
oligonucleotide pair (primer details in appendix table A1.1).
Table 3. 18: Single cell amplification post-MDA, using the DM1 triplex and mTP-PCR protocols.
Allele sizes for patients 19 and 22 may be found in appendix table 3A.1. Patient 19 embryo results may
be compared to amplification results as shown on table 3.7. Unexpected peak sizes are indicated in red
colour. The TP-PCR column indicates the size of the last sizeable peak at the 310 genetic analyzer.
Patient Embryo
number
Cell
number F-PCR readings
TPPCR DM1 D19S112 APOC2 Diagnosis XY
Result
1 ADO/180 128/ADO ADO/157 Unaffected Male 2PN/1
2 195 ADO/180 128/ADO
1 148/ADO ADO/133 137/157 Unaffected Male-ADO
2 ADO/180 129/ADO 137/157 Unaffected Male-ADO
3 153 148/ADO ADO/139
2PN/2
4 185 ADO/180 129/ADO
2PN/3 1 No result No result No result Unaffected Male-ADO
1 183 124/180 128/130 Unaffected Female
DM1
patient
19
2PN/4
2 Contamination in cell Unaffected Female
1 173 141/168 128/130 Unaffected Male DM1
patient
22
1
2 176 ADO/168 128/130 Unaffected Male144
3.2.2 Study of allele transmission from follow-up analysis
3.2.2.1 Affected parent to embryo
In twenty-six PGD cycles where the mother was affected, there were clear results on
diagnosis from 145 maternal transmissions. The non-expanded maternal allele was
transmitted in 68 out of 145 embryos (46.9%), while the expanded allele was
transmitted in the remaining 77 embryos (53.1%). In the remaining 2 PGD cycles,
where the affected parent was the father, there were twelve embryos with diagnosis. The
normal paternal allele was transmitted in 8 out of 12 embryos, and the affected allele
was transmitted in the remaining four embryos.
The difference in the number of affected vs. unaffected embryos from an affected
mother was not statistically significant (NS, binomial test, p=0.5). Additionally,
transmissions from an affected father did not indicate a statistically significant
difference between the number of expanded and non-expanded alleles detected in the
embryos (NS, binomial test, p=0.38). It should be, however, stressed that only a small
number of embryos were available for this analysis (twelve embryos).
3.2.2.2 Unaffected parent to embryo
Similarly, from 26 PGD cycles, there were 118 heterozygous transmissions from an
unaffected father, where the smaller non-expanded allele was transmitted in 66 embryos
(55.9%) and the larger allele in 52 embryos (44.1%) (NS, binomial test, p=0.23).
From the remaining two cycles, there were results from 8 heterozygous normal maternal
transmissions, where the smaller allele was transmitted in three embryos and the larger
allele in five.
If all cases are grouped together, regardless of individual DM1 status and parental sex,
there were 283 transmissions where the smaller allele was transmitted in 145 embryos
(51.2%) and the larger allele (larger normal or expanded allele) in 138 embryos (48.8%)
(NS, binomial test, p=0.7).
Therefore, there was not any preferential transmission of either the smaller or larger
alleles regardless of affected parent sex.145
3.2.2.3 Grouping by repeat allele class
3.2.2.3.1 Sequencing of CTG repeat
The size of the DM1 expansion, estimated by Southern blotting, was known for only
five of the affected individuals undergoing PGD. Primers DMPK2 and DMPK3
(appendix table A1.1) were used to amplify and sequence the DMPK repeat region of
unaffected homozygous individuals. As indicated in figure 3.24, it was possible to
compare the sequencing results with the results following amplification of the repeat
region for these individuals, using primers DMPK1 and DMPK2. The size of the region
outside the repeat, amplified by the DMPK1 and DMPK2 primers, was 107bp. Based on
this, the size of the non-expanded alleles for all remaining patients and their partners
was estimated using the formula:
Number of repeats= (PCR product size-107)/3.
Non-expanded alleles ranged from 5-24 repeats. Thirty-six out of the 69 (52.2%) non-
expanded alleles had 5 CTG repeats, 27/69 alleles (39.1%) had 10-14 repeats, and 6/69
(8.7%) had other repeat size (figure 3.25).
Figure 3. 24: Sizing of the non-expanded DM1 alleles by sequencing using primers DMPK2 and
DMPK3 The y-axis indicates the level of fluorescence emitted by the incorporation of a nucleotide and
the x-axis shows the order in which the nucleotides were added. Lane 1: 5 CTG repeats, Lane 2: 11 CTG
repeats, Lane 3: 12 CAG repeats (lane 3 sequenced from reverse strand). When DNA was amplified from
each of these unaffected homozygous individuals using primers DMPK1 and DMPK2, the size of the
PCR product was 122bp, 140bp and 143bp respectively. Based on this, and depending on the PCR
product size following DMPK1/DMPK2 amplification, it was possible to estimate the number of repeats
in the non-expanded alleles for each individual, whether unaffected heterozygous or affected.146
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Figure 3. 25: Distribution of DM1 CTG repeat alleles amongst the referred couples. Affected
individuals are indicated in the >50 CTG repeat category. The distribution of non-expanded alleles is
bimodal with most alleles having 5 repeats and a second mode at 10-14 repeats.
Repeat alleles were grouped into the following categories: (A) 5-11 repeats, (B) 12-18
repeats, (C) 19-37 repeats and (D) > 50 repeats (Imbert et al., 1993). For the
investigation of allele transmission, every embryo where some indication for allele
transmission could be identified was included, even when diagnosis was incomplete.
3.2.2.3.2 Maternal transmissions
From the 16 couples where the female partner was affected, 10 females (17 cycles) were
of genotype A/D, four females (4 cycles) were of B/D genotype and 2 females (5 cycles)
were of genotype C/D.
There were 96 transmissions from A/D females, leading to 42 unaffected (43.75%) and
54 affected embryos (56.25%) (NS, binomial test, p=0.26). For class B/D, allele B was
transmitted in 6 out of 19 embryos and allele D was transmitted in the remaining 13
embryos (NS, binomial test, p=0.17). Finally, out of 30 transmissions in class C/D the
non-expanded allele (C) was transmitted in 20 embryos and the expanded allele in 10
(NS, binomial test, p=0.09).147
One of the unaffected female partners was a class A/A homozygous, while the other
female had a B/C genotype. In this case allele B was transmitted in 3/8 and allele C in
5/8 embryos (figure 3.26).
Figure 3. 26: Transmissions of repeat alleles from mothers of the genotype: A/D (10 females-96
transmissions), B/C (1 female- 8 transmissions), B/D (4 females- 19 transmissions) and C/D (2 females-
30 transmissions)
3.2.2.3.3 Paternal transmissions
There were 16 couples where the male partner was unaffected. In three of the couples (4
cycles) the unaffected partner was homozygous for class A repeat alleles (5 repeats). In
5 couples (6 cycles), the male was heterozygous but both alleles were in the 5-11 repeat
class (genotype A/A heterozygous). In five out of the six cycles, the protocol used
allowed detection of the smaller allele transmission in 11 embryos, whereas the large
allele was transmitted in 13 cases. Eight unaffected males (16 cycles) were of genotype
A/B. Allele A was transmitted in 55 out of 94 embryos (58.5%) and allele B in the
remaining 39 embryos (41.5%) (NS, binomial test, p=0.12).148
The genotypes of the two affected males, patient number 12 and 6, were A/D and B/D
respectively. Allele transmissions were 2/3 allele A and 1/3 allele D for patient 12, 6/9
allele B and 3/9 allele D for patient 6 (figure 3.27).
Figure 3. 27: Transmissions of repeat alleles from males of genotype: A/A heterozygous (5 males- 24
transmissions), A/B (8 males- 94 transmissions), A/D (1 male- 3 transmissions), and B/D (1 male- 9
transmissions)149
3.2.2.4 Affected and unaffected embryo development
Embryos were scored from day 2 to day 4 or 5 of development. For the purposes of
comparing the preimplantation development of affected vs. unaffected embryos, all
rebiopsied embryos and all embryos biopsied later than day 3 were not included in this
analysis, so that all embryos investigated had undergone exactly the same procedures.
Some embryos were scored both on day 4 and day 5, while other embryos were
excluded from this analysis as they had not been morphologically assessed. Data is
summarised in tables 3.19 and 3.20 and figures 3.28 and 3.29.
A general trend for better development for the affected embryos can be observed. The
group of embryos that had two cells biopsied on day 3 and had been assessed on day 4,
table 3.19, indicated a similar number of affected and unaffected embryos. Comparison
of the development of these embryos showed that more affected embryos developed to
the morula or cavitating morula stage by day 4 compared to the number of unaffected
embryos at the same stage (9/26 vs. 1/25) (p<0.05, Fisher’s exact test).
Table 3. 19: Day 4 scoring of affected and unaffected embryos with one, two or three cells biopsied
on day 3. A statistical analysis was performed for the embryos with two cells biopsied. There was a
statistically significant difference in the number of affected embryos growing to the morula/cavitating
morula stage, compared to the number of unaffected embryos (Fisher’s exact test).
Number of embryos at each developmental
stage
DAY 4 SCORING
Number of
diagnosed and
scored embryos
Number of
cells
biopsied
-
Embryo
diagnosis
2-5
cell
6-8
cell
9 cell-
premorula
Morula/
cavitating
morula
1 cell
5 Affected 3 1 1
3 Unaffected 3
2 cells
26 Affected 5 4 8 9
25 Unaffected 5 16 3 1
p<0.05
3 cells
4 Affected 1 2 1
3 Unaffected 1 2150
The biggest number of embryos where day 5 scoring was available came from the group
that had two cells biopsied on day 3. The majority of these (36/54) were affected and
18/54 were unaffected. More affected embryos in the 2-cell biopsy group developed to
the morula and blastocyst stage (21/36, 58.3%) compared to the number of unaffected
embryos (6/18, 33.3%) but this difference was not statistically significant (Fisher’s
exact test, p=0.15). More data is, however, necessary to allow a more comparable
analysis between the two groups.
Similarly, three out of the four affected embryos that had three cells biopsied on day 3,
had become morulae/blastocysts by day 5, compared to 5 out of the 10 unaffected
embryos that had three cells biopsied. Although the numbers are small, the current
analysis indicates that there is no statistically significant difference between the two
groups (Fisher’s exact test, p=0.58).
Table 3. 20: Day 5 scoring of affected and unaffected embryos with one, two or three cells biopsied
on day 3. Comparison of the affected and unaffected embryos that had two or three cells biopsied on day
3 and grew to the morula/cavitating morula or blastocyst/hatching blastocyst stage by day 5 was
performed, however no statistically significant difference was detected for any group (Fisher’s exact test).
Number of embryos at each developmental stage
DAY 5 SCORING
Number of
diagnosed
and scored
embryos
Number of
cells biopsied
-Embryo
diagnosis
2-5
cell
6-8
cell
9 cell-
premorula
Morula/
cavitating
morula
Blastocyst/
Hatching
blastocyst
1 cell
3 Affected 1 1 1
1 Unaffected 1
2 cells
36 Affected 8 5 2 13 8
18 Unaffected 4 2 6 5 1
3 cells
4 Affected 1 3
10 Unaffected 3 2 2 3151
Figure 3. 28: Day 2 (D2) to Day 4 (D4) scoring of affected embryos at the 2-5 cell stage, 6-8 cell
stage, 9cell-premorula, morula/cavitating morula and blastocyst/hatching blastocyst stage. D3pb:
D3 post-biopsy152
Figure 3. 29: Day 2 (D2) to Day 4 (D4) scoring of unaffected embryos at the 2-5 cell stage, 6-8 cell
stage, 9cell-premorula, morula/cavitating morula and blastocyst/hatching blastocyst stage. D3pb:
D3 post-biopsy153
3.2.3 Summary of findings for section 3.2: DMPK repeat transmission
 Section 3.2.1: TP-PCR sizing
o TP-PCR allows accurate sizing of non-expanded repeat alleles (up to 24
repeats).
o Inability of TP-PCR to differentiate between even strikingly different
expansions.
o Inconsistent amplification of expanded repeats both on genomic DNA
and single cells.
o Blastomere quality has an effect on TP-PCR amplification.
o Potential expansion of the triplet repeat was suggested on analysis of
blastomeres on day 3, compared to amplification from single
lymphocytes, as well as on analysis of blastomeres from the same
embryo between day 3 to day 5 of development.
o Poor TP-PCR amplification and high ADO rates were observed
following MDA.
 Section 3.2.2: DMPK allele analysis in embryos
o No preferential transmission of expanded DMPK alleles.
o No overall preferential transmission of either smaller or larger alleles,
regardless of affected parent sex or repeat size.
o More affected than unaffected embryos developed to the morula/cavitating
morula stage by day 4 (no impact of the number of cells biopsied on embryo
development).154
3.3. Expression work
3.3.1. Sample processing
3.3.1.1 RNA Isolation results
The procedure for extraction of RNA from single cells was initially optimised using
lymphocyte clumps and single lymphocytes. RNA isolation, reverse transcription and
cDNA amplification was performed as described in sections 2.4.2.1 and 2.4.2.2.
Successful cDNA amplification was achieved from single lymphocytes for ACTB and
for a lymphocyte pellet for DMPK (figure 3.30).
Figure 3. 30: cDNA amplification from lymphocyte clumps and single lymphocytes. A) ACTB
amplification was achieved for lymphocyte clumps and single lymphocytes B) DMPK amplification
was only achieved when the whole lymphocyte pellet, following lymphocyte extraction from blood,
was used. HeLa RNA was used as a positive control. Negative controls included a reverse transcription
negative (RNA –ve), which included RNA but where no reverse transcriptase was added, and a PCR
negative, from the cDNA PCR amplification, where no cDNA was added in the tube (methods 2.4.2.2).
The RNA and DNA product sizes are indicated in base pairs (appendix table A1.3). +ve: positive, -ve:
negative.155
Oocyte and embryo samples for microarrays
RNA was isolated from each oocyte and embryo sample (MIIa-MIIe, Ba-Bd and DMa)
using the AllPrep DNA/RNA Micro kit (Qiagen Ltd., UK) (Methods section 2.4.2.1)
and eluted in 14μl of water. The concentration and integrity of eluted RNA was
measured by loading 1μl on a Eukaryote Total RNA Pico Series II chip on the Agilent
Bioanalyzer 2100 (table 3.21, figures 3.31 and 3.32).
Agilent Bioanalyzer analysis can indicate RNA degradation, genomic DNA
contamination, or the presence of other contaminants, by the absence of 28S and/or 18S
peaks, skewing of the 28S peak or the presence of additional peaks or spikes
respectively. The 28S and 18S peaks were detected in all samples, however, they were
lower for the oocytes because of the lower concentration of RNA isolated from these
samples. RNA contamination or fragmentation products were not detected in any of the
samples. High RIN numbers were given by the Agilent Bioanalyzer for all of the
embryo samples, indicating very good RNA quality (methods section 2.5.5.4).
Table 3. 21: Agilent Bioanalyzer RNA concentration readings for each oocyte and embryo sample
prior to RNA amplification. RIN numbers were assigned by the software for all of the embryos and two
of the oocyte samples only, possibly because of the lower RNA concentration of the oocytes.
OOCYTES EMBRYOS
RNA
concentration
(pg/μl)
RIN
number
RNA
concentration
(pg/μl)
RIN
number
MIIa 78 6.2 Ba 393 10
MIIb 65 n/a Bb 191 9.5
MIIc 48 n/a Bc 63 8.7
MIId 50 n/a Bd 246 10
MIIe 52 7 DMa 120 9.3156
Figure 3. 31: Electropherograms and gel-like images indicating RNA integrity for oocytes MIIa-
MIIe, using the Agilent Bioanalyzer. The visual signs of the 28S and 18S ribosomal units, at the
electropherogram (left) and gel-like image (right) are most important in assessing the quality of RNA. No
contamination was detected in samples MIIa-MIIe. The small peak at around 24-29s (100bp) indicates
small RNAs, (shown on the first lane) such as 5S, 5.8S subunits and tRNAs.157
Figure 3. 32: Assessment of RNA Integrity using the Agilent Bioanalyzer for blastocyst stage
embryos Ba-Bd and DMa. The 28S and 18S ribosomal units are clearly detected and no degradation or
contamination can be visualized.158
3.3.1.2 RNA Amplification results
Nine microlitres of each oocyte and embryo RNA sample was converted into labelled
cRNA by a two-round in vitro transcription using the Applied Biosystems, NanoAmp
RT-IVT Labeling kit (section 2.4.2.3). The concentration and integrity of the labelled
cRNA was tested on the NanoDrop
® ND-1000 Spectrophotometer as well as on the
Agilent Bioanalyzer using the Eukaryote Total RNA Nano Series II chip (table 3.22).
The Nano chips were loaded quickly and the working area was thoroughly cleaned.
Bioanalyzer and agarose gel images of amplified cRNA are shown in figures 3.33 and
3.34.
Table 3. 22: Concentration of labelled cRNA samples (Nanodrop and Bioanalyzer readings).
RNA concentration
Nanodrop Bioanalyzer Nanodrop Bioanalyzer
ng/μl ng/μl ng/μl ng/μl
OOCYTES EMBRYOS
MIIa 41.76 36 Ba 59.46 51
MIIb 22.89 18 Bb 126.56 91
MIIc 296.12 292 Bc 232.83 207
MIId 140.18 134 Bd 1115.3 1027
MIIe 206.48 184 DMa 88.26 70159
Figure 3. 33: Electropherograms of amplified cRNA on the Bioanalyzer Nanochip. A broad hump
was seen starting at approximately 25 seconds for all samples, diminishing between 40-50 seconds.160
Figure 3. 34: Example of agarose gel analysis of amplified cRNA. Image indicates a 1.5% agarose gel
stained with ethidium bromide. Amplified cRNA was run alongside a 0.5-10kb RNA Ladder (Invitrogen,
UK). A smear was seen starting from <500bp.
Samples MIIa and MIIb that gave the lowest concentration readings after two rounds of
amplification were pooled together into 186μl of sample MIIa+b (93μl each) and
concentrated down to approximately 95μl by vacuum centrifugation (Concentrator plus,
Eppendorf UK Limited). The concentration of the new sample MIIa+MIIb was
54.06ng/μl.
3.3.1.3 Microarray hybridization
The recommended amount of labelled cRNA for hybridization on the array is 10 μg.
Table 3.23 indicates the total yield in microgram (μg) of labelled cRNA for each sample
from a final volume of 95μl based on the nanodrop readings of table 3.22 (5 out of the
100μl of the eluted sample were kept separately for agarose gel and/or concentration
assessment).
10 μg, the recommended amount, was available for three oocyte and three blastocyst
samples and was used to perform hybridizations in triplicate for each sample type.
Five microgram of labelled cRNA was hybridized for samples MIIa+b, Ba and DMa.161
Table 3. 23: Total RNA yield (μg) for each amplified sample available for hybridization on the
microarray. Shaded areas indicate a yield lower than the recommended 10μg.
The following microarray experiments were performed (patient/sample details as in
section 2.3.3.2):
 MII oocyte triplicates
o MIIc
o MIId
o MIIe
 Blastocyst stage embryo triplicates
o Bb
o Bc
o Bd
 Three microarray experiments were performed for samples MIIa+b, Ba and
DMa, by hybridizing 5μg of labelled cRNA due to the lower yield achieved.
Following scanning and analysis, the Expression Array System software of the
Chemiluminescent genetic analyzer produced heat map images, where the processed
samples were grouped based on the similarity of the detected signals (figure 3.35).
Additionally, hierarchical clustering analysis provided a visual representation of the
data, illustrating in a dendogram (tree graph) the grouping of genes based on the
similarity between them. The gene clusters that are closest to each other are combined
into a higher-level cluster (Quackenbush, 2001) (figures 3.36, 3.37).
The level of expression was also indicated by colouring based on the log2 (ratio), as
described in methods section 2.5.6. Log2 values close to zero were coloured black,
values greater than zero (up-regulated genes) were coloured red and values lower than
zero (down-regulated genes) were coloured green. The intensity of the colour also
represented the level of differential expression.
OOCYTES cRNA yield (μg) EMBRYOS cRNA yield (μg)
MIIa+MIIb 5.14 Ba 5.65
MIIc 28.13 Bb 12.02
MIId 13.32 Bc 22.12
MIIe 19.62 Bd 105.95
DMa 8.38162
Figure 3. 35: Heat map for triplicates of oocytes and embryo samples of over 10 μg yield. Colour
coding indicates the degree of similarity. Red colour is a sign of high similarity, with bright red
representing the highest degree of similarity between two samples, while green colour indicates
dissimilarity. As seen in the image, embryo samples Bb, Bc and Bd were successfully identified as being
similar between them (red squares). The same applies for the oocyte samples, MIIc, MIId and MIIe (here
labelled MIc, MId and MIe).163
Figure 3. 36: Hierarchical clustering analysis of oocyte and embryo (>10μg yield) replicate array
experiments. The dendogram shows a grouping of all genes based on the similarity between them. The
oocyte and blastocyst samples were grouped separately by the software. Red colour: upregulated genes.
Green colour: downregulated genes. The level of up- or down-regulation is reflected by the intensity of
the colour. Samples MIIc, MIId and MIIe were noted MIc, MId and MIe, when setting the sample list for
analysis and are indicated as such in this figure produced by the instrument.164
Figure 3. 37: Hierarchical clustering analysis of all array elements (addition of samples MIIab
(labelled MIab in figure), Ba and DMa, to the previous dendogram). Overall, all oocyte and embryo
samples were grouped separately. The DM1 affected embryo sample (circled) showed the least similarity
compared to the remaining embryo samples.165
3.3.2 Gene expression profiling of human oocytes and embryo blastocysts
3.3.2.1 Determining the level of gene expression
The oocyte and blastocyst samples were analyzed independently and genes in each
sample type were classified into groups of high, medium and low expression. In order to
calculate the cut-offs for each category, the top and bottom 5% of all detected signal
values were eliminated at first, so as to avoid any outlier values. Following that, the
number of detected probes was equally split into three groups according to the signal
value as indicated in table 3.24.
Table 3. 24: Oocyte and blastocyst signal intensity units for high, medium and low expression level
Expression
level
Oocyte signal
Intensity units
(probes/ genes)
Blastocyst signal
Intensity units
(probes/ genes)
High >22686
(4088/3870)
> 29526.36
(4591/4303)
Medium 6016.72-
22681.77
(3504/3326)
7254.45-
29525.33
(3935/3700)
Low < 6015.22
(4087/3788)
< 7253.86
(4592/4282)
3.3.2.2 Assessment of microarray results
The level of expression of cumulus cell-specific genes, kit ligand (KITLG),
steroidogenic acute regulator (STAR), gremlin1 (GREM1), prostaglandin-endoperoxide
synthase 2 (PTGS2), pentraxin-related gene (PTX3), amphiregulin (AREG) and
epiregulin (EREG) was investigated in order to exclude contamination from RNA
belonging to cumulus cells (Kocabas et al., 2006;Menezo, Jr. et al., 2007).
KITLG, STAR, GREM1, PTX3, AREG, and EREG were not detected in any of the
oocyte or embryo replicates. PTGS2 was also absent from the oocyte samples and gave
a very low signal (841 intensity units) in only one of the embryo replicates (Bd).166
Further initial analysis involved the investigation of several genes with known
expression levels in oocytes and embryos, as reported by other investigators, as a way of
assessing the accuracy of these results. For example, the results confirmed higher
expression of programmed cell death 5 (PDCD5) and adenomatosis polyposis coli (APC)
in oocytes compared to blastocysts (fourteen and four times higher respectively), and
higher expression of H2A histone family, member Z (H2AFZ) and beta actin (ACTB) in
the blastocyst samples, compared to the oocytes (showing 180 times and 13 times fold
change respectively). In addition, RB1 was not detected in the oocyte samples, but
showed medium expression level (12700 intensity units) in the blastocyst samples
(Dobson et al., 2004;Wells et al., 2005b).
3.3.2.3 Global characteristics of human oocyte and human blastocyst gene
expression
The total number of probes detected after sorting the microarray data by signal-to-noise
ratio and flags, as described in Methods section 2.5.6, were 14662 (MIIc), 16821 (MIId)
and 15062 (MIIe) for the oocyte samples and 15652 (Bb), 17654 (Bc) and 16011 (Bd)
for the embryo samples. Only genes where probes were consistently detected in all three
replicates of a sample were taken as expressed. Overall, an average signal value from
three replicates was available for 11679 probes for the oocytes and 13118 probes for the
blastocyst samples.
The genes detected in the oocyte and blastocyst samples were mapped to the
PANTHER database biological process categories and compared to the list of genes
available on the microarray (using gene expression tools of the PANTHER database).
The proportion of genes belonging to the protein biosynthesis, protein metabolism and
nucleic acid metabolism categories was greater than statistically expected in both
sample types (p<0.001). Other significantly over-represented categories included cell
cycle, DNA metabolism, DNA repair, DNA replication, oxidative phosphorylation,
translational regulation, mRNA splicing, rRNA metabolism (p<0.001).
The oocyte and blastocyst genes were listed by level of expression. The 50 genes with
highest expression in oocytes and blastocysts are listed in tables A3.1 and A3.2 of
appendix 3. These were investigated in more detail as indicators of the most important
processes involved in each developmental stage. A summary of the most represented167
biological function categories from the fifty genes of highest expression is shown in
table 3.25. Oocytes and blastocysts shared only eight probe IDs, within the fifty genes
of highest expression (table 3.26).
Table 3. 25: Classification by biological process of 50 genes with highest gene expression in the
human MII oocyte and human blastocyst
Percentage of genes
Biological Process Oocyte Blastocyst
Biological process unclassified 27.9 6.9
Protein metabolism and modification 26.5 69
Nucleoside, nucleotide and nucleic acid
metabolism
11.8 5.2
Cell cycle 10.3 -
Transport 4.4 -
Cell proliferation and differentiation 4.4 3.4
Developmental processes 2.9 -
Intracellular protein traffic 2.9 5.2
Cell structure and motility 2.9 1.7
Carbohydrate metabolism 1.5 1.7
Homeostasis 1.5 -
Immunity and defense 1.5 6.9
Oncogenesis 1.5 -
Table 3. 26: List of genes shared between the top 50 of highest signal in both oocyte and embryo
samples.
Gene
Symbol
Gene
Name
Biological process Oocyte
Signal
Position
Blastocyst
Signal
Position
FLJ40448 Unassigned Unclassified 5 13
GPR103 G protein-coupled
receptor 103
G-protein mediated
signalling
7 24
RPLP1 ribosomal protein,
large, P1
Protein biosynthesis 9 14
HNRPA1 heterogeneous
nuclear
ribonucleoprotein
A1
mRNA splicing 12 26
RPL7A ribosomal protein
L7a
Protein biosynthesis 15 34
Unassigned Unassigned Biological process
unclassified
33 29
LOC440055 Unassigned Protein biosynthesis 52 28168
3.3.2.4 Differential expression
There was a statistically significant difference in gene expression (p<0.05) between
oocytes and blastocysts for 5243 probes (4910 genes). The majority of the differentially
expressed genes were of unclassified biological function (37.3%) followed by genes
belonging to the protein metabolism and modification class (18.7%), and the nucleic
acid metabolism class (16.7%).
Overall, 2591 probes were underexpressed, and 2652 probes were overexpressed in the
blastocyst compared to the oocyte (based on log2 ratios, as previously described). Most
genes with higher expression in the blastocyst belonged to the protein metabolism and
modification class, with the majority involved in protein biosynthesis. On the other hand,
genes showing higher expression in the oocyte sample were mostly involved in nucleic
acid metabolism, mainly mRNA transcription (figures 3.38-3.40).
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Figure 3. 38: Genes differentially expressed in the blastocyst compared to the oocyte sample
(p<0.05). Genes were identified using the Celera dataset and grouped per PANTHER biological process
category.x axis: number of genes, y axis: PANTHER biological process
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0 100 200 300 400
Protein biosynthesis
Proteolysis
Protein modification
Protein folding
Translational regulation
Protein complex assembly
Amino acid activation
Other protein metabolism
Higher in blastocyst
Higher in oocyte
Figure 3. 39: Sub-categories of the protein metabolism and modification biological process. Most
genes showing higher expression in the blastocyst are involved in protein biosynthesis. Most protein
modification genes were downregulated at the blastocyst stage. x axis: number of genes, y axis:
PANTHER biological process
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Figure 3. 40: Sub-categories of the nucleic acid metabolism biological process. The majority of genes
involved in mRNA transcription showed higher expression in the oocyte. Genes involved in pre-mRNA
processing, mostly in mRNA splicing, showed higher expression at the blastocyst stage. x axis: number of
genes, y axis: PANTHER biological process
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When this data were further limited to those probes that showed a 10-fold or higher
level change, 1693 probes were identified. Of these, 722 (679 genes) were
overexpressed (log2(ratio)>3.32) and 970 probes (918 genes) were underexpressed
(log2(ratio) < -3.32) in the blastocyst compared to the oocyte.
The 10-fold change genes were analyzed based on molecular function. The majority of
blastocyst upregulated genes belonged to the nucleic acid binding category (131 genes)
and of these most were annotated “ribosomal proteins”, “other RNA-binding proteins”,
“translation factors”, “histone” or “helicase” (figure 3.41).
Figure 3. 41: Grouping of 131 nucleic acid binding category genes (128 function hits) that were 10-
fold up-regulated in the human blastocyst.
The majority of blastocyst downregulated genes were also of “nucleic acid binding”
molecular function (105 genes), and most were annotated “other DNA-binding protein”,
“nuclease” and “chromatin/chromatin-binding protein” (figure 3.42). The second
biggest category of downregulated genes was the “transcription factor” category,
comprising 100 genes, 53% of them being “zinc-finger transcription factors”.171
Figure 3. 42: Grouping of 105 nucleic acid binding genes (80 hits) 10-fold down-regulated in the
blastocyst
3.3.2.5 Oocyte and blastocyst-specific genes
Genes expressed in oocytes only (maternal) or blastocysts only (embryonic) were
identified. Gene search was performed using the Celera dataset gene ID (PANTHER
database). There were 8772 genes with expression common to MII oocytes and
blastocysts, 1909 genes were expressed in oocytes only and 3122 genes in blastocysts
only (figure 3.43).
Figure 3. 43: Identification of genes unique in oocytes and blastocysts. Genes were identified by their
Celera dataset ID.172
The majority of genes uniquely expressed in oocytes, when grouped by biological
process, were annotated unclassified (45.1%), signal transduction (14.1%), nucleic acid
metabolism (12.3%), protein metabolism (10%) and developmental processes (9.8%).
When grouped by molecular function most genes were either of unclassified function
(43.7%), transcription factors (8%) or involved in nucleic acid binding (7.6%). Finally,
when analyzed by PANTHER pathway, oocyte-specific genes mostly belonged to the
following pathways: Wnt signaling pathway, Inflammation mediated by chemokine and
cytokine signalling pathway, Huntington disease, Interleukin signaling pathway, PDGF
signaling pathway, Angiogenesis, Integrin signaling pathway, TGF-beta signaling
pathway, Cadherin signaling pathway, B cell activation and G-protein signaling
pathway.
Similarly, blastocyst-specific genes, when grouped by biological process, were
annotated unclassified (42.9%), nucleic acid metabolism (15%), protein metabolism
(12.1%), signal transduction (10.6%) and developmental processes (8%). By molecular
function 40.7% of genes were unclassified, 12.9% had a role in nucleic acid binding and
8.7% were transcription factors. Important pathways of blastocyst-specific genes were
annotated in the following order: Wnt signaling pathway, Interleukin signaling pathway,
integrin signalling pathway, inflammation mediated by chemokine and cytokine
signalling pathway, angiogenesis, PDGF signaling pathway, TGF-beta signalling
pathway, EGF receptor signaling, FGF signaling pathway and p53 pathway.
Therefore, the main differences in gene expression that were generally observed
between oocytes and embryos were also reflected in the analysis of oocyte and
blastocyst-specific gene expression. Overall, the Wnt signalling pathway was the most
represented in both oocyte and blastocyst-specific genes. Other oocyte pathways,
particularly the inflammation mediated by chemokine and cytokine signaling pathway
showed expression of a similar number of genes as the Wnt signalling pathway.
In order to identify which genes are most significant at each developmental stage, the
oocyte and blastocyst-specific genes were then separately grouped by expression level
(as in table 3.24). There were 349 of the oocyte-specific genes and 431 of the
blastocyst-specific genes that showed high expression levels listed in appendix 3 tables
A3.3 and A3.4. Figures 3.44 and 3.45 allow a direct comparison of these, both by
biological process and molecular function. On analysis by PANTHER pathway of high173
expression genes, the main pathway for MII oocytes remained the Wnt signaling
pathway, whereas the high expression blastocyst specific genes belonged to the integrin
signaling pathway, cytoskeletal regulation by Rho GTPase, angiogenesis and PDGF
signaling pathway. A summary of sample-specific gene expression, with a focus on
highly expressed genes is given in tables 3.27 and 3.28.
Figure 3. 44: Grouping by A) PANTHER Biological process and B) PANTHER Molecular function
of 349 high expression genes unique in oocytes (categories numbered clock-wise). Percentage of gene
hits per category against total number of genes is indicated in brackets. Categories not detected in the
high expression blastocyst-specific genes are underlined. The five biggest categories are indicated in bold
type.
A) Biological process. 1: Unclassified (42.4%) 2.Carbohydrate metabolism (2%). 3. Cell adhesion
(4.6%). 4. Cell cycle (6.3%). 5. Cell proliferation and differentiation (3.7%). 6. Cell structure and
motility (6.6%). 7. Coenzyme and prosthetic group metabolism (0.6%). 8. Developmental processes
(12.9%). 9. Homeostasis (1.4%). 10. Immunity and defense (4.6%). 11. Intracellular protein
trafficking (5.4%). 12. Lipid, fatty acid and steroid metabolism (3.4%). 13. Muscle contraction
(1.7%). 14. Neuronal activities (2.6%). 15. Nucleoside, nucleotide and nucleic acid metabolism
(12%). 16. Oncogenesis (2%). 17. Other metabolism (1.7%). 18. Phosphate metabolism (0.6%). 19.
Protein metabolism and modification (8.6%). 20. Protein targeting and localization (0.9%). 21.
Sensory perception (1.4%). 22. Signal transduction (15.5%). 23. Sulfur metabolism (1.1%). 24.
Transport (6%). 25. Amino acid metabolism (1.1%). 26. Apoptosis (2.3%)
B) Molecular function. 1. Unclassified (43.3%). 2. Nucleic acid binding (7.4%). 3. Oxidoreductase
(2%). 4. Phosphatase (2.3%). 5. Protease (1.4%). 6. Receptor (8.3%). 7. Select calcium binding
protein (1.1%). 8. Select regulatory molecule (3.7%). 9. Signaling molecule (4.6%). 10. Synthase and
synthetase (0.3%). 11. Transcription factor (7.2%). 12. Transfer/carrier protein (0.6%). 13.
Transferase (2.6%). 14. Transporter (2.9%). 15. Cell adhesion molecule (2.9%). 16. Cell junction
protein (0.6%). 17. Chaperone (0.6%). 18. Cytoskeletal protein (5.2%). 19. Defense/immunity
protein (1.4%). 20. Extracellular matrix (2.6%). 21. Hydrolase (4%). 22. Ion channel (1.7%). 23.
Isomerase (1.1%). 24. Kinase (3.7%). 25. Ligase (0.6%). 26. Lyase (0.9%). 27. Membrane traffic
protein (0.6%). 28. Miscellaneous function (3.7%).
B A174
Figure 3. 45: Grouping by A) PANTHER Biological process and B) PANTHER Molecular function
of 431 high expression genes unique in human blastocysts (categories numbered clock-wise).
Percentage of gene hit per category against total number of genes is indicated in brackets. Categories not
detected in high expression oocyte-specific genes are underlined. The five biggest categories are indicated
in bold type.
A) Biological process. 1: Unclassified (31.3%) 2.Blood circulation and has exchange (0.5%). 3.
Carbohydrate metabolism (5.3%). 4. Cell adhesion (0.9%). 5. Cell cycle (3.9%). 6. Cell proliferation
and differentiation (2.8%). 7. Cell structure and motility (11.8%). 8. Coenzyme and prosthetic group
metabolism (2.3%). 9. Developmental processes (12.5%). 10. Electron transport (2.1%). 11.
Homeostasis (0.7%). 12. Immunity and defense (3.2%). 13. Intracellular protein trafficking (5.3%).
14. Lipid, fatty acid and steroid metabolism (4.2%). 15. Miscellaneous (0.9%). 16. Neuronal
activities (2.1%). 17. Nucleoside, nucleotide and nucleic acid metabolism (15.1%). 18.
Oncogenesis (3%). 19. Other metabolism (2.8%). 20. Protein metabolism and modification
(12.5%). 21. Protein targeting and localization (1.9%). 22. Sensory perception (0.7%). 23. Signal
transduction (9.3%). 24. Sulfur metabolism (0.2%). 25. Transport (5.3%). 26. Amino acid
metabolism (1.4%). 27. Apoptosis (2.3%).
B) Molecular function. 1. Unclassified (30.9%). 2. Nucleic acid binding (16.2%). 3. Oxidoreductase
(4.6%). 4. Phosphatase (1.4%). 5. Protease (1.2%). 6. Receptor (2.8%). 7. Select calcium binding
protein (2.1%). 8. Select regulatory molecule (4.2%). 9. Signaling molecule (2.8%). 10. Synthase and
synthetase (1.9%). 11. Transcription factor (6.3%). 12. Transfer/carrier protein (2.6%). 13.
Transferase (5.8%). 14. Transporter (2.6%). 15. Cell adhesion molecule (0.5%). 16. Cell junction
protein (0.7%). 17. Chaperone (0.5%). 18. Cytoskeletal protein (11.1%). 19. Defense/immunity
protein (0.9%). 20. Extracellular matrix (0.2%). 21. Hydrolase (2.6%). 22. Ion channel (0.7%). 23.
Isomerase (1.4%). 24. Kinase (2.3%). 25. Ligase (1.2%). 26. Lyase (0.9%). 27. Membrane traffic
protein (2.3%). 28. Miscellaneous function (10%).
B A175
Table 3. 27: Grouping of oocyte and blastocyst-specific gene categories by PANTHER biological process. Bold type indicates points of discussion.
Biological Process Main represented gene categories
Oocyte-specific genes High expression oocyte-specific genes Blastocyst-specific
genes
High expression blastocyst-specific
genes
Carbohydrate metabolism Other polysaccharide metabolism Glycogen metabolism, glycolysis, other Other polysaccharide
metabolism
Glycolysis
Cell cycle Cell cycle control Cell cycle control, mitosis (chromosome
segregation)
Cell cycle control,
mitosis
Mitosis (chromosome segregation)
Cell structure and motility Cell structure Cell motility, cell structure Cell structure Cell structure
Coenzyme and prosthetic group
metabolism
Vitamin/cofactor transport Vitamin/cofactor transport, other Coenzyme metabolism,
Vitamin/cofactor
transport
Porphyrin metabolism, vitamin
metabolism
Developmental processes Ectoderm development Ectoderm development Ectoderm development Ectoderm development
Electron transport Other n/a Oxidative
phosphorylation
Oxidative phosphorylation
Homeostasis Calcium ion homeostasis, other Calcium ion, growth factor homeostasis Other Other
Immunity and defense Stress response Stress response, blood clotting Stress response Blood clotting,
detoxification,macrophage mediated
immunity, stress response
Intracellular protein trafficking Endocytosis Endocytosis, exocytosis Endocytosis (general
vesicle transport)
General vesicle transport
Lipid, fatty acid and steroid
metabolism
Lipid metabolism Lipid, phospholipid metabolism Steroid metabolism
(cholesterol)
Steroid metabolism (cholesterol)
Neuronal activities Synaptic transmission Synaptic transmission Synaptic transmission Other
Nucleoside, nucleotide and nucleic acid
metabolism
mRNA transcription (regulation) mRNA transcription (regulation) mRNA transcription
(regulation)
mRNA transcription (regulation)
Oncogenesis Tumor suppressor Oncogene, tumor suppressor Other Tumor suppressor, other
Protein metabolism and modification Protein modification Protein modification (phosphorylation) Protein modification
(phosphorylation)
Protein biosynthesis, protein
modification (phosphorylation)
Protein targeting and localization Protein targeting Asymmetric protein localization Protein targeting Protein targeting
Signal transduction Cell surface receptor mediated
signal transduction
Cell surface receptor mediated signal
transduction (G-protein mediated)
Cell surface receptor
mediated signal
transduction (G-protein)
Cell communication (cell-adhesion
mediated signaling)
Transport Ion transport (cation) Ion transport (cation) Ion transport (cation) Ion transport (cation)
Amino acid metabolism Amino acid transport Other metabolism Amino acid catabolism Amino acid biosynthesis, catabolism
Apoptosis Inhibition of apoptosis Inhibition of apoptosis Induction of apoptosis Inhibition of apoptosis176
Table 3. 28: Grouping of oocyte and blastocyst-specific gene categories by PANTHER molecular function. Bold type indicates points of discussion
Molecular Function Main represented gene categories
Oocyte-specific genes High expression oocyte-specific
genes Blastocyst-specific genes High expression blastocyst-specific
genes
Nucleic acid binding Other RNA-binding protein Chromatin/chromatin-binding
protein
Ribosomal protein Other RNA-binding protein
Oxidoreductase Dehydrogenase Dehydrogenase, other oxidoreductase Dehydrogenase Dehydrogenase
Phosphatase Protein phosphatase Protein phosphatase Protein phosphatase Other phosphatase
Protease Serine protease Serine protease Serine protease Metalloprotease
Receptor Other receptor (G-protein) Other receptor G-protein coupled receptor Other receptor
Select calcium binding protein Calmodulin related protein Calmodulin related protein Calmodulin related protein Calmodulin related protein
Select regulatory molecule G-protein modulator G-protein, kinase modulator G-protein modulator (G-protein) G-protein, kinase modulator
Signaling molecule Other signaling molecule Growth factor Other signaling molecule Other signaling molecule
Synthase and synthetase Synthase and synthetase Synthase (100%) Synthase Synthetase
Transcription factor Zinc finger transcription factor Zinc finger transcription factor Zinc finger transcription factor Zinc finger transcription factor
Transfer/carrier protein Other transfer/carrier protein Mitochondrial carrier protein Other transfer/carrier protein Other transfer/carrier protein
Transferase Glycosyltransferase Acyltransferase Methyltransferase Methyltransferase
Transporter Other transporter Other transporter Other transporter Other transporter
Cell adhesion molecule Other cell adhesion molecule Other cell adhesion molecule Other cell adhesion molecule Other cell adhesion molecule
Cell junction protein Tight junction, other Tight junction Tight junction Gap junction
Chaperone Other chaperones Other chaperones Other chaperones Chaperonin
Cytoskeletal protein Microtubule family cytoskeletal
protein
Microtubule family cytoskeletal
protein
Intermediate filament Intermediate filament
Defense/immunity protein Immunoglobulin, other Complement component Immunoglobulin receptor family
member
Antibacterial response protein,
complement component, other
Extracellular matrix Extracellular matrix glycoprotein Extracellular matrix glycoprotein Extracellular matrix glycoprotein Extracellular matrix linker protein
Hydrolase Lipase, other hydrolase Other hydrolase Other hydrolase Other hydrolase
Ion channel Voltage-gated ion channel Voltage-gated ion channel Voltage-gated ion channel Voltage-gated ion channel
Isomerase Epimerase/racemase Other isomerase Epimerase/racemase, other
isomerase
Other isomerase
Kinase Protein kinase Protein kinase Protein kinase Protein kinase
Ligase Ubiquitin-protein ligase Ubiquitin-protein ligase Ubiquitin-protein ligase Other ligase, Ubiquitin-protein ligase
Lyase Cyclase Decarboxylase Dehydratase Dehydratase
Membrane traffic protein Membrane traffic regulatory
protein
Membrane traffic regulatory protein,
SNARE protein
Membrane traffic regulatory
protein
Membrane traffic regulatory protein
Miscellaneous function Other Other Structural protein Structural protein177
3.3.3 Investigation of potential housekeeping gene expression
Housekeeping genes (HKG) investigated in human oocytes and embryos included:
 Genes generally involved in maintaining basic cell functions
 Genes common in three published datasets investigating HK gene expression on
differentiated adult tissue, and
 Genes stably expressed in undifferentiated and differentiating human embryonic
stem cells (hESCs)
3.3.3.1 Genes maintaining basic cell functions
The expression of 411 housekeeping genes involved in transcription, transport,
translation and proteolysis was investigated in MII oocytes and blastocyst stage
embryos, with a focus on those genes with a significantly different expression between
the two samples or higher than 10 times fold change (411 genes reported by Zhu et al.,
2008).
For 164 genes the detected signal value showed a statistically significant difference
between oocytes and blastocysts. Most genes (119) were up-regulated in the blastocyst,
while 45 of them were down-regulated. Although most categories indicated both up-
and down-regulated genes, in certain groups, tRNA synthetase, hnRNP and snRNP, all
genes with a significant difference were found up-regulated in the blastocyst (table
3.29).
In contrast, genes belonging to the nuclear pore complex category were found down-
regulated in the blastocyst sample. The genes with over a 10-fold positive or negative
difference in expression between the two samples are also indicated in table 3.29. The
SFRS2 gene, involved in mRNA splicing, is highlighted (table 3.29) for being over 100
times upregulated in the blastocyst sample.178
3.3.3.2 Genes identified as HKG from adult tissue studies
Further analysis involved other genes commonly considered as housekeeping genes
based on information from three previously published datasets investigating HKG in
differentiated adult tissue. Although each dataset provided a list of approximately 500
genes, only 155 were shared between them. The current investigation focused on these
common genes (list kindly provided by Dr. Zhu, personal communication), excluding
those, mainly ribosomal proteins, that had already being included in the previous search
of 411 genes. A total of 125 genes were investigated. Table 3.30 summarizes results. As
previously, the >10-fold up and down-regulated genes are indicated. Similarly, the
majority of genes with differential expression were up-regulated in the blastocyst
sample. Commonly used genes, ACTB and GAPDH, showed over a 10-fold difference
in expression between the two samples.179
Table 3. 29: Investigation of 411 HKGs in human MII oocytes and blastocyst stage embryos. Each
column indicates the number of probe ID and/or number of genes detected. The human oocyte was used
as the control. Genes up-regulated and down-regulated in the human blastocyst are indicated here. +: up-
regulated genes, -: down-regulated genes, FC: fold change
FC >10
(gene symbol)
Gene category
(number of genes)
Oocytes
(number of
probe ID hits/
number of
genes detected)
Blastocysts
(number of
probe ID hits/
number of
genes detected)
p<0.05
(probe ID/
genes
detected)
(number of
genes +/-)
+ -
Transcription pre-
initiation complex
(40)
32/31 32/30 14/14
(5+/9-) n/a CDK7,
GTF2B
Transcription elongation
complex
(17)
15/15 17/15 12/10
(7+/3-)
SUPT4H1,
TCEB2, RDBP CCNT1
Essential splicing factor
(31) 29/24 33/26 13/12
(11+/1-)
SFRS2, SFRS3,
YBX1 n/a
hnRNP
(18) 18/16 21/17 9/9
(9+) HNRPA3 n/a
snRNP
(32) 29/29 31/31 12/12
(12+) n/a n/a
Capping related genes
(5) 4/3 5/4 1/1
(1+) n/a n/a
Cleavage and
polyadenylation complex
(13)
12/10 13/11 6/6
(4+/2-)
FLJ12529,
COLEC12 n/a
Nuclear Pore complex (28) 25/23 25/23 12/11
(11-) n/a NUP35,
NUP133
Translation initiation,
elongation and
termination factor
(37)
34/31 40/36 24/22
(20+/2-)
ETF1, E1F5,
E1F4A1,
E1F3S1,
E1F4EBP1
n/a
tRNA synthetase
(20) 17/17 19/19 12/12
(12+) AARS, WARS n/a
Cytosolic ribosome
(82) 102/68 103/71 31/26
(24+/2-)
MRPS12,
RPL34 n/a
Ubiquitin mediated
proteolysis
(45)
34/33 32/31 15/14
(4+/10-) CDC23, TCEB2
HERC1,
SKP2,
BTRC,
SKP1A
Proteasome
(43) 31/31 37/35 15/15
(10+/5-) PSMC3, PSME2 n/a
Total: 411 382/331 408/349 176/164
(119+/45-)180
Table 3. 30: Investigation of 125 HKGs genes, common in three HKG datasets, in human oocytes
and blastocyst stage embryos. +: upregulated genes, -: downregulated genes, FC: fold change
Overall, out of the 536 HKGs investigated (411+125 genes, sections 3.3.3.1 and 3.3.3.2),
427 were detected in the oocyte and 452 in the blastocyst. For 277 of HKGs detected in
the oocytes (64.87%), and 355 of the blastocyst genes (78.5%), the probe signal
detected on analysis was high. 90.9% of the high signal oocyte HKGs (252 genes)
remained of high signal in the blastocyst samples. The genes that maintained a high
signal in both oocytes and blastocysts are listed in table A3.5 of appendix 3.
Figure 3.46 indicates the expression levels in oocytes and blastocysts of several of the
commonly used housekeeping genes and figure 3.47 lists genes found in other studies to
be stably expressed during preimplantation development of the human and other
species’ embryos, and the corresponding results from the analysis of human oocytes and
blastocysts in this study. B2M (a major histocompatibility complex antigen),
HIST1H2AA and HIST3H2A (histones) were only detected at the blastocyst stage.
FC >10
(gene symbol)
Gene
category
(number of genes)
Oocytes
(number of
probe ID hits/
number of genes
detected)
Blastocysts
(number of
probe ID hits/
number of
genes detected)
p<0.05
(probe ID/
genes detected)
(number of
genes +/-)
+ -
125 other common
HK genes
105/96 115/103 52/47
(36+/11-)
ACTB,
ALDOA,
ATF4,
ENO1,
GAPDH,
GPX4,
MRPS12,
MYL6,
NCL,
NONO,
RPL34,
TMSB10,
TUBB2A
FKBP1A
USP11181
Figure 3. 46: Expression levels of selected commonly used HKGs in the human oocyte and
blastocyst. **p<0.01, ***p<0.001
Figure 3. 47: Signal values of genes found to be stably expressed in different species. Blue brackets:
human. Red brackets: mouse. Green brackets: rabbit. Orange brackets: bovine.
*p<0.05, **p<0.01, ***p<0.001182
All detected genes in the parametric comparison were listed based on their differences
in expression between the two samples. The smallest differences in expression levels
were observed for the following 20 genes, most of which are involved in protein and
nucleic acid metabolism biological processes (table 3.31).
Table 3. 31: Genes showing similar expression levels between the human MII oocytes and
blastocysts
Gene Symbol Gene Name
CTNNB1 catenin (cadherin-associated protein), beta 1, 88kDa
EEF1D eukaryotic translation elongation factor 1 delta (guanine nucleotide
exchange protein)
ASCC3L1 activating signal cointegrator 1 complex subunit 3-like 1
WDR57 WD repeat domain 57 (U5 snRNP specific)
PCBP2 poly(rC) binding protein 2
RPL23A ribosomal protein L23a
GTF2A2 general transcription factor IIA, 2, 12kDa
SFRS5 splicing factor, arginine/serine-rich 5
RPL28 ribosomal protein L28
POLR2F polymerase (RNA) II (DNA directed) polypeptide F
CLN5 ceroid-lipofuscinosis, neuronal 5
RPL37A ribosomal protein L37a
TCEB1 transcription elongation factor B (SIII), polypeptide 1 (15kDa, elongin C)
PFDN5 prefoldin 5
CARS cysteinyl-tRNA synthetase
EIF3S5 eukaryotic translation initiation factor 3, subunit 5 epsilon, 47kDa
SNRPD3 small nuclear ribonucleoprotein D3 polypeptide 18kDa
PTDSS1 phosphatidylserine synthase 1
RPS23 ribosomal protein S23
ARF1 ADP-ribosylation factor 1
The first twenty signals of highest intensity out of all investigated genes in both oocytes
and blastocysts are shown in table 3.32 in order of expression from high to low.
Amongst these, eight genes were common between the two samples.183
Table 3. 32: List of twenty highest signal probes detected in the human MII oocyte and embryo
blastocyst. Bold type highlights genes present in both sample lists.
Oocyte Blastocyst
Gene
Symbol Gene Name
Gene
Symbol Gene Name
RPLP1 ribosomal protein, large, P1 RPS4X ribosomal protein S4, X-linked
RPLP1 ribosomal protein, large, P1 RPS11 ribosomal protein S11
RPL7A ribosomal protein L7a RPS11 ribosomal protein S11
H3F3B H3 histone, family 3B (H3.3B) RPLP1 ribosomal protein, large, P1
UBB ubiquitin B RPLP1 ribosomal protein, large, P1
SKP2
S-phase kinase-associated
protein 2 (p45) PABPC1
poly(A) binding protein,
cytoplasmic 1
CDK7
cyclin-dependent kinase 7
(MO15 homolog, Xenopus
laevis, cdk-activating kinase) PRDX1 peroxiredoxin 1
EEF1A1
eukaryotic translation elongation
factor 1 alpha 1 RPL24 ribosomal protein L24
RPS12 ribosomal protein S12 ENO1 enolase 1, (alpha)
RPS12 ribosomal protein S12 RPS27A ribosomal protein S27a
RPS11 ribosomal protein S11 RPS27A ribosomal protein S27a
RPS11 ribosomal protein S11 EEF2
eukaryotic translation elongation
factor 2
RPL41 ribosomal protein L41 EEF2
eukaryotic translation elongation
factor 2
EEF1A1
eukaryotic translation elongation
factor 1 alpha 1 RPS7 ribosomal protein S7
SNRPE|
SNRPEL1
small nuclear ribonucleoprotein
polypeptide E|small nuclear
ribonucleoprotein polypeptide
E-like 1 RPLP2 ribosomal protein, large, P2
RPLP2 ribosomal protein, large, P2 RPL18 ribosomal protein L18
RPL41 ribosomal protein L41 RPL18 ribosomal protein L18
RPS23 ribosomal protein S23 RPL5 ribosomal protein L5
EEF2
eukaryotic translation
elongation factor 2 RPL7A ribosomal protein L7a
EEF2
eukaryotic translation
elongation factor 2 ACTB actin, beta
3.3.3.3 Genes identified as HKG from undifferentiated and differentiating stem cell
lines
Synnergren et al., (2007), identified the 24 most stably expressed genes in
undifferentiated and early differentiating hESCs and the expression of these was
investigated in our oocyte and embryo samples. Thirteen out of these 24 genes were
detected (table 3.33). For four of them, underlined in the table, there was a significant
difference (adj. p<0.05) in the signal detected between the two samples. FLJ20186 and184
HDDC2, both of uncharacterized molecular function, were over 10-fold upregulated in
the blastocyst sample.
Table 3. 33: Level of expression in the human oocyte and blastocyst for 13 of the 24 most stably
expressed genes in differentiating hESCs. Underlined gene symbols indicate a statistically significant
difference. The human MII oocyte was used as the control. +FC: up-regulated in the blastocyst, compared
to the MII oocyte, -FC:down-regulated in the blastocyst, compared to the MII oocyte. Bold type indicates
genes that were >10-fold up-regulated.ND: no statistically significant difference observed
Expression level
Gene ID
(Celera ID provided
unless otherwise
indicated)
Gene
Symbol Gene Name Oocyte Blastocyst
Parametric
comparison
(adj.p value)
hCG32850 CDC14A CDC14 cell division cycle 14
homolog A
hCG36828 KIAA0141 KIAA0141
hCG1811676 FLJ20186 hypothetical protein
FLJ20186 Low High <0.01,+FC
hCG1983988 RPL7 ribosomal protein L7
hCG14859 NUBP1 nucleotide binding protein 1 Medium High ND
hCG1646292 FLJ33977 DTW domain containing 2
hCG19988 HDDC2 HD domain containing 2 Medium High <0.01,+FC
hCG41427 PLEKHA1 pleckstrin homology domain
containing, family A High High <0.05,-FC
hCG40180 RIPK3 receptor-interacting serine-
threonine kinase 3 High Medium ND
hCG1999395 RND1 Rho family GTPase 1 Medium Low <0.01, -FC
hCG23905 CPNE2 copine II
hCG1810870 POLE polymerase (DNA directed),
epsilon
hCG32054 VSNL1 visinin-like 1
hCG2033817 GTF2H3 general transcription factor
IIH, polypeptide 3, 34kDa
hCG18037 ELN elastin n/a Low ND
Entrez: 5728 PTEN phosphatase and tensin
homolog High High ND
hCG22397 CA6 carbonic anhydrase VI
hCG23039 SLC5A11
solute carrier family 5
(sodium/glucose
cotransporter), member 11
High n/a
hCG20493 MLH3 mutL homolog 3
hCG15226 STIM1 stromal interaction molecule
1 Medium Medium ND
hCG16633 CREBBP CREB binding protein n/a Medium ND
hCG37392 HM13 histocompatibility (minor) 13 Medium Medium ND
hCG32870 FOXP4 forkhead box P4
Entrez:440026 TMEM41B transmembrane protein 41B Low Medium ND185
3.3.4 Assessment of gene expression for important functional pathways
Further analysis of the gene expression data focused on the investigation of pathways
associated with the disease mechanism in DM1 to identify genes present in oocytes and
embryos that may be affected by the DMPK expansion. Current investigation involved
genes regulating the microRNA processing pathway and methylation.
3.3.4.1 Investigation of genes involved in the microRNA processing pathway
Genes involved in microRNA processing were investigated in the oocyte and embryo
samples (Mtango et al., 2008). Out of the 25 genes examined, 16 were detected in the
oocyte and 17 in the embryo blastocyst sample (table 3.34, figure 3.48).
The investigation of the microRNA processing genes indicated that genes involved in
RNA catabolism, RNASEN and DICER1 are expressed in both oocytes and blastocysts,
with DICER1 showing significantly higher expression at the oocyte stage. High oocyte
activity was also observed for genes involved in mRNA splicing.
GEMIN5, GEMIN2 involved in mRNA splicing, and TNRC6B of the RISC complex
showed higher expression levels in the oocyte. YBX1, GEMIN4 and MOV10, with roles
in regulation of transcription and translation, as well as the exportins XPO1, XPO4 and
XPO5, were significantly upregulated in the blastocyst.186
Table 3. 34: Expression levels of genes involved in the microRNA processing pathway in the human
MII oocyte and blastocyst. +FC: up-regulated in the blastocyst, -FC:down-regulated in the blastocyst,
ND: no statistically significant difference observed
Expression level
Function Celera
Gene ID
Gene
Symbol Oocytes Blastocysts Parametric
comparison
hCG2003777 DROSHA/
RNASEN High High ND
hCG2001933 DGCR8 n/a Low ND
Microprocessing
hCG24439 DICER1 Medium Medium P<0.05, -FC
hCG1986857 XPO1 Medium High P<0.05, +FC
hCG1774337 XPO4 n/a Medium P<0.05, +FC
hCG19013 XPO5 Low Medium P<0.05, +FC
hCG41537 RANGAP1 n/a Low ND
Exportins
hCG18633 FMR1 Medium Medium ND
hCG18813 ADAR Medium n/a ND
RNA editing
hCG401275 ADARB1 Low n/a ND
hCG21235 SIP1 (GEMIN2) Medium Medium P<0.05, -FC
hCG27817 GEMIN4 Low Medium P<0.05, +FC
hCG1979691 GEMIN5 High Low P<0.01, >100-FC
hCG1818032 GEMIN6 High High ND
hCG22150 GEMIN7 n/a n/a n/a
mRNA splicing
4904 YBX1 High High P<0.01, >10+FC
hCG38282 AGO1/EIF2C1 n/a n/a n/a
hCG18139 AGO2/EIF2C2 High High n/a
hCG1640521 EIF2C3 n/a n/a n/a
hCG1787714 EIF2C4 Low Low ND
hCG33381 RISC/SCPEP1 n/a Medium n/a
hCG41115 TNRC6B Low n/a P<0.05, -FC
hCG38463 MOV10 Low Medium P<0.05, +FC
hCG22573 HIWI/PIWIL1 n/a n/a n/a
RISC complex
hCG1818433 MILI/PIWIL2 n/a n/a n/a187
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Figure 3. 48: Expression levels of microRNA machinery genes in human oocytes and embryo
blastocysts.188
3.3.4.2 DNA Methyltransferases in human oocytes and embryo blastocysts
Eighteen enzymes that methylate DNA bases were identified in the PANTHER database,
based on their Celera ID and their expression was investigated. Nine of these were
present in both oocytes and embryos, showing a medium and high expression level.
DNMT3L and METTL4 were detected at the blastocyst stage only. DNMT1, HSMPP8,
MGMT and POLS showed higher expression in the oocyte, while C21orf127, METTL4
and RG9MTD1 gave higher expression signals for the blastocyst sample (table 3.35).
Genes that were not detected included: DNMT2, DNMT3A, KIAA1935, PWWP2,
RG9MTD2 and RG9MTD3.
Table 3. 35: Expression levels of eleven human DNA methyltransferases (Celera database) present
in the human MII oocyte and/or embryo blastocyst. +FC: upregulated in the blastocyst, -
FC:downregulated in the blastocyst, ND: no statistically significant difference observed
Expression level
Celera
Gene ID
Gene
Symbol Oocytes Blastocysts Parametric
Comparison
hCG38847 AOF2 High High
hCG401157 C21orf127 Medium High P<0.05, +FC
hCG28474 DNMT1 High High P<0.01, >10 -FC
hCG37138 DNMT3B Medium High ND
hCG401308 DNMT3L n/a High n/a
hCG1774305 HSMPP8 Medium Low P<0.01, >10 -FC
hCG38411 METTL4 n/a Low P<0.05, +FC
hCG39601 MGMT High Medium P<0.05, -FC
hCG24891 PAPD5 Medium Low ND
hCG18366 POLS High Medium P<0.01, >10 -FC
hCG39275 RG9MTD1 Medium High P<0.05, +FC189
3.3.4.3 Other DM1-related genes
Genes with a previously identified role in the DM1 pathogenesis include several
transcription factors, DNA and RNA-binding proteins, mRNA processing and
translation factors, ribonucleoproteins and genes implicated in DNA repair. Genes from
these categories that have shown altered expression in normal vs. affected adult tissue
experiments were investigated here.
MSH2, MSH3, CUGBP1 and SP3 factor showed significantly higher expression in the
MII oocyte, while MBNL3 was the only identified factor significantly upregulated at the
blastocyst stage. Other important DM1-related genes, for example, DMPK, MBNL1,
MBNL2, PMS2 or SP1 were not detected (table 3.36).
Table 3. 36: Expression levels of DM1-related genes (Celera database) in the human MII oocyte and
embryo blastocyst. +FC: upregulated in the blastocyst, -FC:downregulated in the blastocyst, ND: no
statistically significant difference observed
Expression level
Molecular
Function (process) Gene ID Gene
Symbol Oocytes Blastocysts Parametric
comparison
hCG17836 MSH2 High High P<0.01, -FC
hCG37123 MSH3 Medium Low P<0.05, -FC
DNA-binding
protein
(DNA repair)
hCG2008664 PMS2
hCG28368 RAR,RAB40B
hCG15683 PABPC1 High High ND
hCG25183 CUGBP1 Medium Low P<0.01, -FC
hCG41209 hnRNP,HNRPC High High ND
RNA-binding
protein
(mRNA splicing)
hCG22986 hnRNP,HNRPDL n/a Medium ND
hCG25794 STAT1 Medium Medium ND
hCG1746842 REST n/a Low ND
hCG2007196 RAR,RARA Low Low ND
hCG1813145 STAT3 Low Medium ND
hCG1787889 SP1
hCG17424 SP3 Medium Low P<0.01,>10 -FC
Transcription factor
(mRNA
transcription)
hCG1789927.2 SIX5 Medium Medium ND
hCG27557 MBLL,MBNL2
hCG28028 MBNL1
Double stranded
binding protein
(muscle
development) hCG14618 MBNL3 n/a High P<0.01,>10 +FC
Protein Kinase hCG1996612 DMPK
Translation
elongation factor hCG23415 EF1A190
5 µg hybridizations
A total of 13170 probe IDs were detected in the Ba unaffected sample and 13768 were
detected in the DMa affected sample. For both of these, 5µg labeled RNA was
hybridized on the microarrays. When these two samples were compared using the
PANTHER database gene expression tools, there was a significant over-representation
of the mRNA transcription category in the DM1 affected sample (more genes involved
in mRNA transcription were detected compared to the unaffected sample). No other
differences were observed between the two samples. The two samples with the low
RNA yield both showed expression of some genes, such as SP1, that were not detected
in the 10µg hybridizations.
Even though no further analysis can be performed from the samples of low RNA yield,
due to the lack of replicates, the information obtained can also provide information to
assist further experiments for validation of the results by real-time PCR.191
3.3.5 Summary of findings for section 3.3: Expression work
 Gene expression profiling of human oocytes and embryo blastocysts
o A higher proportion of genes belonging to the nucleic acid metabolism and
protein metabolism categories, in comparison to the other biological process
categories, was detected in both human MII oocytes and blastocysts.
o 5243 genes showed statistically significant differences in expression between
oocytes and blastocysts. Of these, 2591 were under-expressed and 2652 were
over-expressed in the blastocyst compared to the oocyte.
o Genes with higher expression in the blastocyst belonged to the ‘protein
metabolism and modification’ class and were mostly involved in protein
biosynthesis.
o The majority of over 10-fold blastocyst up-regulated genes, when grouped
by molecular function, included “ribosomal proteins”, “other RNA-binding
proteins” or “translation factors”, while most 10-fold blastocyst down-
regulated genes were “other DNA-binding proteins”, “nuclease” and
“chromatin binding” proteins.
o There were 8772 genes common to MII oocytes and blastocysts, 1909 genes
were present in oocytes only and 3122 genes as blastocyst only.
 Investigation of potential housekeeping gene expression
o The majority of genes with a potential housekeeping role were detected
in oocytes and blastocysts with high expression levels
o 90.9% of the high signal oocyte candidate HKGs remained of high signal
in the blastocyst
o Some commonly used housekeeping genes, including some identified to
be stable during preimplantation development in human and other
species, showed significant differences in expression between the two
stages. B2M, HIST1H2AA and HIST3H2A were only detected at the
blastocyst stage. Other genes with most similar expression levels were
identified.
o The majority of genes indicating stable expression during development
according to studies on hESCs, showed significantly different expression
between oocytes and blastocysts.192
 Assessment of gene expression for important functional pathways
o Detection of genes involved in the microRNA pathway, methylation, and
DM1-related genes were identified and their levels of expression
characterised as high, medium or low.193
4. Discussion194
4.1 Protocol development for preimplantation genetic diagnosis for a
single gene disorder
4.1.1 PGD protocol development: general discussion
Preliminary genetic analysis is the first step in protocol development for PGD and
involves determining conditions for mutation detection on genomic DNA as well as
searching for informative polymorphic markers. When a couple is uninformative for all
linked markers tested, an informative unlinked marker may be multiplexed along with
the mutation primers instead. In this study, mutation detection was performed by F-PCR
analysis to detect differences in size of the DMPK repeat alleles. F-PCR enables a
cheaper, faster and less labour-intensive diagnosis, compared to other techniques, such
as SSCP, RFLP or mini-sequencing. The main aim in protocol development was to
simultaneously maximise PCR efficiency and accuracy. A fast diagnostic protocol is
generally preferred because of the limited time period in which the analysis has to be
performed, since the growing embryos may be held in culture up to day 6. Longer
diagnostic protocols, for example CGH, therefore require embryo cryopreservation,
followed by freezing and transfer in a subsequent cycle, after completion of the
diagnosis.
In one occasion during this study, however, the PGD protocol involved a ‘split PCR’
reaction, to improve protocol efficiency. In ‘split PCR’, an initial multiplex reaction is
performed and aliquots from the first reaction product are re-amplified in subsequent
individual amplification reactions for each locus. This method is generally applied in
PGD for monogenic disorders as it reduces optimisation time, although it increases the
diagnosis time by introducing more amplification reactions.
Another way to reduce optimisation time is by performing blastocyst biopsy, which
involves removal and amplification of more than a single cell for diagnosis so that
protocols do not need to be optimised at the single cell level (McArthur et al., 2008).
Other problems, however, may be encountered with blastocyst-stage biopsy, such as the
smaller number of embryos that reach the blastocyst stage, the reduced time available
for embryo transfer or the requirements for freezing. Additionally, due to time limitation,
re-biopsy and re-testing in case of inconsistencies is not possible.
Overall, ‘split-PCR’ or other long PGD protocols, are used for isolated referred cases of
uncommon mutations in order to reduce optimisation time, while for groups of patients195
with a common mutation, such as the patients with DM1 in this study, efforts were
focused towards establishing a universal, rather than patient-specific, PGD protocol.
This would reduce the time required for workup at the single-cell level prior to PGD
and eventually increase the number of patients that could be treated in a certain period
of time.
Careful assessment of amplification, allele dropout and contamination rates was
performed during optimisation to allow assessment of the risk of misdiagnosis
following results from a PGD case. Several measures were established as standard
practice during clinical diagnosis. For example, single lymphocytic cells from both the
affected and unaffected partner were freshly isolated prior to the relevant PGD case, and
stored at -80°C to be amplified alongside the blastomeres, as an indicator of successful
amplification during the actual diagnosis procedure and to allow comparison of
amplification between the single parental lymphocytes and single embryo blastomeres.
Moreover, two, rather than one, PCR-mix negative controls were obtained during setup.
These were additional to the cell-negative controls for monitoring contamination (table
3.12). The first negative control was obtained following setup of the PCR master mix
and prior to aliquoting into the cell tubes, while the second negative control was
obtained at the end of all aliquoting. The lack of amplification from the first PCR
negative provided evidence that the reagents used for the setup of the PCR reaction
were clear of contamination, while detection of contamination in the second PCR blank,
indicated that contamination had occurred during the aliquoting. Finally, all cells were
kept in the same order as obtained during cell biopsy, up until the last PCR reaction and
analysis of results, so as to reduce the likelihood of handling errors and generally
facilitate with monitoring of the procedure.
Overall, optimisation at the single cell level required the isolation and testing of
approximately 50-200 single cells, while each optimised PCR-PGD protocol was tested
on a minimum of 50 single cells prior to clinical application. At the early stages of
protocol development, human blastomeres were also used on two occasions to confirm
the single cell amplification efficiencies and allele-dropout rates prior to the clinical
application. The amplification results of a number of blastomeres isolated from the
same embryo were combined to identify the expected embryo genotype (as parental
alleles from the IVF patient donors were unknown). Because of the difficulties
associated with obtaining the parental genotype from the blastomere analysis, but also196
identifying true ADO or amplification failure and differentiating from a potential
chromosomal abnormality, this practice was stopped.
The practice of optimisation at the single cell level changed considerably over time,
regarding both the type of cell used and the method of cell lysis.
4.1.1.1 Impact of cell type
The impact of cell type on single cell amplification has been previously investigated.
One study compared the amplification efficiencies from single blastomeres, fibroblasts
and polar bodies, and indicated significantly higher allele dropout (ADO) rates in
blastomeres (Rechitsky et al., 1998). In another study, blastomeres were associated with
slightly lower, but not significantly different, amplification efficiency and ADO rates
compared to buccal cells (Piyamongkol et al., 2003). In our analysis, amplification
efficiency for the single blastomeres was significantly lower compared to results from
single lymphocytes or buccal cells.
At the beginning of this study buccal cells were preferred for protocol optimisation, as
they were more readily available and obtained in a less invasive way. When buccal cells,
however, were compared with amplification from single lymphocytes, results indicated
a lower amplification efficiency and higher ADO rate in the former. An example of this
is seen in the optimised DM1 triplex protocol (protocol 3), where the ADO rate from
fifty-five single lymphocytes was lower (0-3.64% for the three markers) compared to
analysis from fifty-three buccal cells (3.78-11.3%) (table 3.4). This difference is
important considering that the general guidelines for good PGD practice from the
Preimplantation Genetic Diagnosis International Society (PGDIS) (2004) emphasize
that ADO over 10% is the main cause of PGD misdiagnosis. The differences in ADO
detected with the different cell types are possibly the result of differences in cell quality,
as single lymphocytes were in most cases freshly extracted and isolated cells, whereas
buccal cells were often collected by the patients and sent by post (Piyamongkol et al.,
2003).
Most problems regarding the cell type were observed during initial optimisation of the
TP-PCR protocol, which involved the use of single buccal cells. The TP-PCR results
from 160 buccal cells were very poor, inconsistent and generally associated with very
high amplification failure rates. When practice moved over to testing of single197
lymphocytes, the results were markedly improved. This finding agrees with previously
reported recommendations that DNA of high quality should be used as the template
particularly for TP-PCR amplification (Falk et al., 2006).
As a result, lymphocyte isolation became the standard practice for development of PGD
protocols in general, despite the more time-consuming cell separation from blood and
the generally more difficult isolation of the considerably smaller in size cells (buccal
cell diameter ~65μm vs. lymphocyte diameter ~7 μm) (Ziyyat et al., 1999;Paszkiewicz
et al., 2008). We reserved the use of buccal cells for DNA extraction and single cell
work only for cases where relative’s DNA had to be obtained from very young children
(such as during phase allele investigation), or during follow-up of babies born after
PGD.
4.1.1.2 Investigation of cell lysis methods
The method of cell lysis has also been proven to play an important role on the actual
PCR amplification. Early studies supported ALB lysis for extraction of DNA from
single cells over other methods such as freeze-thawing and the distilled water lysis
method. In another study ALB lysis was associated with allele-specific amplification
failure, which was not noted as a problem with PK/SDS lysis (Gitlin et al., 1996;el
Hashemite and Delhanty, 1997). PK/SDS and ALB lysis were also compared by
Thornhill et al., (2001) who investigated amplification for three genes (CFTR, LAMA3
and PKP1) at different chromosomal loci on single lymphocytes. Amplification
efficiencies were found to be comparable between the two methods but for two out of
the three loci tested there was a statistically significant difference in ADO rates, with
ALB lysis giving much lower ADO. Finally, a more recent study compared
amplification efficiencies and ADO rates between five different cell lysis methods
(liquid nitrogen method, distilled water lysis, alkaline lysis, proteinase K/SDS lysis
buffer and N-lauroylsarcosine salt solution), using single lymphocytes as a template.
The highest amplification efficiency and lowest ADO was observed with alkaline lysis,
followed by PK/SDS lysis (Kim et al., 2008).
Results from the current study are also favourable towards alkaline lysis. The change in
the proteinase K enzyme activity over time, possibly due to freeze-thawing, was one of198
the difficulties encountered. To confirm that the required PK activity was still attained,
a PK titration step was performed and cells were isolated in different concentrations of
PK/SDS lysis buffers. The lysed cells were amplified using an optimised single cell
PCR protocol, to determine which PK concentration allowed reproducibility of the
results (i.e. expected efficiency, ADO rates). This requirement for adjustments of the
PK enzyme concentration over time was not compatible with complete protocol
standardisation, which is important in clinical practice. Furthermore, single cell
amplification efficiencies were generally lower with PK lysis, compared to ALB (table
3.4).
For all the above reasons, our practice moved towards ALB lysis. The initial set up was
more labour-intensive as it required the preparation and testing of a number of stock
solutions of wash buffer (DB), tricine, BSA and DTT aliquots, as well as NaOH and
KOH. Following this, however, the ALB lysis protocol was faster, requiring a 15min
lysis step compared to 75min with PK. The single cells were almost immediately lysed
when placed into the ALB lysis buffer. In the earlier stages of the study, this was
considered to be a disadvantage, as it did not allow viewing of the cell under the
microscope after tubing. This practice is, however, only considered necessary while
practicing the technique of single cell tubing and is no longer required once proficiency
and confidence in the technique is attained. During the learning curve of the tubing
technique, however, the use of PK lysis, and viewing of the cell in the tube, allowed
confirmation that any subsequent failure of amplification was not due to loss of the cell
during transfer in the tube, thus ensuring that protocol efficiency was accurately
estimated. With ALB lysis, the volume of wash buffer (DB) placed in the tube along
with the cell was also critical and in several cases a large amount of buffer transferred
along with the cell was associated with amplification failure. This difficulty was also
overcome with practice, by ensuring that the single cells were transferred into a small
volume, of just 1-2μl of wash buffer.199
4.1.2 PGD for DM1
The decision to have a family can be very difficult for the DM1-affected individuals due
to the unpredictability in DM1 inheritance, and the consequent difficulties in assessing
the impact of a DM1 diagnosis on future pregnancies, offspring and other family
members (Salehi et al., 2007).
From our group of patients, the major motivator for a DM1-affected couple in pursuing
PGD was the experience of having relatives affected with the condition (22/23 couples).
Because DM1 is a dominantly inherited disorder, couples may be faced with a number
of terminations (TOP) before achieving a normal pregnancy. Overall, eight couples had
experienced an affected pregnancy, and six of them had experienced TOP one or more
times. One of the couples who had a TOP also had an affected daughter, while two other
couples had lost a congenitally affected child. Seven of the referred couples had
infertility problems, though not all necessarily DM1 related.
The main aim of developing PGD for DM1 has been to ensure the availability of widely
applicable and reliable PGD protocols that can minimise the workup time. In this way,
in cases of infertility, where IVF treatment is required, the availability of readily
applicable PGD protocols would render PGD simply an additional step to the standard
IVF procedure.
The emotional difficulties of the IVF/PGD procedure were underlined in this study by
the two couples producing only two embryos following IVF. In both of these cases, the
couples were adamant that they did not wish to proceed with the treatment. They found
the procedure extremely stressful and with only two embryos available for testing they
felt the chances of detecting and transferring an unaffected embryo and hopefully
establishing an unaffected pregnancy were very low.
The emotional, along with the physical burden of the procedure but also the
considerable cost of the IVF/PGD treatment (to cover fertility checks, IVF cycle,
preimplantation testing), further highlighted the requirements for an accurate and
efficient diagnosis, offering the greatest chance for an unaffected pregnancy with the
lowest risk of misdiagnosis.200
4.1.2.1 DM1 PGD protocol development
Since the expanded DM1 allele is refractory to PCR amplification, the DM1 mutation
cannot be directly visualised, making diagnosis more difficult compared to diagnosis for
other single gene disorders. Diagnosis of an unaffected embryo is indicated by detection
of the affected individual’s non-expanded allele, while absence of this non-expanded
allele implies the presence of an unamplifiable expanded allele. Further difficulties
present in cases where the two parental alleles in an embryo are of equal size, where it is
impossible to confirm that the affected partner’s non-expanded allele has been inherited.
In these cases, diagnosis can be facilitated by the incorporation of linked markers and
the detection or absence of the phase alleles.
Previously described PGD protocols have involved the co-amplification of linked
markers, but in cases of patient uninformativity for the linked markers, unlinked
markers have also been used for contamination detection or protocols have involved the
amplification of only the mutated region by TP-PCR.
The unlinked polymorphic markers D21S1414 and D21S11, described in several single-
gene PGD protocols, were tested during initial tests, but were found to be associated
with low amplification and very high allele dropout rates. These protocols were tested
but have not been included here, as they were not optimised to a level considered
acceptable for clinical application. Other previously used linked markers, for example,
D19S207 and D19S219, were also tested during preliminary genetic analysis for several
of the patients. These markers, however, showed low patient informativity, presented
difficulties with multiplexing, as well as yielding difficult to interpret stutter patterns
even on genomic DNA analysis. Possibly for this reason, DM1 PGD protocols from
other centres, using these two markers, have involved hemi-nested PCR reactions, with
an extended time needed for diagnosis (Dean et al., 2001;Fiorentino et al., 2006). These
markers were, therefore, not optimised for use in PGD in our department.
Intragenic markers such as the Alu insertion/deletion polymorphism have also been
described but not applied to PGD, as, although they may be useful in identifying the
expanded allele, they are not suitable for contamination detection (Mahadevan et al.,
1993b). Other intragenic polymorphisms have also been identified within introns and
noncoding regions of the DMPK gene. Some of these alter restriction enzyme
recognition sequences and PCR assays have been developed for their detection.201
However, these polymorphisms are not of use for PGD either, as they are due to single
base changes and cannot allow for contamination detection (Mahadevan et al., 1993a).
The amplification of a commonly used linked marker, either APOC2 or D19S112, along
with the DMPK region was generally preferred for diagnosis in our group of patients.
Protocols 1, 2 and 4 (DM1/APOC2, DM1/D19S112 and TP-PCR), as indicated in table
3.4, are similar to previously described protocols, with some modifications in the
method of cell lysis and concentration of reagents in the PCR reaction. The TP-PCR
protocol was used for couples that were uninformative at DMPK. The 5CTG repeat
allele was present in 10/23 (43.5%) affected and in 17/23 unaffected (73.9%)
individuals, and was shared in 9/23 (39%) couples. This presented problems with
diagnosis for these couples, as TP-PCR could not safely detect the 5 CTG repeat
homozygous embryos.
For couples who were fully informative for the DMPK region, the linked marker
allowed detection of contamination, while providing back up diagnostic information, in
cases where the phase allele was known. For couples partially informative or
completely uninformative at the DMPK locus, only half or none of the normal embryos,
respectively, could be identified by DMPK analysis alone. In these cases, diagnosis was
based solely on assessment of the phase alleles. In this study a cross-over event was
detected between DMPK and APOC2 in two cases. This is related to the greater distance
between DM1 and APOC2, compared to that between D19S112 and DM1 (Kakourou et
al., 2007). A similar event has been reported in another PGD case for Charcot-Marie-
Tooth disease type 1a, where recombination was detected in an embryo that was still
considered unaffected and transferred, leading to an affected pregnancy (Gutierrez-
Mateo et al., 2008). The detection of the crossover underlined the potential danger of
making a diagnosis, solely on the result of the linked marker, and highlighted the
importance of not using the relatively distantly linked APOC2 as the sole marker to
identify the DMPK mutation in semi-informative couples, as has been previously
described (Piyamongkol et al., 2001b). The co-amplification of another linked marker,
on the opposite side of the DMPK gene would provide extra information on the cross-
over event, and could be used as an extra measure to prevent misinterpretation of the
results.
Further protocol development focused on overcoming the problems of misdiagnosis
associated with marker recombination, as well as the TP-PCR scoring difficulties of the202
5 CTG repeat homozygous samples, in order to improve DM1 diagnosis and reduce the
chance of misdiagnosis.
4.1.2.2 New diagnostic protocols for PGD for DM1
The above led to the development of two new protocols, not previously reported in the
diagnosis of DM1. Our strategy was to devise a protocol that could exclude the presence
of the mutant allele but also confirm the presence of the non-expanded allele. The latter
was particularly important especially for the 5 CTG repeat homozygous embryos. The
DM1/APOC2/D19S112 protocol (protocol 3) was a triplex PCR, amplifying the two
commonly used linked markers, APOC2 and D19SS12, which are on either side of the
DMPK gene, along with the mutated region. The mTP-PCR protocol (protocol 5)
allowed DMPK allele amplification both by standard PCR and TP-PCR along with
amplification of a linked marker. In this way mTP-PCR permitted detection of the
expansion and estimation of the repeat number of the non-expanded alleles by TP-PCR,
detection of the 5 CTG repeat allele and other non-expanded alleles by standard PCR,
detection of the phase allele of the linked marker to support the diagnosis and/or
detection of contamination.
The availability of these protocols facilitated diagnosis for all patients. For these reasons
the remaining optimised protocols (1, 1a, 2 and 4) are not currently being used in PGD
for DM1 in our department. Following initial testing of parental DNA, either the DM1
triplex or the mTP-PCR protocol is selected for diagnosis, depending on couple
informativity.
This has had major clinical implications for PGD practice and modified the course of
treatment for all patients with DM1 undergoing PGD, by reducing the time required for
initial genomic DNA testing and eliminating the protocol optimisation step. In previous
practice, blood sample analysis of the prospective parents during the pre-PGD workup,
for the identification of informative polymorphic markers, included testing an average
of seven polymorphic markers per couple (range 4-16) in search of an informative one.
This was followed by setting up protocols for multiplexing the informative marker with
the DMPK region on genomic DNA, testing of additional family members if available,
and single cell optimisation of the new protocol. Currently, genomic DNA testing203
simply involves performing the DM1 triplex and mTP-PCR protocols, and can,
therefore, be completed within a few days.
The approach to IVF/PGD treatment has changed since the beginning of this study
(figure 4.1). Until recently, because of the long time required for protocol optimisation,
protocol workup was initiated immediately after the initial consultation had taken place.
Applications for funding, reproductive assessment and application to the Human
Fertilisation and Embryology Authority (HFEA) were performed only after or near
completion of the workup at the single cell level. Consequently, on several occasions,
though a diagnostic protocol had been optimised, the patients failed to come through for
treatment due to a diminished ovarian reserve, funding problems, or due to change of
mind. Currently, the HFEA application is put forward when the source of funding is
known or after the initial consultation when the patients feel certain that they wish to
proceed with the treatment.
As a general rule, although reproductive assessment is crucial, it is not performed until
after treatment funding and HFEA license have been granted, due to the considerable
cost of these fertility tests. Protocol development is initiated after completion of these
initial fertility checks and may generally increase the waiting time for treatment by a
further 6 months to maybe over a year for new single gene diagnoses.
As the protocols for PGD of DM1 are available for diagnostic application almost
immediately, the couple interested in undergoing PGD can proceed through the
remaining treatment steps without further delays, taking overall approximately 6 months
from referral to treatment for DM1 cases, rather than over 1 year, which is the case for
other single gene disorders.204
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Figure 4. 1: Steps towards IVF/PGD treatment following patient referral. The funding and HFEA applications require a minimum of 5-8 months. Overall, excluding genomic
DNA and single cell workup, the whole procedure can take 6-12 months from referral to the beginning of the IVF treatment (IVF cycle to egg collection: 6 weeks). This study
reduced the PGD protocol workup time (genomic DNA and single cell work) for patients with DM1 to approximately 1 week, compared with new PGD single gene workups, which
can take up to 6-12 months. As the HFEA license for PGD of DM1 has been obtained, HFEA application is also not performed for patients with DM1.205
The mTP-PCR protocol could also be of use in PND. A recent study suggested that
confirmation of diagnosis or prenatal testing for the detection of the DM1 expanded
alleles should involve a two-step protocol, where standard PCR can be used for basic
screening and, following that, the detected homozygous samples can be subjected to
further analysis by TP-PCR to differentiate normal homozygotes from affected
individuals. The suggested method was compared to other protocols available for
detection of the expansion and was found to be the most rapid and least labour intensive,
whilst also offering a straightforward interpretation of results (Falk et al., 2006). With
the mTP-PCR protocol, the two-step protocol is performed in a single step, thereby
saving further on time and cost. Finally, the incorporation of polymorphic markers can
be extended to triplet-primed based protocols for the diagnosis of other conditions, such
as FRDA and several types of SCA.
4.1.3 IVF/PGD practice at the UCL Centre for PGD
4.1.3.1 Embryo biopsy
4.1.3.1.1 One vs. two-cell biopsy
Several studies have attempted to define whether the removal of one or two cells during
embryo biopsy has an impact on the efficiency of PCR-based or FISH-based diagnostic
protocols, embryo development to the blastocyst stage, implantation or live birth rate.
Overall, testing two rather than one blastomere has been recommended as a safer
procedure as far as the diagnostic efficacy goes (Van de Velde et al., 2000). One study
investigating FISH diagnosis suggested that the overall diagnostic efficiency was
similar between the one-cell and two-cell groups, although a false negative result was
detected in the one-cell blastomere group (Emiliani et al., 2004). Goossens et al., (2008a)
analyzed results from 592 ICSI cycles and concluded that the PCR-based diagnosis
showed higher efficiency when two cells were biopsied, while no differences were
detected for all cases with FISH diagnosis. Finally, in another recent study, the biopsy
of a second blastomere was associated with decreased percentage of false positive
results, as well as a reduced chance of misdiagnosis due to ADO (Dreesen et al., 2008).206
Regarding embryo development, it has generally been shown that the more cells
removed from human embryos, the fewer embryos develop to the blastocyst stage by
day 5, although the removal of up to two cells has not been shown to have an adverse
effect on later development (Hardy et al., 1990;Tarin et al., 1992). A similar observation
has been made on mouse embryos, where it was indicated that when up to three cells
were removed from 8-cell biopsied embryos, there was not a significant effect on the
rate of blastocyst formation (Liu et al., 1993). On the other hand, Goossens et al.,
(2008a) suggested that removal of two blastomeres decreases the likelihood of
blastocyst formation, but also observed that the embryo stage and grade on day 3 was a
stronger predictor for embryo development compared to the number of cells removed.
The same study concluded that live birth rates were not significantly different whether
one or two cells were removed (data showed that for every 33 cycles there was one less
delivery following removal of two blastomeres). This is also supported by Fiorentino et
al., (2006), although data from other studies has generally been contradicting
(Vandervors et al., 2000;Spanos et al., 2002;Pickering et al., 2003;Grace et al.,
2006;Feyereisen et al., 2007). Finally, a study on the impact of aneuploidy screening
indicated that the improved implantation rate and lower miscarriage rate, which is the
aim of the screening technique, are not achieved when more than one cell is removed
(Cohen et al., 2007).
The above arguments remain the topic of hot debate; there is, however, a tendency to
support the one-cell biopsy policy, particularly because of the observed, though not
significant, findings regarding live birth rate (Goossens et al., 2008a). Another
important advantage of the one-cell biopsy is that it represents a lower work burden
(Dreesen et al., 2008). It is, therefore, generally agreed that as long as a PGD protocol is
available that can provide accurate diagnosis using a single blastomere, a one-cell
biopsy should be recommended.
In this study, two cells were biopsied from all embryos with 6 or more cells on day 3.
As mentioned previously, where either an informative linked marker was not included
in the protocol, or when diagnosis involved use of the TP-PCR protocol, independent
results from two cells from each embryo were required for diagnosis. In contrast, a
diagnosis could be made on the results from one cell for couples that were informative
for the mutation and one or two linked markers. Even in these cases, however, two cells
were still biopsied. When one of the biopsied cells did not give a diagnostic result, a207
diagnosis could be made from the results of the other cell. As a general rule, when either
none of the biopsied cells gave a clear result or the protocol required a result from two
cells, the embryos were rebiopsied and the protocol was repeated on the rebiopsied cells.
Reanalysis of 10 out of the 11 DM1 cycles where the DM1 triplex (protocol 3) was used
for diagnosis, was performed in order to assess the impact of the numbers of cells
biopsied on diagnostic rate. The DM1 triplex was selected as it was the protocol most
likely to allow a one-cell diagnosis, due to the incorporation of two linked polymorphic
markers, and also because the protocols with TP-PCR analysis required results from two
cells. The one cycle where a combination of two protocols was used for diagnosis, was
excluded from the analysis. Results based solely on the first biopsied cell indicated that
if one-cell biopsy had been performed, the diagnostic rate in these cases would drop
from 73.4% to 53.1%, indicating a statistically significant difference (p<0.05, Fisher’s
exact test). This supports previous findings on increased diagnostic efficiency following
two-cell biopsy.
Because of this impact on diagnosis, the one-cell biopsy has not been implemented in
our department. The main priority has been to obtain a result from every single embryo,
in order to increase the number of unaffected embryos available for transfer. For that
reason, our practice has also included biopsy of additional cells where the first biopsy
yielded anucleate or poor quality cells, as well as rebiopsy or delayed biopsy for slow-
growing embryos. Therefore, in some cases (patient/cycle number 9/1, 8/2 and 23/1)
embryos had up to four cells removed. In two of these cycles (9/1 and 23/1) there was
no unaffected embryo for transfer following PGD. In cycle 2 of patient 8, where a
combination of two protocols was used for diagnosis, there were two embryos with four
cells biopsied each. Of these, one was a morula and was transferred following PGD
along with another unaffected embryo, while the second embryo with four cells
biopsied (a cavitating morula) was frozen and transferred in a subsequent cycle. No
pregnancy was established in either case.
It is, however, expected that the new diagnostic protocols, due to their increased
efficiency and improved diagnostic rate, will not only help reduce the number of
embryos that need to be rebiopsied but also enable one-cell diagnosis for many more
patients than was previously possible. The decision on the number of cells required to
achieve a safe diagnosis may remain patient-specific.208
Finally, it is worth mentioning that our approach in trying to achieve a diagnosis from
every single embryo was independent of the number of the embryos available for biopsy
from that specific cycle. This is contrary to practice from other centres, where when few
embryos are available, embryo biopsy may be cancelled (Grace et al., 2006).
4.1.3.1.2 Number of pronuclei
Biopsy of five 0PN embryos, one 1PN and one 3PN embryo that had grown to the six or
more cell-stage on day 3 was performed in cases where a limited number of embryos
were available for testing (i.e. 2-4 embryos). These non-2PN embryos would be
considered for transfer, if unaffected, only if no other embryos were available.
Despite the failure to detect pronuclei at the time of fertilisation check, which might be
because of the embryo’s accelerated or slow development, 0PN embryos can still cleave
and develop to the blastocyst stage. Evidence from a FISH study has shown that 57% of
0PNs form diploid embryos, and more recently, 0PNs that cleave early have been
associated with high chances of blastocyst development, implantation and pregnancy
(Manor et al., 1996). These 0PN embryos can, therefore, be considered for transfer, but
since it is unknown how many pronuclei were present, it is important to base the
decision for transfer not only on the diagnostic result but also on other indicators such
as the presence or absence of polar bodies, oocyte and embryo morphology, or other
observations. For example, other events and observations detected in this study include
fertilisation of a giant oocyte (cycle 3 of patient number 8), which is associated with
numerical chromosomal abnormalities, or the presence of multinucleated blastomeres,
which have been associated with poor development and lower clinical pregnancy rate
(Tesarik et al., 1987;Jackson et al., 1998;Balakier et al., 2002). All four embryos where
a multinucleate blastomere was biopsied were of poor quality on day 4: two embryos
arrested, and the remaining two were at the 7 and 8-cell stage. One of these embryos
was transferred but a pregnancy was not established. A similar association was observed
for the embryos with binucleate cells, three of which gave a result and were all found to
be affected. Lastly, micronuclei are known to be present in approximately 20-25% of
embryos between days 3 -5 and are thought to possibly arise from chromosome loss
although no significant observations were made on the four embryos in which
micronuclei were observed in this study (Norppa and Falck, 2003;Chatzimeletiou et al.,
2005).209
Over 50% of 1PN embryos from IVF have been shown to be diploid, although the
incidence of diploid 1PNs from ICSI cases is significantly lower (Staessen and Van
Steirteghem, 1997). It has been suggested that ICSI 1PN embryos should not be
transferred because of their higher chance to be parthenogenetically activated, an event
which is, in turn, associated with chromosomal abnormalities and a risk of implantation
failure (Sultan et al., 1995). This should not be a problem particularly with PCR
analysis, as the presence of both parental genomes can be readily identified. It is,
therefore, generally accepted that 1PNs may be transferred when no other embryo is
available, as successful pregnancies with 1PN embryos have been reported (Feenan and
Herbert, 2006).
In contrast to the above, the majority of 3PN embryos are predicted to have a triploid,
greater than triploid, or mosaic chromosome content, which is associated with
spontaneous abortion and neonatal death; transfer of triploid embryos should therefore
be avoided (Feenan and Herbert, 2006).
The removal of the extra male pronucleus in a 3PN dispermic zygote and transfer of the
resulting embryo leading to the birth of a healthy baby boy has been described (Kattera
and Chen, 2003). This limited data is promising. Attempts to recover the abnormally
fertilised oocytes may be particularly important to further increase the chances of an
unaffected pregnancy, in cases of poor response to the IVF treatment and therefore,
limited availability of oocytes and embryos, as has been described in patients with DM1.
This practice should be combined with relevant preimplantation analysis (such as FISH)
to confirm the absence of triploidy in the embryo.
In any case, assessment of fertilisation, embryo development and careful interpretation
of data is vital for both 2PN and non-2PN embryos, as abnormalities are common even
in apparently normally fertilised embryos (Delhanty et al., 1997). An example seen in
our results is the detection of two paternal alleles in one embryo and the detection of
only one parental genome in eight 2PN embryos, when the DM1 triplex and mTP-PCR
protocols were used, which might indicate monosomy for chromosome 19.210
4.1.3.2 Outcome of DM1 PGD cycles
Each couple completed on average 1.5 PGD cycles (fifteen couples had one cycle, four
couples had two cycles and another four couples had three cycles each). For one couple,
the results from their first cycle provided useful information regarding the phase, which
had not been previously available.
The overall diagnosis rate of 74.12% (129/174) is relatively low compared to results
from other studies, where chromosomal and single gene PGD diagnosis ranges from
80.7 to 94.3% (Pickering et al., 2003;Fiorentino et al., 2006;Feyereisen et al.,
2007;Gutierrez-Mateo et al., 2008; Goossens et al., 2008b). Data specific on diagnosis
for DM1 from two of the studies, indicates a diagnosis rate of 85% and 93.3%
(Goossens et al., 2008b;Fiorentino et al., 2006).
It should be noted that our diagnosis rate quoted above includes diagnoses with older
protocols no longer in use in our department. When analysis is limited to results with
the two currently used protocols, 80% of embryos (52/65) were diagnosed with the
DM1 triplex protocol and 91.6% embryos (22/24) were diagnosed with mTP-PCR,
giving overall a diagnosis rate of 83% (74/89 embryos). It is expected that the total
diagnosis rate will increase with future cases, since, following validation of the mTP-
PCR protocol on several cycles, it should be the protocol preferred for diagnosis when
possible.
This study also indicates the importance of carefully assessing the quality of each
embryo and each biopsied blastomere. Diagnostic efficiency can be improved by
ensuring that biopsied and amplified cells are morphologically sound with a clearly
visible nucleus. Our data shows that only 4 out of the 33 blastomeres that were lysing
during the biopsy but in which the nucleus was seen, failed to amplify. On the contrary,
41 out of 42 cells where a nucleus was not seen, failed to give a result following PCR.
This is in keeping with previously reported findings (Piyamongkol et al.,
2003;Gutierrez-Mateo et al., 2008).
Out of the 45 embryos that remained undiagnosed, twenty-seven gave inconclusive
results, ten showed total amplification failure and eight embryos could not be diagnosed
due to the biopsied cell result indicating the presence of a single parental genome. Out
of the 27 embryos with inconclusive results, the lack of diagnosis was due to couple
uninformativity in 51.9% of the embryos (14/27), which included cases completed prior
to the mTP-PCR protocol becoming available, contamination in 5/27 (18.52%), “other”
findings, such as detection of two paternal alleles in 4/27 (14.81%), allele dropout in211
3/27 (11.11%), or, in one of the embryos, result from only one cell when using a
protocol requiring results from two cells for diagnosis (3.7%).
The implantation rate (IR) was 28.2% (11/39 embryos transferred). This is comparable
to results from other studies with IR ranging from 23-28% (Pickering et al.,
2003;Fiorentino et al., 2006;Grace et al., 2006;Goossens et al., 2008b; Gutierrez-Mateo
et al., 2008).
Considering that two cells were biopsied from the majority of embryos, and over two
cells were biopsied from several embryos, it is noteworthy that our IR is much higher
than the reported rate of 12.8% and 14%, from two other groups where two-cell biopsy
was also performed (Feyereisen et al., 2007;Vandervors et al., 2000). Finally, this study
indicates a pregnancy rate per embryo transfer of 36.5%, including the two transfers of
frozen-thawed embryos, where no pregnancy was established. This rate is high
considering that pregnancy rates per ET from other studies have ranged between 21.5-
43.4%, with most being ≤ 33% (Grace et al., 2006;Fiorentino et al., 2006;Feyereisen et
al., 2007;Dreesen et al., 2008;Goossens et al., 2008b; Gutierrez-Mateo et al., 2008).
Pregnancies were established even from embryos considered to be of poor quality. Four
of the eleven embryos that implanted had eight or fewer cells at the time of transfer, and
three of the implanted embryos, including a 5-cell embryo, had been rebiopsied. Post-
natal DNA analysis in case no.10 revealed that it was the slow growing rebiopsied
embryo, that had had two cells removed, that implanted. This differentiation could not
be made for case no.1 as both of the embryos transferred, one of which was rebiopsied
and the other not, had given the same genotype on analysis.212
4.1.3.3 Follow-up analysis
4.1.3.3.1 Analysis of spare embryos
Despite relevant counseling, none of the couples opted for prenatal diagnosis, so as not
to risk losing the precious pregnancy achieved following the physically and emotionally
stressful IVF/PGD cycle. This further underlines the importance of ensuring diagnostic
accuracy during PGD.
Confirmation of diagnosis was routinely performed for all embryos that were affected or
unaffected but unsuitable for cryopreservation, in order to test the validity of the
assessment and estimate the chance of misdiagnosis.
Overall, 86 embryos were available for confirmatory analysis, of which 53 had been
diagnosed as affected or unaffected during PGD, 20 had given an inconclusive result, 6
had no result and 7 had not been biopsied. In most, but not all, cases, confirmation
involved application of the same protocol that was used for genotyping and blastomere
diagnosis, although some follow-up analyses included a combination of the DM1 triplex
and mTP-PCR protocols on single cells or blastomere clumps. When possible,
depending mainly on the number of cells present, both a single blastomere and a
blastomere clump were obtained for reanalysis from each embryo. In cases where the
embryo quality was poor or when disaggregation was difficult because of the embryo
being very compact, the embryo was tubed whole.
Forty-seven out of the 53 embryos where a diagnosis had been obtained were confirmed
during follow-up (7/8 unaffected and 40/45 affected). From the 6 embryos where the
diagnostic result was not confirmed, one unaffected embryo and three affected embryos
gave an inconclusive result during reanalysis. The reasons for these embryos being
inconclusive were the presence of a cell showing amplification from one parental
genome only (one unaffected embryo), ADO (one affected embryo) and contamination
(two affected embryos). The two remaining affected embryos, a three-cell and a four-
cell embryo, failed to amplify on reanalysis. Overall, the reanalysis result concurred
with the primary diagnostic result, i.e. no false negatives or false positives were detected.
The embryos that had not given a result during PGD and the embryos that had not
grown to a stage to allow biopsy on day 3 were tubed whole during reanalysis, and all of
them were successfully analysed and yielded an affected/unaffected result. This
provided additional information on the number of affected and unaffected embryos
obtained from this group of patients. From the twenty embryos tested that had been213
inconclusive on diagnosis, ten remained inconclusive during re-analysis, one did not
give a result (9-cell embryo), while a diagnosis was achieved for the remaining nine.
Most of the embryos that remained inconclusive despite reanalysis came from couples
sharing marker alleles (7 embryos), while two other embryos showed evidence of
contamination in the biopsied cells and one embryo had ADO. Use of the mTP-PCR
protocol in cases of couple uninformativity would reduce the number of undiagnosed
embryos due to inconclusive results.
The data from follow-up analysis using MDA, though limited, gave very poor results.
Further investigation and potential protocol optimisation was not deemed necessary in
this study as the available optimised protocols did not only provide faster results but
also combined direct mutation detection with linkage analysis.
4.2 Investigation of DMPK repeat transmission
4.2.1 Allele transmission
Preferential transmission of large non-expanded alleles at the DMPK locus has been
reported in offspring and human preimplantation embryos, however, results regarding
transmission of the expanded allele have been contradicting (introduction section
1.2.3.1). Investigation of transmission of the DMPK repeat from the affected parent to
the preimplantation embryo has not been previously available. Allele transmission was
investigated by analyzing data in three ways. First of all, observing the number of
affected vs. unaffected embryos on diagnosis. Secondly, separating parental alleles into
‘small’ or ‘large’ (expanded or the larger non-expanded) and finally, by grouping of
parental alleles into different repeat classes to detect potential differences in
transmission depending on allele size.
In summary, transmission ratio distortion (TRD) was not observed from the above
analysis; our results do not support preferential transmission of the expanded repeat
allele to the preimplantation embryo, agreeing with the results from the two prenatal
studies (Zunz et al., 2004;Martorell et al., 2007). This is also indicated by the non-
significant difference in the number of embryos diagnosed as affected and unaffected. It214
should be noted, however, that the level of expansion was unknown in most cases and
this might also influence transmission. Previous investigators similarly reported no
significant TRD for non-expanded 5-18 repeat alleles, but detected preferential
transmission of 19-37 repeat alleles (Dean et al., 2006a). In this study there was
information from a total of 30 transmissions involving alleles of 19-37 repeats, and in
these individuals, the second repeat allele was expanded. Statistical analysis did not
indicate a significant difference in the transmission of these repeat classes (binomial
test) , however, more data would be necessary due to the small sample size.
A similar analysis was performed focusing on results from patients with a previous
history of an affected pregnancy, but, again, there was no statistically significant
difference between the number of embryos diagnosed affected or unaffected from this
group.
4.2.2 Instability of repeat transmission
In a previous study, intergenerational instability at the level of human gametes and
preimplantation embryos was detected by use of a specific PCR for long fragments,
followed by Southern blot analysis for detection of the expansion, as well as a second
round PCR for detection of the smaller alleles. In this way significant increases in repeat
number were detected in oocytes and embryos from female patients with DM1, while
smaller increases were detected in spermatozoa and embryos from male patients (De
Temmerman et al., 2004). It is noteworthy, however, that the technique used had
limitations in detecting large expansions. A subsequent study reported the use of TP-
PCR for sizing of the non-expanded as well as the expanded DMPK repeat alleles, in
both oocytes and embryos, based on the specific ladder patterns produced following
amplification from each sample. In particular, expansions were sized as “maternal-type”,
when the results were similar to amplification from maternal lymphocytes,
“intermediate” and “congenital”, corresponding to precisely 170-190bp, 200-240bp, and
>250bp on F-PCR analysis, based on results from two patients (Dean et al., 2006b). A
variable degree of expansion was detected in preimplantation embryos, with several
indicating expansion in the congenital range. Additionally, instability was seen during
transmission of non-expanded 19-37 repeats from the father to the preimplantation215
embryo, in keeping with previous observations of instability in transmission of normal
alleles at the level of offspring (Dean et al., 2006b).
In this study we attempted to optimise the TP-PCR technique in order to reproduce
similar experiments that would enable detection of instability in our larger group of
patients with DM1 undergoing PGD. The results presented here, however, are
contradicting to the previous study. From our experience, TP-PCR was unable to size
expansions even when comparing control genomic DNA samples with small, medium,
larger and congenital range expansions. This observation was supported by a recent
study concluding that TP-PCR could only accurately size alleles of up to 50 repeats
(Falk et al., 2006). We, therefore, conclude that Southern blotting still remains the best
way to estimate the triplet repeat size.
We also noted that, in affected samples, TP-PCR amplification was extremely variable
even amongst single lymphocytes of the same individual, while the previous study
reported this to be consistent. Differences were also detected when blastomeres from the
same affected embryo were amplified, which could, however, also be due to differences
in cell quality. Regardless of this variation, we described TP-PCR amplification
products in several day 3 embryos as being larger than any of the patient lymphocyte
results. Several day 5 embryos showed bigger amplification products compared to their
day 3 result, which would suggest a case of mitotic postzygotic expansion. Pre- and
post-zygotic expansion of the CTG repeat has also been proposed for Fragile X,
however, the significance of the above observations remains unverified (Ashley and
Sherman, 1995).
On the other hand, TP-PCR was more accurate in sizing non-expanded repeat alleles.
This allowed to detect a potential allele instability in 3/37 (8%) unaffected blastomeres
analyzed. Similar changes in the number of repeat units during transmission (>7%) have
been reported (Dean et al., 2006b).
4.2.3 Embryo development and CTG repeat allele transmission
Embryos were generally scored by the embryologists on day 2, day 3, pre- and post-
biopsy, day 4 and/or day 5. Following diagnosis and follow-up, development of all
known unaffected embryos was compared to the development of affected embryos. To
allow a fair comparison, only embryos biopsied on the morning of day 3 were included216
and embryos that had been rebiopsied were excluded from the analysis. In addition,
most embryos had one to three cells removed, but the majority of them were in the two-
cell category. Development of unaffected embryos with two cells biopsied on day 3 was
compared to development of the affected embryos that had two cells biopsied on day 3.
Results indicate that a greater number of affected embryos developed to the morula or
cavitating morula stage by day 4, compared to the number of unaffected embryos at the
same stage.
This observation is significant as an increased survival of affected DM1 embryos might
indicate a mechanism by which expanded alleles are maintained in the population.
Another study has shown that the presence of large non-expanded alleles, of 19-38
repeats, does not influence preimplantation development however it could be that
different sized repeats might have a different impact on the embryo (Dean et al., 2006a).
It has also been reported that expanded cells of lymphoblastoid cell lines present a
growth advantage and faster cell proliferation over cells with smaller expansions
(Khajavi et al., 2001). The accumulation of more data from DM1 PGD cases is
necessary to further support these findings at the preimplantation stage.
In conclusion, the first part of this study (aims 1 and 2) enabled the development and
clinical implementation of new universal protocols that can be routinely applied for the
diagnosis of DM1 at the preimplantation stage. The results from our 28 DM1 IVF/PGD
cycles, the largest number of cycles in the UK, demonstrate that PGD for DM1 is a
practical, reliable and effective option for couples to avoid passing the disorder on to
their children without the need for termination of affected pregnancies (Kakourou et al.,
2008). The implantation and pregnancy rates have been very encouraging and this is
fundamental to the PGD program. PGD for DM1 can be applied within one month after
patient referral and should be suggested as another alternative to PND during
counselling of couples with increased genetic risk. Furthermore, this study has provided
additional information regarding the impact of the number of cells biopsied, which has
recently accumulated a lot of debate. Since completion of analysis in this study, several
of the patients have had additional IVF/PGD cycles. In particular, patients 8 and 23
have now had a total of 4 cycles each and patient 19 has had a total of 3 cycles. This
emphasizes that these couples are willing to go to great lengths to avoid passing on
DM1 to their children and underlines the importance of obtaining an accurate diagnosis
for every single embryo to improve the chances of a successful IVF/PGD cycle. Both of217
the new optimised protocols, the DM1 triplex and the mTP-PCR, involve a single PCR
amplification step. Therefore, these methods enable a faster and significantly cheaper
diagnosis compared to other described attempts for the establishment of universal PGD
protocols, that involve an MDA approach (Burlet et al., 2006;Renwick et al., 2006).
This study has also provided information from 28 couples regarding repeat transmission
from affected parent to embryos at the preimplantation stage, mostly affected female to
embryo and unaffected male to embryo. Transmission ratio distortion was not observed,
though a growth advantage of DM1 affected vs. unaffected embryos was detected.
Implementation of the new protocols in clinical practice will allow accumulation of data
to further support the findings described in this study regarding allele transmission and
embryo development.
4.3 Expression work
4.3.1 Sample processing for microarrays
The difficulties associated with obtaining and generally working with human oocytes
and embryos pose limitations to research in this field. Several studies have been
conducted using poor quality oocytes and embryos that would be discarded during IVF,
or oocytes that were injected with sperm but failed to fertilise, similarly of no use in
IVF. The human oocytes used in this study were immature at the time of collection, and,
therefore, unsuitable for IVF treatment, but matured in culture prior to processing. The
human embryo blastocysts had been cryopreserved and were donated for research
following the couples’ decision not to use them for embryo transfer.
Microarray work with such precious samples requires great attention to ensure that an
accurate expression profile is obtained. Careful evaluation of the developmental stage of
the sample is essential prior to sample selection, pooling and processing, as well as
complete removal of the zona pellucida, to prevent nucleic acid contamination. Overall
handling should be swift to prevent RNA degradation. Oocyte and embryo samples
were stored at -80°C until enough were collected to be able to pool them in groups of
three. Though a microarray result can also been obtained from a single oocyte, many218
transcripts were not detected due to the lack of sensitivity for low template mRNA. For
that reason, it has been recommended that a minimum of three oocytes are pooled
together for microarray experiments (Jones et al., 2007).
For experimental designs that involve comparison of two groups for differential
expression testing, such as comparison of the blastocyst to the human MII oocyte in this
study, it is indicated that a minimum of five biological cases per group should be
analyzed (Pavlidis et al., 2003). The more biological samples tested, the greater the
significance of the microarray results. Pooling of mRNA from biological replicates
increases the biological sample size without the need to utilise more arrays. The samples
pooled together were from different donors in order to overcome individual variation. In
this way inter-individual variation cannot be assessed, but this practice generates an
overall representative gene expression profile from the tested sample. Biological
replicates are considered essential and should be preferred to technical replicates
(testing of mRNA from a single sample on multiple arrays), as they allow to not only
estimate the effects of measurement variability but also account for any biological
differences (Allison et al., 2006).
Additionally, samples were processed a few at a time in order to minimize the overall
handling time during the RNA isolation particularly in view of the long protocol for the
RNA amplification procedure. Careful planning of each experimental step was essential
in order to avoid unnecessary delays and minimize freezing-thawing of the samples.
The triplicate array experiments for blastocyst-oocyte comparison were all performed
using arrays from a single batch. All arrays were processed at the same time to avoid
influences on the results by other unknown factors.
The experience with single cell work for PGD and the availability of the PGD
laboratory set-up, designed so as to reduce the chances of DNA contamination, along
with the incorporation of practice guidelines specifically for RNA work, provided the
necessary environment for successful processing of the samples to be used for
microarrays. Optimal conditions for working with RNA were first tested on lymphocyte
samples prior to commencing the microarray work. Good practice was then confirmed
by the Bioanalyser results for the samples used for microarrays, indicating good RNA
integrity and the absence of DNA contamination.
Reported estimates of the total RNA amount per human oocyte range between 55-330pg
(Neilson et al., 2000;Dobson et al., 2004;Kocabas et al., 2006). In our study RNA
concentrations extracted from pooled samples ranged between 48-78pg/µl, on average
(from all samples) 58.6pg/µl (14μl of eluted volume for each sample set of three219
oocytes), i.e. 273pg/oocyte (0.27ng/oocyte). The amount of RNA from the human
blastocyst sets (the DM1 affected sample excluded) ranged from 63-393pg/µl, with an
average from all readings, of 223.3pg/µl, i.e. 1042pg/ blastocyst (or 1ng/blastocyst).
As microarrays require at least 10µg RNA for hybridization, the samples were amplified
using a two-round linear RNA amplification protocol, which amplifies more than
100,000 times the initial RNA input, achieving a new RNA concentration range for
pooled oocyte samples between 22.9ng/µl to 296ng/µl and 59.5-232.8 ng/µl for the
embryo samples.
It is noteworthy that the lowest concentrations were obtained from oocytes and embryos
processed in the early part of our experience, indicating the importance of careful set up
and expertise with each new experimental procedure. The three sets of oocytes and
embryos for which hybridization of 10µg was possible for the microarrays were used as
biological replicates. The amplification protocol used has been previously validated by
other investigators and the amplified material is thought to be representative of the
original samples (Bermudez et al., 2004;Patrizio et al., 2007).
This study overcame limitations, such as the use of discarded human oocytes that failed
to fertilise, as well as the lack of sufficient biological and technical replicates. In
addition, the use of a very sensitive microarray platform in this study, allowing the
interrogation of over 29,000 genes has overcome the limited coverage of several
previous array experiments (Kocabas et al., 2006).
4.3.2 Microarray results analysis: general expression profiling
The differences in the number of probes detected between the three replicates for
oocytes and blastocysts can be attributed to the random pooling of samples from
different donors, with a different genetic background, to differences in the
microenvironment of each oocyte and embryo, the time required for collection and
tubing for each sample as well as differences in RNA quality and amplification.
Overall, 11679 probes and 13118 probes were detected in all three replicates of oocytes
and blastocysts respectively. As only the probes common between all samples were
considered for further analysis we assume that sample-specific differences are
eliminated.
Failure to detect expression from cumulus-cell specific genes in the oocytes and
blastocysts was taken as a confirmation that all samples were successfully denuded of220
the zona pellucida. Examples of these included PTGS2, PTX3, GREM1 and STAR,
which are downstream targets of the oocyte-secreted factor GDF9 and have been
described as cumulus cell markers of oocyte competence. Other cumulus cell markers
that were undetected included the KIT ligand (KITLG), which is produced by the
granulosa cells and binds to its receptor on the oocyte surface to stimulate oocyte
growth, as well as epidermal growth factor (EGF)- like proteins of the granulosa cells,
amphiregulin and epiregulin, that have been associated with oocyte maturation
(Mehlmann, 2005;Cillo et al., 2007;Li et al., 2008). The levels of expression of several
genes previously investigated were also assessed in our sample data.
The majority of genes detected in each sample broadly belonged to the nucleic acid and
protein metabolism categories and most genes with highest expression in both samples,
excluding the unclassified function genes, were involved in protein metabolism.
Additionally, the oocyte also showed generally high expression in the categories of
nucleic acid metabolism and cell cycle. Despite the main differences, however, several
genes showed similarly very high levels of expression in both samples, such as the
heterogeneous nuclear ribonucleoprotein A1 (HNRPA1) involved in mRNA splicing,
and the ribosomal protein L7a (RPL7A), involved in protein biosynthesis, suggesting a
fundamental role of these transcripts in preimplantation development.
When the gene expression was compared between the two samples, taking the human
oocyte as the control, 4910 genes showed statistically significant differences in
expression (p<0.05). Of these, 2652 genes were over expressed in the blastocyst and
2591 genes were under expressed in the blastocyst compared to the oocyte. Excluding
the genes of unclassified function, the majority of the remaining genes showing higher
expression in the blastocyst belonged to the protein biosynthesis category, while other
important categories included intracellular protein traffic, transport, and immunity and
defense. On the other hand, genes that showed higher expression in the oocyte are
associated with nucleic acid metabolism, signal transduction, developmental processes
or the cell cycle.
The protein metabolism (higher expression in blastocyst) and nucleic acid metabolism
(higher expression in oocyte) categories were investigated in more detail. Genes over
expressed in the blastocyst were involved in protein biosynthesis, protein folding,
translational regulation, protein complex assembly or amino acid regulation, while most221
protein modification genes showed higher expression in the oocyte. From the nucleic
acid binding category the blastocyst showed higher expression for genes that had to do
with pre-mRNA processing, rRNA and tRNA metabolism, purine and pyrimidine
metabolism, while the oocyte showed higher expression for genes involved in DNA
processing, chromatin packaging and remodeling, RNA localization or metabolism of
cyclic nucleotides.
The genes that showed over a 10-fold difference in gene expression between the two
samples were further analyzed by molecular function. It was found that the blastocyst
showed over expression of ribosomal proteins and translation factors, while the oocyte
showed over expression of chromatin-binding factors, transcription factor, and DNA
methyltransferases.
Overall, the oocyte was rich in genes involved in DNA metabolism, while the blastocyst
was mostly active in protein metabolism. The initial analysis supports previous findings
that human oocytes, though transcriptionally silent, are well equipped with transcripts
and proteins in order to be able to support chromatin remodeling during fertilisation as
well as early preimplantation development until initiation of transcription in the embryo
(Kocabas et al., 2006). On the other hand, the human blastocyst is very active in
synthesizing proteins, but also shows high activity in genes that have to do with DNA or
chromosomes. This has also been previously suggested to be associated with the higher
number of nuclei in the blastocyst sample (Wells et al., 2005b).222
4.3.3 Oocyte and blastocyst-specific genes
Once the genes expressed in a tested sample are known, the next important goal is to
understand the impact of their expression and what function they contribute to
preimplantation development.
For that purpose, we proceeded to investigate the genes that are uniquely expressed in
oocytes and blastocysts, as this might reveal which genes play a critical role in
maturation, fertilisation and development and which genes are expressed as a result of
embryonic genome activation. Previous comparisons of oocytes, of different maturation
stages, with their surrounding cumulus cells, and investigation of genes expressed in
embryos at different developmental stages have provided some additional intriguing
information (introduction section 1.3.2). The investigation and comparison of oocyte
and blastocyst-specific genes, however, possibly indicating genes with important roles
pre- and post- embryonic genome activation, has not been previously reported.
A total of 1909 genes were uniquely expressed in the oocytes, while 3122 were
uniquely expressed in the blastocyst samples. Oocyte-specific genes included the zona
pellucida glycoproteins (ZP1, ZP2, ZP3, ZP4) and members of the TGF-beta
superfamily, such as GDF9 and BMP15, that are known to play a role in follicle growth,
maturation and cumulus expansion (McKenzie et al., 2004). In addition, known germ-
cell specific genes were included in this category, such as factor in the germline alpha
(FIGLA), deleted in azoospermia-like (DAZL), v-mos Moloney murine sarcoma viral
oncogene homolog (MOS), nucleophosmin/nucleoplasmin 2 (NPM2) and H1 histone
family, member O (H1FOO). Genes unique in human blastocysts included annexins A2
and A3 (ANXA2, ANXA3), gap junction protein, alpha 1 (GJPA1), GTP binding protein
4 (GTPBP4), ATPase H+ transporting, lysosomal accessory protein 1 (ATP6AP1).
Uniquely expressed transcription factors represented an important molecular function
category in both sample types.
When grouped by level of expression, 349 of the oocyte-specific genes (18.3%) and 431
of the blastocyst-specific genes (13.8%) showed high expression levels.
Amongst the oocyte-specific genes, high expression was detected for genes regulating
glycogen metabolism, lipid metabolism and calcium homeostasis, while important
molecular function categories involved mitochondrial carrier proteins, cyclases and the
microtubule family of cytoskeletal proteins. On the other hand, the blastocyst-specific223
genes were associated with oxidative phosphorylation, glycolysis, sterol metabolism,
and were rich in RNA-binding proteins, methyltransferases, gap junction proteins and
intermediate filaments.
Experiments on porcine and bovine oocytes have demonstrated the role of lipid
metabolism in the oocyte and the use of triglycerides (TG) as endogenous substrates for
the generation of ATP (Sturmey et al., 2006). TG is stored as lipid droplets, which have
been shown to be in close proximity to the mitochondria, where the free fatty acids are
transported in order to be oxidized by beta-oxidation and the TCA cycle. Mitochondria
actively relocate and surround the newly formed pronuclei, following fertilisation of the
human oocyte, to concentrate ATP and calcium to support normal developmental
processes (Sousa et al., 1997;Sun et al., 2001). In mouse oocytes, the movement of
mitochondria is mediated by microtubules, which also justifies the high expression level
of the microtubule family of cytoskeletal proteins in these cells. The pre-existing
oocyte mitochondrial proteins and transcripts are necessary to generate ATP until new
biosynthetic activity develops following embryonic genome activation. Their significant
role is also underlined by the fact that mitochondrial DNA defects, either pre-existing or
age-related, have been associated with reduced meiotic competence and fertilizability of
the oocyte as well as developmental failure in the preimplantation embryo (Van et al.,
2000). Our findings support that the human oocyte has all the machinery required to
support the synthesis of cAMP, which controls nuclear maturation (Kawamura et al.,
2004;Richard, 2007). This includes receptors, guanosine 5’-triphosphate-binding (G)
proteins, cyclases (which synthesize cyclic nucleotides) and phosphodiesterases
(degrading cyclic nucleotides), which were found to be amongst the oocyte-unique
genes and also of high expression level. The identification of the above unique oocyte
genes is significant and may be further investigated to provide information on the
oocyte quality (Van et al., 2000).
Highly expressed human blastocyst genes were associated with oxidative
phosphorylation as well as glycolysis. These processes control ATP generation during
pre-compaction and cavitation stages respectively (Van et al., 2000). Therefore, these
genes probably exist from the point of embryonic genome activation and onwards. The
blastocyst, contrary to the oocyte, showed high expression in genes involved in the
conversion of acetate to cholesterol. The sterol synthetic pathway has also been shown
in mouse oocytes and embryos not to be operative until the blastocyst stage of
development. These processes were not significantly detected in the oocyte samples,
which is an expected finding as the oocytes can obtain the necessary nutrients from the224
surrounding cumulus cells. For example, BMP15 has been shown to stimulate the
glycolytic activity in granulosa cells since the oocytes are not able to generate ATP
(Sugiura et al., 2007). In addition, mouse oocytes can stimulate cholesterol synthesis in
cumulus cells, which in turn supply the oocytes with cholesterol (Su et al., 2008).
Finally, highly expressed blastocyst genes were involved in the platelet derived growth
factor (PDGF) pathway, which plays a critical role in cellular proliferation and
metabolism, the Rho GTPase control pathway that regulates cytoskeletal changes
occurring during cell growth and development and the Integrin signalling pathway, also
important in actin reorganization. Most oocyte genes, on the other hand belonged to the
Wnt signalling pathway, important in recruitment of membrane proteins and general
transcription regulation.
4.3.4 Investigation of housekeeping gene expression
Housekeeping genes are highly and stably expressed in a variety of tissues and cell
types. Because of their role in regulating basic cell processes, they generally provide
some information on the quality and function of a cell, while their expression might be
indicative of the expression of a number of other genes. Additionally, housekeeping
genes can be used as endogenous standards for normalization of gene expression data
across various samples. This approach requires careful validation of the housekeeping
gene expression under different developmental stages and experimental conditions,
involving, to ensure accuracy, a rather large number of test samples as well as biological
and technical replicates.
The above are difficult with regards to human preimplantation embryo work, where
there is limited availability of material. For that reason, several studies have attempted
different methods of normalization, however, none of them is ideal for working with
minute amounts of RNA. The absolute RNA quantification is impractical for sizing
small samples, while the approach of adding exogenous template has been challenged
for competing for enzyme and nucleotides with the endogenous sequence, while at the
same time increasing the cost and introducing extra procedures (Huggett et al.,
2005;Jeong et al., 2005;Mamo et al., 2007;Mamo et al., 2008).
In this study, microarray data obtained from human oocytes and embryos was analyzed
for the identification of the level of expression of genes with a potential housekeeping225
role. The analysis has identified the genes that are highly expressed in these samples,
which can be taken as an indicator of the different pathways regulating these complex
developmental stages, and also identified several potentially stably expressed genes that
may be further validated.
Five hundred and sixty (560) genes were analyzed in total. Most genes showed high
expression levels in both samples, and 90.9% of the high expression genes of the oocyte
remained of high expression in the blastocyst sample. The majority of these were
ribosomal proteins.
Two hundred and eleven (211) of all detected genes showed significant differences in
expression between the two samples. The majority of them, 155 genes, were up
regulated in the blastocyst, while the remaining ones, 56, showed higher expression in
the oocyte. Most gene groups included both up- and down-regulated genes from the
oocyte to blastocyst stage. Differentially expressed genes from the tRNA synthetase,
hnRNP and snRNP categories were all upregulated in the blastocyst, while differentially
expressed genes from the nuclear pore complex category were all found to be down
regulated in the blastocyst sample. This also underlines the importance of nuclear
transport and cytoskeletal organization in the oocyte and provides another list of genes
with potential significance for the normal function and development of the human
oocyte. On the other hand, the snRNPs and hnRNPs, involved in mRNA splicing and
protein methylation and modification along with tRNA synthetases controlling amino
acid activation and general tRNA metabolism, play a significant role in the growing
blastocyst.
Previous experiments have demonstrated major differences between the housekeeping
genes validated from studies on adult tissue and those from embryonic stem cells or
stages of preimplantation development. Overall, the most frequently used housekeeping
genes, GAPDH and ACTB, have been determined from experiments involving adult
tissues and cell lines. These have shown very high variability both on embryonic stem
cell studies and during human preimplantation development. ACTB showed an over 10-
fold increase in expression in the human blastocyst as compared to the human oocyte.
This difference has also been identified in other human and mouse studies (Wells et al.,
2005b;Mamo et al., 2007). In particular, ACTB has been shown to fluctuate between the
5-10 cell to the morula stage and then rapidly increase in the morula and the blastocyst
(Wells et al., 2005b). In one recent study, comparing the expression of genes on day 3
human embryos to their expression in human oocytes, GAPDH was used as a reference
gene to normalise expression data to control mRNA recovery and reverse transcription226
efficiency; its expression was assumed to be constant, without prior validation (Dobson
et al., 2004). In this study, however, GAPDH was found highly up regulated in the
human blastocyst compared to the human oocyte (table 3.30). ACTB was also suggested
as a control in a mouse preimplantation development study (Willems et al., 2006). From
the current analysis, amongst other commonly used housekeeping genes, eukaryotic
translation elongation factor 1 epsilon 1 (EEF1E1, protein biosynthesis) and ubiquitin C
(UBC, proteolysis) showed the most stable expression, with UBC showing overall
higher expression signals in both samples.
A recent study on immature oocytes and embryo developmental stages using
cryopreserved human embryos, recommended the use of the eukaryotic translation
elongation factor A (EEF1A1) and the proteasome subunit beta, type 6 (PSMB6),
associated with translational regulation and proteolysis respectively, as reference genes
in human preimplantation studies (Zhang et al., 2008). Other preimplantation studies on
mouse, rabbit and bovine embryos have indicated the comparative stable expression of
PPIA, CHUK, TBP, Histone H2A, H2AFZ, YWHAZ and HPRT1 (Robert et al.,
2002;Falco et al., 2006;Willems et al., 2006;Mamo et al., 2007;Mamo et al., 2008).
From all of the above genes, in our analysis CHUK gave a stable signal between the
oocytes and blastocysts, but the remaining genes do not seem to be suitable as control
genes for human preimplantation studies as they showed significant expression
variability.
4.3.5 Assessment of gene expression for other functional pathways
DM1 is a multifactorial disease and affects many different pathways, including some
that play a significant role during preimplantation development, such as methylation.
Other genes, for example genes encoding components of the microRNA processing
machinery, also known to play a critical role in oocyte maturation and embryo
development, have not been previously investigated at the human preimplantation stage
(Murchison et al., 2007;Tang et al., 2007).227
MicroRNAs are short, non-coding endogenous RNAs that bind to conserved sequences
within the 3’ untranslated regions of specific mRNAs and inhibit their translation,
regulating, in this way, the expression of up to one third of human genes (Lewis et al.,
2005). MicroRNAs are derived from long primary transcripts transcribed by RNA
polymerase II (pri-miRNA), cropped by nuclear RNAse III Drosha into 70 nucleotide-
long pre-miRNAs, exported out of the nucleus by XPO5 and cleaved by cytoplasmic
RNAse III DICER into the 17-25 nucleotide-long miRNA duplexes. One strand of the
miRNA duplex is incorporated, along with the Argonaute protein Ago2, into the RNA-
induced silencing complex (RISC), which scans cellular mRNA in an attempt to locate
the miRNA target (Mtango et al., 2008;Schmittgen, 2008). A recent study on human
embryonic stem cells (hESCs) has revealed that most of the hESC miRNAs are located
on chromosomes X and 19 (Cao et al., 2008).
In this study, the expression of genes from this pathway was investigated in the human
MII oocytes and embryos. Significant observations included strong maternal expression
of DICER1 and significant downregulation of GEMIN5, SIP1 and TNRC6B at the
blastocyst compared to the oocyte stage. The expression of RNASEN was high in both
oocytes and blastocysts. On the other hand, YBX1, GEMIN4, MOV10 and the exportin
genes (XPO1, XPO4, XPO5) were all significantly up regulated in the blastocyst.
Several genes were only detected at one of the two stages.
The above results from the human samples can be compared with studies on mouse and
rhesus monkey preimplantation oocyte and blastocyst embryo development regarding
the level of expression of these genes (Zheng et al., 2004;Mtango et al., 2008).
Some similarities and differences are observed in the expression of these genes between
the three species. The expression patterns of RNASEN, DICER1, GEMIN5 and TNRC6B
are similar to the results from the mouse study, while upregulation of YBX1 at the
blastocyst stage was also detected in the rhesus monkey study. XPO4 increased during
development in all three species. PIWIL1 was not detected in either oocytes or
blastocysts, similarly to the other studies. MOV10, which was not detected in the
monkey, was found highly up regulated in the human blastocyst, suggesting that some
of these processes might be controlled differently in different species (Zheng et al.,
2004; Cui et al., 2007;Mtango et al., 2008).228
Data analysis also identified the expression level of methyltransferases and other DM1-
associated genes, thereby providing a useful foundation of information for experiments
on DM1 affected samples, in comparison to unaffected samples.
Expression of the DMPK gene was not detected in the oocyte or blastocyst samples
tested in this study. However, a previous study reported detection of maternal DMPK
transcripts in two unfertilised oocytes and detection of transcripts from the paternally
inherited allele in 16 out of 19 preimplantation embryos, of up to four blastomeres each,
donated by IVF patients (Daniels et al., 1995). It is unknown whether expression of
DMPK may serve a specific function at this early developmental stage, however,
considering the potential differences in development between affected and unaffected
embryos suggested in this study, this would be something interesting to further
investigate. Additionally, the above give further emphasis to the requirement for
continuation of the microarray experiments using more sensitive analyses, to investigate
the absence of several transcripts. Lack of amplification or underrepresentation of some
transcripts may be associated with the oligo(dT) amplification step performed for
generating the microarray data (Bell et al., 2008).
In summary, this work confirmed several previously described findings from studies on
preimplantation development of human and other species and provided the opportunity
to study the level of expression of a large number of genes, not previously investigated,
in healthy human oocytes and embryos. The identification of genes that maintain high
expression levels during the initial and latest stages of preimplantation development, as
well as genes uniquely expressed at each of these developmental stages, is expected to
be of used in future experiments, potentially providing important information regarding
sample quality. More generally, alterations in the level of expression of the microRNA
processing genes, that play a significant role during development and have an impact in
the expression of other genes, might also be used as an indicator of oocyte and embryo
quality. Additionally, this study identified genes which may show a stable expression
between human oocyte and blastocyst stage and may thus be candidate ‘housekeeping’
genes. Further work on validation of these results is important, especially as it has
recently been recommended that more than one reference genes should be used for
accurate normalization and interpretation of the expression results (Vandesompele et al.,
2002). Finally, the DM1-associated genes detected in the oocyte and embryo samples229
could form the focus of further investigations for the comparison of gene expression
between DM1-affected and unaffected samples.230
4.4 Future work
The results presented in this study have provided the basis for future experiments to
expand on current knowledge of the mechanism and pathogenesis of DM1. The
availability of the new protocols will increase the number of patients with DM1 that can
undergo PGD. The continuing PGD work, combined with analysis of data from
diagnosis and follow-up analysis of embryos unsuitable for transfer, may provide a
clearer picture regarding transmission of different sized repeat alleles, the mechanisms
involved in repeat transmission as well as affected vs. unaffected embryo development.
The results from this study have also raised several questions that could be addressed in
future work. Interesting findings and observations have included abnormally fertilised
oocytes, poor quality embryos and identification of chromosomally abnormal embryos
from patients with DM1. The possible incidence of monosomy 19 could not be
confirmed. The co-amplification of several markers on chromosome 19 may be of use in
identifying cases of monosomy, while testing of markers on different chromosomes may
suggest cases of haploid embryos. However, such an approach would be very difficult at
the single-cell level. For that purpose, chromosomal analysis of embryos from patients
with DM1 and comparison with results from other single gene PGD cases has already
been initiated in our department. It remains to be seen whether a combination of
chromosomal and molecular analysis of the preimplantation embryo will be of benefit
for patients with DM1, in order to enable the identification of embryos more likely to
implant. This analysis has been previously attempted by combining WGA followed by
F-PCR and CGH analysis, and may, in the future, be possible by genetic analysis of
single biopsied cells by DNA microarray technology (Kuliev and Verlinsky, 2008).
Follow-up analysis of spare embryos following PGD may also be extended by
optimising a new protocol at the single cell level, to co-amplify the AMLXY primer
along with the other markers of the DM1 triplex or mTP-PCR protocols. The aim of
this would be to establish whether there is an association between repeat size, embryo
sex and/or embryo development. In this study this analysis was initiated on only a few
embryos following amplification by MDA. Since these results indicated a very high
ADO rate, it is expected that a more accurate and faster at the same time, analysis will
be possible by simple F-PCR. Because of the small product size of the AMXY primer, it231
is anticipated that its amplification on single cells and co-amplification along with the
other markers in a multiplex PCR will not require extensive optimisation.
This study also included testing of buccal cells from two babies born following PGD for
two families. The continuing analysis may provide interesting results regarding the
characteristics and grade of implanting embryos. Additionally, embryo rebiopsy has not
been previously described by another PGD centre; although it increases the rate of
embryo diagnosis further evidence is necessary to investigate the possible impact of
rebiopsy on embryo development and implantation.
Finally, during the course of this study several immature oocytes were collected from
patients with DM1 and stored at -80°C (section 2.3.2.2). These were destined to be used,
following validation of the TP-PCR protocol, for estimation of the repeat size. The aim
was to obtain some indication regarding the timing of the repeat expansion, at the same
time focus on a more patient-specific analysis concerning the size of the expansion and
associate oocyte analysis with remaining embryo diagnosis. Because of the inaccuracy
of sizing by TP-PCR, as found in this study, these oocytes were not processed and may
be used instead for repeat sizing by Southern blotting, as has been previously reported
(De Temmerman et al., 2004). Further work for this may be, however, necessary as
protocols for performing Southern blotting from a single cell have not as yet become
available.
The results from the microarray analysis have provided important information to guide
further experiments by real-time PCR technology. The identification of genes that may
play a significant role at the oocyte and blastocyst stages of preimplantation
development, as well as genes that may indicate good oocyte and embryo quality, will
be of use in future expression studies. The identified list of housekeeping genes with
apparently similar expression between the two stages indicates which genes to further
target for investigation by real-time PCR.
One of the difficulties encountered in this study, due to the limited number of DM1
PGD cases at the time, was the collection of DM1 affected oocytes and embryos.
Hopefully, the collection of more of these samples in the future will enable a
comparison of the normal to the disease state, using the information regarding the232
expression level of relevant genes, as provided by the microarray data and possibly
focusing on transcription factors and microRNA pathway genes. Affected and
unaffected immature oocytes may be identified by isolation of the oocyte polar bodies
and testing each PB using the mTP-PCR protocol. The suggested oocyte genotype may
also be confirmed by simultaneous DNA/RNA isolation of the oocyte and testing of the
DNA using mTP-PCR. Expression studies on the affected and unaffected oocytes may
indicate additional differences in chromosomal constitution or expression.
In summary, future work stemming from this study may involve accumulation of data
from PGD and follow-up analysis, including development of a new mTP-PCR with
AMXY protocol, chromosomal analysis of embryos from patients with DM1 and
comparison with other monogenic disorders, repeat sizing by Southern blotting and real-
time PCR analysis. Understanding the molecular events of early preimplantation
development and investigating the changes that may be associated with the presence of
the CTG repeat expansion may provide a further insight into the mechanisms
controlling DM1 development and progression; genes that play a role in the expansion
pathway may become future targets for therapeutic intervention not only in DM1 but
also other repeat expansion disorders.233
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A1. Appendix 1
A1.1 Chemicals
Most chemicals were supplied by Sigma® Chemical company and BDH (later merged
with VWR International) and were of Molecular Biology (for Sigma) or AnalaR Grade
(BDH), unless otherwise indicated. The molecular formula or abbreviation for each
chemical is shown below.
SIGMA® Chemical Company:
Agarose Type I: low EEO, Bovine serum albumin (BSA), Dimethyl sulfoxide >99.9%
(DMSO), DL-Dithiothreitol (DTT) for molecular biology, minimum 99% titration,
ethylenediaminetetra-acetic acid anhydrous 99% (EDTA), gelatine from porcine skin
type A, glucose (anhydrous), Igepal CA-630, mineral oil, phenol red sodium salt,
phosphate buffered saline (PBS), sodium bicarbonate (NaHCO3), sodium chloride
(NaCl), sodium dodecyl sulfate 10% solution 0.2μm filtered (SDS), sodium phosphate
monobasic 99.0% (NaH2PO4), Tricine
VWR International:
Ethanol 99.7-100% v/v, formaldehyde, glycerol, orthoboric acid, potassium hydroxide
(KOH), pottasium chloride (KCl), silver nitrate, sodium borohydride (BNaH4), sodium
hydrogen carbonate (NaHCO3), sodium hydrogen orthophosphate, sodium hydroxide
pellets (NaOH), potassium hydroxide pellets (KOH), sodium thiosulphate pentahydrate
(Na2S2O3 5H2O), Tris (hydroxymethyl) methylamine (TRIS)258
A1.2 Solutions
All solutions were prepared with deionized water and sterilized by autoclaving at 121°C,
1 Bar for 30 minutes (Swiftlock compact autoclave, Astell Scientific Ltd).
A1.2.1 DNA extraction
TKM1
10 mM Tris-HCl (pH 7.6), 10 mM KCl, 10 mM MgCl2, 2 mM EDTA (pH 8.0).
Autoclaved and stored at room temperature.
TKM2
10 mM Tris-HCl (pH 7.6), 10 mM KCl, 10 mM MgCl2, 0.4 M NaCI, 2 mM EDTA (pH
8.0). Autoclaved and stored at room temperature.
10x TE
10mM Tris-HCl (pH 7.4); 0.1M EDTA (pH 8.0). Autoclaved and stored at room
temperature.
6M NaCl
292.2g of NaCl dissolved in 800ml of distilled H2O
10% SDS
100g of electrophoresis-grade SDS dissolved in 900ml of H2O (may need to heat to
68C). Adjust the pH to 7.2 by adding a few drops of concentrated hydrochloric acid
(HCl).
A1.2.2 Lymphocyte isolation
0.9% NaCl
9 g NaCl dissolved in 1000ml H2O. Autoclaved and stored at room temperature.259
A1.2.3 Single cell isolation/lysis
Dissociation buffer (DB)
0.8% NaCl, 0.02% KCl, 0.005% NaH2PO4, 0.1% Glucose, 0.1% EDTA, 0.1% NaHCO3,
0.01% Phenol Red
PK lysis buffer
1.25μg/μl proteinase K, 17.5μM sodium dodecyl sulphate
1M NaOH
8g NaOH were dissolved in 200ml distilled H20. The solution was sterilized by
autoclaving and stored at 4°C
1M KOH
11.2g KOH dissolved in 200ml distilled H20. The solution was sterilized by autoclaving
and stored at 4°C
ALB lysis buffer
200mM NaOH or KOH, 50mM DTT
DTT aliquots of 0.007g each (molecular weight: 154.25) were weighed into sterile
1.5ml PCR tubes and stored at 4°C. The lysis buffer was freshly made by adding 200ml
of the prepared 1M NaOH or KOH solution to the DTT aliquot to use and adjusting to
the final volume of 1ml with nuclease-free water. The volumes of NaOH/KOH and
nuclease-free water varied accordingly depending on the amount of DTT in each aliquot.
The freshly made ALB lysis buffer was stored at 4°C and was used for up to two
consecutive days.
Tricine (200mM)
0.358g of Tricine was dissolved in 10ml distilled H2O and passed through a 0.2μm
sterile filter (Sartorius Minisart®, UK). The solution was aliquoted into 0.5ml PCR
tubes, 200μl each, and stored at -20°C.260
A1.2.4 Electrophoresis
TBE (10x)
90mM Tris-HCl, 90mM boric acid, 2mM EDTA (pH 8.0). Autoclaved and stored at
room temperature.
Loading buffer for agarose gel
40% sucrose; 0.025%w/v bromophenol blue; 0.025% w/v xylene cyanol
Ethidium bromide (stock solution: 10mg/ml)
Diluted to 0.5 μg/ml in 50ml 1X TBE (agarose gel electrophoresis, section 2.5.4.1).261
A1.3 Oligonucleotides
Details for oligonucleotides of tables A1.1 and A1.2 were obtained using Ensembl genome browser website, ensemble version 50
(http://www.ensembl.org) or GDB Human Genome Database for the STR markers, heterozygosity details were from GDB.
Table A1.1: Details of oligonucleotide primers for mutation detection and testing of specific targeted regions (ACTB, AMXY)
Primer details
Modification
(as in section
2.4.1.3)
Primer binding site
Basepairs on chromosome (bp)
Product size
(bp)
Chromosome 7
Beta-actin, ENST00000331789 (august 27
th 2008)
ACTB Exon 4/5
ACTB Forward GTTGCTATCCAGGCTGTGCT HEX™ 5534276-5534295
ACTB Reverse CGGATGTCCACGTCACACTT 5534821-5534840
470
Chromosome 19
DMPK gene, Ensembl Sequence ENSG00000104936 (august 27
th 2008)
DMPK exon 7/8
DMPK7/8Forward GGAGACCTATGGCAAGATCG FAM™ 50972776-50972795
DMPK7/8Reverse AGCAACCGCTGAATGAAGTC 50972618-50972637
102
DMPK exon 15
DMPK1/Forward GAACGGGGTCGAAGGGTCCTTGTAGC 50965371-50965398
DMPK2/Reverse CTTCCCAGGCCTGCAGTTTGCCCATC VIC® 50965226-50965251
>122 depending
on repeat number
DMPK3/Forward CAGCTCCAGTCCTGTGATCC 50965448-50965467 241bp with
DMPK2
TP-PCR primers
P2 GAACGGGGCTCGAAGGGTCCTTGTAGCCG FAM™ 50965369-50965397
P4CAG TACGCATCCCAGTTTGAGACGCAGCAGCAGCAGCAGCA
P3R TACGCATCCCAGTTTGAGACG
Peak detected
every 3bp
Chromosomes X-Y
Amelogenin gene, Ensembl Sequence ENSG00000125363 (Chr:X), ENSG0000099721 (Chr:Y)(august 27
th 2008) Chr: X Chr: Y
AMELX-Y/ Forward ATCAGAGCTTAAACTGGGAAGCTG NED™ 11224997-11225020 6797888-
6797911 105 (chr:X)
AMELX-Y/ Reverse CCCTGGGCTCTGTAAAGAATAGTG 11224915-11224935 6797979-
6797999 111 (chr:Y)262
Table A1.2: Microsatellite markers used in optimised DM1 PGD protocols for detection of contamination
Microsatellite markers
Primer details Modification
Primer binding site
Base pairs on
chromosome (bp)
Product size
(bp) Heterozygosity
(%)
Chromosome 19
APOC2 gene Ensembl sequence ENSG00000213044 (august 27
th 2008)
APOC2 Forward GGCTACATAGCGAGACTCCATCTCC FAM™ 50141347- 50141371
APOC2 Reverse GGGAGAGGGCAAAGATCGATAAAGC 50141216-50141240
134-170 85.2
D19S219 Forward CAGGAAGCGGAGGTTGCAGTGAG FAM™ 50685602-50685625
D19S219 Reverse GTGGAATTGCTGGGTGGACTGGT 50685746-50685768
152-182 77
D19S207 Forward TGCGGTGTTTGAACCCTCGCTG HEX™ 50995802-50995823
D19S207 Reverse ACTGCACTGCAGCCTGAGTGAC 50995932-50995953
135-157 78.4
D19S112 Forward GCCAGCCATTCAGTCATTTGAAG NED™ 51070821-51070843
D19S112 Reverse CTGAAAGACACGTCACACTGGT 51070929-51070950
120-142 86.3
Chromosome 21
D21S11 Forward TATGTGAGTCAATTCCCCAAGTGA FAM™ 19476131-19476154
D21S11 Reverse GTTGTATTAGTCAATGTTCTCCAG 19476331-19476354
172-264 90
D21S1414F AAATTAGTGTCTGGCACCCAGTA FAM™ 19476463-19476485
D21S1414R CAATTCCCCAAGTGAATTGCCTTC 19476140-19476163
291-370 87.5263
Table A1.3: Position of primers for RNA/DNA amplification from ACTB and DMPK genes. Salmon-coloured regions indicate the
position of exons. Yellow sequences represent the primer annealing sites.
ACTB (ENSG00000075624): DNA product size: 547bp, RNA product size: 452bp
5534898 ATGGTGTATCTCTGCCTTACAGATCATGTTTGAGACCTTCAACACCCCAGCCATGTACGT 5534839
5534838 TGCTATCCAGGCTGTGCTATCCCTGTACGCCTCTGGCCGTACCACTGGCATCGTGATGGA 5534779
5534778 CTCCGGTGACGGGGTCACCCACACTGTGCCCATCTACGAGGGGTATGCCCTCCCCCATGC 5534719
5534718 CATCCTGCGTCTGGACCTGGCTGGCCGGGACCTGACTGACTACCTCATGAAGATCCTCAC 5534659
5534658 CGAGCGCGGCTACAGCTTCACCACCACGGCCGAGCGGGAAATCGTGCGTGACATTAAGGA 5534599
5534598 GAAGCTGTGCTACGTCGCCCTGGACTTCGAGCAAGAGATGGCCACGGCTGCTTCCAGCTC 5534539
5534538 CTCCCTGGAGAAGAGCTACGAGCTGCCTGACGGCCAGGTCATCACCATTGGCAATGAGCG 5534479
5534478 GTTCCGCTGCCCTGAGGCACTCTTCCAGCCTTCCTTCCTGGGTGAGTGGAGACTGTCTCC 5534419
5534418 CGGCTCTGCCTGACATGAGGGTTACCCCTCGGGGCTGTGCTGTGGAAGCTAAGTCCTGCC 5534359
5534358 CTCATTTCCCTCTCAGGCATGGAGTCCTGTGGCATCCACGAAACTACCTTCAACTCCATC 5534299
5534298 ATGAAGTGTGACGTGGACATCCGCAAAGACCTGTACGCCAACACAGTGCTGTCTGGCGGC 5534239
5534238 ACCACCATGTACCCTGGCATTGCCGACAGGATGCAGAAGGAGATCACTGCCCTGGCACCC 5534179
5534178 AGCACAATGAAGATCAAGGTGGGTGTCTTTCCTGCCTGAGCTGACCTGGGCAGGTCGGCT 5534119
5534118 GTGGGGTCCTGTGGTGTGTGGGGAGCTGTCACATCCAGGGTCCTCACTGCCTGTCCCCTT 5534059
DMPK (ENSG00000104936): DNA product size: 176bp, RNA product size: 99bp
50973035 AGGGCCCAGAGCTGGTGGGCCCAGAGGGGTGGGCCCAAGCCTCGCTCTGCTCCTTTTGGT 50972976
50972975 CCAGGTGCGGTCGCTGGTGGCTGTGGGCACCCCAGACTACCTGTCCCCCGAGATCCTGCA 50972916
50972915 GGCTGTGGGCGGTGGGCCTGGGACAGGCAGCTACGGGCCCGAGTGTGACTGGTGGGCGCT 50972856
50972855 GGGTGTATTCGCCTATGAAATGTTCTATGGGCAGACGCCCTTCTACGCGGATTCCACGGC 50972796
50972795 GGAGACCTATGGCAAGATCGTCCACTACAAGGTGAGCACGGCCGCAGGGAGACCTGGCCT 50972736
50972735 CTCCCGGTAGGCGCTCCCAGGCTATCGCCTCCTCTCCCTCTGAGCAGGAGCACCTCTCTC 50972676
50972675 TGCCGCTGGTGGACGAAGGGGTCCCTGAGGAGGCTCGAGACTTCATTCAGCGGTTGCTGT 50972616
50972615 GTCCCCCGGAGACACGGCTGGGCCGGGGTGGAGCAGGCGACTTCCGGACACATCCCTTCT 50972556
50972555 TCTTTGGCCTCGACTGGGATGGTCTCCGGGACAGCGTGCCCCCCTTTACACCGGATTTCG 50972496
50972495 AAGGTGCCACCGACACATGCAACTTCGACTTGGTGGAGGACGGGCTCACTGCCATGGTGA 50972436
50972435 GCGGGGGCGGGGTAGGTACCTGTGGCCCCTGCTCGGCTGCGGGAACCTCCCCATGCTCCC 50972376264
A2. Appendix 2
Table A2.1: Results from fluorescent PCR analysis for all DM1 patients and their relatives for the
CTG repeat region, as well as APOC2 and D19S112 polymorphic markers. Underlined alleles
indicate the phase. Exp= expanded allele.
Patient number CTG repeat (bp) APOC2 (bp) D19S112 (bp)
1
affected female 146/Exp 149/151 130/132
unaffected male 122/122 126/149 130/136
2
affected female 122/Exp 126/154 128/130
unaffected male 122/138 142/149 117/123
female's father (affected) 170/Exp 150/154 128/130
3
unaffected female 141/160 127/127 128/132
affected male 122/Exp 150/152 130/132
4
affected female 122/Exp 150/154 130/134
unaffected male 122/146 127/156 118/136
female's cousin (affected) 181/Exp 151/155 128/130
5
affected female 146/Exp 151/153 117/124
unaffected male 143/143 147/149 128/128
affected foetus (CVS) 146/Exp 151/153 117/128
6
unaffected female 154/178 126/143 126/128
affected male 142/Exp 151/153 128/130
affected foetus (CVS) 178/Exp 143/151 128/130
7
affected female 149/Exp 127/143 117/132
unaffected male 122/149 135/154 117/127
female's father (unaffected) 136/136 143/147 117/132
female's uncle (affected) 122/Exp 143/154 123/132
8
affected female 122/Exp 135/149 117/128
unaffected male 122/146 127/147 117/134
female's mother (affected) 152/Exp 135/149 128/128
female's father (unaffected) 123/150 149/152 117/133
female's brother (affected) 150/Exp 135/149 129/133
male's mother (unaffected) 122/122 127/129 117/125
male's father (unaffected) 146/146 148/156 129/134265
Patient number CTG repeat (bp) APOC2 (bp) D19S112 (bp)
9
affected female 122/Exp 127/150 117/132
unaffected male 122/149 150/152 128/132
female's mother (unaffected) 122/145 127/152 117/138
female's father (affected) 145/Exp 148/150 132/134
female’s brother (affected) 122/Exp 127/150 117/132
female’s cousin (affected) 139/Exp 127/150 132/140
10
affected female 145/Exp 148/152 130/134
unaffected male 122/122 127/154 132/136
affected son 122/Exp 147/154 130/132
11
affected female 139/Exp 149/149 125/130
unaffected male 122/142 127/151 128/130
12
unaffected female/ egg donor 122/122 150/152 130/136
affected male 122/Exp 143/151 123/128
male's mother (unaffected) 122/122 147/151 123/134
male's brother (unaffected) 122/145 147/153 117/134
13
affected female 122/Exp 135/153 130/130
unaffected male 122/142 153/153 117/128
female's sister (affected) 139/Exp 153/153 130/130
14
affected female 122/Exp 127/150 130/130
unaffected male 122/122 149/153 132/134
female’s mother (unaffected) 122/122 127/150 130/130
15
affected female 122/Exp 128/152 130/132
unaffected male 122/137 143/150 117/138
female's father (affected) 176/Exp 128/135 128/130
female's grandmother
(unaffected) 122/142 152/159 128/128
female's sister (unaffected) 122/176 135/152 128/132
16
affected female 139/Exp 148/158 129/129
unaffected male 122/139 150/152 127/127
female's father (affected) 122/Exp 148/150 129/136266
Patient number CTG repeat (bp) APOC2 (bp) D19S112 (bp)
17
unaffected female 122/144 150/150 130/137
affected male 170/Exp 150/154 128/130
male's brother (affected) 122/Exp 150/154 118/130
18
affected female 122/Exp 149/149 128/137
unaffected male 140/143 149/153 117/130
female's mother (unaffected) 122/141 149/149 128/137
female's father (affected) 147/Exp 149/149 118/128
female's sister1 (affected) 122/Exp 149/149 128/137
female's sister2 (affected) 122/Exp 149/149 128/137
female's sister3 (affected) 122/Exp 149/149 128/128
19
affected female 180/Exp 157/157 128/130
unaffected male 123/148 129/137 130/133
female's mother (unaffected) 123/180 151/157 128/130
female's father (affected) 144/Exp 149/157 130/130
20
affected female 141/Exp 151/153 118/137
unaffected male 123/141 151/157 129/131
affected daughter 141/Exp 153/157 118/129
21
affected female 144/Exp 129/151 128/130
unaffected male 122/147 151/155 117/136
female's mother (unaffected) 144/144 129/153 130/134
female's father (affected) 140/Exp 129/151 128/130
22
affected female 168/Exp 128/144 117/127
unaffected male 137/140 152/155 117/129
female's mother (unaffected) 122/168 144/150 123/127
23
affected female 122/Exp 151/151 131/131
unaffected male 122/122 147/153 118/118267
Table A2.2 Details of PCR conditions for optimised protocols for PGD for DM1 showing
concentration of PCR reaction components as well as PCR cycle programmes performed. Protocols
1-5 had clinical application 20mM Tricine was added as part of the ALB lysis (NaOH or KOH/ DTT) in
protocols 2-5. Optimisation also required the use of different enzymes, Amplitaq Gold (protocol 1),
Expand High Fidelity (protocols 2 and 3), or Expand Long Template (protocols 4 and 5). In addition,
DMSO or glycerol were added in protocols 4 and 5 to improve amplification.
PCR program Protocol
number/ name
(lysis)
Reaction
Components Concentration
Temperature Time Number
of cycles
DM1Forward primer-
FAM (DMPK1) 0.3μM 94°C 12min 1 1/
DM1/APOC2
(PK/SDS) DM1 Reverse primer
(DMPK2) 0.3μM 96°C 45secs
APOC2 Forward
primer- Hex 0.3μM 60°C 45secs
APOC2 Reverse 0.3μM 72°C 1min
10
10mM dNTP 0.2mM 96°C 45secs
10x buffer (with
15mM MgCl2)
1x (1.5mM
MgCl2) 60°C 45secs
Amplitaq Gold 5U/μl 1.5 units 72°C 1min
30
Nuclease-free water make up to 22μl 72°C 5min 1
DM1Forward primer-
VIC (DMPK1) 0.3μM 95°C 2min 1 2/
DM1/D19S112
(NaOH/DTT) DM1 Reverse primer
(DMPK2) 0.3μM 96°C 15secs
D19S112 Forward
primer- NED 0.4μM 60°C 45secs
D19S112 Reverse 0.4μM 72°C 45secs
10
dNTP (10mM) 0.2mM 94°C 45secs
10x Hifi buffer II
(with 15mM MgCl2)
1x (1.5mM
MgCl2) 60°C 45secs
Expand High Fidelity
enzyme 5U/μl 1.5units 72°C 45secs
30
Tricine (200mM) 20mM 72°C 7min 1
Nuclease-free water make up to
21.5μl268
PCR program Protocol
number
(lysis)
Reaction
Components Concentration
Temperature Time Number
of cycles
DM1Forward
primer- VIC
(DMPK1)
0.2μM 95°C 2min 1 3/
DM1/APOC2/
D19S112
(NaOH/DTT) DM1 Reverse
primer (DMPK2) 0.2μM 96°C 15secs 10
APOC2 Forward
primer- Fam 0.3μM 58°C 45secs
APOC2 Reverse 0.3μM 72°C 1min
D19S112 Forward
primer- NED 0.3μM 94°C 15secs
D19S112 Reverse 0.3μM 58°C 45secs
dNTP (10mM) 0.2mM 72°C 1min
30
10x Hifi buffer II
(with 15mM
MgCl2)
1x (1.5mM
MgCl2) 72°C 7min 1
Expand High
Fidelity enzyme
5U/μl
1.5units
Tricine (200mM) 20mM
Nuclease-free water make up to 21.5μl
P2 0.2μM 95°C 2min 1 4/
TP-PCR
(KOH/DTT) P3R 0.2μM 96°C 30secs
P4CAG 0.1μM 65°C 45secs
dNTP (10mM) 0.5mM 72°C 1min
46
Expand Long
Template Buffer 3
(27.5mM MgCl2)
1x (2.75mM
MgCl2) 72°C 5min 1
Expand Long
Template enzyme
5U/μl
2 units
DMSO 5%
Tricine (200mM) 20mM
Nuclease-free water make up to 21.5μl269
PCR program
Protocol
number
Reaction
Components Concentration
Temperature Time Number
of cycles
P2FAM 0.6μM 95°C 2min 1 5/
TP-PCR/DM1/
D19S112 or
mTP-PCR
(KOH/DTT)
DMPK2 0.3μM 96°C 40secs
P4CAG 0.2μM 59°C 1min
P3R 0.3μM 72°C 1min
10
D19S112F- NED 0.2μM 94°C 40secs
D19S112R 0.2μM 59°C 1min
dNTP (10mM) 0.7mM 72°C 1min
30
Expand Long
Template Buffer 3
(27.5mM MgCl2)
1x (2.75mM
MgCl2) 72°C 7min 1
Extra MgCl2 0.6mM
Expand Long
Template enzyme
5U/μl
2 units
Glycerol 10%
Tricine (200mM) 20mM
Nuclease-free water make up to 21.5μl
6/ P2FAM 0.3μM 95°C 2min 1
(KOH/DTT) P4CAG 0.2μM 95°C 30s
P3R 0.3μM 57°C 45s
D19S112F- NED 0.2μM 72°C 1min
10
D19S112R 0.2μM 95°C 30secs
dNTP (10mM) 0.7mM 57°C 45s
Expand Long
Template Buffer 3
(27.5mM MgCl2)
1x (2.75mM
MgCl2) 72°C 1min
36
Expand Long
Template enzyme
5U/μl
2 units 72°C 7min
Glycerol 10%
Tricine (200mM) 20mM
Nuclease-free water make up to 21.5μl270
Table A2.3: Detailed analysis of blastomere amplification, allele dropout (ADO) and diagnosis rate from five DM1 PGD cases using protocols 1 and modification 1a.
*: semi/uninformative patients, unknown phase, h: detection of blastomeres showing amplification from one parental genome
Protocol Patient
Number
Number
of embryos
Number of
blastomeres Amplification ADO Diagnosis
DMPK APOC2 DMPK APOC2
1. DM/APOC2 1 4 8 7/8 5/8 1/4 0/4 3/4
6 10 15 10/15 11/15 0/5 1/9 8/10
7
h 10 13 9/13 9/13 0/3 0/6 7/10
8* 6 12 12/12 10/12 n/a 2/10 1/6
1a. DM/APOC2
split 2 4 6 5/6 3/6 n/a 1/3 3/4
Table A2.4: Detailed analysis of blastomere amplification, allele dropout (ADO) and diagnosis rate from two DM1 PGD cases using protocol 2 for diagnosis,
*: semi/uninformative patients, unknown phase
Protocol Patient
Number
Number
of embryos
Number of
blastomeres Amplification ADO Diagnosis
DMPK D19S112 DMPK D19S112
2. DM/D19S112 4 7 14 13/14 13/14 0/3 1/13 6/7
9* 4 10 8/10 7/10 n/a n/a 2/4271
Table A2.5: Detailed analysis of blastomere amplification, allele dropout (ADO) and diagnosis rate from eleven DM1 PGD cases using protocol 3 for diagnosis, *:
semi/uninformative patients, unknown phase, †: diagnosis using two different protocols, h: blastomeres with amplification from one parental genome, H: embryo where both of the
biopsied cells indicated amplification from one parental genome only
Protocol Patient
Number/Cycle
Number of
embryos
Number of
blastomeres Amplification ADO Diagnosis
DMPK APOC2 D19S112 DMPK APOC2 D19S112
3. DM/APOC2/
D19S112 10 4 5 5/5 5/5 5/5 0/3 0/4 0/4 3/4
11/1
h 12 22 21/22 20/22 20/22 0/4 1/16 0/16 8/12
12
h 3 6 6/6 6/6 6/6 n/a n/a 0/2 1/3
8*
† 5 8 7/8 7/8 7/8 0/2 0/7 0/2 5/5
11/2
h 15 32 27/32 25/32 25/32 0/14 0/17 0/17 12/15
15 6 7 6/7 5/7 5/7 n/a 0/2 0/1 1/6
3H
19/1 2 4 3/4 3/4 3/4 0/3 0/3 0/3 2/2
22/1
h 7 12 11/12 11/12 11/12 0/3 0/10 0/6 7/7
19/2
h 5 10 10/10 10/10 10/10 0/7 0/9 0/9 5/5
22/2 5 7 5/7 6/7 6/7 0/2 0/5 0/5 4/5
19/3
h 5 9 9/9 9/9 9/9 0/5 0/7 0/5 4/5
1H272
Table A2.6: Detailed analysis of blastomere amplification, allele dropout (ADO) and diagnosis rate from five DM1 PGD cases using protocol 4. TP-PCR amplification was
scored for non-122 homozygous samples *: semi/uninformative patients, unknown phase, †: diagnosis using two different protocols
Protocol Patient
Number/Cycle
Number
of embryos
Number of
blastomeres Amplification Diagnosis
TPPCR
4. TPPCR 9/2* 8 16 9/9 5/8
13/1* 4 10 9/10 4/4
8/2*† 5 4
TPPCR 3/4 5/5
13/2* 10 19 12/15 7/10
16/1 10 18 13/18 9/10
Table A2.7: Detailed analysis of blastomere amplification, allele dropout (ADO) and diagnosis rate from six DM1 PGD cases using protocol 5 for diagnosis, h: blastomeres
with amplification from one parental genome, H: embryo where both of the biopsied cells indicated amplification from one parental genome only, *: semi/uninformative patients,
unknown phase
Protocol Patient
Number/Cycle
Number
of embryos
Number
of blastomeres Amplification ADO Diagnosis
TPPCR DMPK D19S112 DMPK D19S112
13/3*
h 8 17 6/6 14/17 14/17 0/2 0/10 5/8
3H 5.
TPPCR/DM1/
D19S112 20/1 4 8 7/8 6/8 7/8 0/2 0/6 3/4
21/1
h 7 13 12/13 9/9** 12/13 n/a 0/8 5/7
1H
8/3* 3 6 4/4 6/6 6/6 1/2 0/4 3/3
23/1 3 6 6/6 6/6 6/6 n/a 0/6 3/3
23/2 3 10 n/a 7/10 7/10 n/a 0/6 3/3273
A3. Appendix 3
Table A3.1: Summary of the fifty genes with highest level of expression in the human MII oocyte
Gene_
Symbol
Gene_Name Panther_Process Entrez
Gene
ID
Celera
Gene ID
FTL ferritin, light polypeptide Transport|Cation
transport;Homeostasis|Other homeostasis
activities|Ion transport
2512 hCG39405.3
DNMT1 DNA (cytosine-5-)-methyltransferase 1 DNA metabolism 1786 hCG28474.3
Unassigned Unassigned Chromatin packaging and remodeling hCG2000758
CKS1B CDC28 protein kinase regulatory
subunit 1B
Unclassified 1163 hCG1988891.1|
hCG1739274.3|
hCG40061.4|hC
G15521.3
FLJ40448 Unassigned Unclassified 339059
FTL ferritin, light polypeptide Cation transport;Homeostasis| Ion
transport
2512 hCG39405.3
GPR103 G protein-coupled receptor 103 Signal transduction|G-protein mediated
signaling
84109
Unassigned Unassigned Unclassified hCG2040258.1
RPLP1 ribosomal protein, large, P1 Protein biosynthesis 6176 hCG38799.3
FAM44B family with sequence similarity 44,
member B
Unclassified 91272 hCG41131.4
SH3KBP1
|SMC5L1
SH3-domain kinase binding protein
1|SMC5 structural maintenance of
chromosomes 5-like 1 (yeast)
DNA repair|Biological process
unclassified|DNA metabolism|
HNRPA1 heterogeneous nuclear ribonucleoprotein
A1
Pre-mRNA processing|mRNA splicing 3178
LOC400500
|Unassigned
Unassigned Unclassified 400500 hCG1814062.2
Unassigned Unassigned Unclassified hCG1788212.3
RPL7A ribosomal protein L7a Protein biosynthesis 6130 hCG2032998.1|
hCG17890.2
RPL7A ribosomal protein L7a Protein biosynthesis 6130 hCG2001684
PCNA proliferating cell nuclear antigen Unclassified 5111 hCG39115.3
Unassigned Unassigned Intracellular protein traffic|Chromosome
segregation|Cell structure|Cell motility
hCG1995887.1
Unassigned Unassigned Unclassified hCG2011918
UNG uracil-DNA glycosylase DNA repair|Carbohydrate
metabolism;Nucleoside, nucleotide and
nucleic acid metabolism
7374 hCG38494.3
Unassigned Unassigned Protein phosphorylation|Cell cycle
control|Mitosis
hCG39453.2
STELLAR
|DPPA3
developmental pluripotency associated 3 Unclassified hCG1659192.3
|hCG2013511.1
H3F3B H3 histone, family 3B (H3.3B) Chromatin packaging and remodeling 3021 hCG1989319.1
PTTG3 pituitary tumor-transforming 3 DNA repair|mRNA transcription
regulation|Cell cycle control|Chromosome
segregation|Oncogene
26255
PAIP1 poly(A) binding protein interacting
protein 1
Protein Biosynthesis 10605 hCG1751685.2
Unassigned Unassigned Unclassified hCG1820938.2
Unassigned Unassigned Unclassified hCG1820954.2
Unassigned Unassigned Intracellular protein traffic|Chromosome
segregation|Cell structure|Cell motility
hCG1773636.2
C3orf34 chromosome 3 open reading frame 34 Unclassified 84984
Unassigned Unassigned Unclassified
Unassigned Unassigned Translational regulation
Unassigned Unassigned Unclassified hCG18484.4
Unassigned Unassigned Unclassified hCG1820573.1
Unassigned Unassigned Proteolysis hCG1993742.1
Unassigned Unassigned Proteolysis hCG1643561.2
DPPA3 developmental pluripotency associated 3 Unclassified 359787 hCG1659192.3
TMSB4X thymosin, beta 4, X-linked Unclassified 7114 hCG1646598.4
UBB ubiquitin B Proteolysis|Protein metabolism and
modification
7314 hCG1998947
Unassigned Unassigned Protein Biosynthesis hCG1789827.2
TPRXL tetra-peptide repeat homeobox-like Unclassified 348825 hCG2042888
RPL7A ribosomal protein L7a Protein biosynthesis 6130 hCG2032998.1
|hCG2028724.1
EEF1A1 eukaryotic translation elongation factor Biological process hCG2033271.2274
|DKFZP434F0318 1 alpha 1 unclassified|Translational
regulation|Protein metabolism and
modification
Unassigned Unassigned Protein Biosynthesis hCG1820440.2
DPPA5 developmental pluripotency associated 5 Unclassified 340168 hCG22904.2
SKP2 S-phase kinase-associated protein 2
(p45)
Proteolysis;Oncogenesis|Protein
metabolism and modification
6502 hCG36893.3
MORF4L1 mortality factor 4 like 1 mRNA transcription
regulation;Developmental processes
10933 hCG2005375
NALP4 NACHT, leucine rich repeat and PYD
containing 4
Unclassified 147945 hCG1733040.2
UHRF1 ubiquitin-like, containing PHD and
RING finger domains, 1
Nucleoside, nucleotide and nucleic acid
metabolism|Other cell cycle process;Cell
proliferation and
differentiation|Nucleoside, nucleotide and
nucleic acid transport;Transport
29128 hCG23497.3
|hCG23738.3
GTF2B general transcription factor IIB |mRNA transcription initiation; mRNA
transcription regulation|
2959
GDF9 growth differentiation factor 9 Gametogenesis|Developmental
processes|Oogenesis
2661 hCG24129.2
TPT1 tumor protein, translationally-controlled
1
Immunity and defense 7178 hCG32792.2
LOC440055 Unassigned Protein biosynthesis 440055 hCG27404.2
CDK7 cyclin-dependent kinase 7 (MO15
homolog, Xenopus laevis, cdk-activating
kinase)
Cell cycle control|Protein
phosphorylation;Cell cycle|Protein
metabolism and modification|
1022 hCG1988840
EEF1A1 eukaryotic translation elongation factor
1 alpha 1
Translational regulation|Protein
metabolism and modification
1915 hCG2033271.2
|hCG28097.4
|hCG1640413.5
Table A3.2: Summary of the fifty genes with highest level of expression in the human blastocyst
Gene_Symbol Gene_Name Panther_Process Entrez
Gene ID
Celera
Gene ID
LOC440085 Unassigned Cell proliferation and
differentiation
440085 hCG2003508.1|
hCG26572.3
RPL10A ribosomal protein L10a Protein metabolism and
modification
4736 hCG1787790.1
Unassigned Unassigned Protein biosynthesis hCG2000392.1
RPL37P6 ribosomal protein L37 pseudogene 6 Protein biosynthesis 346950 hCG39750.2
Unassigned Unassigned Protein biosynthesis hCG2043433
RPS2 ribosomal protein S2 Protein biosynthesis 6187 hCG1990006|hCG1983409|
hCG2018618.2|hCG201625
0
RPS3A ribosomal protein S3A Protein biosynthesis 6189 hCG33299.3
RPS4X ribosomal protein S4, X-linked Protein biosynthesis 6191 hCG18634.3
Unassigned Unassigned Protein folding|Nuclear
transport|Immunity and
defense
hCG1794401.2
RPL12 ribosomal protein L12 Protein biosynthesis 6136
RPS11 ribosomal protein S11 Protein biosynthesis 6205 hCG16209.3
RPL26 ribosomal protein L26 Protein biosynthesis 6154 hCG1985370
FLJ40448 hypothetical protein FLJ40448 Biological process
unclassified
339059
RPLP1 ribosomal protein, large, P1 Protein biosynthesis 6176 hCG38799.3
Unassigned Unassigned Protein folding|Nuclear
transport|Immunity and
defense
hCG32230.3
LOC401896 Unassigned Protein
biosynthesis|Protein
metabolism and
modification
401896 hCG1775736.1
PABPC1 poly(A) binding protein, cytoplasmic 1 mRNA end-processing
and stability
26986 hCG15683.3
RPS25 ribosomal protein S25 Unclassified 6230 hCG1641401.2
PRDX1 peroxiredoxin 1 Antioxidation and free
radical
removal|Immunity and
defense
5052 hCG1780053.2275
RPL24 ribosomal protein L24 Protein biosynthesis 6152 hCG2023003.1
HSPE1 heat shock 10kDa protein 1 (chaperonin 10) Protein metabolism and
modification
3336 hCG21429.4
Unassigned Unassigned Protein biosynthesis hCG1981229
RPL7|
LOC441896|
EIF3S10
ribosomal protein L7|eukaryotic translation
initiation factor 3, subunit 10 theta,
150/170kDa
Biological process
unclassified|Protein
biosynthesis;Protein
metabolism and
modification|Translationa
l regulation
hCG31916.3|hCG17114.3|
hCG1783090.1|hCG198398
8|
hCG1640398.3
GPR103 G protein-coupled receptor 103 Cell surface receptor
mediated signal
transduction|Signal
transduction|G-protein
mediated signaling
84109
ENO1 enolase 1, (alpha) Glycolysis|Carbohydrate
metabolism
2023 hCG22399.3
HNRPA1 heterogeneous nuclear ribonucleoprotein A1 Pre-mRNA
processing|mRNA
splicing
3178
KRT18 keratin 18 Cell structure and
motility
3875 hCG43757.3
LOC440055 Unassigned| Similar to ribosomal protein
S12
Protein biosynthesis 440055 hCG27404.2
Unassigned Unassigned Unclassified hCG1820573.1
RPS27A ribosomal protein S27a Proteolysis|Protein
metabolism and
modification
6233 hCG1987923
EEF2 eukaryotic translation elongation factor 2 Protein biosynthesis 1938 hCG23520.3
LOC388339 Unassigned | similar to ribosomal protein
S18
Protein biosynthesis 388339 hCG1640711.4
RPS7 ribosomal protein S7 Protein metabolism and
modification
6201 hCG31799.1|hCG2043512|
hCG1639825.4|hCG178426
6.2
RPL7A ribosomal protein L7a Protein biosynthesis 6130 hCG2032998.1|hCG17890.2
Unassigned Unassigned Unclassified hCG1816993.1
RPL7A ribosomal protein L7a Protein biosynthesis 6130 hCG2001684
RPS2 ribosomal protein S2 Protein biosynthesis| 6187 hCG1990006|hCG2018618.
2|
hCG2016250
LOC343384 Unassigned |
similar to peptidylprolyl isomerase A
isoform 1
Protein metabolism and
modification|Nuclear
transport;Immunity and
defense|Protein
folding;Intracellular
protein traffic
343384 hCG1792358.3
RPL37 ribosomal protein L37 Protein biosynthesis 6167
RPLP2 ribosomal protein, large, P2 Protein biosynthesis 6181 hCG1778304.2
Unassigned Unassigned Protein biosynthesis hCG22004.2
HSPE1|
LOC387880
heat shock 10kDa protein 1 (chaperonin 10) Protein metabolism and
modification
hCG2040162|hCG21429.4|
hCG26559.2
Unassigned Unassigned Protein biosynthesis hCG1999595.1
Unassigned Unassigned Biological process
unclassified
hCG1643652.1
LOC401859 Unassigned Protein metabolism and
modification|Nuclear
transport;Immunity and
defense|Protein
folding;Intracellular
protein traffic
401859 hCG1655497.4
LOC391062 Unassigned Protein metabolism and
modification|Nuclear
transport;Immunity and
defense|Protein
folding;Intracellular
protein traffic
391062 hCG1643204.4276
GOLGA8A|
SLC25A6
golgi autoantigen, golgin subfamily a,
8A|solute carrier family 25 (mitochondrial
carrier; adenine nucleotide translocator),
member 6
Protein targeting and
localization|Nucleoside,
nucleotide and nucleic
acid
transport;Transport|Nucle
oside, nucleotide and
nucleic acid metabolism|
hCG1746794.2
RPL18 ribosomal protein L18 Protein biosynthesis 6141 hCG2000370.1
Table A3.3: List of 349 high expression oocyte-specific genes. Genes are listed in ascending order by
their Celera ID.
hCG14713
hCG14841
hCG15000
hCG15050
hCG15108
hCG15138
hCG15256
hCG15364
hCG15438
hCG15525
hCG15532
hCG15558
hCG15574
hCG15670
hCG15959
hCG16030
hCG1639758
hCG1640673
hCG1640820
hCG1640936
hCG1642455
hCG1643224
hCG1645228
hCG1645324
hCG1646184
hCG1646296
hCG1648127
hCG1649960
hCG1652542
hCG16537
hCG1654498
hCG16610
hCG16630
hCG16631
hCG16632
hCG16730
hCG16811
hCG16828
hCG16929
hCG17062
hCG1729956
hCG1733021
hCG17382
hCG1742115
hCG1743207
hCG1743785
hCG1744908
hCG17542
hCG17601
hCG17664
hCG1773636
hCG1773884
hCG1775361
hCG1776311
hCG1777406
hCG1777721
hCG1779020
hCG1779729
hCG1779876
hCG1780614
hCG1781169
hCG1781628
hCG1782268
hCG1784522
hCG1784573
hCG1784779
hCG1785346
hCG1785623
hCG1786105
hCG1786193
hCG1786829
hCG1786864
hCG17871
hCG1788005
hCG1788604
hCG1791825
hCG1792164
hCG1792234
hCG1793655
hCG1796067
hCG1803572
hCG18043
hCG18066
hCG1810759
hCG1810859
hCG1810884
hCG1811008
hCG1811012
hCG1811035
hCG1811036
hCG1811059
hCG1811092
hCG1811301
hCG1811428
hCG1811512
hCG1811857
hCG1811876
hCG1812169
hCG1812722
hCG1813574
hCG1814062
hCG1814125
hCG1814486
hCG1814527
hCG1815686
hCG1817290
hCG1817498
hCG1817751
hCG1817877
hCG1818446
hCG1818459
hCG1820440
hCG1820599
hCG1821231
hCG18324
hCG18601
hCG18988
hCG19156
hCG19212
hCG19607
hCG19614
hCG19657
hCG1979388
hCG1979495
hCG1983051
hCG1983510
hCG1984799
hCG1987869
hCG1988045
hCG1988995
hCG1989524
hCG1990670
hCG1990839
hCG1991018
hCG19911
hCG1991909
hCG1993933
hCG19952
hCG1995942
hCG1997847
hCG2000011
hCG2000584
hCG2001986
hCG2003734
hCG2003750
hCG20042
hCG20064
hCG2006852
hCG2008598
hCG2009388
hCG2009910
hCG2010233
hCG2010889
hCG2011013
hCG20111
hCG2011580
hCG2011781
hCG2012284
hCG2013331
hCG2015975
hCG2016229
hCG2017381
hCG2018215
hCG2020974
hCG2020975
hCG2021087
hCG2022610
hCG2026013
hCG2026687
hCG2027083277
hCG2028192
hCG2029590
hCG2030297
hCG2032408
hCG2032644
hCG2033524
hCG2033819
hCG2036556
hCG2036560
hCG2036573
hCG2036806
hCG2036813
hCG2036869
hCG2038156
hCG2038216
hCG2038584
hCG2038661
hCG2038731
hCG2039068
hCG2039417
hCG2039566
hCG2039875
hCG2039945
hCG2039979
hCG2040243
hCG2040324
hCG2040656
hCG2040899
hCG2040997
hCG2041111
hCG2041254
hCG2041389
hCG2041810
hCG2041922
hCG2042091
hCG2042450
hCG2042571
hCG2042895
hCG2042959
hCG2043425
hCG2045906
hCG2045907
hCG20711
hCG20715
hCG20893
hCG20960
hCG21077
hCG21309
hCG21329
hCG21344
hCG21358
hCG21652
hCG21731
hCG21983
hCG22192
hCG22215
hCG22390
hCG22899
hCG23039
hCG23318
hCG23447
hCG23626
hCG23667
hCG23672
hCG23837
hCG23972
hCG24112
hCG24113
hCG24129
hCG24574
hCG24794
hCG24796
hCG24865
hCG24964
hCG25031
hCG25127
hCG25456
hCG26491
hCG26558
hCG26763
hCG26948
hCG27387
hCG27456
hCG27671
hCG27690
hCG27752
hCG27926
hCG27927
hCG27946
hCG28273
hCG28318
hCG28377
hCG28718
hCG28984
hCG29469
hCG29614
hCG30009
hCG30288
hCG30333
hCG31079
hCG32235
hCG32352
hCG32377
hCG32610
hCG32735
hCG32909
hCG32918
hCG33075
hCG33085
hCG33087
hCG33190
hCG33516
hCG34128
hCG34805
hCG34806
hCG36755
hCG36838
hCG36946
hCG37128
hCG37158
hCG37562
hCG37727
hCG37737
hCG37802
hCG38014
hCG38025
hCG38088
hCG38094
hCG38109
hCG38241
hCG38242
hCG38309
hCG38627
hCG38829
hCG38835
hCG38864
hCG39059
hCG39145
hCG39179
hCG39261
hCG39323
hCG39347
hCG39450
hCG39453
hCG39463
hCG39637
hCG39667
hCG39684
hCG39762
hCG39779
hCG39788
hCG39798
hCG39814
hCG40002
hCG40021
hCG401120
hCG401169
hCG401172
hCG401209
hCG401218
hCG401272
hCG40256
hCG40279
hCG40396
hCG40452
hCG40463
hCG40828
hCG40969
hCG40983
hCG41011
hCG41052
hCG41358
hCG41502
hCG41795
hCG41855
hCG43352
hCG44065
hCG95858
hCG96668278
Table A3.4: List of 431 high expression blastocyst-specific genes. Genes are listed in ascending order
by their Celera ID.
hCG14618
hCG14649
hCG14659
hCG14677
hCG14678
hCG14847
hCG14929
hCG15413
hCG15518
hCG15580
hCG15695
hCG15708
hCG15752
hCG15917
hCG16023
hCG16097
hCG16292
hCG16295
hCG1639748
hCG1639843
hCG1639963
hCG1640153
hCG1640184
hCG1640242
hCG1640272
hCG1640390
hCG1640406
hCG1640549
hCG1640610
hCG1640751
hCG1640879
hCG1640970
hCG1641138
hCG1641204
hCG1641569
hCG1641604
hCG1641789
hCG1641902
hCG1642370
hCG1642703
hCG1643070
hCG1643162
hCG1643175
hCG16432
hCG1643228
hCG1643231
hCG1643466
hCG1643663
hCG1643722
hCG1643895
hCG1644263
hCG1644378
hCG1644435
hCG1644607
hCG1646237
hCG1646720
hCG1647067
hCG1651416
hCG1657259
hCG1660125
hCG16678
hCG16827
hCG1685830
hCG16920
hCG16946
hCG17039
hCG17108
hCG17225
hCG17250
hCG1726843
hCG1730394
hCG1730824
hCG17325
hCG1735238
hCG1736101
hCG1736511
hCG17376
hCG1738619
hCG1739142
hCG1739343
hCG1740373
hCG1741622
hCG1742531
hCG1743761
hCG1743779
hCG1743861
hCG1745153
hCG1746935
hCG1748768
hCG1757059
hCG1759133
hCG17638
hCG1770271
hCG17757
hCG1776197
hCG1776475
hCG1776677
hCG1780024
hCG1780842
hCG1780948
hCG1781103
hCG1781910
hCG1782057
hCG1782327
hCG1782581
hCG17829
hCG1783391
hCG1784039
hCG1784107
hCG1784432
hCG1784504
hCG1785265
hCG1786960
hCG1787379
hCG1787380
hCG1787521
hCG1788236
hCG1788612
hCG1789710
hCG1790391
hCG1792076
hCG1794543
hCG1795423
hCG1795553
hCG1795633
hCG17996
hCG18049
hCG1807414
hCG18100
hCG1810958
hCG1811060
hCG1811095
hCG1811258
hCG1811302
hCG1811547
hCG1812757
hCG1812787
hCG1812951
hCG18135
hCG1814536
hCG18153
hCG1817354
hCG1817472
hCG1817599
hCG1817746
hCG1817985
hCG1818367
hCG1818503
hCG1818525
hCG1818651
hCG1820431
hCG1820468
hCG1820516
hCG1820586
hCG1820647
hCG1820745
hCG1820912
hCG18278
hCG18435
hCG18485
hCG18525
hCG19108
hCG19232
hCG19408
hCG19468
hCG19516
hCG19609
hCG19672
hCG19693
hCG1981097
hCG1981800
hCG1984423
hCG1985920
hCG1986317
hCG1986432
hCG1986580
hCG1987797
hCG1988058
hCG1988300
hCG1988320
hCG1988454
hCG19906
hCG1990963
hCG1990983
hCG1991474
hCG1991560
hCG1992111
hCG1992407
hCG1993582
hCG1994498
hCG19946
hCG1996391
hCG1997251
hCG1998331
hCG1998384
hCG1998392
hCG1999033
hCG1999172
hCG1999887
hCG2002932
hCG2004008
hCG2004157
hCG2004161
hCG2004404
hCG2004932279
hCG2005740
hCG2010765
hCG2011004
hCG2011423
hCG201191
hCG201245
hCG2013610
hCG2013819
hCG20142
hCG2014502
hCG2014568
hCG2014892
hCG2015268
hCG2015274
hCG2016736
hCG2017435
hCG2018184
hCG2019820
hCG2019888
hCG2020139
hCG2020552
hCG2021371
hCG2022032
hCG2022619
hCG2022772
hCG2025279
hCG2025667
hCG2026171
hCG2026794
hCG2027246
hCG2027322
hCG2027596
hCG20299
hCG2030721
hCG2032547
hCG2032955
hCG2033672
hCG2033702
hCG2036618
hCG2036645
hCG2036753
hCG2038863
hCG2039083
hCG2039386
hCG2039420
hCG2039620
hCG2039995
hCG2039996
hCG2040013
hCG20401
hCG2040228
hCG2040233
hCG2040291
hCG2040298
hCG2040351
hCG2040365
hCG2040606
hCG2041332
hCG2042151
hCG2042785
hCG2043046
hCG2043341
hCG2043376
hCG2043377
hCG2043431
hCG2043508
hCG2043539
hCG2043597
hCG20459
hCG20487
hCG20535
hCG20599
hCG20682
hCG20913
hCG21032
hCG21055
hCG21174
hCG21230
hCG21336
hCG21525
hCG21638
hCG21682
hCG21844
hCG21906
hCG21985
hCG21988
hCG22086
hCG22165
hCG22225
hCG22593
hCG22755
hCG22783
hCG22878
hCG23101
hCG23188
hCG23234
hCG23542
hCG23634
hCG23676
hCG23989
hCG24009
hCG24101
hCG24350
hCG24422
hCG24698
hCG25017
hCG25143
hCG25185
hCG25596
hCG25636
hCG25780
hCG25942
hCG26002
hCG26012
hCG26797
hCG27168
hCG27479
hCG27512
hCG27612
hCG27800
hCG27811
hCG27833
hCG28013
hCG28119
hCG28214
hCG28314
hCG28366
hCG28439
hCG28483
hCG28819
hCG29185
hCG29302
hCG29617
hCG30597
hCG30600
hCG30902
hCG31372
hCG31406
hCG31440
hCG31492
hCG31497
hCG31729
hCG31749
hCG32037
hCG32191
hCG32473
hCG32739
hCG32779
hCG33003
hCG33030
hCG33071
hCG33191
hCG34058
hCG34196
hCG34454
hCG36855
hCG37044
hCG37127
hCG37191
hCG37261
hCG37525
hCG37572
hCG37613
hCG37641
hCG37696
hCG37734
hCG37853
hCG37922
hCG37997
hCG38021
hCG38030
hCG38062
hCG38480
hCG38568
hCG38709
hCG38806
hCG38953
hCG38986
hCG39037
hCG39149
hCG39157
hCG39228
hCG39249
hCG39324
hCG39359
hCG39383
hCG39398
hCG39465
hCG39510
hCG39512
hCG39534
hCG39580
hCG39636
hCG39689
hCG39760
hCG39777
hCG39823
hCG39829
hCG39882
hCG39988
hCG39991
hCG40096
hCG401161
hCG401308
hCG40151
hCG40163
hCG40270
hCG40338
hCG40602
hCG40623
hCG40703
hCG40734
hCG40887
hCG40991
hCG41030
hCG41100
hCG41139
hCG41245
hCG41344
hCG41785280
hCG42023
hCG42708
hCG42867
hCG43349
hCG43758
hCG96709281
Table A3.5: Genes with high expression in oocytes and embryos out of the 525 housekeeping genes investigated.
Oocytes
(number of genes)
Blastocysts
(number of genes)
Shared genes of high signal
(number of genes)
Transcription
pre-initiation
complex
CCNH, CDK7, GTF2A2, GTF2B, GTF2E1,
GTF2F2, GTF2H2, MNAT1, POLR2F, POLR2H,
POLR2K, TAF10, TAF12, TAF4B, TAF5, TAF6,
TAF9, TBP (18)
CDK7, GTF2A2, GTF2B, GTF2E1, GTF2E2,
GTF2F2, POLR2B, POLR2E, POLR2F, POLR2G,
POLR2H, POLR2I, POLR2K, TAF10, TAF12, TAF6,
TAF7, TAF9, TBP (19)
CDK7, GTF2A2, GTF2B, GTF2E1, GTF2F2,
POLR2F, POLR2H, POLR2K, TAF10, TAF12, TAF6,
TAF9, TBP (13)
Transcription
elongation
complex
CDK9, SSRP1, TCEB1, WHSC2 (4) CDK9, RDBP, SSRP1, TCEA1, TCEB1, TCEB2 (6) CDK9, SSRP1, TCEB1 (3)
Essential
splicing factor
CCAR1, DNAJC8, FLJ10292, FUS, MAGOH,
NFX1, RBM8A, RNPS1, SF1, SFRS11, SFRS4,
SFRS5, SFRS7, SFRS9, U2AF1, YBX1 (16)
CCAR1, DHX9, DNAJC8, FLJ10292, FUS, MAGOH,
RBM8A, RNPS1, SF1, SF4, SFRS1, SFRS11, SFRS2,
SFRS3, SFRS4, SFRS5, SFRS6, SFRS7, SFRS9,
SRRM1, THOC4, U2AF1, YBX1 (23)
CCAR1, DNAJC8, FLJ10292, FUS, MAGOH,
RBM8A, SF1, SFRS11, SFRS4, SFRS5, SFRS7,
SFRS9, U2AF1 (13)
hnRNP HNRPA2B1, HNRPA3|HNRPA3P1, HNRPC,
HNRPF, HNRPK, HNRPM, PCBP1, RBMX (8)
HNRPA1, HNRPA2B1, HNRPA3|HNRPA3P1,
HNRPC, HNRPD, HNRPF, HNRPH1, HNRPK,
HNRPM, HNRPR, HNRPU, PTBP1, RBMX (13)
HNRPA2B1, HNRPA3|HNRPA3P1, HNRPC,
HNRPF, HNRPK, HNRPM, RBMX (7)
snRNP HNRPC, SF3A3, SF3B1, SF3B2, SNRPB,
SNRPB2, SNRPD1, SNRPD2, SNRPD3,
SNRPE|SNRPEL1, SNRPF|ENO1, SNRPG,
TXNL4A, WDR57 (14)
EFTUD2, HNRPC, LSM2, NHP2L1, SF3A3, SF3B1,
SF3B2, SF3B3, SF3B4, SF3B5, SNRPA, SNRPB,
SNRPB2, SNRPC, SNRPD1, SNRPD2, SNRPD3,
SNRPE|SNRPEL1, SNRPF|ENO1, SNRPG, TXNL4A,
WDR57 (22)
HNRPC, SF3A3, SF3B1, SF3B2, SNRPB, SNRPB2,
SNRPD1, SNRPD2, SNRPD3, SNRPE|SNRPEL1,
SNRPF|ENO1, SNRPG, TXNL4A, WDR57 (14)
Capping related
genes
NCBP1 (1) NCBP2, NCBP1 (2) NCBP1 (1)
Cleavage and
polyadenylation
complex
CPSF2, CPSF4, CSTF1, CSTF2, NUDT21 (5) COLEC12, CPSF2, CPSF3, CPSF4, CSTF1, CSTF2,
CSTF3, FLJ12529, NUDT21, PAPOLA (10)
CPSF2, CPSF4, CSTF1, CSTF2, NUDT21 (5)
Nuclear Pore
Complex
AAAS, NUP107, NUP133, NUP153, NUP35,
NUP37, NUP50, NUP62, NUP85, NUP88,
NUP93, NUP98, NUPL2, RAE1, RANBP2 (15)
AAAS, NUP133, NUP153, NUP188, NUP35, NUP37,
NUP50, NUP62, NUP85, NUP93, RANBP2 (11)
RANBP2, AAAS, NUP133, NUP153, NUP35, NUP37,
NUP50, NUP62, NUP85, NUP93 (10)282
Translation,
initiation,
elongation and
termination
factor
EEF1A1, EEF1B2, EEF1D, EEF1G, EEF2, EIF1,
EIF1AX|EIF1AP1, EIF2B1, EIF2B2, EIF2S1,
EIF3S10, EIF3S12, EIF3S2, EIF3S3,
EIF3S5|LOC339799, EIF3S6, EIF3S7, EIF3S8,
EIF4A1, EIF4A2, EIF4E, EIF5B, WBSCR1 (23)
EEF2, EEF1A1, EEF1B2, EEF1D, EEF1G, EIF1,
EIF1AX|EIF1AP1, EIF2B1, EIF2B2, EIF2B3,
EIF2S1, EIF2S2, EIF3S1, EIF3S10, EIF3S12,
EIF3S2, EIF3S3, EIF3S4, EIF3S5|LOC339799,
EIF3S6, EIF3S7, EIF3S8, EIF3S9, EIF4A1, EIF4A2,
EIF4B, EIF4E, EIF4EBP1, EIF4G1, EIF5, ETF1,
WBSCR1 (32)
EEF1A1, EEF1D, EEF2, EIF1, EIF1AX|EIF1AP1,
EIF2B1, EIF2B2, EIF2S1, EIF3S10, EIF3S12,
EIF3S2, EIF3S3, EIF3S5|LOC339799, EIF3S6,
EIF3S7, EIF3S8, EIF4A1, EIF4A2, EIF4E, WBSCR1
(20)
tRNA synthesis AARS, DARS, EPRS, GARS, NARS, QARS (6) AARS, DARS, EPRS, GARS, GART, KARS, LARS,
MARS, NARS, QARS, RARS, SARS, TARS, VARS,
WARS, YARS (16)
AARS, DARS, EPRS, GARS, NARS, QARS (6)
Cytosolic
ribosome
C15orf15, FAU, LOC387907|RPS7,
LOC388654|LOC388524|LOC387867|LAMR1P15|
RPSA, LOC440520|RPS27, LOC441136|RPL35A,
LOC497661, MRPL13, RPL10A,
RPL13|LOC388344, RPL13A|LOC283340|RP11-
365K22.1, RPL14, RPL15, RPL17|LOC390773,
RPL18, RPL18A, RPL19, RPL23, RPL23A, RPL24,
RPL26, RPL26L1, RPL27, RPL27A, RPL28,
RPL29, RPL3|ZNF114, RPL30, RPL31, RPL35,
RPL36, RPL37A, RPL38, RPL4, RPL41, RPL5,
RPL7A, RPL8, RPL9, RPLP0, RPLP1, RPLP2,
RPS11, RPS12, RPS15|LOC401019, RPS15A,
RPS16, RPS17, RPS18, RPS19, RPS20, RPS21,
RPS23, RPS24, RPS25, RPS27A,
RPS28|LOC441618, RPS29, RPS4X, RPS5, RPS6,
RPS7, RPS8, RPS9, SLC36A2|RPL24, UBA52 (66)
C15orf15, FAU,
LOC388654|RPSA|LOC388954|LOC388122|LOC441
447, LOC440520|RPS27, LOC441136|RPL35A,
LOC497661, MRPL13, MRPS12, RPL10A, RPL11,
RPL13|LOC388344, RPL13A|LOC283340|RP11-
365K22.1, RPL14, RPL15, RPL17|LOC390773,
RPL18, RPL18A, RPL19, RPL23, RPL23A, RPL24,
RPL26, RPL26L1, RPL27, RPL27A, RPL28, RPL29,
RPL3|ZNF114, RPL30, RPL31, RPL35, RPL36,
RPL36AL, RPL37A, RPL38, RPL4, RPL41, RPL5,
RPL7A, RPL8, RPL9, RPLP0, RPLP1, RPLP2,
RPS11, RPS12, RPS14, RPS15|LOC401019, RPS15A,
RPS16, RPS17, RPS18, RPS19, RPS2, RPS20, RPS21,
RPS23, RPS24, RPS25, RPS27A, RPS28|LOC441618,
RPS29, RPS3, RPS4X, RPS4Y1, RPS5, RPS6, RPS7,
RPS8, RPS9, SLC36A2|RPL24, UBA52 (72)
C15orf15, FAU,
LOC388654|RPSA|LOC388954|LOC388122|LOC441
447, LOC440520|RPS27, LOC441136|RPL35A,
LOC497661, MRPL13, RPL10A, RPL13|LOC388344,
RPL13A|LOC283340|RP11-365K22.1, RPL14,
RPL15, RPL17|LOC390773, RPL18, RPL18A,
RPL19, RPL23, RPL23A, RPL24, RPL26, RPL26L1,
RPL27, RPL27A, RPL28, RPL29, RPL3|ZNF114,
RPL30, RPL31, RPL35, RPL36, RPL37A, RPL38,
RPL4, RPL41, RPL5, RPL7A, RPL8, RPL9, RPLP0,
RPLP1, RPLP2, RPS11, RPS12, RPS15|LOC401019,
RPS15A, RPS16, RPS17, RPS18, RPS19, RPS20,
RPS21, RPS23, RPS24, RPS25, RPS27A,
RPS28|LOC441618, RPS29, RPS4X, RPS5, RPS6,
RPS7, RPS8, RPS9, SLC36A2|RPL24, UBA52 (65)
Ubiquitin
mediated
proteolysis
ANAPC10, ANAPC11, ANAPC4, BTRC, CDC20,
CUL1, FBXW11, RBX1, SKP1A, SKP2, TCEB1,
UBE2C, UBE2D1, UBE2D2, UBE2D3, UBE2R2
(16)
ANAPC10, ANAPC11, CDC16, RBX1, SKP1A, SKP2,
TCEB1, TCEB2, UBE2C, UBE2D1, UBE2D2,
UBE2D3, UBE2R2 (13)
ANAPC10, ANAPC11, RBX1, SKP1A, SKP2, TCEB1,
UBE2C, UBE2D1, UBE2D2, UBE2D3, UBE2R2 (11)283
Proteasome PSMA2, PSMA3, PSMA4, PSMA5, PSMA7,
PSMB1, PSMB2, PSMB3, PSMB4, PSMB5,
PSMB6, PSMB7, PSMC1, PSMC2, PSMC4,
PSMC6, PSMD1, PSMD11, PSMD14, PSMD2,
PSMD6, PSMD7, PSME3 (23)
PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6,
PSMA7, PSMB1, PSMB2, PSMB3, PSMB4, PSMB5,
PSMB6, PSMB7, PSMC1, PSMC2, PSMC3, PSMC4,
PSMC5, PSMC6, PSMD1, PSMD11, PSMD14,
PSMD2, PSMD4, PSMD6, PSMD7, PSME2, PSME3
(29)
PSMA2, PSMA3, PSMA4, PSMA5, PSMA7, PSMB1,
PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7,
PSMC1, PSMC2, PSMC4, PSMC6, PSMD1,
PSMD11, PSMD14, PSMD2, PSMD6, PSMD7,
PSME3 (23)
Other common
HK genes*,
excluding genes
shared with
other datasets
ACTB, ACTG1, ANP32B, ARF1, ARF4, ARPC2,
ATF4, ATP5A1, ATP5G1, ATP5G3, ATP5O,
ATP6V1F, BAT1, CALM2, CANX, CASC3, CLN5,
CLTA, COX4I1, COX6A1, COX7A2, COX7C,
COX8A, CSNK2B, CSTB, CYB5R3, DAZAP2,
DDX39, EEF1A1, ERH, FTH1, GNAS, GNB2L1,
H3F3A, H3F3B, HINT1, HSPA8, HSPCB, JUND,
LDHA, MDH1, NEDD8, PABPC1, PFDN5, PFN1,
PGK1, PRDX1, RAC1, RHOA, RPA2,
RPL3|ZNF114, SEPT2, SLC25A3, SOD1, SRP14,
SSR2, TEGT, UBB, UBC, USP11, VIL2, YWHAB,
ZNF91 (62)
ACTB, ACTG1, ALDOA, ANP32B, APLP2, ARF1,
ARF4, ARPC2, ATF4, ATP5A1, ATP5G1, ATP5G3,
ATP5O, ATP6V1F, BAT1, BCAP31, BTF3, CALM2,
CANX, CD81, CFL1, CLN5, CLTA, COPS6, COX4I1,
COX6A1, COX7A2, COX7C, COX8A, CSNK2B,
CSTB, CYB5R3, DAZAP2, DDT, DDX39, DYNLL1,
EEF1A1, ENO1, ERH, FTH1, G10, GAPDH, GNAS,
GNB2L1, H3F3A, H3F3B, HINT1, HSPA8, HSPCB,
JUND, KARS, LDHA, MDH1, MRPS12, MYL6,
NACA, NCL, NEDD8, NONO, PABPC1, PFDN5,
PFN1, PGK1, PHB2, PRDX1, RAC1, RHOA, RPA2,
RPL3|ZNF114, RPS14, RPS2, SARS, SEPT2,
SLC25A3, SOD1, SRP14, SSR2, TEGT, TMSB10,
TUBB2A, UBB, UBC, VIL2, YWHAB, YWHAQ,
YWHAZ, ZNF91 (87)
ACTB, ACTG1, ANP32B, ARF1, ARF4, ARPC2,
ATF4, ATP5A1, ATP5G1, ATP5G3, ATP5O,
ATP6V1F, BAT1, CALM2, CANX, CLN5, CLTA,
COX4I1, COX6A1, COX7A2, COX7C, COX8A,
CSNK2B, CSTB, CYB5R3, DAZAP2, DDX39,
EEF1A1, ERH, FTH1, GNAS, GNB2L1, H3F3A,
H3F3B, HINT1, HSPA8, HSPCB, JUND, LDHA,
MDH1, NEDD8, PABPC1, PFDN5, PFN1, PGK1,
PRDX1, RAC1, RHOA, RPA2, RPL3|ZNF114, SEPT2,
SLC25A3, SOD1, SRP14, SSR2, TEGT, UBB, UBC,
VIL2, YWHAB, ZNF91 (61)284
A4. Published papers
Kakourou G, Dhanjal S, Mamas T, Gotts S, Doshi A, Fordham K, Serhal P, Ranieri DM, Delhanty JD,
Harper JC, SenGupta SB. Preimplantation genetic diagnosis for myotonic dystrophy type 1 in the UK.
Neuromuscul Disord. 2008 Feb; 18(2):131-6
Dhanjal S, Kakourou G, Mamas T, Saleh N, Doshi A, Gotts S, Nuttall S, Fordham K, Serhal P, Delhanty
J, Harper J, Sengupta S. Preimplantation genetic diagnosis for retinoblastoma predisposition. Br J
Ophthalmol. 2007 Aug; 91(8):1090-1
Kakourou G, Dhanjal S, Daphnis D, Doshi A, Nuttall S, Gotts S, Serhal P, Delhanty J, Harper J,
SenGupta S. Preimplantation genetic diagnosis for myotonic dystrophy type 1: detection of crossover
between the gene and the linked marker APOC2. Prenat Diagn. 2007 Feb; 27(2):111-6
Souraya Jaroudi, Georgia Kakourou, Suzanne Cawood, Alpesh Doshi, Domenico M Ranieri, Paul
Serhal, Joyce C. Harper and Sioban B. SenGupta Expression profiling of DNA repair genes in human
oocytes and blastocysts using microarrays, Human Reproduction (accepted)
In preparation:
Georgia Kakourou, Souraya Jaroudi, Sarah Gotts, Alpesh Doshi, Domenico M Ranieri, Paul Serhal,
Joyce C. Harper and Sioban B. SenGupta Gene expression profiling of human oocytes and embryo
blastocysts (in preparation)
A5. Abstract presentations
Mamas T., Kakourou G., Dhanjal S., Cawood S., Doshi A., Serhal P., Xanthopoulou L.,
Mantzouratou A., Delhanty J., Harper J., SenGupta S. Detection of chromosomal aneuploidy in
embryos from preimplantation genetic diagnosis cases for monogenic disorders Preimplantation
Genetic Diagnosis International Society (PGDIS), Miami, 23-25 April, 2009.
S Dhanjal, G Kakourou, T Mamas, JC Harper and SB SenGupta Follow up analysis of untransferred
embryos following PGD for monogenic disorders PGDIS 2009 Preimplantation Genetic Diagnosis
International Society (PGDIS), Miami, 23-25 April, 2009
Seema Dhanjal, Georgia Kakourou, Thalia Mamas, Alpesh Doshi, Sarah Gotts, Paul Serhal,
Domenico M Ranieri, Joyce C Harper, Joy DA Delhanty, Sioban B SenGupta, The pursuit of a
diagnosis for every embryo in PGD British Fertility Society / ACE / Society for Reproduction and
Fertility, Edinburgh 7-9 January 2009
Georgia Kakourou, Souraya Jaroudi, Suzanne Cawood, Alpesh Doshi, Paul Serhal, Joyce C Harper,
Joy DA Delhanty, Sioban B SenGupta. Gene expression profiling of human oocytes and embryo
blastocysts. UCL Elizabeth Garrett Anderson Institute for Women’s Health, 4
th annual meeting,
December 2008
Kakourou G., Dhanjal S, Mamas T, Doshi A., Gotts S., Cawood S., Serhal P., Ranieri DM, Delhanty
JDA, Harper JC, SenGupta SB, Inheritance of the DMPK CTG repeat in couples undergoing PGD for
DM1. British Society for Human Genetics Conference, University of York, September 15-17, 2008.
Thalia Mamas, Georgia Kakourou, Seema Dhanjal, Alpesh Doshi, Sarah Gotts, Paul Serhal, Joy
Delhanty, Joyce Harper, Sioban Sengupta. Detection of aneuploidy in embryos from PGD cases for
single gene disorders. British Society for Human Genetics Conference, University of York, September
15-17, 2008285
Seema Dhanjal, Georgia Kakourou, Thalia Mamas, Alpesh Doshi, Sarah Gotts, Paul Serhal,
Domenico M Ranieri, Joyce C Harper, Joy DA Delhanty, Sioban B SenGupta, The pursuit of a
diagnosis for every embryo in PGD. British Society for Human Genetics Conference, University of
York, September 15-17, 2008
SenGupta S, Dhanjal S, Mamas T, Jaroudi S, Kakourou G, Fordhan K, Doshi A, Gotts, S, Serhal P,
Harper JC, Delhanty J. Preimplantation Genetic Diagnosis for Cancer Predisposition. Prenatal
Diagnosis, (2008), 28:Supplement S3, 2-3 International Society for Prenatal Diagnosis, Vancouver
Canada June 1-4 2008
S Dhanjal, T Mamas, G Kakourou, P Serhal, J Harper, J Delhanty and S SenGupta, Preimplantation
genetic diagnosis for Familial Hypercholesterolaemia Preimplantation Genetic Diagnosis International
Society, Barcelona 23-26 April 2008
SenGupta S, Dhanjal S, Mamas T, Jaroudi S, Kakourou G, Fordham K, Doshi S, Gotts S, Serhal P,
Ranieri D, Harper J and Delhanty J. Preimplantation genetic diagnosis for cancer predispostion
Innovations & Progress in Healthcare for Women, Queen Elizabeth II Conference Centre, London,
April 7-8, 2008
Georgia Kakourou, Seema Dhanjal, Thalia Mamas, Sarah Gotts, Alpesh Doshi, Karen Fordham, Paul
Serhal, Domenico M. Ranieri, Joy DA. Delhanty, Joyce C. Harper and Sioban B. SenGupta.
Preimplantation Genetic Diagnosis for Myotonic Dystrophy Type 1 in the UK. UCL Elizabeth Garrett
Anderson Institute for Women’s Health, 3
rd annual meeting, December 2007
Kakourou G, Dhanjal S, Mamas T, Delhanty JDA, Harper JC, SenGupta SB. Investigation of the
myotonic dystrophy type 1 (DM1) triplet repeat expansion and gene expression in oocytes and
preimplantation embryos. UCL Elizabeth Garrett Anderson Institute for Women’s Health, 3
rd annual
meeting, December 2007
Mamas T, Kakourou G, Dhanjal S, Doshi A, Gotts S, Serhal P, Delhanty J, Harper J and SenGupta
SB. Detection of aneuploidy in embryos from PGD cases for single gene disorders. UCL Elizabeth
Garrett Anderson Institute for Women’s Health, 3
rd annual meeting, December 2007
Souraya Jaroudi, Soha A. Tashkandi, Radha Bhat, Stavros Glentis, Georgia Kakourou, Joyce C.
Harper and Sioban B. SenGupta. Assessment of MDA as a cDNA amplification technique for gene
expression analysis. UCL Elizabeth Garrett Anderson Institute for Women’s Health, 3
rd annual
meeting, December 2007
SenGupta S, Dhanjal J, Mamas T, Jaroudi S, Kakourou G, Fordham K, Serhal P, Harper J and
Delhanty J. Difficulties of Preimplantation Genetic Diagnosis for Cancer Predisposition British
Society of Human Genetics, Cancer Genetics Group, Guy’s Hospital London, 7th December 2007
Kakourou G, Dhanjal S, Mamas T, Doshi A, Gotts S, Serhal P, Ranieri DM, Delhanty JDA, Harper
JC, SenGupta SB. Protocol development for Preimplantation Genetic Diagnosis (PGD) of Myotonic
Dystrophy Type 1 (DM1) in the UK: experience from 25 cycles., University of Milan, September 2007
6
th International Myotonic Dystrophy Consortium Meeting, IDMC-6
Thalia Mamas, Seema Dhanjal, Souraya Jaroudi, Georgia Kakourou and Sioban SenGupta.
Preimplantation Genetic Diagnosis for inherited cancer predisposition – Different Strategies. British
Society for Human Genetics Conference University of York, September 2007
Georgia Kakourou, Seema Dhanjal, Thalia Mamas, Sarah Gotts, Paul Serhal, Domenico Massimo
Ranieri, Joy DA. Delhanty, Joyce C. Harper and Sioban B. SenGupta. Preimplantation Genetic
Diagnosis of myotonic dystrophy type 1. European Human Genetics Conference , 16-19 June 2007,
Nice, France.
Seema Dhanjal, Georgia Kakourou, Thalia Mamas, Alpesh Doshi, Sarah Gotts, Sarah Laver, Joyce
Harper, Sioban SenGupta. Does the number of cells biopsied affect the implantation of embryos in
Preimplantation Genetic diagnosis? European Human Genetics Conference 16-19 June 2007, Nice,
France286
Georgia Kakourou, Seema Dhanjal, Richa Sud, Thalia Mamas, Alpesh Doshi, Sarah Nuttall, Sarah
Gotts, Paul Serhal, Joy Delhanty, Joyce Harper, Sioban SenGupta. Preimplantation Genetic Diagnosis
for Non-syndromic deafness. UCL Elizabeth Garrett Anderson Institute for Women’s Health, 2
nd
annual meeting, December 2006
Thalia Mamas, Farah Kilani, Georgia Kakourou, Seema Dhanjal, Jasmin Lee, Joy Delhanty, Joyce
Harper and Sioban SenGupta. Preimplantation Genetic Diagnosis for dominant monogenic disorders.
UCL Elizabeth Garrett Anderson Institute for Women’s Health, 2
nd annual meeting, December 2006
Seema Dhanjal, Georgia Kakourou, Natasha Saleh, Thalia Mamas, Alpesh Doshi Sarah Gotts, Sarah
Nuttal, Karen Fordham, Paul Serhal, Joy Delhanty, Joyce Harper and Sioban SenGupta.
Preimplantation Genetic Diagnosis for Retinoblastoma Predisposition. UCL Elizabeth Garrett
Anderson Institute for Women’s Health, 2
nd annual meeting, December 2006
G Kakourou, S Dhanjal, R Sud, T Mamas, A Doshi, S Nuttall, S Gotts, P Serhal, JD Delhanty, JC
Harper, S SenGupta. Preimplantation Genetic Diagnosis for non-syndromic deafness. British Society
for Human Genetics Conference 18-20 September, University of York, September 2006
S Dhanjal, G Kakourou, N Saleh, T Mamas, A Doshi, S Gotts, S Nuttall, K Fordham, P Serhal, J
Delhanty, JC Harper, S SenGupta. Preimplantation Genetic Diagnosis for Retinoblastoma
predisposition. British Society for Human Genetics Conference 18-20 September, University of York,
September 2006
Kakourou G, Dhanjal S, Doshi A, Gotts S, Nuttall S, Serhal P, SenGupta SB. Preimplantation
Genetic Diagnosis (PGD) of Myotonic Dystrophy type 1 (DM1). UCL Elizabeth Garrett Anderson
Institute for Women’s Health, 1
st annual meeting, December 2005 (first prize for oral presentation).
Seema Dhanjal, Georgia Kakourou, Farah Kilani, Thalia Mamas, Nestor Phoenix, Sioban Sengupta.
Preimplantation Genetic Diagnosis for inherited cancer predisposition- Strategies and problems. UCL
Elizabeth Garrett Anderson Institute for Women’s Health, 1
st annual meeting, December 2005.